

# Acute Coronary Syndromes

## [A] Evidence review for antiplatelet therapy

*NICE guideline*

*Intervention evidence review*

*February 2020*

*Draft for Consultation*

*This evidence review was developed by  
the National Guideline Centre*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© National Institute for Health and Care Excellence, 2020

# Contents

<b>1</b>	<b>Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI .....</b>	<b>6</b>
1.1	Review question: Which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?.....	6
1.2	Introduction .....	6
1.3	PICO table.....	7
1.4	Clinical evidence .....	8
1.4.1	Included studies .....	8
1.4.2	Excluded studies.....	8
1.4.3	Summary of clinical studies included in the evidence review.....	9
1.4.4	Quality assessment of clinical studies included in the evidence review ....	38
1.4.5	Network meta-analysis.....	60
1.5	Economic evidence .....	64
1.5.1	Included studies .....	64
1.5.2	Excluded studies.....	64
1.5.3	Summary of studies included in the economic evidence review .....	65
1.5.4	Health economic modelling .....	72
1.6	Evidence statements .....	80
1.6.1	Clinical evidence statements.....	80
1.6.2	Health economic evidence statements.....	88
1.7	The committee's discussion of the evidence.....	89
1.7.1	Interpreting the evidence.....	89
1.7.2	Other factors the committee took into account .....	97
	Appendix A: Review protocols .....	126
	Appendix B: Literature search strategies .....	136
	B.1 Clinical search literature search strategy .....	136
	B.2 Health Economics literature search strategy.....	141
	Appendix C: Clinical evidence selection.....	150
	Appendix D: Clinical evidence tables .....	152
	Appendix E: Forest plots.....	252
	E.2 Prasugrel + ASA versus clopidogrel + ASA .....	265
	E.3 Ticagrelor + ASA versus prasugrel + ASA .....	275
	Appendix F: GRADE tables .....	282
	Appendix G: Health economic evidence selection.....	306
	Appendix H: Health economic evidence tables .....	307
	H.1 Ticagrelor + aspirin versus prasugrel + aspirin versus clopidogrel + aspirin	307
	H.2 Ticagrelor + aspirin versus clopidogrel + aspirin .....	310
	H.3 Ticagrelor + aspirin versus prasugrel + aspirin .....	315
	H.4 Prasugrel + aspirin versus clopidogrel + aspirin.....	316

Appendix I: Excluded studies.....	320
I.1 Excluded clinical studies.....	320
I.2 Excluded health economic studies.....	326
Appendix J: Research recommendations .....	<b>Error! Bookmark not defined.</b>

# 1 Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

## 1.1 Review question: Which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?

### 1.2 Introduction

9 The mechanism of acute coronary syndromes (ACS) involves a break in the inner (intimal) lining of the coronary arteries that exposes underlying atheroma to blood flow in the artery. 10 When this occurs platelets in the circulating blood are stimulated causing them to aggregate, 11 release vasoconstrictive products, and promote blood clot development. Antiplatelet drugs 12 work by disrupting these pathways and reducing the harmful impact of platelet activation. 13 Aspirin (ASA) blocks cyclooxygenase, an enzyme produced by platelets, and is a well- 14 established treatment for acute coronary syndromes reducing further vascular events. 15 Newer antiplatelet drugs have been developed that work in different ways (thienopyridine 16 group inhibiting adenosine diphosphate pathways) and can be used in combination with 17 aspirin to improve outcomes further. 18

19 Coronary intervention, particularly with implantation of a stent into the coronary artery, acts 20 as a further promoter of platelet activation and benefits from more aggressive antiplatelet 21 medication to reduce the risk of stent thrombosis. Clopidogrel was the first of the newer 22 agents to be widely used and showed improved outcomes in comparison to aspirin alone in 23 those with ACS at higher risk or likely to undergo percutaneous coronary intervention (PCI). 24 However, some patients were observed to not gain maximal benefit from the combination of 25 aspirin and clopidogrel (termed 'clopidogrel resistance') and newer antiplatelet drugs have 26 been developed that have been reported to be more effective at reducing vascular events, 27 but at the cost of higher bleeding complications.

28 The use of dual anti-platelet therapy, DAPT, (i.e. aspirin plus one of clopidogrel, prasugrel or 29 ticagrelor) has therefore become accepted practice, but there has been no consensus 30 regarding the best agent to combine with aspirin. All 3 have been assessed by NICE and are 31 available for use in the NHS. Following the recommendation for clopidogrel in TA80, updated 32 in CG94, TA236 recommended ticagrelor plus aspirin as an option for people with STEMI 33 intended to be treated with primary percutaneous coronary intervention (PPCI) and for 34 people with UA/NSTEMI. Whereas clopidogrel and ticagrelor can be used in those managed 35 medically as well as people undergoing PCI, prasugrel is licensed only for those in whom 36 PCI is intended, and TA317 recommended prasugrel plus aspirin as an option in this 37 situation.

38 This guideline update will incorporate and contextualise the existing TA guidance by 39 reviewing the current evidence comparing DAPT options to evaluate which is the most 40 clinically and cost effective in people with ACS.

41  
42

## 1.3 PICO table

2 For full details see the review protocol in appendix A.

3 **Table 1: PICO characteristics of review question**

<b>Population</b>	<p>People with acute coronary syndromes (UA/NSTEMI and STEMI)</p> <p>Analysed as the overall ACS population, STEMI + revascularisation, UA/NSTEMI + revascularisation and UA/NSTEMI with no revascularisation.</p>
<b>Interventions</b>	<p>The following drug combinations will be included:</p> <ul style="list-style-type: none"> <li>• Clopidogrel + aspirin</li> <li>• Prasugrel + aspirin</li> <li>• Ticagrelor + aspirin</li> </ul> <p>Must be initiated as part of acute management: for example peri-procedural, or during index hospitalisation</p>
<b>Comparisons</b>	Pairwise comparisons of the above dual antiplatelet therapies
<b>Outcomes</b>	<p><b>CRITICAL</b></p> <ul style="list-style-type: none"> <li>• All-cause mortality – up to 30 days</li> <li>• All-cause mortality at 1 year</li> <li>• Cardiac mortality – up to 30 days</li> <li>• Cardiac mortality at 1 year</li> <li>• Re-infarction up to 30 days</li> <li>• Re- infarction at 1 year</li> <li>• Complications related to bleeding including haemorrhagic stroke the following hierarchy of bleeding scales will be used:             <ul style="list-style-type: none"> <li>○ BARC</li> <li>○ Author’s definition</li> <li>○ TIMI</li> <li>○ GUSTO</li> </ul> </li> <li>• Where possible, bleeding outcomes will be categorised into:             <ul style="list-style-type: none"> <li>○ Major bleeding (including BARC 3-5 , TIMI, GUSTO and as reported by author)</li> <li>○ Minor bleeding (including BARC 1-2, TIMI, GUSTO and as reported by author).</li> </ul> </li> <li>• Health-related quality of life including EQ5D and SF-36</li> </ul> <p><b>IMPORTANT</b></p> <ul style="list-style-type: none"> <li>• Stroke (any, type not specified)</li> <li>• Need for revascularisation</li> <li>• Early and late stent thrombosis</li> <li>• Breathing adverse effects</li> <li>• Bradycardic adverse effects (bradycardia, pauses and pacemaker insertion)</li> <li>• Other adverse effects</li> <li>• Unplanned urgent readmission within 30 days for any reason</li> </ul> <p>Where multiple timepoints are reported up to and including 30 days, only 30 day outcomes will be included. Where multiple timepoints beyond 30 days are reported and including up to 1 year, only up to 1 year outcomes will be reported.</p>

	Where 30-day outcomes are not reported, we will include the next longest follow-up; where up to 1 year outcomes are not reported, we will include outcomes at the longest available timepoint
<b>Study design</b>	<ul style="list-style-type: none"><li>• Randomised Controlled Trials (RCT)</li><li>• Systematic Reviews (SR) of RCTs</li></ul>

## 1.4 Methods and process

2 This evidence review was developed using the methods and process described in  
3 Developing NICE guidelines: the manual.<sup>28</sup> Methods specific to this review question are  
4 described in the review protocol in appendix A.

5 Network meta-analysis (NMA) was conducted in the review, following methods described in  
6 the NMA document. The results for the NMAs informed health economic modelling and the  
7 committee's decision-making.

8 Declarations of interest were recorded according to NICE's 2014 conflicts of interest policy.

9

## 1.5 Clinical evidence

### 1.5.1 Included studies

12 Twenty-eight studies (33 papers) were included in the review.<sup>8, 12, 20, 26, 35, 41, 43, 52, 55, 64, 68, 75, 83,</sup>  
13 <sup>92, 99, 102, 115, 118, 182, 183, 201, 219, 223, 245, 261, 282, 287-289, 306, 311, 319, 325</sup> Evidence from these studies is  
14 summarised in the clinical evidence summary below (Table 3).

15 See also the study selection flow chart in appendix C, study evidence tables in appendix D,  
16 forest plots in appendix E and GRADE tables in appendix H.

### 1.5.2 Excluded studies

18 See the excluded studies list in appendix I.

19

20



### 1.5.3 Summary of clinical studies included in the evidence review

2 **Table 2: Summary of studies included in the evidence review**

Study	Intervention and comparison	Population	Outcomes	Comments
Alexopoulos 2012 <sup>8</sup>	<p>Intervention (n=28): ticagrelor + aspirin (ASA). Ticagrelor 180mg loading dose followed by 90mg bid maintenance dose starting 12±6 hours post loading dose, until day 5. All patients received oral aspirin 325mg at first medical contact. After PCI, all patients received aspirin 100mg/d indefinitely. Duration 5 days.</p> <p>Comparison (n=27): prasugrel + ASA. Prasugrel 60mg loading dose followed by 10mg daily maintenance dose starting 24 hours post loading dose, until day 5. All patients received oral aspirin 325mg at first medical contact. After PCI, all patients received aspirin 100mg/d indefinitely. Duration 5 days.</p>	<p>n=55</p> <p>People with STEMI and undergoing revascularisation</p> <p>Age: ticagrelor group: mean 58 (SD 12); prasugrel group: mean 61 (SD 13)</p> <p>Male/Female ratio: 44/11</p> <p>Ethnicity: not reported</p> <p>Greece</p>	<p>All-cause mortality at 5 days (at 30 days)</p> <p>Complications related to bleeding (major) at 5 days (at 30 days)</p> <p>Complications related to bleeding (minor or minimal) at 5 days (at 30 days)</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: All patients received 70 U/kg of unfractionated heparin intravenously at first medical contact and additional heparin or bivalirudin at the time of PCI per operator's discretion</p>
Angiolillo 2016 <sup>12</sup>	<p>Intervention (n=51): ticagrelor + ASA. Ticagrelor 180mg loading dose after diagnostic angiography, then 90mg maintenance dose 12±1 hour after the loading</p>	<p>n=100</p> <p>People with ACS and undergoing revascularisation</p>	<p>All-cause mortality at 14 days (at 30 days)</p> <p>Complications related to bleeding (minor or minimal)</p>	<p>Setting: '15 US centres'</p> <p>Concurrent medication/care: Morphine use in catheterisation laboratory. Access site, choice of</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>dose. Study drug loading dose was administered in the catheterisation laboratory after defining coronary anatomy and before starting PCI. Afterwards, antiplatelet treatment was left to the discretion of the treating physician. All patients received a loading dose of aspirin, as per institutional standards (160-500mg), and then 75 to 100mg daily. Duration unclear.</p> <p>Comparison (n=49): clopidogrel + ASA. Clopidogrel 600mg loading dose after diagnostic angiography. Study drug loading dose was administered in the catheterisation laboratory after defining coronary anatomy and before starting PCI. Afterwards, antiplatelet treatment was left to the discretion of the treating physician. All patients received a loading dose of aspirin (160-500mg), as per institutional standards, and then 75 to 100mg daily. Duration unclear.</p>	<p>Age: ticagrelor group: mean 60.1 (SD 10.7); clopidogrel group mean: 63.0 (SD 9.1)</p> <p>Male/Female ratio: 70/30</p> <p>Ethnicity: ticagrelor group: 71.7% white, 23.9% black or African American, 4.4% other; clopidogrel group: 71.7% white; 23.9% black or African American; 4.3% other</p> <p>USA</p>	<p>at 14 days (at 30 days)</p> <p>Other adverse events at 14 days (at 30 days)</p>	<p>anticoagulant, stent type and procedural technique were at the physicians's discretion</p>
Bonello 2015 <sup>20</sup>	<p>Intervention (n=106): ticagrelor + ASA. Ticagrelor 180mg loading dose as soon as possible after diagnosis of NSTEMI-ACS</p>	<p>n=213</p> <p>People with UA/NSTEMI and undergoing revascularisation</p>	<p>All-cause mortality at 30 days</p> <p>Cardiac mortality (death resulting from cardiovascular</p>	<p>Setting: not reported</p> <p>Concurrent medication/care: All patients received their loading dose at least 4 hours before PCI</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>followed by 90mg twice daily as maintenance dose. All patients received a loading dose of 150mg aspirin IV at the time of PCI. Duration 1 month post-PCI.</p> <p>Comparison (n=107): prasugrel + ASA.</p> <p>Patients undergoing PCI received a 60mg loading dose of prasugrel as soon as the coronary anatomy was known and the decision to proceed to PCI taken. They received prasugrel 10mg daily as maintenance dose. All patients received a loading dose of 150mg aspirin IV at the time of PCI. Duration 1 month post-PCI.</p>	<p>Age: ticagrelor group: mean 61.5 (SD 10.4); prasugrel group: mean 60 (SD 9.6).</p> <p>Male/Female ratio: 159/54</p> <p>Ethnicity: not reported</p> <p>France</p>	<p>disease) at 30 days</p> <p>Complications related to bleeding (major, BARC &gt;2) at 30 days</p> <p>Stroke (any, type not specified) at 30 days</p>	<p>(13.4 ± 8.3 hours). PCI was performed using the radial route in all cases but 2 patients in the ticagrelor group. All patients received either a bolus of heparin (100 IU/kg) during the procedure followed by ACT-adjusted additional bolus or standard bivalirudin infusion. Drug-eluting stents were used in all patients.</p>
Cannon 2007 <sup>26</sup> : (DISPERSE-2)	<p>Intervention (n=334): ticagrelor + ASA.</p> <p>Patients received either 90mg of ticagrelor twice daily. Patients were scheduled to receive 1, 2 or 3 months of study drug, depending on when during the trial period they were enrolled. Patients received aspirin at an initial dose of up to 325mg followed by 75 to 100mg daily. For patients undergoing PCI within 48 hours post-randomisation, an</p>	<p>n=661</p> <p>People with UA/NSTEMI</p> <p>Age: ticagrelor 90 mg group: mean 64 (SD 12.1 years); ticagrelor 180mg group: mean 63 (SD 11.4); clopidogrel group: mean 62 (SD 11.0 years) based on primary safety cohort</p> <p>Male/Female ratio: 632/352</p>	<p>All-cause mortality at 30 days</p> <p>Cardiac mortality (cardiovascular death) at 30 days</p> <p>Re-infarction (myocardial infarction) at 30 days</p> <p>Complications related to bleeding (major) at 30 days</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: Patients received standard medical (anti-ischaemic and antithrombotic) and interventional treatment for ACS, including with or without a glycoprotein IIb/IIIa inhibitor, heparin, beta-blockers and statins. Patients who received clopidogrel before randomisation were permitted in the study, but open-label clopidogrel was discontinued after</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>additional 300mg placebo could be administered at the discretion of the treating physician. Duration 4-12 weeks.</p> <p>Comparison (n=327): clopidogrel + ASA. Patients received 300mg clopidogrel followed by 75mg once daily. Patients were scheduled to receive 1, 2 or 3 months of study drug, depending on when during the trial period they were enrolled. Patients received aspirin at an initial dose of up to 325mg followed by 75 to 100mg daily. For patients undergoing PCI within 48 hours post-randomisation, an additional 300mg clopidogrel could be administered at the discretion of the treating physician. Duration 4-12 weeks.</p>	<p>(based on primary safety cohort)</p> <p>Ethnicity: ticagrelor group (90mg and 180mg groups combined): white 95%, non-white 5%; clopidogrel group: white 94%, non-white 6%</p> <p>Multiple countries</p>	<p>Complications related to bleeding (minor) at 30 days</p> <p>Stroke (any, type not specified) at 30 days</p>	<p>randomisation and replaced with study drug.</p>
Dasbiswas 2013 <sup>35</sup>	<p>Intervention (n=111): prasugrel + ASA. Prasugrel loading dose of 60mg between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. Following loading dose, patients received prasugrel 10mg once daily. All patients were prescribed aspirin 325mg per day during</p>	<p>n=220</p> <p>People with ACS and undergoing revascularisation</p> <p>Age: prasugrel group, mean male: 54.8 (SD 9.67); prasugrel group, mean female: 58.7 (SD 8.10); clopidogrel group, mean</p>	<p>All-cause mortality at 30 days</p> <p>Cardiac mortality at 30 days</p> <p>Re-infarction (non-fatal myocardial infarction) at 30 days</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: not reported</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>the study. The maintenance dose was started from the next day of loading dose. Duration 12 weeks</p> <p>Comparison (n=109): clopidogrel + ASA. Clopidogrel loading dose of 300mg between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. Following loading dose, patients received clopidogrel 75mg once daily. All patients were prescribed aspirin 325mg per day during the study. The maintenance dose was started from the next day of loading dose. Duration 12 weeks</p>	<p>male: 54.6 (SD 9.65); clopidogrel group, mean female: 60.4 (SD 10.50).</p> <p>Male/Female ratio: not reported</p> <p>Ethnicity: not reported</p> <p>India</p>	<p>Complications related to bleeding (major) at 30 days</p> <p>Complications related to bleeding (minor) at 30 days</p> <p>Need for revascularisation (urgent revascularisation) at 30 days</p> <p>Stent thrombosis (acute) at 30 days</p> <p>Stroke (any, type not specified) at 30 days</p> <p>Other adverse effects at 30 days</p> <p>Unplanned urgent readmission (rehospitalisation due to cardiac arrest) at 30 days</p>	
Dehghani 2017 <sup>43</sup>	<p>Intervention (n=76): ticagrelor + ASA. Ticagrelor 180mg loading dose followed by 90mg PO twice daily. Duration 30 days*.</p> <p>Comparison (n=68): clopidogrel + ASA. Clopidogrel loading dose of 300mg followed by 75mg PO</p>	<p>n=144</p> <p>People with STEMI and undergoing revascularisation</p> <p>Age: ticagrelor group mean: 62.1 (SD 10.2); clopidogrel group mean: 64.1 (SD 14.0).</p>	<p>All-cause mortality at 30 days</p> <p>Re-infarction (myocardial infarction) at 30 days</p> <p>Complications related to bleeding (major, BARC 3-5) at 30 days</p>	<p>Setting: Hospital</p> <p>*Concurrent medication/care: All patients received 162 to 325mg of aspirin and clopidogrel adjunctive therapy at the time of fibrinolysis as per guidelines.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	daily*. Duration 30 days.	Male/Female ratio: 107/37  Ethnicity: ticagrelor group: white (93.4%); clopidogrel group: white (97.1%)  Canada	Complications related to bleeding (minor, BARC 1-2) at 30 days  Need for revascularisation (unplanned revascularisation) at 30 days  Stroke (any, type not specified) at 30 days  Breathing adverse effects at 30 days  Bradycardic adverse effects at 30 days  Other adverse effects at 30 days  Unplanned urgent readmission (rehospitalisation) at 30 days	
Goto 2015 <sup>52</sup> : PHILO trial	Intervention (n=401): ticagrelor + ASA. Ticagrelor. An initial loading dose of 180mg ticagrelor, followed by 90mg twice daily and once daily matching placebo tablets. In patients undergoing CABG, the blinded study drug (eg. active drug or	n=801  People with ACS and undergoing revascularisation  Age: ticagrelor group: mean 67 (SD 12); clopidogrel group: mean 66 (SD 11).	All-cause mortality at 1 year  Cardiac mortality (including cardiovascular/vascular) at 1 year  Re-infarction (myocardial infarction excluding silent	Setting: Hospital  Concurrent medication/care: not reported

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>placebo) was withheld for 24-72 hours in the ticagrelor group. All patients received aspirin at a dose of 75-100mg once daily (a loading dose of up to 330mg was permitted) unless aspirin was contraindicated or poorly tolerated. Duration 12 months.</p> <p>Comparison (n=400): clopidogrel + ASA.</p> <p>Patients who were clopidogrel naive received an initial loading dose of 300mg clopidogrel orally or matching placebo, then 75mg once daily and placebo capsules twice daily thereafter. Patients in the clopidogrel group who had already received a loading dose or who were already taking maintenance doses of clopidogrel or ticlopidine for ≥5 days prior to randomisation were given clopidogrel 75mg once daily plus placebo capsules twice daily. All patients received aspirin at a dose of 75-100mg once daily (a loading dose of up to 330mg was permitted) unless aspirin was contraindicated or poorly tolerated. Duration 12 months.</p>	<p>Male/Female ratio: ticagrelor group: 306/95; clopidogrel group: 302/98</p> <p>Ethnicity: Asian (Chinese, Japanese, Korean and unknown ethnic groups)</p> <p>Multiple countries</p>	<p>myocardial infarction) at 1 year</p> <p>Complications related to bleeding (major) at 1 year</p> <p>Complications related to bleeding (minor) at 1 year</p> <p>Stroke (any, type not specified) at 1 year</p> <p>Breathing adverse effects at 1 year</p> <p>Bradycardic adverse effects at 1 year</p> <p>Other adverse effects at 1 year</p>	
Han 2019 <sup>55</sup>	Intervention (n=60): ticagrelor +	n=120	Cardiac mortality at 30 days	Setting: Hospital

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>ASA. Ticagrelor loading dose of 180mg and 300mg of aspirin. After PCI, patients took 90mg of ticagrelor, twice a day. Patients also orally took 100mg of aspirin once a day. Duration 12 months.</p> <p>Comparison (n=60): clopidogrel + ASA. Clopidogrel load dose of 600mg and 300mg of aspirin. After PCI, patients took 75mg of clopidogrel once a day. Patients also orally took 100mg of aspirin once a day. Duration 12 months.</p>	<p>People with STEMI undergoing emergency PCI</p> <p>Age – mean (SD): ticagrelor group: 67 (8); clopidogrel group: 67 (8) years</p> <p>Male/Female ratio: 65/56</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>Re-infarction at 30 days</p> <p>Complications related to bleeding (major) at 30 days</p> <p>Complications related to bleeding (minor) at 30 days</p>	<p>Concurrent medication/care: not reported</p>
Jing 2016 <sup>64</sup>	<p>Intervention (n=94): ticagrelor + ASA. Ticagrelor loading dose of 180mg and 300mg aspirin. After the primary PCI, 90mg ticagrelor was used daily for at least 12 months. Aspirin 100mg daily was used indefinitely. Duration Not reported.</p> <p>Comparison (n=94): clopidogrel + ASA. Loading dose of 600mg clopidogrel and 300mg aspirin. After the primary PCI, a maintenance dose of 75mg</p>	<p>n=188</p> <p>People with STEMI and undergoing revascularisation</p> <p>Age: Clopidogrel group: 55 (16); ticagrelor group: 59 (21)</p> <p>Male/Female ratio: 112/76</p> <p>Ethnicity: Chinese</p> <p>China</p>	<p>All-cause mortality in-hospital (up to 30 days)</p> <p>Cardiac mortality in-hospital (up to 30 days)</p> <p>Complications related to bleeding (life threatening or intracranial haemorrhage) in-hospital (up to 30 days)</p> <p>Complications related to bleeding (mild) in-hospital (up to 30 days)</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: not reported</p>



Study	Intervention and comparison	Population	Outcomes	Comments
	clopidogrel was used daily for at least 12 months. Aspirin 100mg daily was used indefinitely. Duration Not reported			
Kitano 2019 <sup>75</sup>	<p>Intervention (n=39): prasugrel + ASA. Prasugrel loading dose of 20mg and 162mg of aspirin. After primary PCI, patients were given 3.75 mg of prasugrel once a day and 100mg once a day or aspirin. Duration 8 months.</p> <p>Comparison (n=39): clopidogrel + ASA. Clopidogrel loading dose of 75 mg once a day and 100mg once a day. After primary PCI, patients were 75mg clopidogrel once a day and 100mg of aspirin once a day. Duration 8 months.</p>	<p>n=78</p> <p>People with ACS (STEMI, NSTEMI and unstable angina)</p> <p>Age: prasugrel group: 66 (13); clopidogrel group: 64 (11)</p> <p>Male/Female ratio: 64/14</p> <p>Ethnicity: not reported</p> <p>Japan</p>	<p>All-cause mortality at 1 year</p> <p>Stroke (any, type not specified) at 1 year</p> <p>Need for revascularisation at 1 year</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: not reported</p>
Laine 2014 <sup>83</sup>	<p>Intervention (n=50): ticagrelor + ASA. Patients in both groups received a 250mg intravenous loading dose of aspirin on admission followed by 75mg per dose daily indefinitely. After randomisation, patients received 180mg ticagrelor as a</p>	<p>n=100</p> <p>People with UA and undergoing revascularisation</p> <p>Age: ticagrelor group: 64.8 (8.9); prasugrel group: 62.8 (8.2)</p>	<p>All-cause mortality in-hospital (up to 30 days)</p> <p>Cardiac mortality in-hospital (up to 30 days)</p> <p>Re-infarction in-hospital (up to 30 days)</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: Glycoprotein 2b/3a inhibitors were not used, and all patients received a 4,000 UI bolus of heparin intravenously during PCI.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>loading dose. The maintenance dose of ticagrelor was 90mg twice daily. Duration Unclear duration of follow-up.</p> <p>Comparison (n=50): prasugrel + ASA.</p> <p>Patients in both groups received a 250mg intravenous loading dose of aspirin on admission followed by 75mg per dose daily indefinitely. After randomisation, patients received 60mg prasugrel as a loading dose. The maintenance dose of prasugrel was 10mg daily. Duration Unclear duration of follow-up.</p>	<p>Male/Female ratio: 76/24</p> <p>Ethnicity: not reported</p> <p>France</p>	<p>Complications related to bleeding (major, BARC &gt;3) in-hospital (up to 30 days)</p> <p>Stroke (any, type not specified) in-hospital (up to 30 days)</p>	
Lee 2015 <sup>92</sup>	<p>Intervention (n=20): ticagrelor + ASA.</p> <p>Ticagrelor loading dose of 180mg in combination with 300mg aspirin in the emergency room prior to arrival at the cardiac catheterisation room. Ticagrelor 90mg twice daily was administered continuously during the follow-up as the maintenance dose. Duration 30 days.</p> <p>Comparison (n=19): prasugrel + ASA.</p> <p>Prasugrel loading dose of 60mg in combination with</p>	<p>n=39</p> <p>People with STEMI and undergoing revascularisation</p> <p>Age: ticagrelor group: mean 55 (SD 11); prasugrel group: mean 55 (SD 10)</p> <p>Male/Female ratio: 35/4</p> <p>Ethnicity: Korean</p> <p>South Korea</p>	Other adverse effects at 30 days	<p>Setting: Hospital</p> <p>Concurrent medication/care: Glycoprotein IIb/IIIa inhibitors intracoronary only were permitted for use at the discretion of the attending physician.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	300mg aspirin in the emergency room prior to arrival at the cardiac catheterisation room. Prasugrel 10mg 4 times daily was administered continuously during the follow-up as the maintenance dose. Duration 30 days.			
Li 2018 <sup>99</sup>	<p>Intervention (n=329): ticagrelor + ASA. Ticagrelor loading dose of 180mg ticagrelor in combination with 300mg loading dose of aspirin. After primary PCI, patients received 90mg twice a day along with 100 mg aspirin daily, as a maintenance dose. Duration 12 months.</p> <p>Comparison (n=324): clopidogrel + ASA. Clopidogrel loading dose of 600mg in combination with 300mg of aspirin. After primary PCI, patients received 75mg once daily along with 100mg aspirin daily, as a maintenance dose. Duration 12 months.</p>	<p>n=653</p> <p>People with STEMI undergoing primary PCI</p> <p>Age – mean (SD): ticagrelor group: 60 (11); clopidogrel group: 63 (13)</p> <p>Male/Female ratio: 346/96</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>Re-infarction at 1 year</p> <p>Cardiac mortality at 1 year</p> <p>Stroke (ischemic ) at 1 year</p> <p>Complications related to bleeding (major, BARC – 3a and 3b) at 1 year</p> <p>Complications related to bleeding (minor, BARC = 1) bleeding at 1 year</p> <p>Need for revascularisation at 1 year</p> <p>Stent thrombosis at 1 year</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: Other drugs (i.e. beta-blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker and proton pump inhibitor) decisions were made by the treating physicians</p>
Motovska 2016 <sup>118</sup> : PRAGUE-18	<p>Intervention (n=596): ticagrelor + ASA. Ticagrelor 180mg loading dose and 90mg twice daily as a</p>	<p>n=1230</p> <p>People with ACS with or without revascularisation</p>	<p>All-cause mortality at 30 days</p> <p>Cardiac mortality (death</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: The decision to administer any</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>maintenance dose. Administration of the loading dose was recommended immediately after the patients signed the informed consent. In individual cases in which the physician could not exclude the need for urgent surgical revascularisation on the basis of previous assessments or in cases involving haemodynamic instability, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI. The decision to perform the procedure was left to the discretion of the treating physician. Patients were advised to use the study medication for 12 months. Use of aspirin was also required with a recommendation of 100mg daily. Duration 30 days.</p> <p>Comparison (n=634): prasugrel + ASA. Prasugrel 60mg loading dose and 10mg once daily as a maintenance dose. In patients aged &gt;75 years of age or in those with a weight &lt;60kg, the maintenance dose of prasugrel was reduced to 5mg once daily. Administration of the loading dose was recommended</p>	<p>Age: ticagrelor group: 61.8 (44.6-79.8); prasugrel group: 61.8 (42.7-78.7)</p> <p>Male/Female ratio: 928/302</p> <p>Ethnicity: not reported</p> <p>Czech Republic</p>	<p>resulting from cardiovascular disease) at 30 days</p> <p>Re-infarction at 30 days</p> <p>Complications related to bleeding (major, BARC 3 or 5) at 30 days</p> <p>Complications related to bleeding (minor, BARC 1-2) at 30 days</p> <p>Stent thrombosis (definite) at 30 days</p>	<p>adjunctive medication to support PCI was left to the discretion of the treating physician.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>immediately after the patients signed the informed consent. In individual cases in which the physician could not exclude the need for urgent surgical revascularisation on the basis of previous assessments or in cases involving haemodynamic instability, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI. In cases in which primary PCI was not performed, prasugrel therapy was discontinued and replaced by clopidogrel. The decision to perform the procedure was left to the discretion of the treating physician. Patients were advised to use the study medication for 12 months. Use of aspirin was also required with a recommendation of 100mg daily. Duration 30 days.</p>			
<p>Parodi 2013<sup>183</sup>: RAPID</p>	<p>Intervention (n=25): ticagrelor + ASA. Ticagrelor 180mg loading dose before PPCI. The loading dose was performed as soon as possible in the Emergency Room or in the Cath Lab. Dual antiplatelet therapy (100mg aspirin associated with 180mg prasugrel) was recommended for 12 months, with a loading</p>	<p>n=50 People with STEMI undergoing revascularisation Age: ticagrelor group: mean 67 (SD 10); prasugrel group: mean 67 (SD 14) Male/Female ratio: 39/11</p>	<p>All-cause mortality in-hospital (up to 30 days) Re-infarction (myocardial infarction) in-hospital (up to 30 days) Complications related to bleeding (major, TIMI) in-hospital (up to 30 days)</p>	<p>Setting: Hospital Concurrent medication/care: Bivalirudin: bolus 0.75mg/kg followed by 1.75mg/kg/h infusion during PCI, after PPCI a bivalirudin infusion of 0.25mg/kg/h for 4 hours was allowed; unfractionated heparin use was discouraged; and glycoprotein IIb/IIIa inhibitors were not allowed.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>dose of 500mg of aspirin followed by 100mg daily dose. Duration Unclear.</p> <p>Comparison (n=25): prasugrel + ASA.</p> <p>Prasugrel 60mg loading dose before PPCI. The loading dose was performed as soon as possible in the Emergency Room or in the Cath Lab. Dual antiplatelet therapy (100mg aspirin associated with 5 or 10mg prasugrel) was recommended for 12 months, with a loading dose of 500mg of aspirin followed by 100mg daily dose. Duration Unclear.</p>	<p>Ethnicity: not reported</p> <p>Italy</p>	<p>Stroke in-hospital (up to 30 days)</p> <p>Complications related to bleeding (minor, TIMI) in-hospital (up to 30 days)</p> <p>Stent thrombosis in-hospital (up to 30 days)</p> <p>Bradycardiac adverse effects in-hospital (up to 30 days)</p> <p>Other adverse effects in-hospital (up to 30 days)</p>	
Parodi 2014 <sup>182</sup> : RAPID 2	<p>Intervention (n=25): ticagrelor + ASA.</p> <p>A loading dose of 500mg intravenous aspirin was administered in the ambulance or at the patient's home followed by 100mg daily dose. A 360mg loading dose of ticagrelor was given before PPCI. The loading dose of ticagrelor was performed as soon as possible in the emergency department or in the catheterisation laboratory. Dual antiplatelet therapy (100mg aspirin associated with 180mg ticagrelor) was recommended for 12 months.</p>	<p>n=50</p> <p>People with STEMI undergoing revascularisation</p> <p>Age: ticagrelor group: mean 63 (SD 11); prasugrel group: mean 67 (SD 12)</p> <p>Male/Female ratio: 32/18</p> <p>Ethnicity: not reported</p> <p>Italy</p>	<p>All-cause mortality at 12 hours (up to 30 days)</p> <p>Re-infarction at 12 hours (up to 30 days)</p> <p>Complications related to bleeding (major, TIMI) at 12 hours (up to 30 days)</p> <p>Complications related to bleeding (minor, TIMI) at 12 hours (up to 30 days)</p> <p>Stent thrombosis (acute; type not specified) at 12 hours (up to 30 days)</p>	<p>Setting: Emergency department (with prior administration of aspirin in ambulance or at patient's home)</p> <p>Concurrent medication/care: Bivalirudin: bolus of 0.75mg/kg followed by 1.75mg (kg h) infusion during PPCI. After PPCI, a bivalirudin infusion of 0.25mg (kg h) for 4 hours was performed in all the patients. Unfractionated heparin use was discouraged. Glycoprotein IIb/IIIa inhibitors were not allowed.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Duration 12 months.</p> <p>Comparison (n=25): prasugrel + ASA.</p> <p>A loading dose of 500mg intravenous aspirin was administered in the ambulance or at the patient's home followed by 100mg daily dose. A 60mg loading dose of prasugrel was given before PPCI. The loading dose of prasugrel was performed as soon as possible in the emergency department or in the catheterisation laboratory. Dual antiplatelet therapy (100mg aspirin associated with 5 or 10mg prasugrel) was recommended for 12 months. Duration 12 hours.</p>		<p>Stroke (any, type not specified) at 12 hours (up to 30 days)</p> <p>Bradycardic adverse effects at 12 hours (up to 30 days)</p> <p>Other adverse effects at 12 hours (up to 30 days)</p>	
<p><b>Roe 2012<sup>201</sup></b>; Kaul 2016<sup>68</sup>: TRILOGY*</p>	<p>Intervention (n=4663): prasugrel + ASA.</p> <p>Patients who underwent randomisation within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 30mg of prasugrel, which was followed by daily blinded maintenance administration of a study drug. Patients who did not undergo randomisation within 72 hours were required to be treated with open-label clopidogrel before</p>	<p>n=9326</p> <p>People with UA/NSTEMI and not undergoing revascularisation</p> <p>Age: prasugrel group: median 66 (IQR 58-74); clopidogrel group: median 66 (IQR 59-73).</p> <p>Male/Female ratio: prasugrel group: 2835/1828; clopidogrel group: 2840/1823</p>	<p>All-cause mortality up to 30 days</p> <p>Cardiac mortality (cardiovascular death in people aged &lt;75 years) up to 1 year</p> <p>Cardiac mortality (cardiovascular death) up to 30 days</p> <p>Re-infarction (myocardial infarction in people aged &lt;75</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: Not reported in study methods but the majority of patients received concomitant beta-blocker, ACE inhibitor or angiotensin-receptor blocker and statin at randomisation. Angiography was performed before randomisation in 41.2% of the prasugrel group; angiography was performed before randomisation in 41.4% of the clopidogrel group.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>randomisation and were started on daily maintenance administration of a study drug after randomisation. The prasugrel maintenance dose was 10mg, which was adjusted to 5mg for patients who were 75 years of age or older or who weighed less than 60kg. Concomitant treatment with aspirin was required, and a daily dose of 100mg or less was strongly recommended. Duration 30 months.</p> <p>Comparison (n=4663): clopidogrel + ASA.</p> <p>Patients who underwent randomisation within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 300mg of clopidogrel, which was followed by daily blinded maintenance administration of a study drug. Patients who did not undergo randomisation within 72 hours were required to be treated with open-label clopidogrel before randomisation and were started on daily maintenance administration of a study drug after randomisation. The clopidogrel maintenance dose was 75mg for all patients.</p>	<p>Ethnicity: not reported</p> <p>Multiple countries</p>	<p>years) up to 1 year</p> <p>Re-infarction (myocardial infarction) up to 30 days</p> <p>Complications related to bleeding (major, TIMI) up to 30 days</p> <p>Complications related to bleeding (minor, TIMI) up to 30 days</p> <p>Health-related quality of life (EQ5D in people aged &lt;75 years) at 1 year</p> <p>Health-related quality of life (SAQ Physical in people aged &lt;75 years) at 1 year</p> <p>Health-related quality of life (SF-12 Physical in people aged &lt;75 years) at 1 year</p> <p>Health-related quality of life (SF-12 Mental in people aged &lt;75 years) at 1 year</p> <p>Health-related quality of life (SF-36 Mental in people aged &lt;75 years) at 1 year</p> <p>Stroke (any, type not</p>	<p>*30 day outcome data was requested and received from authors</p>



Study	Intervention and comparison	Population	Outcomes	Comments
	Concomitant treatment with aspirin was required, and a daily dose of 100mg or less was strongly recommended. Duration 30 months.		specified in people aged <75 years) up to 1 year  Stroke (any, type not specified) up to 30 days	
Savonitto 2018 <sup>219</sup>	Intervention (n=720): prasugrel +ASA. Prasugrel 60mg loading dose followed by 5mg once daily. In patients with STEMI undergoing primary PCI, the drugs could be given as soon as possible after the diagnosis, yet the first administration of the study drug could also take place after angiography or soon after PCI (eg. on arrival in the coronary care unit), particularly in patients treated during PCI with glycoprotein IIb/IIIa receptor blockers. For patients treated with bivalirudin monotherapy during PCI, it was strongly recommended that the loading dose of the investigational drugs be administered before PCI. In patients with NSTEMI-ACS, randomisation was to take place after angiography, and the loading dose should be administered either immediately before PCI or on arrival in the coronary care unit.	n=1455  People with ACS and undergoing revascularisation  Age: median 80 (IQR 77-84 years).  Male/Female ratio: 867/576  Ethnicity: not reported  Italy	All-cause mortality at 1 year  Cardiac mortality (cardiovascular death) at 1 year  Re-infarction (myocardial infarction) at 1 year  Complications related to bleeding (major, BARC 3 or 5) at 1 year  Complications related to bleeding (minor, BARC 2) at 1 year  Stent thrombosis (probable, or definite) at 1 year  Stroke (any, type not specified) at 1 year  Other adverse effects at 1 year	Setting: Hospital  Concurrent medication/care: Proton pump inhibitors were recommended in all patients throughout the study. The selection of periprocedural anticoagulants and glycoprotein IIb/IIIa receptor blockers was left to the investigators' discretion. Whereas the use of oral anticoagulants at the time of the index event was a contraindication to enrollment in the study, their subsequent use for conditions that could have developed during follow-up (eg. atrial fibrillation) was left to the discretion of the attending physician as clinically indicated.

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Ongoing clopidogrel treatment, either preexisting or started as soon as the diagnosis of NSTEMI-ACS was made (with a loading dose of 300 or 600mg left to the investigators' discretion), did not preclude enrollment. In this case, those randomised to prasugrel received a 30mg loading dose immediately after randomisation. All patients were to receive 325mg aspirin on admission and then 75 to 100mg daily throughout follow-up. Duration 12 months.</p> <p>Comparison (n=735): clopidogrel + ASA.                      Clopidogrel 300-600mg loading dose (at investigators' discretion) followed by 75mg once daily. In patients with STEMI undergoing primary PCI, the drugs could be given as soon as possible after the diagnosis, yet the first administration of the study drug could also take place after angiography or soon after PCI ((eg. on arrival in the coronary care unit), particularly in patients treated during PCI with glycoprotein IIb/IIIa receptor blockers. For patients treated with bivalirudin monotherapy during PCI, it was strongly</p>		<p>Unplanned urgent readmission (rehospitalisation for cardiovascular causes or bleeding) at 1 year</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>recommended that the loading dose of the investigational drugs be administered before PCI. In patients with NSTEMI-ACS, randomisation was to take place after angiography, and the loading dose should be administered either immediately before PCI or on arrival in the coronary care unit. Ongoing clopidogrel treatment, either preexisting or started as soon as the diagnosis of NSTEMI-ACS was made (with a loading dose of 300 or 600mg left to the investigators' discretion), did not preclude enrollment. In this case, those randomised to clopidogrel were to continue clopidogrel 75mg daily without a further loading dose. All patients were to receive 325mg aspirin on admission and then 75 to 100mg daily throughout follow-up. Duration 12 months.</p>			
<p><b>Schüpke 2019<sup>223</sup></b> ISAR-REACT 5</p>	<p>Intervention (n=2012): Ticagrelor + ASA. Loading dose of ticagrelor, 180 mg and continued at a maintenance dose of 90 mg twice daily. At discharge 94.5% of patients had aspirin (100mg or less). Duration 12 months.</p> <p>Comparison (n=2006):</p>	<p>n=4018</p> <p>People with acute coronary syndrome for which invasive evaluation was planned (i.e., the patient was scheduled to undergo coronary angiography) STEMI –41.2%</p>	<p>All-cause mortality at 1 year</p> <p>Cardiac mortality at 1 year</p> <p>Re-infarction at 1 year</p> <p>Stroke at 1 year</p> <p>Stent thrombosis (definite or</p>	<p>Setting: Hospitals and cardiac centres (multicentre trial)</p> <p>Concurrent medication/care: not reported</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	Prasugrel + ASA. Loading dose of prasugrel, 60 mg and continued at a maintenance dose of 10 mg once per day. At discharge 94.5% of patients had aspirin (100mg or less). Duration 12 months.	UA/NSTEMI –46.1% Unstable angina – 12.7% PCI – 84.1% of participants  Age: Ticagrelor group: 64.5 (12) years; Prasugrel group: 64.6 (12.1) years Male/Female ratio: 3062/956  Ethnicity: not reported  Germany and Italy	probable) at 1 year  Major bleeding (major, BARC 3,4 or 5) at 1 year	
Tang 2016 <sup>261</sup>	Intervention (n=210): ticagrelor + ASA. Patients received 300mg of aspirin and a loading dose of 180mg ticagrelor before PPCI. After PPCI, the patients were given 100mg of aspirin daily and 90mg of ticagrelor twice daily. Duration 6 months.  Comparison (n=210): clopidogrel + ASA. Patients received 300mg of aspirin and a loading dose of 600mg of clopidogrel before PPCI. After PPCI, the patients were given 100mg of aspirin daily and 75mg of clopidogrel once daily. Duration 6 months.	n=420  People with STEMI and undergoing revascularisation  Age: ticagrelor group: mean 64.36 (SD 11.409); clopidogrel group: mean 64.18 (SD 11.088).  Male/Female ratio: 288/112  Ethnicity: not reported  China	All-cause mortality at 6 months  Cardiac mortality (cardiovascular cause) at 6 months  Re-infarction (non-fatal myocardial infarction) at 6 months  Complications related to bleeding (major, TIMI) at 6 months  Complications related to bleeding (minor, TIMI) at 6 months  Need for revascularisation	Setting: All patients were hospitalised in the cardiac intensive care unit. During the 6-month follow-up, the data were recorded via telephone interviews or outpatient follow-up visits  Concurrent medication/care: All patients without any contraindication also received conventional drugs, such as $\beta$ -blockers, angiotensin-converting enzymes/angiotensin receptor blockers, and statins in accordance with the 2013 ACCF/AHA guideline for the management of STEMI: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Some

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>(unplanned revascularisation) at 6 months</p> <p>Stent thrombosis at 6 months</p> <p>Stroke (any, type not specified) at 6 months</p>	<p>patients were treated with GPIIb/IIIa inhibitors [intracoronary bolus of tirofiban (10µg/kg) plus maintenance infusion (0.15µg-1.kg-1.min-1) for 24-36 hours] in accordance with the 2014 European Society of Cardiology and the European Association for Cardio-Thoracic Surgery Guidelines on myocardial revascularisation. The doctors who performed coronary angiography decided whether clopidogrel or ticagrelor treatments were supplemented with GPIIb/IIIa inhibitors after coronary angiography, but the doctors were blinded regarding the groups to which the patients belonged.</p>
<p><b>Wallentin 2009</b><sup>282</sup>; Lindholm 2014<sup>102</sup>; Steg 2010<sup>245</sup> (PLATO)*</p>	<p>Intervention (n=9333): ticagrelor + ASA. Ticagrelor loading dose of 180mg followed by a dose of 90mg twice daily. Patients undergoing PCI after randomisation received, in a blind fashion, an additional dose of ticagrelor at the time of PCI: 90mg of ticagrelor for patients who were undergoing PCI more than 24 hours after randomisation. In patients undergoing CABG, it was recommended that the study drug be withheld - in the</p>	<p>n=18,624</p> <p>People with ACS with or without revascularisation</p> <p>Age: ticagrelor group median: 62 (IQR or range not reported); clopidogrel group median: 62 (IQR or range not reported)</p> <p>Male/Female ratio: 13336/5288</p> <p>Ethnicity: ticagrelor group:</p>	<p>All-cause mortality at 30 days</p> <p>All-cause mortality up to 1 year</p> <p>Cardiac mortality (death from including vascular causes and unknown deaths) at 30 days</p> <p>Cardiac mortality (death from vascular causes) at 1 year</p> <p>Cardiac mortality (cardiovascular death</p>	<p>Setting: Multicentre trial</p> <p>Concurrent medication/care: All patients received acetylsalicyclic acid (aspirin) at a dose of 75 to 100mg daily unless they could not tolerate the drug. For those who had not been receiving aspirin, 325mg was the preferred loading dose; 325mg was also permitted as the daily dose for 6 months after stent placement.</p> <p>*30 day outcome data was requested and received from authors</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>ticagrelor group, for 24 to 72 hours. Duration 12 months.</p> <p>Comparison (n=9291): clopidogrel + ASA.</p> <p>Patients in the clopidogrel group who had not received an open-label loading dose and had not been taking clopidogrel for at least 5 days before randomisation received a 300-mg loading dose followed by a dose of 75mg daily. Others in the clopidogrel group continued to receive a maintenance dose of 75mg daily. Patients undergoing PCI after randomisation received, in a blind fashion, an additional dose of clopidogrel at the time of PCI: 300mg of clopidogrel, at the investigator's discretion. In patients undergoing CABG, it was recommended that the study drug be withheld - in the clopidogrel group, for 5 days. Duration 12 months.</p>	<p>white (91.8%), black (1.2%), asian (5.8%), other (1.2%); clopidogrel group: white (91.6%), black (1.2%), asian (6.0%), other (1.2%)</p> <p>Multiple countries</p>	<p>including vascular and unknown deaths) up to 1 year</p> <p>Re-infarction at 30 days</p> <p>Re-infarction up to 1 year</p> <p>Complications related to bleeding (major) at 30 days</p> <p>Complications related to bleeding (major) at 1 year</p> <p>Complications related to bleeding (minor) at 1 year</p> <p>Stent thrombosis (definite) at 1 year</p> <p>Stent thrombosis (probable or definite) at 1 year</p> <p>Stent thrombosis (possible, probable or definite) at 1 year</p> <p>Stroke (any, type not specified) at 30 days</p> <p>Stroke (any, type not specified) up to 1 year</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
			Breathing adverse effects up to 1 year  Bradycardic adverse effects at 30 days  Bradycardic adverse effects at 1 year  Other adverse effects up to 1 year	
Wang 2016a <sup>287</sup>	Intervention (n=100): ticagrelor + ASA. Ticagrelor 180mg loading dose, and then a maintenance dose of 90mg twice daily. The initial loading dose was administered as soon as possible after randomisation with the first maintenance dose administered at the usual time. All patients took aspirin at a loading dose of 300mg followed by a maintenance dose of 100mg once daily, unless aspirin was intolerant. Duration 12 months.  Comparison (n=100): clopidogrel +ASA. Clopidogrel 300mg loading dose with a maintenance dose of 75mg once daily. The initial loading dose was administered	n=200  People with ACS with or without revascularisation  Age: median (range): 79 (65-93)  Male/Female ratio: ticagrelor group: 69/31; clopidogrel group: 66/33;  Ethnicity: Chinese  China	All-cause mortality up to 1 year  Cardiac mortality (cardiovascular death) up to 1 year  Re-infarction (myocardial infarction) up to 1 year  Complications related to bleeding (major) up to 1 year  Complications related to bleeding (minor) up to 1 year  Stroke (any, type not specified) up to 1 year	Setting: not reported  Concurrent medication/care: not reported

Study	Intervention and comparison	Population	Outcomes	Comments
	as soon as possible after randomisation with the first maintenance dose administered at the usual time. All patients took aspirin at a loading dose of 300mg followed by a maintenance dose of 100mg once daily, unless aspirin was intolerant. Duration 12 months.			
Wang 2016b <sup>288</sup>	<p>Intervention (n=87): ticagrelor + ASA. Ticagrelor loading dose of 180mg and then switched to an oral maintenance dose of 90mg twice daily. Duration 30 days.</p> <p>Comparison (n=87): clopidogrel + ASA. Clopidogrel loading dose of 600mg and then switched to an oral maintenance dose of 75mg daily. Duration 30 days.</p>	<p>n=174</p> <p>People with STEMI and undergoing revascularisation</p> <p>Age: range: 60-79</p> <p>Male/Female ratio: ticagrelor group: 48/39; clopidogrel group: 50/37</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>Cardiac mortality (vascular cause of death) at 30 days</p> <p>Re-infarction (recurrent myocardial infarction) at 30 days</p> <p>Stent thrombosis at 30 days</p> <p>Stroke (any, type not specified) at 30 days</p> <p>Breathing adverse effects at 30 days</p> <p>Bradycardic adverse effects at 30 days</p> <p>Other adverse effects at 30 days</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: If patients were not already taking aspirin, they received aspirin at a loading dose of 300mg. After the loading dose of aspirin, patients immediately underwent coronary arteriography and PCI.</p>
Wang 2019 <sup>289</sup>	Intervention (n=150): ticagrelor + ASA.	n=298	All-cause mortality at 30 days and 6 months (up to 1	Setting: Hospital



Study	Intervention and comparison	Population	Outcomes	Comments
	<p>Ticagrelor loading dose of 180mg with aspirin. After primary PCI, patients received ticagrelor at 90mg twice daily. Duration not reported.</p> <p>Comparison (n=148): clopidogrel + ASA. Clopidogrel loading dose of 600mg with aspirin. After primary PCI, patients received clopidogrel at 75mg daily. Duration not reported.</p>	<p>People with STEMI who underwent PCI</p> <p>Age - mean (SD): ticagrelor group: 60 (13); clopidogrel group: 61 (12)</p> <p>Male/Female ratio: 236/62</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>year)</p> <p>Re-infarction at 30 days and 6 months (up to 1 year)</p> <p>Need to revascularisation at 30 days and 6 months (up to 1 year)</p> <p>Complications relating to bleeding (major, TIMI) during hospitalisation (up to 30 days)</p> <p>Complications relating to bleeding (minor, TIMI) during hospitalisation (up to 30 days)</p>	<p>Concurrent medication/care: All patients were managed in the cardiac care unit to receive standard pharmacological treatment, including aspirin, clopidogrel, ticagrelor, <math>\beta</math>-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, unless contraindicated</p>
<p><b>Wiviott 2007</b><sup>306</sup>; De Servi 2014<sup>41</sup>; Montalescot 2009<sup>115</sup> (TRITON)</p>	<p>Intervention (n=6813): prasugrel + ASA. Prasugrel loading dose of 60mg administered anytime between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. After</p>	<p>n=13,608</p> <p>People with ACS and undergoing revascularisation</p> <p>Age: prasugrel group median (25th percentile, 75th percentile): 61 (53-69); clopidogrel group median (25th percentile, 75th percentile): 61 (53-70).</p> <p>Male/Female ratio: prasugrel</p>	<p>All-cause mortality at 15 months (up to 1 year)</p> <p>Cardiac mortality (cardiovascular death) at 30 days</p> <p>Cardiac mortality (death from cardiovascular causes) at 15 months (up to 1 year)</p> <p>Re-infarction (myocardial infarction) at 30 days</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: The choice of vessels treated, devices used, and adjunctive medication administered to support PCI was left to the discretion of the treating physician.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>PCI, patients received a maintenance dose of 10mg prasugrel daily. Use of aspirin was required, and a daily dose of 75 to 162mg was recommended. Duration 15 months.</p> <p>Comparison (n=6795): clopidogrel + ASA.</p> <p>Clopidogrel loading dose of 300mg administered anytime between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. After PCI, patients received a maintenance dose of 75mg clopidogrel daily. Use of aspirin was required, and a daily dose of 75 to 162mg was recommended. Duration 15 months.</p>	<p>group: 5110/1703; clopidogrel group: 4960/1835</p> <p>Ethnicity: prasugrel group: white 92%, non-white 8%; clopidogrel group: white 93%, non-white 7 %</p> <p>Multiple countries</p>	<p>Re-infarction (non-fatal or all myocardial infarctions (TRITON)) at 15 months (up to 1 year)</p> <p>Re-infarction (myocardial infarction) at 15 months (up to 1 year)</p> <p>Complications related to bleeding (non-CABG related major, TIMI) at 30 days</p> <p>Complications related to bleeding (CABG-related major, TIMI) at 15 months (up to 1 year)</p> <p>Complications related to bleeding (non-CABG-related major, TIMI) at 15 months</p> <p>Complications related to bleeding (non-CABG-related, minor, TIMI) at 30 days</p> <p>Need for revascularisation (urgent target vessel revascularisation) at 15 months (up to 1 year)</p> <p>Stent thrombosis at 30 days</p>	

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>Stent thrombosis (probable or definite) at 15 months (up to 1 year)</p> <p>Stroke (any, type not specified) at 30 days</p> <p>Stroke (any, including non-fatal, type not specified) at 15 months (up to 1 year)</p> <p>Other adverse effects at 15 months (up to 1 year)</p>	
Wu 2018 <sup>311</sup>	<p>Intervention (n=129): ticagrelor + ASA. Ticagrelor administered as a loading dose of 180mg with 300mg of aspirin. Patients received 90mg of ticagrelor for maintenance. Duration not reported.</p> <p>Comparison (n=128): clopidogrel + ASA. Clopidogrel administered as a loading dose of 300mg with 300mg of aspirin. Patients received 75 mg of clopidogrel for maintenance. Duration not reported.</p>	<p>n=257</p> <p>People being treated with acute myocardial infarction (ACS) treated within PCI. 95% - STEMI patients 5% - NSTEMI patients</p> <p>Age – mean (SD): ticagrelor group: 59 (10); clopidogrel group: 61 (12)</p> <p>Male/Female ratio: 192/52</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>Re-infarction at 1 year</p> <p>Cardiac mortality at 1 year</p> <p>Stroke (any, type not specified) at 1 year</p> <p>Bradycardia at 1 year</p> <p>Complications related to bleeding (not specified) at 1 year</p> <p>Stent thrombosis at 1 year</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: not reported</p>

Study	Intervention and comparison	Population	Outcomes	Comments
Yao 2017 <sup>319</sup>	<p>Intervention (n=60): ticagrelor + ASA. Before the emergency PCI surgery, a loading dose of ticagrelor 180 mg and aspirin 300 mg were administered orally. Duration 6 months.</p> <p>Comparison (n=60): clopidogrel + ASA. Before the emergency PCI surgery, a loading dose of clopidogrel 600 mg and aspirin 300 mg were administered orally. Duration 6 months.</p>	<p>n=120</p> <p>People with ACS and undergoing revascularisation</p> <p>Age: 'average age of 60.2 ± 12.3' (ticagrelor group: 60.4 ± 12.7; clopidogrel group: 59.8 ± 10.8)</p> <p>Male/Female ratio: 74/46</p> <p>Ethnicity: not reported</p> <p>China</p>	<p>All-cause mortality up to 6 months (up to 1 year)</p> <p>Re-infarction (second myocardial infarction) up to 6 months (up to 1 year)</p> <p>Complications related to bleeding (major, BARC 3-5) up to 6 months (up to 1 year)</p> <p>Complications related to bleeding (minor, BARC 1-2) up to 6 months (up to 1 year)</p> <p>Need for revascularisation (second PCI) at 6 months (up to 1 year)</p> <p>Other adverse effects up to 6 months (up to 1 year)</p>	<p>Setting: Hospital</p> <p>Concurrent medication/care: All patients received basic treatment for AMI, including 'atorvastatin, isosorbide mononitrate, metoprolol and so forth every day. After PCI, they were all hypodermic injected with enoxaparin sodium (brand name: clexane, brought from Sanofi-Aventis Co. Ltd., licence number: H20100484 for anticoagulation'</p>
Zeymer 2015 <sup>325</sup> : ETAMI trial	<p>Intervention (n=32): prasugrel + ASA. Prasugrel loading dose of 60 mg and 8 tablets of clopidogrel</p>	<p>n=63</p> <p>People with STEMI and undergoing revascularisation</p>	<p>All-cause mortality at 30 days</p> <p>Re-infarction at 30 days</p>	<p>Setting: In the ambulance or in the emergency department of a PCI hospital</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>placebo as early as possible. Aspirin (500 mg intravenously or 300 mg orally). Duration 30 days.</p> <p>Comparison (n=31): clopidogrel + ASA. Clopidogrel loading dose of 600 mg and 6 tablets of prasugrel placebo as early as possible. Aspirin (500 mg intravenously or 300 mg orally). Duration 30 days.</p>	<p>Age: prasugrel group: 59 (55-70); clopidogrel group: 640 (49-70)</p> <p>Male/Female ratio: 45/17</p> <p>Ethnicity: Germany</p>	<p>Complications related to bleeding (major or minor, TIMI) at 30 days</p> <p>Stent thrombosis at 30 days</p> <p>Other adverse effects at 30 days</p>	<p>Concurrent medication/care: The administration of GP IIb/IIIa inhibitors after the diagnostic angiography and prior to or during PPCI was left to the discretion of the treating physician.</p>

See appendix D for full evidence tables.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10

### 1.5.4 Quality assessment of clinical studies included in the evidence review

2 Table 3: Clinical evidence summary: ticagrelor + aspirin (ASA) versus clopidogrel + aspirin (ASA)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
All-cause mortality - ACS with/without revascularisation	19812 (6 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>6</sup>	23 per 1000	4 fewer per 1000 (from 7 fewer to 0 more)
All-cause mortality - STEMI + revascularisation	630 (3 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.48 (0.17 to 1.39)	32 per 1000	17 fewer per 1000 (from 27 fewer to 13 more)
All-cause mortality - UA/NSTEMI + revascularisation	6218 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.64 (0.44 to 0.93)	-	N/A <sup>4</sup>
All-cause mortality - UA/NSTEMI + no revascularisation	4514 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.84 (0.63 to 1.12)	-	N/A <sup>4</sup>
All-cause mortality - ACS with/without revascularisation	20443 (6 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.78 (0.69 to 0.88)	53 per 1000	12 fewer per 1000 (from 6 fewer to 17 fewer)
All-cause mortality - STEMI + revascularisation	8242 (3 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.8 (0.66 to 0.97)	55 per 1000	11 fewer per 1000 (from 2 fewer to 19 fewer)
All-cause mortality - UA/NSTEMI + revascularisation	5648 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.75 (0.53 to 1.06)	-	N/A <sup>4</sup>

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
All-cause mortality - UA/NSTEMI + no revascularisation	5217 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.73 (0.57 to 0.93)	-	N/A <sup>4</sup>
Cardiac mortality - ACS with/without revascularisation	1143 (4 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.1 (0.45 to 2.69)	16 per 1000	2 more per 1000 (from 9 fewer to 27 more)
Cardiac mortality - STEMI + revascularisation	482 (3 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.57 (0.17 to 1.92)	29 per 1000	12 fewer per 1000 (from 24 fewer to 27 more)
Cardiac mortality - UA/NSTEMI + revascularisation	6218 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.67 (0.43 to 1.04)	-	N/A <sup>4</sup>
Cardiac mortality - UA/NSTEMI + no revascularisation	4514 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.84 (0.62 to 1.14)	-	N/A <sup>4</sup>
Cardiac mortality - ACS with/without revascularisation	20711 (6 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.78 (0.69 to 0.89)	46 per 1000	10 fewer per 1000 (from 5 fewer to 14 fewer)
Cardiac mortality - STEMI + revascularisation	8630 (4 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.81 (0.66 to 0.98)	48 per 1000	9 fewer per 1000 (from 1 fewer to 16 fewer)
Cardiac mortality - UA/NSTEMI + revascularisation	5648 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias,	HR 0.76 (0.52 to 1.11)	-	N/A <sup>4</sup>

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
Cardiac mortality - UA/NSTEMI + no revascularisation	5217 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.75 (0.58 to 0.97)	-	N/A <sup>4</sup>
Re-infarction - ACS with/without revascularisation	19818 (6 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.69 (0.56 to 0.86)	20 per 1000	6 fewer per 1000 (from 3 fewer to 9 fewer)
Re-infarction - STEMI + revascularisation	736 (4 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.37 (0.15 to 0.89)	47 per 1000	30 fewer per 1000 (from 5 fewer to 40 fewer)
Re-infarction - UA/NSTEMI + revascularisation	5934 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.86 (0.63 to 1.17)	-	N/A <sup>4</sup>
Re-infarction - UA/NSTEMI + no revascularisation	4479 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.89 (0.68 to 1.16)	-	N/A <sup>4</sup>
Re-infarction - ACS with/without revascularisation	21129 (8 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.83 (0.74 to 0.93)	61 per 1000	10 fewer per 1000 (from 4 fewer to 16 fewer)
Re-infarction - STEMI + revascularisation	8928 (5 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.75 (0.61 to 0.91)	49 per 1000	12 fewer per 1000 (from 4 fewer to 19 fewer)
Re-infarction - UA/NSTEMI + revascularisation	5438 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup>	HR 0.90 (0.68 to 1.19)	-	N/A <sup>4</sup>



Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
	1 year	due to risk of bias, imprecision			
Re-infarction - UA/NSTEMI + no revascularisation	5201 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.94 (0.75 to 1.18)	-	N/A <sup>4</sup>
Major bleeding - ACS with/without revascularisation	19832 (6 studies) 30 days	⊕⊕⊕⊕ MODERATE <sup>1</sup> due to risk of bias	N/A <sup>6</sup>	68 per 1000	0 fewer per 1000 (from 7 fewer to 7 more)
Major bleeding - STEMI + revascularisation	750 (4 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>6</sup>	14 per 1000	5 more per 1000 (from 8 fewer to 43 more)
Major bleeding - UA/NSTEMI + revascularisation	4958 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.14 (0.84 to 1.55)	-	N/A <sup>4</sup>
Major bleeding - UA/NSTEMI + no revascularisation	3964 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.18 (0.91 to 1.53)	-	N/A <sup>4</sup>
Major bleeding - ACS with/without revascularisation	20206 (6 studies) 1 year	⊕⊕⊕⊕ MODERATE <sup>1</sup> due to risk of bias	RR 1.04 (0.96 to 1.13)	96 per 1000	4 more per 1000 (from 4 fewer to 13 more)
Major bleeding - STEMI + revascularisation	8135 (3 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,5</sup> due to risk of bias, inconsistency	RR 0.96 (0.83 to 1.12)	78 per 1000	3 fewer per 1000 (from 13 fewer to 9 more)
Major bleeding - UA/NSTEMI + revascularisation	4983 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias,	HR 1.10 (0.84 to 1.44)	-	N/A <sup>4</sup>

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
		imprecision			
Major bleeding - UA/NSTEMI + no revascularisation	4931 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.05 (0.88 to 1.25)	-	N/A <sup>4</sup>
Minor bleeding - ACS with/without revascularisation	1511 (6 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.49 (1.02 to 2.16)	54 per 1000	26 more per 1000 (from 1 more to 62 more)
Minor bleeding - STEMI + revascularisation	750 (4 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.36 (0.91 to 2.02)	97 per 1000	35 more per 1000 (from 9 fewer to 99 more)
Minor bleeding - ACS with/without revascularisation	20384 (6 studies) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2,5</sup> due to risk of bias, inconsistency, imprecision	RR 1.34 (1.18 to 1.53)	37 per 1000	13 more per 1000 (from 7 more to 20 more)
Minor bleeding - STEMI + revascularisation	8313 (3 studies) 1 year	⊕⊕⊕⊕ LOW <sup>2</sup> due to risk of bias, imprecision	RR 1.37 (1.12 to 1.68)	37 per 1000	14 more per 1000 (from 4 more to 25 more)
Bleeding (type not specified) at 1 year – UA/NSTEMI with revascularisation	244 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 3.39 (1.15 to 10)	33 per 1000	80 more per 1000 (from 5 more to 300 more)
Stroke (type not specified) - ACS with/without revascularisation	19400 (4 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>6</sup>	5 per 1000	2 more per 1000 (from 0 fewer to 4 more)
Stroke (type not specified) - STEMI +	318	⊕⊕⊕⊕	N/A <sup>6</sup>	13 per 1000	0 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
revascularisation	(2 studies) 30 days	VERY LOW <sup>1,3</sup> due to risk of bias, imprecision			(from 11 fewer to 77 more)
Stroke (type not specified) - UA/NSTEMI + revascularisation	6188 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.14 (0.54 to 2.41)	-	N/A <sup>4</sup>
Stroke (type not specified) - UA/NSTEMI + no revascularisation	4502 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.84 (0.50 to 1.41)	-	N/A <sup>4</sup>
Stroke (type not specified) - ACS with/without revascularisation	20711 (6 studies) 1 year	⊕⊕⊕⊕ MODERATE <sup>1</sup> due to risk of bias	RR 1.13 (0.89 to 1.43)	12 per 1000	2 more per 1000 (from 1 fewer to 5 more)
Stroke (type not specified) - STEMI + revascularisation	8630 (4 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,5</sup> due to risk of bias, inconsistency	RR 1.29 (0.88 to 1.9)	11 per 1000	3 more per 1000 (from 1 fewer to 10 more)
Stroke (type not specified) - UA/NSTEMI + revascularisation	5632 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.18 (0.60 to 2.32)	-	N/A <sup>4</sup>
Stroke (type not specified) - UA/NSTEMI + no revascularisation	5209 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.92 (0.58 to 1.46)	-	N/A <sup>4</sup>
Need for revascularisation - STEMI + revascularisation	442 (2 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	Peto OR 0.29 (0.08 to 1)	37 per 1000	26 fewer per 1000 (from 34 fewer to 0 more)
Need for revascularisation - ACS	1260	⊕⊕⊕⊕	RR 0.31	68 per 1000	47 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
with/without revascularisation	(4 studies) 1 year	MODERATE <sup>1</sup> due to risk of bias	(0.16 to 0.6)		(from 27 fewer to 57 fewer)
Need for revascularisation - STEMI + revascularisation	1140 (3 studies) 1 year	⊕⊕⊕⊖ MODERATE <sup>1</sup> due to risk of bias	RR 0.27 (0.13 to 0.57)	67 per 1000	49 fewer per 1000 (from 29 fewer to 58 fewer)
Stent thrombosis (type not specified) - STEMI + revascularisation	174 (1 study) 30 days	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	Peto OR 0.13 (0.02 to 0.94)	46 per 1000	40 fewer per 1000 (from 3 fewer to 45 fewer)
Stent thrombosis (probable or definite) - ACS with/without revascularisation	11289 (1 study) 1 year	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.75 (0.59 to 0.95)	28 per 1000	7 fewer per 1000 (from 1 fewer to 11 fewer)
Stent thrombosis (probable or definite) - STEMI + revascularisation	7544 (1 study) 1 year	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.73 (0.54 to 0.98)	27 per 1000	7 fewer per 1000 (from 1 fewer to 12 fewer)
Stent thrombosis (type not specified)- ACS with/without revascularisation	1086 (3 studies) 1 year	⊕⊕⊖⊖ LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>6</sup>	12 per 1000	10 fewer per 1000 (from 3 fewer to 11 fewer)
Stent thrombosis (type not specified) - STEMI + revascularisation	644 (2 studies) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>6</sup>	9 per 1000	8 fewer per 1000 (from 9 fewer to 16 more)
Stent thrombosis (type not specified) - NSTEMI + revascularisation	442 (1 study) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	Peto OR 0.21 (0.03 to 1.58)	14 per 1000	11 fewer per 1000 (from 14 fewer to 8 more)
Breathing adverse effects - STEMI + revascularisation	318 (2 studies)	⊕⊕⊖⊖ LOW <sup>1,2</sup>	RR 2.39 (1.09 to 5.27)	52 per 1000	72 more per 1000 (from 5 more to 220 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
	30 days	due to risk of bias, imprecision			
Breathing adverse effects - ACS with/without revascularisation	19222 (2 studies) 1 year	⊕⊕⊕⊖ MODERATE <sup>1</sup> due to risk of bias	RR 1.76 (1.62 to 1.92)	76 per 1000	58 more per 1000 (from 47 more to 70 more)
Breathing adverse effects - STEMI + revascularisation	7471 (1 study) 1 year	⊕⊕⊕⊖ MODERATE <sup>1</sup> due to risk of bias	RR 1.5 (1.31 to 1.72)	84 per 1000	42 more per 1000 (from 26 more to 60 more)
Bradycardic adverse effects - ACS with/without revascularisation	2309 (3 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.36 (0.8 to 2.29)	20 per 1000	7 more per 1000 (from 4 fewer to 26 more)
Bradycardic adverse effects - STEMI + revascularisation	318 (2 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.6 (0.62 to 4.1)	39 per 1000	23 more per 1000 (from 15 fewer to 120 more)
Bradycardic adverse effects - ACS with/without revascularisation	13632 (3 studies) 1 year	⊕⊕⊕⊖ MODERATE <sup>1</sup> due to risk of bias	RR 1.09 (0.96 to 1.23)	47 per 1000	4 more per 1000 (from 2 fewer to 11 more)
Bradycardic adverse effects - STEMI + revascularisation	7715 (2 studies) 1 year	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.04 (0.87 to 1.25)	56 per 1000	2 more per 1000 (from 7 fewer to 14 more)
Other adverse effects - ACS with/without revascularisation	418 (3 studies) 30 days	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.26 (0.85 to 1.88)	167 per 1000	43 more per 1000 (from 25 fewer to 147 more)
Other adverse effects - STEMI + revascularisation	318 (2 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.14 (0.70 to 1.85)	161 per 1000	23 more per 1000 (from 48 fewer to 137 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
Other adverse effects - ACS with/without revascularisation	19342 (3 studies) 1 year	⊕⊕⊕⊖ MODERATE <sup>1</sup> due to risk of bias	RR 1.02 (0.94 to 1.11)	50 per 1000	1 more per 1000 (from 3 fewer to 6 more)
Other adverse effects - STEMI + revascularisation	7471 (1 study) 1 year	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.25 (0.9 to 1.75)	17 per 1000	4 more per 1000 (from 2 fewer to 12 more)
Unplanned urgent readmission (rehospitalisation) - STEMI + revascularisation	144 (1 study) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.45 (0.08 to 2.37)	59 per 1000	32 fewer per 1000 (from 54 fewer to 81 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs  
3 Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%- no imprecision  
4 Absolute effects could not be calculated as event rates were not reported  
5 Downgraded by 1 or 2 increments because heterogeneity, I<sup>2</sup> > 50%, p = > 0.04, unexplained by subgroup analysis  
6 No relative effect due to 0 events. Risk difference calculated in Review Manager

1 **Table 4: Clinical evidence summary: prasugrel + aspirin (ASA) versus clopidogrel + aspirin (ASA)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
All-cause mortality - ACS with/without revascularisation	13142 (4 studies) 30 days	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.77 (0.56 to 1.05)	14 per 1000	3 fewer per 1000 (from 6 fewer to 1 more)
All-cause mortality - STEMI +	3596	⊕⊕⊖⊖	RR 0.63	26 per 1000	9 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
revascularisation	(2 studies) 30 days	LOW <sup>1,2</sup> due to risk of bias, imprecision	(0.40 to 1.00)		(from 15 fewer to 0 more)
All-cause mortality – UA/NSTEMI + no revascularisation	9326 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1</sup> due to imprecision	RR 0.89 (0.58 to 1.36)	9 per 1000	1 fewer per 1000 (from 4 fewer to 3 more)
All-cause mortality - ACS with/without revascularisation	15126 (3 studies) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias	RR 1 (0.83 to 1.2)	30 per 1000	0 fewer per 1000 (from 5 fewer to 6 more)
All-cause mortality - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.76 (0.54 to 1.06)	43 per 1000	10 fewer per 1000 (from 20 fewer to 3 more)
Cardiac mortality - ACS with/without revascularisation	13049 (3 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.75 (0.54 to 1.05)	12 per 1000	3 fewer per 1000 (from 6 fewer to 1 more)
Cardiac mortality - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.61 (0.37 to 1)	23 per 1000	9 fewer per 1000 (from 15 fewer to 0 more)
Cardiac mortality – UA/NSTEMI + no revascularisation	9326 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1</sup> due to imprecision	RR 0.92 (0.58 to 1.46)	8 per 1000	1 fewer per 1000 (from 3 fewer to 4 more)
Cardiac mortality - ACS with/without	15051	⊕⊕⊕⊕	RR 0.88	24 per 1000	3 fewer per 1000

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
revascularisation	(2 studies) 1 year	LOW <sup>1,2</sup> due to risk of bias, imprecision	(0.71 to 1.09)		(from 7 fewer to 2 more)
Cardiac mortality - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.74 (0.5 to 1.09)	33 per 1000	9 fewer per 1000 (from 16 fewer to 3 more)
Cardiac mortality - UA/NSTEMI + revascularisation	10074 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.98 (0.73 to 1.3)	18 per 1000	0 fewer per 1000 (from 5 fewer to 5 more)
Cardiac mortality - UA/NSTEMI + no revascularisation	9326 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 1.00 (0.78 to 1.28)	-	N/A <sup>4</sup>
Re-infarction - ACS with/without revascularisation	13111 (4 studies) 30 days	VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>8</sup>	31 per 1000	6 fewer per 1000 (from 1 fewer to 11 fewer)
Re-infarction - STEMI + revascularisation	3596 (2 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>8</sup>	68 per 1000	20 fewer per 1000 (from 5 fewer to 32 fewer)
Re-infarction - UA/NSTEMI + revascularisation	9326 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1</sup> due to imprecision	RR 0.95 (0.69 to 1.3)	17 per 1000	1 fewer per 1000 (from 5 fewer to 5 more)



Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
Re-infarction - ACS with/without revascularisation	15051 (3 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.76 (0.68 to 0.85)	87 per 1000	21 fewer per 1000 (from 13 fewer to 28 fewer)
Re-infarction - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.76 (0.6 to 0.95)	89 per 1000	21 fewer per 1000 (from 4 fewer to 36 fewer)
Re-infarction - UA/NSTEMI + revascularisation	10074 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.77 (0.67 to 0.87)	95 per 1000	22 fewer per 1000 (from 12 fewer to 31 fewer)
Re-infarction - UA/NSTEMI + no revascularisation	9326 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.97 (0.78 to 1.21)	-	N/A <sup>4</sup>
Major bleeding - ACS with/without revascularisation	12994 (3 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>8</sup>	4 per 1000	1 fewer per 1000 (from 2 fewer to 2 more)
Major bleeding - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.74 (0.4 to 1.38)	13 per 1000	3 fewer per 1000 (from 8 fewer to 5 more)
Major bleeding – UA/NSTEMI + no revascularisation	9240 (1 study)	⊕⊕⊕⊕ LOW <sup>1</sup>	RR 1.17 (0.39 to	1 per 1000	0 more per 1000 (from 1 fewer to 3 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
	30 days	due to imprecision	3.46)		
Bleeding (major and minor) - STEMI + revascularisation	62 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1</sup> due to imprecision	Peto OR 7.39 (0.15 to 372.38)	0 per 1000	N/A <sup>7</sup>
Major bleeding - ACS with/without revascularisation	14900 (2 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.42 (1.13 to 1.77)	17 per 1000	7 more per 1000 (from 2 more to 13 more)
Major bleeding - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.12 (0.71 to 1.76)	19 per 1000	2 more per 1000 (from 6 fewer to 15 more)
Major bleeding - UA/NSTEMI + revascularisation	9981 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.4 (1.05 to 1.87)	15 per 1000	6 more per 1000 (from 1 more to 13 more)
Minor bleeding - ACS with/without revascularisation	3754 (2 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2,5</sup> due to risk of bias, inconsistency, imprecision	RR 0.69 (0.46 to 1.02)	31 per 1000	10 fewer per 1000 (from 17 fewer to 1 more)
Minor bleeding - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.61 (0.4 to 0.93)	32 per 1000	13 fewer per 1000 (from 2 fewer to 19 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
Minor bleeding - ACS with/without revascularisation	1443 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 2.05 (0.88 to 4.75)	11 per 1000	12 more per 1000 (from 1 fewer to 41 more)
Health-related quality of life - UA/NSTEMI + no revascularisation EQ5D. Scale from: 0 to 100.	5764 (1 study) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias		The mean health-related quality of life in the control groups was 84.6	The mean health-related quality of life in the intervention groups was 1 higher (0.22 to 1.78 higher)
Health-related quality of life - UA/NSTEMI + no revascularisation SAQ Physical. Scale from: 0 to 100.	1774 (1 study) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias		The mean health-related quality of life in the control groups was 77	The mean health-related quality of life in the intervention groups was 1 higher (1.17 lower to 3.17 higher)
Health-related quality of life - UA/NSTEMI + no revascularisation SF-12 Physical. Scale from: 0 to 100.	1774 (1 study) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias		The mean health-related quality of life in the control groups was 43.7	The mean health-related quality of life in the intervention groups was 0.3 higher (0.7 lower to 1.3 higher)
Health-related quality of life - UA/NSTEMI + no revascularisation SF-12 Mental. Scale from: 0 to 100.	1774 (1 study) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias		The mean health-related quality of life in the control groups was 49.7	The mean health-related quality of life in the intervention groups was 0 higher (0.97 lower to 0.97 higher)
Health-related quality of life - UA/NSTEMI + no revascularisation SF-36. Scale from: 0 to 100.	1774 (1 study) 1 year	⊕⊕⊕⊕ MODERATE <sup>2</sup> due to risk of bias		The mean health-related quality of life in the control groups was 47.8	The mean health-related quality of life in the intervention groups was 0.4 higher (0.64 lower to 1.44 higher)
Stroke (type not specified) - ACS with/without revascularisation	13049 (3 studies)	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup>	RR 0.71 (0.4 to	4 per 1000	1 fewer per 1000 (from 3 fewer to 1 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
	30 days	due to risk of bias, imprecision	1.27)		
Stroke (type not specified) - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.44 (0.18 to 1.06)	9 per 1000	5 fewer per 1000 (from 7 fewer to 1 more)
Stroke (type not specified) – UA/NSTEMI + no revascularisation	9326 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1</sup> due to imprecision	RR 1.09 (0.48 to 2.47)	2 per 1000	0 more per 1000 (from 1 fewer to 3 more)
Stroke (type not specified) - ACS with/without revascularisation	15126 (3 studies) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.93 (0.67 to 1.29)	10 per 1000	1 fewer per 1000 (from 3 fewer to 3 more)
Stroke (type not specified) - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.04 (0.6 to 1.79)	14 per 1000	1 more per 1000 (from 6 fewer to 11 more)
Stroke (type not specified) - UA/NSTEMI + revascularisation	10074 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.06 (0.71 to 1.59)	9 per 1000	1 more per 1000 (from 3 fewer to 5 more)
Stroke (type not specified) in people aged <75 years - (UA/NSTEMI + no revascularisation)	9326 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	HR 0.86 (0.50, 1.48)	-	N/A <sup>4</sup>

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
Need for revascularisation - ACS with/without revascularisation	3723 (2 studies) 30 days	⊕⊕⊕⊕ LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>8</sup>	18 per 1000	6 fewer per 1000 (from 11 fewer to 2 more)
Need for revascularisation - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.67 (0.39 to 1.14)	19 per 1000	6 fewer per 1000 (from 11 fewer to 3 more)
Need for revascularisation - ACS with/without revascularisation	13683 (2 studies) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.67 (0.55 to 0.82)	34 per 1000	11 fewer per 1000 (from 6 fewer to 15 fewer)
Need for revascularisation - STEMI + revascularisation	3534 (1 study) 1 year	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.7 (0.47 to 1.06)	31 per 1000	9 fewer per 1000 (from 16 fewer to 2 more)
Stent thrombosis (definite or probable) - STEMI + revascularisation	3534 (1 study) 30 days	⊕⊕⊕⊕ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.49 (0.28 to 0.84)	22 per 1000	11 fewer per 1000 (from 4 fewer to 16 fewer)
Stent thrombosis (type not specified) - ACS with/without revascularisation	282 (2 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>2,3</sup> due to risk of bias, imprecision	N/A <sup>8</sup>	7 per 1000	6 fewer per 1000 (from 7 fewer to 39 more)
Stent thrombosis (type not specified) - STEMI + revascularisation	62 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup>	Not estimable	-	N/A- <sup>6</sup>

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
	30 days	due to risk of bias, imprecision	<sup>6</sup>		
Stent thrombosis (definite or probable) - ACS with/without revascularisation	15051 (2 studies) 1 year	⊕⊕⊕⊖ MODERATE <sup>2</sup> due to risk of bias	RR 0.47 (0.35 to 0.62)	21 per 1000	11 fewer per 1000 (from 8 fewer to 13 fewer)
Other adverse effects - ACS with/without revascularisation	282 (2 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.7 (0.23 to 2.17)	50 per 1000	15 fewer per 1000 (from 38 fewer to 59 more)
Other adverse effects - STEMI + revascularisation	62 (1 study) 30 days	⊕⊕⊖⊖ LOW <sup>1</sup> due to imprecision	RR 0.5 (0.05 to 5.23)	65 per 1000	32 fewer per 1000 (from 61 fewer to 273 more)
Other adverse effects - ACS with/without revascularisation	14900 (2 studies) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.13 (0.44 to 2.94)	10 per 1000	1 more per 1000 (from 5 fewer to 19 more)
Unplanned urgent readmission - ACS with/without revascularisation	189 (1 study) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.03 (0.07 to 16.26)	10 per 1000	0 more per 1000 (from 10 fewer to 159 more)
Unplanned urgent readmission - ACS with/without revascularisation	1443 (1 study) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.05 (0.77 to 1.45)	93 per 1000	5 more per 1000 (from 21 fewer to 42 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with clopidogrel + ASA	Risk difference with prasugrel + ASA (95% CI)
2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias					
3 Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%- no imprecision					
4 Absolute effects could not be calculated as event rates were not reported					
5 Downgraded by 1 or 2 increments because heterogeneity, I <sup>2</sup> > 50%, p > 0.04, unexplained by subgroup analysis					
6 Zero events in both arms. Relative risk and absolute effects could not be calculated.					
7 Absolute effects could not be calculated due to zero events in one of the arms					
8 No relative effect due to 0 events. Risk difference calculated in Review Manager					

1 **Table 5: Clinical evidence summary: ticagrelor + aspirin (ASA) versus prasugrel + aspirin (ASA)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with prasugrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
All-cause mortality - ACS with/without revascularisation	1698 (6 studies) 30 days	⊕⊕⊖⊖ LOW <sup>3</sup> due to imprecision	N/A <sup>5</sup>	22 per 1000	2 more per 1000 (from 9 fewer to 22 more)
All-cause mortality - STEMI + revascularisation	1385 (4 studies) 30 days	⊕⊕⊖⊖ LOW <sup>1</sup> due to imprecision	RR 0.94 (0.51 to 1.75)	28 per 1000	2 fewer per 1000 (from 14 fewer to 21 more)
All-cause mortality - UA/NSTEMI + revascularisation	313 (2 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	6 per 1000	4 fewer per 1000 (from 6 fewer to 45 more)
All-cause mortality - ACS with/without revascularisation	4018 (1 study) 1 year	⊕⊕⊖⊖ LOW <sup>1</sup> due to imprecision	RR 1.23 (0.9 to 1.66)	36 per 1000	8 more per 1000 (from 4 fewer to 24 more)
Cardiac mortality - ACS with/without revascularisation	1543 (3 studies) 30 days	⊕⊕⊖⊖ LOW <sup>3</sup> due to imprecision	N/A <sup>5</sup>	11 per 1000	1 fewer per 1000 (from 7 fewer to 16 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with prasugrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
Cardiac mortality - STEMI + revascularisation	1230 (1 study) 30 days	⊕⊕⊕⊖ LOW <sup>1</sup> due to imprecision	RR 1.06 (0.4 to 2.82)	13 per 1000	1 more per 1000 (from 8 fewer to 23 more)
Cardiac mortality - UA/NSTEMI + revascularisation	313 (2 studies) 30 days	⊕⊕⊕⊖ LOW <sup>3</sup> due to imprecision	N/A <sup>5</sup>	6 per 1000	4 fewer per 1000 (from 6 fewer to 45 more)
Cardiac mortality - ACS with/without revascularisation	4018 (1 study) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.06 (0.75 to 1.51)	29 per 1000	2 more per 1000 (from 7 fewer to 15 more)
Re-infarction - ACS with/without revascularisation	1430 (4 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	14 per 1000	3 fewer per 1000 (from 9 fewer to 12 more)
Re-infarction - STEMI + revascularisation	1330 (3 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	12 per 1000	1 more per 1000 (from 7 fewer to 20 more)
Re-infarction - UA/NSTEMI + revascularisation	100 (1 study) 30 days	⊕⊕⊕⊖ LOW <sup>1</sup> due to imprecision	Peto OR 0.14 (0.00 to 6.82)	20 per 1000	17 fewer per 1000 (from 20 fewer to 102 more)
Re-infarction - ACS with/without revascularisation	4018 (1 study) 1 year	⊕⊕⊕⊖ LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.6 (1.16 to 2.19)	30 per 1000	18 more per 1000 (from 5 more to 36 more)
Major bleeding - ACS with/without revascularisation	1698 (6 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	16 per 1000	4 fewer per 1000 (from 11 fewer to 10 more)
Major bleeding - STEMI + revascularisation	1385 (4 studies)	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup>	N/A <sup>5</sup>	8 per 1000	4 fewer per 1000 (from 7 fewer to 9 more)



Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with prasugrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
	30 days	due to risk of bias, imprecision			
Major bleeding - UA/NSTEMI + revascularisation	313 (2 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	51 per 1000	6 fewer per 1000 (from 34 fewer to 69 more)
Major bleeding - ACS with/without revascularisation	3762 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.06 (0.79 to 1.42)	45 per 1000	3 more per 1000 (from 9 fewer to 19 more)
Minor bleeding - STEMI + revascularisation	1385 (4 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.25 (0.75 to 2.09)	35 per 1000	9 more per 1000 (from 9 fewer to 38 more)
Stroke (type not specified) - ACS with/without revascularisation	1593 (4 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	4 per 1000	2 fewer per 1000 (from 3 fewer to 6 more)
Stroke (type not specified) - STEMI + revascularisation	1280 (2 studies) 30 days	⊕⊕⊕⊕ VERY LOW <sup>1,3</sup> due to risk of bias, imprecision	N/A <sup>5</sup>	3 per 1000	1 fewer per 1000 (from 3 fewer to 13 more)
Stroke (type not specified) - UA/NSTEMI + revascularisation	313 (2 studies) 30 days	⊕⊕⊕⊕ LOW <sup>3</sup> due to imprecision	N/A <sup>5</sup>	6 per 1000	5 fewer per 1000 (from 6 fewer to 36 more)
Stroke (any type) - ACS with/without revascularisation	4018 (1 study) 1 year	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.16 (0.62 to 2.13)	9 per 1000	2 more per 1000 (from 4 fewer to 11 more)
Need for revascularisation - STEMI + revascularisation	1230 (1 study)	⊕⊕⊕⊕ LOW <sup>1</sup>	RR 0.83 (0.31 to 2.21)	14 per 1000	2 fewer per 1000 (from 10 fewer to 17 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with prasugrel + ASA	Risk difference with ticagrelor + ASA (95% CI)
	30 days	due to imprecision			
Stent thrombosis (definite) - STEMI + revascularisation	1230 (1 study) 30 days	⊕⊕⊕⊖ LOW <sup>1</sup> due to imprecision	RR 1.77 (0.43 to 7.39)	5 per 1000	4 more per 1000 (from 3 fewer to 30 more)
Stent thrombosis (type not specified) - STEMI + revascularisation	100 (2 studies) 30 days	⊕⊕⊕⊖ LOW <sup>3</sup> due to imprecision	N/A <sup>5</sup>	20 per 1000	17 fewer per 1000 (from 20 fewer to 102 more)
Stent thrombosis (definite or probable) - ACS with/without revascularisation	4018 (1 study) 1 year	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.30 (0.73 to 2.31)	10 per 1000	3 more per 1000 (from 3 fewer to 13 more)
Breathing adverse effects - STEMI + revascularisation	50 (1 study) 30 days	⊕⊕⊕⊖ LOW <sup>1</sup> due to imprecision	Peto OR 8.83 (1.42 to 54.99)	0 per 1000	N/A <sup>4</sup>
Bradycardic adverse effects - STEMI + revascularisation	50 (1 study) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	Peto OR 7.39 (0.15 to 372.38)	0 per 1000	N/A <sup>4</sup>
Other adverse effects - STEMI + revascularisation	139 (3 studies) 30 days	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.59 (0.53 to 4.74)	58 per 1000	34 more per 1000 (from 27 fewer to 217 more)
<p>1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>2 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>3 Imprecision was assessed by calculating the optimal information size and graded as follows: &lt;80% - very serious imprecision, 80-90%- serious imprecision, &gt;90%- no imprecision</p> <p>4 Absolute effects could not be calculated due to zero events in one of the arms</p> <p>5 No relative effect due to 0 events. Risk difference calculated in Review Manager</p>					

1 See appendix F for full GRADE tables.



## 1.5.5 Network meta-analysis

2 The dual antiplatelets review for this guideline update (comparing aspirin plus one of  
3 clopidogrel, prasugrel or ticagrelor in people with ACS) formed a connected network of RCT  
4 evidence and so an NMA was considered. This topic was considered a high clinical priority  
5 for the guideline due to variations in practice and uncertainty about the most clinically and  
6 cost effective strategy. It was also given the highest priority for new economic modelling.  
7 Given this, the committee agreed that network meta-analysis was warranted to facilitate cost  
8 effectiveness analysis and help decision making in this area. For full details behind the  
9 rationale and results, see the NMA write-up document.

### 10 **Outcomes selected for the network meta-analysis**

11 The following five outcomes were selected for the NMA:

- 12 • All-cause mortality at 30 days
- 13 • New myocardial infarction at 30 days
- 14 • Stroke at 30 days
- 15 • Major bleeding at 30 days
- 16 • Minor bleeding at 30 days

17 NMA of 1 year outcomes was considered but there was inconsistency in the network and so  
18 it was not considered appropriate to undertake NMA. For example, using the data for  
19 prasugrel and ticagrelor each compared to clopidogrel generated an odds ratio for ticagrelor  
20 versus prasugrel of 0.77 (0.61 to 0.97) which favours ticagrelor but the direct evidence from  
21 ISAR-REACT 5 gave an odds ratio of 1.24 (0.90 to 1.70) which favours prasugrel. The  
22 committee therefore considered the pairwise data for the decision-making and took into the  
23 account the inconsistency identified. Health economic modelling also explored the  
24 implications of this inconsistency (treatment effects used can be seen in Table 18).


25 Following consideration of the pairwise meta-analyses the committee concluded that it was  
26 reasonable to assume that relative treatment effects were consistent and use the combined  
27 ACS population for the NMA given the same underlying disease process and an absence of  
28 a clear signal that relative treatment effects were different in different subgroups. For the  
29 purpose of the NMAs, all of the ACS populations were combined as heterogeneity was not  
30 identified in the pairwise meta-analyses. This suggests that the study populations did not  
31 differ in factors that interacted with the relative treatment effects.

### 32 **Network diagram**

33 For all the outcomes, the structure of the network meta-analyses was the same with direct  
34 evidence available for the comparisons: clopidogrel, prasugrel and ticagrelor (see Figure 1).  
35 The number of studies included in each comparison varied for each network meta-analysis  
36 can be seen in Table 6 . Full details can be found in the NMA write-up document.

37

**Figure 1: Network structure**



1 X = number of studies which would be included in each comparisons

2 **Table 6: Number of studies included in each arm of the network meta-analysis**

Outcomes	Ticagrelor versus Clopidogrel	Prasugrel versus Clopidogrel	Prasugrel versus Ticagrelor
All-cause mortality	5	4	5
New MI	6	2	3
Stroke	3	3	2
Major bleeding	4	2	3
Minor bleeding	5	1	4

3

4 **Studies included in the network meta-analyses**

5

Study and population	All-cause mortality	New myocardial infarction	Stroke	Major bleeding	Minor bleeding
Dehghani 2017 <sup>43</sup> STEMI + revascularisation	✓	✓	-	✓	✓
Cannon 2007 (DISPERSE-2) <sup>26</sup> UA/STEMI	✓	✓	✓	✓	✓
Wallentin 2009 (PLATO) <sup>282</sup> ACS + with/without revascularisation	✓	✓	✓	✓	-

Roe 2012 (TRILOGY) <sup>201</sup> UA/NSTEMI + no revascularisation	✓	✓	✓	✓	-
Zeymer 2015 (ETAMI) <sup>325</sup> STEMI + revascularisation	✓	-	-	-	-
Montalescot 2009 (TRITON) <sup>115</sup> ACS + with revascularisation	✓	✓	✓	✓	✓
Alexopoulos 2012 <sup>8</sup> STEMI + revascularisation	✓	-	-	-	✓
Motovska 2016 (PRAGUE18) <sup>118</sup> ACS + with/without revascularisation	✓	✓	✓	✓	✓
Parodi 2013 (RAPID I) <sup>183</sup> STEMI + revascularisation	✓	✓	✓	✓	✓
Parodi 2014 (RAPID II) <sup>182</sup> STEMI + revascularisation	✓	-	-	✓	✓
Wang 2016b <sup>287</sup> STEMI + revascularisation	-	✓		-	-
Wang 2019 <sup>289</sup> STEMI + revascularisation	✓	✓	-	✓	✓
Han 2019 <sup>55</sup> STEMI + revascularisation	-	✓	-	-	✓
Bonello 2015 <sup>20</sup> UA/NSTEMI + revascularisation	-	-	✓	✓	-
Jing 2016 <sup>64</sup> STEMI + revascularisation	✓	-	-	-	✓
Dasbiswas 2013 <sup>35</sup> ACS + revascularisation	✓	-		-	-
Laine 2014 <sup>83</sup> UA/NSTEMI + revascularisation	✓		-	-	-

## 1 Summary of results

2 Table 7, Table 8, Table 9, Table 10, and Table 11 show the risk ratios calculated for the  
3 pairwise meta-analysis in this evidence review compared to the risk ratios calculated from  
4 the network meta-analysis. Additional summary statistics were calculated following the  
5 network meta-analysis, results can be seen in the NMA write-up document.

## 6 Table 7: Risk ratios for all-cause mortality at 30 days; direct pairwise meta-analysis 7 results and NMA results

Intervention	Comparison	Pairwise fixed effects model - mean (95% confidence intervals)	NMA fixed effects model - median (95% credible intervals)
Ticagrelor	Clopidogrel	0.84 (0.70, 1.02)	0.85 (0.70, 1.02)
Prasugrel		0.83 (0.64, 1.06)	0.81 (0.64, 1.02)

Intervention	Comparison	Pairwise fixed effects model - mean (95% confidence intervals)	NMA fixed effects model - median (95% credible intervals)
Prasugrel	Ticagrelor	0.91 (0.50, 1.67)	0.96 (0.72, 1.26)

1 **Table 8: Risk ratios for new myocardial infarction at 30 days; direct pairwise meta-**  
2 **analysis results and NMA results**

Intervention	Comparison	Pairwise fixed effects model - mean (95% confidence intervals)	NMA fixed effects model (with pooled baseline estimate) - median (95% credible intervals)
Ticagrelor	Clopidogrel	0.69 (0.55, 0.86)	0.72 (0.56, 0.98)
Prasugrel		0.80 (0.65, 0.98)	0.83 (0.66, 1.00)
Prasugrel	Ticagrelor	1.31 (0.53, 3.23)	1.13 (0.89, 1.53)

3 **Table 9: Risk ratios for stroke at 30 days; direct pairwise meta-analysis results and**  
4 **NMA results**

Intervention	Comparison	Pairwise fixed effects model - mean (95% confidence intervals)	NMA fixed effects model (with pooled baseline estimate) - median (95% credible intervals)
Ticagrelor	Clopidogrel	1.32 (0.90, 1.93)	1.25 (0.86, 1.82)
Prasugrel		0.71 (0.40, 1.27)	0.81 (0.47, 1.39)
Prasugrel	Ticagrelor	2.24 (0.33, 15.06)	0.65 (0.34, 1.22)

5 **Table 10: Risk ratios for major bleeding at 30 days; direct pairwise meta-analysis**  
6 **results and NMA results**

Intervention	Comparison	Pairwise fixed effects - mean (95% confidence intervals)	NMA fixed effects (with pooled baseline estimate) – median (95% credible intervals)
Ticagrelor	Clopidogrel	1.00 (0.90, 1.11)	1.00 (0.90, 1.10)
Prasugrel		0.83 (0.48, 1.42)	0.98 (0.64, 1.46)
Prasugrel	Ticagrelor	1.37 (0.62, 3.02)	0.99 (0.64, 1.47)

7 **Table 11: Risk ratios for minor bleeding at 30 days; direct pairwise meta-analysis**  
8 **results and NMA results**

Intervention	Comparison	Pairwise fixed effects model - mean (95% confidence intervals)	NMA fixed effects model - median (95% credible intervals)
Ticagrelor	Clopidogrel	1.44 (0.99, 2.10)	1.25 (0.88, 1.77)
Prasugrel		0.61 (0.40, 0.93)	0.74 (0.52, 1.04)
Prasugrel	Ticagrelor	0.80 (0.48, 1.34)	0.59 (0.40, 0.87)

1 **Conclusion**

2 The committee reviewed the results for the five critical outcomes and noted that the evidence  
3 suggests that prasugrel and ticagrelor are both more clinically effective than clopidogrel for  
4 most of the outcomes. Prasugrel appeared more effective than ticagrelor in a majority of the  
5 outcome measures, but this difference was not clearcut and there was some uncertainty in  
6 the networks with overlapping credible intervals. For full details, see the NMA write-up  
7 document

8

9

10

## 1.6 Economic evidence

### 1.6.1 Included studies

13 Five health economic studies with relevant comparisons have been included in this review.<sup>2,</sup>  
14 <sup>53, 63, 124, 301</sup> Note that two papers were identified for one study as one of these (Greenhalgh  
15 2015<sup>53</sup>) is the evidence review group analysis for prasugrel TA317.<sup>123</sup> These are summarised  
16 in the health economic evidence profiles below (Table 12 to Table 15) and the health  
17 economic evidence tables in appendix H.

18 Note that as prasugrel is only indicated for people with ACS undergoing PCI the relevant  
19 comparators for an analysis vary by subpopulation. Ideally all clinical options should be  
20 included in an economic analysis to allow full incremental comparison; this would therefore  
21 be prasugrel, ticagrelor and clopidogrel in people undergoing PCI but only clopidogrel and  
22 ticagrelor with alternative management strategies.

### 1.6.2 Excluded studies

24 Eleven economic studies relating to this review question were identified but excluded due to  
25 methodological limitations or the availability of more applicable evidence.<sup>36-38, 50, 54, 56, 101, 166,</sup>  
26 <sup>187, 265, 293</sup> These are listed in appendix I, with reasons for exclusion given.

27 See also the health economic study selection flow chart in appendix G.



### 1.6.3 Summary of studies included in the economic evidence review

2 **Table 12: Health economic evidence profile: ticagrelor + aspirin versus prasugrel + aspirin versus clopidogrel + aspirin**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Abdel-Qadir 2015 <sup>2</sup> (Canada)	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>Markov cohort state transition model with baseline risks and treatment effects obtained from data collected in DISPERSE-2, PLATO and TRITON-TIMI 38 RCTs</li> <li>Cost-utility analysis (QALYs)</li> <li>Population: ACS (STEMI and UA/NSTEMI) patients who have undergone a PCI.</li> <li>Comparators:                             <ul style="list-style-type: none"> <li>Intvn 1: Clopidogrel + aspirin</li> <li>Intvn 2: Prasugrel + aspirin</li> <li>Intvn 3: Ticagrelor + aspirin</li> </ul> </li> <li>Time horizon: lifetime</li> </ul>	Intvn 2-1: £462 <sup>(c)</sup>  Intvn 3-2: £128 <sup>(c)</sup>	Intvn 2-1: 0.02 QALYs  Intvn 3-2: 0.07 QALYs	Intvn 3 vs 1: £6,556 per QALY gained  Intvn 2: extendedly dominated	Probability most cost-effective option at £11,275/£16,912 threshold: Intervention 1: 17%/8% Intervention 2: 9%/8% Intervention 3: 74%/84%  A wide range of sensitivity analyses around event rates, hazard ratios, utilities and costs were undertaken. This showed that varying the parameters did not impact the conclusions except for when the hazard ratio for death associated with ticagrelor relative to clopidogrel was greater than 0.89, which resulted in the ICER exceeding £28,187.

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Wisloff 2016 <sup>301</sup> (Norway)	Partially applicable <sup>(d)</sup>	Potentially serious limitations <sup>(e)</sup>	<ul style="list-style-type: none"> <li>Markov cohort state transition model with efficacy data of prasugrel and ticagrelor compared with clopidogrel based on the PLATO and TRITON-TIMI 38 RCTs</li> <li>Cost-utility analysis was conducted as part of sensitivity analysis (QALYs); primary analysis used life years<sup>(f)</sup></li> <li>Population: ACS patients who have undergone a PCI</li> <li>Comparators:                             <ul style="list-style-type: none"> <li>Intvn 1: Clopidogrel + aspirin</li> <li>Intvn 2: Prasugrel + aspirin</li> <li>Intvn 3: Ticagrelor + aspirin</li> </ul> </li> <li>Time horizon: lifetime</li> </ul>	Intvn 2-1: £1,710 <sup>(g)</sup> Intvn 3-2: £1,863 <sup>(g)</sup>	Intvn 2-1: 0.36 life years Intvn 3-2: 0.38 life years  Intvn 2-1: 0.28 QALYs  Intvn 3-2: 0.30 QALYs	Intvn 3 vs 2: £6,210 per QALY gained  Intvn 2 vs 1: £6,107 per QALY gained  Intvn 3 is the most cost-effective option <sup>(h)</sup>  Intvn 3 vs 2: £4,903 per life year gained  Intvn 2 vs 1: £4,750 per life year gained	Probability most cost-effective option for QALY results: NR  Probability most cost effective option (£31,428 threshold per life year gained): Intervention 3: 76% Intervention 2: 27%  A range of scenario analyses were conducted for the results in relation to cost per life year gained and showed that ticagrelor remained cost-effective in all scenarios.

1 Abbreviations: ACS = acute coronary syndromes; ICER= incremental cost-effectiveness ratio; PCI = percutaneous coronary intervention; QALY= quality-adjusted life years;  
 2 RCT= randomised controlled trial  
 3 (a) 2012 Canadian healthcare perspective may not reflect the current UK context, the cost of clopidogrel used in the model is higher than the cost in the UK, discount rate  
 4 used not in line with NICE reference case methods and unclear if methods used to derive utilities are consistent with NICE reference case methods.  
 5 (b) Health states incorporated in the model were different from other models in this area (it does not include stroke as a health state which is a limitation), baseline risks were  
 6 obtained by calculating the weighted mean of the event rates in the clopidogrel arm of the 3 international trials and the average age used was lower than the UK average.  
 7 It is unclear where information on resource use was obtained and the analysis does not reflect full body of available evidence for this area as identified in clinical review  
 8 (based on 3 trials)

- 1 (c) 2012 Canadian dollars converted to UK pounds.<sup>173</sup> Cost components included: drug costs, hospitalisation, major bleed, consultations with an emergency physician, a  
2 cardiologist and an interventional cardiologist, angiography and percutaneous coronary intervention, transthoracic echocardiogram, follow-up appointments  
3 (d) 2014 Norwegian healthcare perspective may not reflect the current UK context, the cost of clopidogrel used in the model is higher than the cost in the UK, EQ-5D used but  
4 unclear if fully in line with NICE reference case methods as tariff not reported and population collected in not stated.  
5 (e) Health states incorporated in the model were different from other models in this area (it does not include stroke as a health state which is a limitation), did not give details  
6 of how baseline risks were derived, average age used in the model is lower than UK average, it is unclear where resource use was obtained, only conducted sensitivity  
7 analyses on results related to life years and not QALYs. Analysis does not reflect full body of available evidence for this area as identified in clinical review (based on 2  
8 trials)  
9 (f) QALY results are presented as this is the preferred QALY outcome as per the NICE reference case; life year results also presented as uncertainty is only reported for this  
10 analysis.  
11 (g) 2014 Norwegian kroner converted to UK pounds <sup>173</sup> Cost components included: drug costs, costs of treatment (MI, revascularisation and bleeding), GP visits and  
12 laboratory test costs.  
13 (h) When comparing multiple comparators, a fully incremental approach is adopted that compares the treatments sequentially in rank order of effectiveness (or cost).  
14 Incremental cost-effectiveness ratios are estimated by dividing the incremental cost by the incremental effect for each consecutively more effective comparator.

15 **Table 13: Health economic evidence profile: ticagrelor + aspirin versus clopidogrel + aspirin**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
NICE TA236 2011 <i>Manufacturer submission</i> <sup>124</sup> (UK)	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>Decision tree based on within-trial analysis of the PLATO RCT to model first year, followed by Markov model to extrapolate</li> <li>Cost utility analysis (QALYs)</li> <li>Comparators: <ul style="list-style-type: none"> <li>Clopidogrel + aspirin</li> <li>Ticagrelor + aspirin</li> </ul> </li> <li>Population: adults with ACS (STEMI, NSTEMI and UA), including those managed medically or those with PCI or</li> </ul>	<u>All ACS:</u> £405 <sup>(c)</sup> <u>STEMI:</u> £339 <sup>(c)</sup> <u>NSTEMI:</u> £512 <sup>(c)</sup> <u>UA:</u> £488 <sup>(c)</sup>	<u>All ACS:</u> 0.106 QALYs <u>STEMI:</u> 0.120 QALYs <u>NSTEMI:</u> 0.098 QALYs <u>UA:</u> 0.091 QALYs	<u>All ACS:</u> £3,805 per QALY gained <u>STEMI:</u> £2,825 per QALY gained <u>NSTEMI:</u> £5,230 per QALY gained <u>UA:</u> £5,374 per QALY gained	<i>Probability ticagrelor cost effective (£20K/£30K threshold):</i> <u>All ACS:</u> 99.9%/NR <u>STEMI:</u> NR/NR <u>NSTEMI:</u> NR/NR <u>UA:</u> NR/NR  A wide range of sensitivity analyses around event rates, hazard ratios, utilities and costs were undertaken. This showed that varying the parameters did not impact the

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
			<p>CABG</p> <ul style="list-style-type: none"> <li>Time horizon: lifetime</li> </ul>				<p>conclusions apart from the cost of the 'no further event' health state, where ticagrelor became dominant if the lowest value for the cost of ticagrelor was used. Where the lowest value was used for clopidogrel, ticagrelor was borderline cost-effective.</p> <p>See Table 16 for additional scenario analyses</p>
Janzon 2015 <sup>63</sup> (UK)	Partially applicable <sup>(d)</sup>	Potentially serious limitations <sup>(e)</sup>	<ul style="list-style-type: none"> <li>Decision tree based on within-trial analysis of the PLATO RCT to model first year, followed by Markov model to extrapolate</li> <li>Cost utility analysis (QALYs)</li> <li>Comparators: <ul style="list-style-type: none"> <li>Clopidogrel + aspirin</li> <li>Ticagrelor + aspirin</li> </ul> </li> <li>Population: adults with ACS intended for non-invasive therapy but could undergo revascularisation if</li> </ul>	£468 <sup>(g)</sup>	0.16 QALYs	£2,925 per QALY gained	<p><i>Probability ticagrelor cost effective (£20K/£30K threshold):</i> 99.9%/99.9%</p> <p>Alternative scenarios were explored by altering the value of input parameters not associated with sampling uncertainty (therefore not varied in the probabilistic sensitivity analysis). These scenarios did not change conclusions about cost effectiveness.</p>

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
			necessary <sup>(f)</sup> <ul style="list-style-type: none"> <li>Time horizon: lifetime</li> </ul>				

1 Abbreviations: ACS = Acute coronary syndrome; CABG = coronary artery bypass graft; NR = not reported; NSTEMI = non-ST-elevation myocardial infarction; PCI =  
2 percutaneous coronary intervention; QALY = quality-adjusted life years; RCT = randomised controlled trial; STEMI = ST-elevation myocardial infarction; UA = unstable angina  
3 (a) International resource use from 2006-2008 and 2008/09 UK unit costs may not reflect current UK practice. UK practice is to give a clopidogrel loading dose of 600mg and  
4 the study allowed a clopidogrel loading dose of 300-600mg with only one fifth of patients received 600mg. Does not do a three way comparison including prasugrel for  
5 those who are eligible for it.  
6 (b) Mean age of patients in the PLATO trial was lower than UK average and proportion of older patients different to UK setting but an age-adjusted event rate was used in  
7 the clopidogrel arm to attempt to address this. Analysis does not reflect full body of available evidence for this area as identified in clinical review; main analysis based on  
8 a single study (PLATO). Uncertainty in estimates of effectiveness due to participants being able to leave the trial early and not followed up for 12 months - which affects  
9 the long-term patient outcomes in the Markov model. The health economic sub-study was used to derive data on resource use and utilities; however there was no  
10 information on how this sub-study was recruited for. Study funded by AstraZeneca.  
11 (c) Cost components included: drug costs (ticagrelor, clopidogrel, prasugrel and aspirin), hospitalisation, investigations, blood products and reoperations due to bleeding and  
12 drugs, event costs (stroke and myocardial infarction).  
13 (d) International resource use from 2006-2008 and 2010 UK unit costs may not reflect current UK practice. Only looks at patients intended for non-invasive management.  
14 Start age used in the cohort is younger than the average age of UK ACS patients.  
15 (e) Does not state if bleeding was incorporated in the model, analysis does not reflect full body of available evidence for this area as identified in clinical review; analysis  
16 based on a single study (PLATO). Study was funded by AstraZeneca.  
17 (f) Although patients were intended for non-invasive management approximately half of the patients had coronary angiography, a third had PCI, and one tenth had CABG  
18 during the course of the study. 9% of patients had STEMI, 56% had NSTEMI and 35% had unstable angina/other.  
19 (g) Cost components included: drug costs (ticagrelor, clopidogrel and aspirin), bed days due to hospitalisation, investigations, blood product and reoperations due to bleeding  
20 and event costs (stroke and MI).

21 **Table 14: Health economic evidence profile: ticagrelor + aspirin versus prasugrel + aspirin**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
NICE TA236 2011 (UK) Manufacturer submission <sup>12</sup> 4	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>Decision tree for the first year, followed by Markov model, based on an indirect comparison of ticagrelor and prasugrel from PLATO and TRITON-TIMI 38 RCTs<sup>18</sup></li> </ul>	£277 <sup>(c)</sup>	0.065 QALYs	£3,482 per QALY gained	<p>Probability ticagrelor cost effective (£20K/£30K threshold): 91.6%/NR</p> <p>Deterministic results using a different time horizon showed that ticagrelor remained cost-effective at</p>

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
			<ul style="list-style-type: none"> <li>• Cost utility analysis (QALYs)</li> <li>• Comparators:                             <ul style="list-style-type: none"> <li>○ Prasugrel + aspirin</li> <li>○ Ticagrelor + aspirin</li> </ul> </li> <li>• Population: ACS patients managed invasively (angiography followed by PCI/CABG if indicated)</li> <li>• Time horizon: lifetime</li> </ul>				20, 10 and 5 years as demonstrated in Table 16.

1 Abbreviations: ACS = Acute coronary syndrome; CABG = coronary artery bypass graft; NR = not reported; PCI = percutaneous coronary intervention; QALY = quality-adjusted life years; RCT = randomised controlled trial

- 2  
3 (a) International resource use from PLATO RCT which recruited 2006-2008 and 2008/09 UK unit costs may not reflect current UK practice. Does not include clopidogrel in  
4 the analysis.  
5 (b) Baseline event rates were taken from the PLATO international trial, which may not reflect UK practice, however the analysis used an age-adjusted event rate to address  
6 this. Relative treatment effects for prasugrel compared to ticagrelor were estimated from an indirect comparison using studies that compared each drug to clopidogrel;  
7 while using an indirect comparison is not necessarily inappropriate the manufacturer highlighted issues with the indirect comparison and the technology appraisal  
8 committee did not think the analysis was appropriate due to differences in the target populations of the two trials, differences in the usage of clopidogrel (dosing and  
9 timing) and differences in the assessment of MI. Health state costs were calculated based on resource use collected in ticagrelor arm of the PLATO trial; in the absence  
10 of a head-to-trial collecting such data, it was assumed that these costs would be the same with prasugrel. Study was funded by AstraZeneca.  
11 (c) Cost components included: drug costs (ticagrelor, prasugrel and aspirin), hospitalisation, investigations, blood products and reoperations due to bleeding and drugs,  
12 event costs (stroke and MI).  
13  
14

15 **Table 15: Health economic evidence profile: prasugrel + aspirin versus clopidogrel + aspirin**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Greenhalgh 2015 <sup>53</sup> (UK) ERG analysis for	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>• Markov model structure with two phases; the first phase models the within-trial</li> </ul>	<u>STEMI patients with diabetes</u> : £447	<u>STEMI patients with diabetes</u> : 0.28 QALYs	<u>STEMI patients with diabetes</u> : £1,732 per	Probability prasugrel cost effective (£20K/£30K threshold): <u>STEMI patients with</u>

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
NICE TA317 <sup>123</sup>			<p>period of the TRITON-TIMI 38 RCT and the second phase extrapolates beyond one year and is based on the CAPRIE RCT</p> <ul style="list-style-type: none"> <li>• Cost-utility analysis (QALYs)</li> <li>• Comparators: <ul style="list-style-type: none"> <li>○ Clopidogrel + aspirin</li> <li>○ Prasugrel + aspirin</li> </ul> </li> <li>• Population: ACS patients managed with PCI</li> <li>• Time horizon: lifetime</li> </ul>	<p><u>STEMI patients without diabetes:</u> £555</p> <p><u>UA/NSTEMI patients with diabetes:</u> -£77</p> <p><u>UA/NSTEMI patients without diabetes:</u> £248</p>	<p><u>STEMI patients without diabetes:</u> 0.08 QALYs</p> <p><u>UA/NSTEMI patients with diabetes:</u> 0.18 QALYs</p> <p><u>UA/NSTEMI patients without diabetes:</u> 0.05 QALYs</p>	<p>QALY gained</p> <p><u>STEMI patients without diabetes:</u> £7,073 per QALY gained</p> <p><u>UA/NSTEMI patients with diabetes:</u> Prasugrel dominant</p> <p><u>UA/NSTEMI patients without diabetes:</u> £4,154 per QALY gained</p>	<p><u>diabetes:</u> NR/NR</p> <p><u>STEMI patients without diabetes:</u> NR/NR</p> <p><u>UA/NSTEMI patients with diabetes:</u> NR/NR</p> <p><u>UA/NSTEMI patients without diabetes:</u> NR/NR</p> <p>Univariate sensitivity analyses were performed on all model variables subject to uncertainty, and prasugrel remained cost-effective.</p> <p>Different time horizons were explored and are presented in Table 17.</p>

1 Abbreviations: ACS = acute coronary syndromes; ERG = evidence review group; NSTEMI = non-ST segment elevation myocardial infarction; PCI = percutaneous coronary  
2 intervention; QALY= quality-adjusted life years; RCT= randomised controlled trial; STEMI = ST segment elevation myocardial infarction; UA = unstable angina  
3 (a) International resource use from 2004-2007 and 2012 UK unit costs may not reflect current UK practice. The trial used a clopidogrel loading dose of 300mg instead of  
4 600mg which does not reflect UK practice and analysis does not include ticagrelor.  
5 (b) Mean age of patients in the TRITON-TIMI 38 trial was different to UK average but this was accounted for by adjusting the initial health state utilities of each subgroup.  
6 Did not use new cost data for the relevant year; instead unit costs from the previous TA report were inflated to 2012 prices. Analysis does not reflect full body of available  
7 evidence identified in clinical review, main analysis based on a single study (TRITON-TIMI 38).  
8 (c) Cost components included: drug costs, repeat hospitalisations, health care costs associated events (fatal MI, non-fatal MI, fatal stroke, non-fatal non –disabling stroke,  
9 non-fatal disabling stroke, non-vascular death, and other vascular death).

1 Additional results from the ticagrelor manufacturer submission are summarised in Table 16  
2 below.

3 **Table 16: Incremental cost-effectiveness ratios with different time horizons in NICE**  
4 **TA236**

Time horizon	Ticagrelor versus clopidogrel				Ticagrelor versus prasugrel
	All ACS	STEMI	NSTEMI	UA	
Lifetime	£3,696	£2,825	£5,230	£5,374	£3,482
20 years	£3,705	£2,847	£5,233	£5,410	£3,598
10 years	£4,182	£3,334	£5,727	£6,484	£4,562
5 years	£6,075	£4,946	£8,162	£10,172	£7,047
1 year	£36,177	£31,933	£45,810	£78,288	NR

5 Abbreviations: NR = not reported  
6

7 Additional results from the prasugrel ERG report are summarised in Table 17 below.

8 **Table 17: Incremental cost-effectiveness ratios with different time horizons in**  
9 **Greenhalgh 2015**

Time horizon	Prasugrel versus clopidogrel			
	STEMI with diabetes	STEMI without diabetes	UA/NSTEMI with diabetes	UA/NSTEMI without diabetes
Lifetime	£1,640	£6,626	Dominant	£4,667
20 years	£1,537	£7,670	Dominant	£5,688
10 years	£2,139	£13,370	Dominant	£14,276
5 years	£4,603	£29,607	£2,846	£52,288
1 year	£31,915	£224,302	£76,856	£1,101,662

## 1.6.4 Health economic modelling

11 The committee agreed that which DAPT option to use in people with ACS undergoing PCI  
12 was the highest priority for new economic analysis. This was due to there being variation in  
13 current practice and substantial differences in the cost of the interventions. Therefore, a  
14 recommendation for a particular agent would result in a significant change in clinical practice  
15 that could have a substantial resource impact to the NHS in England.

### 16 Model methods

17 A technical report for this analysis including full details of all methods and model inputs is  
18 available in a separate document 'Health Economic Analysis\_DAPT'. A summary is provided  
19 below.

20 A cost-utility analysis was undertaken to compare aspirin plus one of clopidogrel, prasugrel or  
21 ticagrelor for people with UA/NSTEMI or STEMI undergoing PCI from a current UK NHS and  
22 personal social services perspective. A two-part model was constructed which included a  
23 decision tree to model events in the first year followed by a Markov model for long term  
24 extrapolation in order to calculate lifetime costs and QALYs. Both costs and QALYs were  
25 discounted at a rate of 3.5% per annum in line with NICE methodological guidance. An  
26 incremental analysis was undertaken.

27 The comparators selected for the model were:

- 28 • Clopidogrel 75mg once daily + aspirin 75-150mg once daily (300-600mg clopidogrel  
29 loading dose) for 12 months



- 1 • Prasugrel 5-10mg once daily + aspirin 75-150mg once daily (60mg prasugrel loading
- 2 dose) for 12 months
- 3 • Ticagrelor 90mg twice daily + aspirin 75-150mg once daily (180mg ticagrelor loading
- 4 dose) for 12 months


5 The population considered in the analysis was adults with UA/NSTEMI or STEMI undergoing  
 6 PCI. STEMI and UA/NSTEMI were modelled separately as baseline risks were considered  
 7 likely to be different, although relative treatment effects were assumed to be the same  
 8 following consideration of the clinical evidence review. The economic analysis did not  
 9 consider people with UA/NSTEMI that are medically managed. This is because prasugrel is  
 10 not indicated in this population and two published UK economic analyses indicated that  
 11 ticagrelor is cost-effective compared to clopidogrel in this population and additional economic  
 12 analyses was not considered necessary.

13 Following review of the clinical evidence, it was agreed that the following outcomes should  
 14 be captured in the 1 year model as they potentially vary between DAPT options:

- 15 • All-cause mortality
- 16 • Reinfarction
- 17 • Stroke
- 18 • Major bleed
- 19 • Minor bleed

20 The initial decision tree was broken down into two time periods, 0 to 30 days and 31 days to  
 21 1 year, in order to make best use of the available clinical data. The decision tree comprised  
 22 four potential health states including no further event, reinfarction, stroke and death. Major  
 23 and minor bleeding were incorporated as adverse events as the effects were considered to  
 24 have a short-term impact. Figure 2 shows the structure of the decision tree.


**Figure 2: Model structure: one year treatment period decision tree**



*Notes: Probabilities of events are dependent on DAPT being received. People who are alive are also at risk of a short-term major or minor bleeding adverse event.*

1 People alive at the end of the 1 year decision tree entered the post-one year Markov model  
 2 to extrapolate 1 year outcomes to a lifetime perspective. Figure 3 shows the structure of the  
 3 Markov model. The Markov model consisted of six health states: no further event,  
 4 reinfarction, post-reinfarction, stroke, post-stroke and dead. Those that experienced no  
 5 further event at the end of the decision tree entered the 'no further event' health state in the  
 6 Markov model. Those that had reinfarction (either once or twice) at the end of the decision  
 7 tree entered the 'post-reinfarction' health state. Those that had a stroke at the end of the  
 8 decision tree or had both a stroke and reinfarction entered the 'post-stroke' health state.  
 9 Those in the no further event health state could only go on to have one event (reinfarction or  
 10 stroke). Once someone entered the post-reinfarction or post-stroke health state, they could  
 11 not experience a second event. Transition probabilities in the Markov model were the same  
 12 irrespective of the DAPT received in year 1, however as the number of people entering the  
 13 Markov in each state will vary (that is the number of people who have died, had an MI and  
 14 had a stroke by one year), costs and QALYs will continue to vary between DAPT groups  
 15 after one year.

**Figure 3: Model structure: post-one year extrapolation Markov model**



*Note: 1 year cycles; model was run for 40 years at which point most people will be in the dead state; the state people enter model depends on events experienced in year 1 decision tree.*

16 Model inputs are described in full in the separate technical report. In summary, baseline risks  
 17 were sourced from published analyses using national audit data where possible to reflect real  
 18 world risks in people with ACS undergoing PCI in England. Relative treatment effects were  
 19 based on the systematic review and meta analyses of RCTs undertaken for this guideline  
 20 update. UK costs were used. Health-related quality of life weights were based on the  
 21 published literature.

22 The unit costs of aspirin, clopidogrel, prasugrel and ticagrelor that are used in the model  
 23 shown in Table 18. DAPT costs varied by comparator in the first year.

1 **Table 18: Model inputs: DAPT costs**

Drug	Loading dose	Loading dose cost	Daily maintenance dose	Cost per day	Cost per year
Aspirin	n/a	n/a	75mg	£0.03	£9.26
Clopidogrel	300mg	£0.21	75mg	£0.05	£18.77
	600mg	£0.41	75mg	£0.05	£18.77
Prasugrel	60mg	£1.82	5mg	£1.03	£375.95
			10mg	£0.30	£110.67
Ticagrelor	180mg	£1.95	180mg	£1.95	£711.75

2 *Source: British National Formulary<sup>66</sup>, Accessed 7<sup>th</sup> February 2020*

3 The model was populated with baseline risks for those receiving clopidogrel and aspirin (e.g.  
4 the probability of death at 30 days). When running the model for those receiving ticagrelor  
5 and prasugrel a relative treatment effect obtained from the clinical review and evidence  
6 syntheses (compared to clopidogrel) was applied to this in order to estimate the difference in  
7 number of events with these alternative treatments. Costs and clinical events therefore vary  
8 by comparator.

9 The relative treatment effects applied in the model are summarised in Table 19. For the 0 –  
10 30 day period odds ratios were obtained from the network meta-analysis at 30 days which  
11 combined RCT evidence for ticagrelor versus clopidogrel, prasugrel versus clopidogrel and  
12 ticagrelor versus prasugrel into a single set of consistent relative treatment effects. Network  
13 meta-analysis combining all available data was not possible for 1 year outcomes due to  
14 inconsistency in the network and so three different data scenarios were analysed using  
15 different set of data. This resulted in three data scenarios. The relative treatment effects for  
16 each scenario are shown in the table. For each scenario the black text indicates the direct  
17 data used and the grey text shows the implied relative treatment effects for the remaining  
18 comparison. Note that ISAR-REACT 5 (that compared prasugrel and ticagrelor at 1 year) did  
19 not report minor bleeding and so relative treatment effects in scenarios 2 and 3 remain the  
20 same as in scenario 1.

21 **Table 19: Model inputs: relative treatment effects**

	0 to 30 day	31 days to 1 year		
		Scenario 1	Scenario 2	Scenario 3
Data used	Network meta-analysis OR (95% CI)	Ticagrelor vs clopidogrel (meta-analysis) Prasugrel vs clopidogrel (meta-analysis) OR (95% CI)	Prasugrel vs clopidogrel (meta-analysis) Ticagrelor versus prasugrel (ISAR REACT 5) OR (95% CI)	Ticagrelor vs clopidogrel (meta-analysis) Ticagrelor versus prasugrel (ISAR REACT 5) OR (95% CI)
Ticagrelor vs clopidogrel				
All-cause mortality	0.84 (0.69 to 1.01)	0.77 (0.68 to 0.88)	1.24 (0.86 to 1.79)	0.77 (0.68 to 0.88)
Reinfarction	0.68 (0.55 to 0.84)	0.81 (0.72 to 0.92)	1.22 (1.54 to 3.07)	0.81 (0.72 to 0.92)
Stroke	1.28 (0.86 to 1.83)	1.13 (0.89 to 1.44)	1.08 (0.62 to 2.51)	1.13 (0.89 to 1.44)
Major bleed	1.00 (0.89 to 1.11)	1.04 (0.95 to 1.14)	1.52 (0.51 to 1.08)	1.04 (0.95 to 1.14)
Minor bleed	1.28 (0.88 to 1.81)	1.37 (1.19 to 1.57)	1.37 (1.19 to 1.57) <sup>(a)</sup>	1.37 (1.19 to 1.57)
Prasugrel vs clopidogrel				
All-cause mortality	0.76 (0.56 to 0.99)	1.00 (0.83 to 1.21)	1.00 (0.83 to 1.21)	0.62 (0.44 to 0.87)

	0 to 30 day	31 days to 1 year		
		Scenario 1	Scenario 2	Scenario 3
Reinfarction	0.80 (0.65 to 0.98)	0.75 (0.66 to 0.84)	0.75 (0.66 to 0.84)	0.50 (0.35 to 0.70)
Stroke	0.84 (0.46 to 1.39)	0.93 (0.67 to 1.30)	0.93 (0.67 to 1.30)	0.97 (0.50 to 1.88)
Major bleed	0.99 (0.61 to 1.52)	1.43 (1.14 to 1.79)	1.43 (1.14 to 1.79)	0.98 (0.71 to 1.35)
Minor bleed	0.74 (0.51 to 1.04)	2.07 (0.88 to 4.87) (a)	2.07 (0.88 to 4.87) (a)	2.07 (0.88 to 4.87) (a)
<b>Ticagrelor vs prasugrel</b>				
All-cause mortality	1.04 (0.79 to 1.39)	0.77 (0.61 to 0.97)	1.24 (0.90 to 1.70)	1.24 (0.90 to 1.70)
Reinfarction	0.84 (0.64 to 1.14)	1.08 (0.92 to 1.27)	1.63 (1.17 to 2.26)	1.63 (1.17 to 2.26)
Stroke	1.47 (0.82 to 2.98)	1.22 (0.80 to 1.84)	1.16 (0.62 to 2.14)	1.16 (0.62 to 2.14)
Major bleed	1.00 (0.65 to 1.64)	0.73 (0.57 to 0.93)	1.06 (0.78 to 1.44)	1.06 (0.78 to 1.44)
Minor bleed	0.59 (0.39 to 0.86)	0.66 (0.28 to 1.57) <sup>(b)</sup>	0.66 (0.28 to 1.57) <sup>(b)</sup>	0.66 (0.28 to 1.57) <sup>(b)</sup>

1 Abbreviations: 95% CI = 95% confidence interval; OR = odds ratio.

2 Note: For 31 days to 1 year, black text indicates the direct data used in that particular scenario and grey text  
3 shows the implied relative treatment effects for the remaining comparison. All text is black in the 0 to 30  
4 days column as an NMA was used to combine all data into a single set of consistent treatment effects.

5 (a) ISAR-REACT 5 did not report minor bleeding therefore treatment effects remained the same as scenario 1.

6 (b) These estimates are the implied treatment effects for minor bleeding using the data for ticagrelor versus  
7 clopidogrel and prasugrel versus clopidogrel

8 Source: Systematic review and meta analyses of RCTs undertaken for the guideline update, see 'Clinical  
9 evidence' section for details.

10 The model was built probabilistically to account for the uncertainty around input parameter  
11 point estimates. A probability distribution was defined for each model input parameter. When  
12 the model was run, a value for each input was randomly selected simultaneously from its  
13 respective probability distribution; mean costs and mean QALYs were calculated using these  
14 values. The model was run repeatedly – 5000 times for the base-case analysis and each  
15 sensitivity analysis – and results were summarised in terms of mean costs and QALYs, and  
16 the percentage of time each comparator was the most cost-effective strategy at a threshold  
17 of £20,000/£30,000 per QALY gained.

18 In addition, various one way and scenario sensitivity analyses were undertaken to test the  
19 robustness of model assumptions. In these, one or more inputs were changed and the  
20 analysis rerun to evaluate the impact on results and whether conclusions on which  
21 intervention should be recommended would change.

## 22 Results

23 Base case analysis results are presented in Table 20. Results are presented for the three  
24 scenarios that utilise different data to inform the relative treatment effects between 31 days  
25 and 1 year in the model (all scenarios use the 30-day NMA to inform the relative treatment  
26 effects 0 to 30 days in the model):

- 27 1. Ticagrelor vs clopidogrel (meta-analysis); prasugrel vs clopidogrel (meta-analysis)
- 28 2. Prasugrel vs clopidogrel (meta-analysis); ticagrelor versus prasugrel (ISAR-REACT 5)
- 29 3. Ticagrelor vs clopidogrel (meta-analysis); Ticagrelor versus prasugrel (ISAR-REACT 5)

30 In the base case analysis, the DAPT option that was most cost effective depended on the  
31 clinical data used to inform relative treatment effects between 31 days and 1 year and the  
32 ACS subpopulation. Prasugrel was the most cost effective DAPT option except in a  
33 UA/NSTEMI population when data from studies comparing prasugrel to clopidogrel and  
34 ticagrelor to clopidogrel was used to inform the relative treatment effects between 31 days

1 and 1 year in the model (data scenario 1). In addition, although prasugrel was overall the  
2 most cost effective option in a STEMI population in scenario 1, there was a lot of uncertainty  
3 between whether prasugrel or ticagrelor was the most cost effective option, with prasugrel  
4 only being the most cost effective option in 53% of simulations and ticagrelor in 47%. Also,  
5 although ticagrelor was the most cost effective option for UA/NSTEMI in scenario 1, there  
6 was some degree of uncertainty as it was only the most cost effective option in 63% of  
7 simulations. There was however little uncertainty that prasugrel was the most cost-effective  
8 option in data scenarios 2 and 3 that utilise the recent ISAR-REACT 5 RCT comparing  
9 prasugrel and ticagrelor to inform the relative treatment effects between 31 days and 1 year  
10 in the model. Ticagrelor had the highest costs in all scenarios and ACS subgroups but only  
11 had the highest QALYs in scenario 1. In scenarios 2 and 3, prasugrel had lower costs than  
12 ticagrelor and higher QALYs. Clopidogrel had the lowest costs in all scenarios and had the  
13 lowest QALYs in all scenarios for STEMI and scenarios 1 and 3 for UA/NSTEMI.  
14

**Table 20: Base case analysis results (probabilistic analysis) – cost effectiveness results (mean per person)**

Intervention	Mean lifetime costs undisc	Mean lifetime costs disc	Mean life years	Mean lifetime QALYs Undisc	Mean lifetime QALYs disc	Incr. cost	Incr. QALYs	ICER	NMB (£20k)	Rank at £20k	% CE at £20k*	% Rank 2nd (£20k)	% Rank 3rd (£20k)	% CE at £30k**
<b>Scenario 1 – Ticagrelor vs clopidogrel (meta-analysis); prasugrel vs clopidogrel (meta-analysis)</b>														
<i>STEMI</i>														
Clopidogrel	£23,123	£17,369	13.05	8.29	6.42				£111,108	3	0%	6%	94%	0%
Prasugrel	£23,473	£17,639	13.22	8.40	6.51	£270	0.09	£3,157	£112,546	1	53%	43%	4%	42%
Ticagrelor	£24,374	£18,448	13.31	8.45	6.55	£809	0.04	£21,822	£112,479	2	47%	51%	2%	58%
<i>UA/NSTEMI</i>														
Clopidogrel	£19,358	£14,869	12.95	8.21	6.44				£113,922	3	0%	17%	83%	0%
Prasugrel	£19,509	£15,002	13.01	8.25	6.47	£133	0.03	£4,550	£114,373	2	37%	48%	16%	21%
Ticagrelor	£20,303	£15,739	13.11	8.31	6.52	£737	0.05	£15,915	£114,562	1	63%	36%	1%	79%
<b>Scenario 2 – Prasugrel vs clopidogrel (meta-analysis); ticagrelor versus prasugrel (ISAR-REACT 5)</b>														
<i>STEMI</i>														
Clopidogrel	£23,073	£17,334	13.05	8.29	6.42				£111,139	2	4%	69%	28%	3%
Prasugrel	£23,424	£17,605	13.23	8.40	6.51	£270	0.08	£3,182	£112,568	1	91%	7%	2%	90%
Ticagrelor	£23,900	£18,131	13.07	8.30	6.43	£526	-0.08	Dominated	£110,452	3	5%	24%	71%	7%
<i>UA/NSTEMI</i>														
Clopidogrel	£19,334	£14,854	12.95	8.21	6.44				£113,925	2	16%	80%	4%	14%
Prasugrel	£19,484	£14,987	13.01	8.25	6.47	£133	0.03	£4,644	£114,364	1	82%	16%	2%	82%
Ticagrelor	£19,981	£15,522	12.87	8.16	6.40	£535	-0.07	Dominated	£112,472	3	2%	4%	94%	4%
<b>Scenario 3 – Ticagrelor vs clopidogrel (meta-analysis); Ticagrelor versus prasugrel (ISAR-REACT 5)</b>														
<i>STEMI</i>														
Clopidogrel	£23,149	£17,390	13.05	8.29	6.42				£111,065	3	0%	2%	98%	0%
Prasugrel	£23,842	£17,891	13.42	8.53	6.61	£501	0.18	£2,747	£114,213	1	95%	5%	0%	93%
Ticagrelor	£24,402	£18,471	13.31	8.45	6.55	£580	-0.06	Dominated	£112,442	2	5%	93%	2%	7%

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

Intervention	Mean lifetime costs undisc	Mean lifetime costs disc	Mean life years	Mean lifetime QALYs Undisc	Mean lifetime QALYs disc	Incr. cost	Incr. QALYs	ICER	NMB (£20k)	Rank at £20k	% CE at £20k*	% Rank 2nd (£20k)	% Rank 3rd (£20k)	% CE at £30k**
<i>UA/NSTEMI</i>														
Clopidogrel	£19,396	£14,898	12.95	8.21	6.44				£113,902	3	0%	2%	99%	0%
Prasugrel	£19,791	£15,199	13.21	8.37	6.56	£301	0.12	£2,452	£116,054	1	99%	1%	0%	98%
Ticagrelor	£20,342	£15,768	13.11	8.31	6.52	£569	-0.05	Dominated	£114,539	2	1%	98%	1%	2%

Abbreviations: CE = cost effective; disc. = discounted; Incr. = incremental; NMB = net monetary benefit; QALY = quality-adjusted life years; undisc = undiscounted

\* at a threshold of £20,000 per QALY gained

\*\* at a threshold of £30,000 per QALY gained

1 In addition to probabilistic sensitivity analysis a range of one-way and scenario sensitivity  
 2 analysis were undertaken including varying the baseline risk of stroke, inclusion of stroke  
 3 treatment effects, inclusion of dyspnoea as a side effect, varying bleeding and stroke costs,  
 4 varying dosing assumptions, incorporation of post-ACS rivaroxaban use, varying event-  
 5 related mortality in the extrapolation model and varying the baseline risk of stroke and  
 6 reinfarction to account for overestimation of people alive with an event. The conclusions did  
 7 not change in the majority of sensitivity analyses, except for STEMI in data scenario 1. When  
 8 the stroke treatment effects were excluded, utilities were not age-adjusted and the lower  
 9 discount rate was used, ticagrelor became the most cost effective option for STEMI in data  
 10 scenario 1. However, the percentage of simulations that ticagrelor was cost effective in these  
 11 analyses ranged from 49% to 58%, emphasising the degree of uncertainty in this scenario for  
 12 STEMI. When the rivaroxaban treatment effects were included in the clopidogrel arm this  
 13 didn't impact conclusions on which treatment option was the most cost effective but resulted  
 14 in clopidogrel (with rivaroxaban) having the highest costs due to including the rivaroxaban  
 15 treatment costs. QALYs were also increased due to the treatment effects of rivaroxaban  
 16 being included.

17 All results and a full discussion of limitations and interpretation of the analysis are included in  
 18 the full technical report for this analysis available in a separate document 'Health Economic  
 19 Analysis\_DAPT'. The committee's discussion and interpretation is summarised in section 1.8  
 20 of this report.

## 1.7 Evidence statements

### 1.7.1 Clinical evidence statements

23

#### 24 Ticagrelor versus clopidogrel

##### 25 ACS with/without revascularisation

- 26 • There was a clinically important benefit of ticagrelor compared to clopidogrel for all-cause  
 27 mortality at 30 days (1391 participants in 5 studies, very low quality evidence) and in all-  
 28 cause mortality at 1 year (20443 participants in 6 studies, low quality evidence) for ACS  
 29 with/without revascularisation.
- 30 • There was a clinically important harm in cardiac mortality at 30 days (1143 participants in  
 31 4 studies, very low quality evidence) when ticagrelor + aspirin was compared to  
 32 clopidogrel. There was however a clinically important benefit of ticagrelor compared to  
 33 clopidogrel for cardiac mortality at 1 year (20711 participants in 6 studies, low quality  
 34 evidence) for ACS with/without revascularisation.
- 35 • There was no clinically important difference of ticagrelor compared to clopidogrel for re-  
 36 infarction at 30 days (1397 participants in 5 studies, low quality evidence). There was  
 37 however a clinically important benefit of ticagrelor compared to clopidogrel for re-  
 38 infarction at 1 year (21129 participants in 8 studies, low quality evidence) for ACS  
 39 with/without revascularisation.
- 40 • There was no clinically important difference between ticagrelor and clopidogrel for major  
 41 bleeding at 30 days (1411 participants in 5 studies, very low quality evidence) and major  
 42 bleeding at 1 year (20206 participants in 6 studies, moderate quality evidence) for ACS  
 43 with/without revascularisation.
- 44 • There was a clinically important increase in minor bleeding at 30 days (1511 participants  
 45 in 6 studies, low quality evidence) when ticagrelor was compared to clopidogrel. There  
 46 was however no clinically important difference between ticagrelor and clopidogrel for  
 47 minor bleeding at 1 year (20384 participants in 6 studies, very low quality evidence) for  
 48 ACS with/without revascularisation.



- 1 • There was no clinically important difference between ticagrelor and clopidogrel for stroke  
2 at 30 days (979 participants in 3 studies, very low quality evidence) and stroke at 1 year  
3 (20711 participants in 6 studies, moderate quality evidence) for ACS with/without  
4 revascularisation.
- 5 • There was a clinically important benefit of ticagrelor compared to clopidogrel for need for  
6 revascularisation at 1 year (1260 participants in 4 studies, moderate quality evidence) for  
7 ACS with/without revascularisation.
- 8 • There was no clinically important difference between ticagrelor and clopidogrel for stent  
9 thrombosis (type not specified) at 1 year (1086 participants in 3 studies, moderate quality  
10 evidence) and stent thrombosis (definite and probable) at 1 year (11289 participants in 1  
11 study, low quality evidence) for ACS with/without revascularisation.
- 12 • There was a clinically important increase in breathing adverse effects at 1 year (19222  
13 participants in 2 studies, moderate quality evidence) when ticagrelor was compared to  
14 clopidogrel for ACS with/without revascularisation.
- 15 • There was no clinically important difference between ticagrelor and clopidogrel for  
16 bradycardiac adverse effects at 30 days (2309 participants in 3 studies, very low quality  
17 evidence) and bradycardiac adverse effects at 1 year (13632 participants in 3 studies,  
18 moderate quality evidence) for ACS with/without revascularisation.
- 19 • There was a clinically important increase in other adverse effects at 30 days (324  
20 participants in 2 studies, very low quality evidence) and when ticagrelor was compared to  
21 clopidogrel. There was however no clinically difference between ticagrelor and  
22 clopidogrel for other adverse effects at 1 year (19342 participants in 3 studies, moderate  
23 quality evidence) for ACS with/without revascularisation.

#### 24 UA/NSTEMI - with/without revascularisation

##### 25 *With revascularisation*

- 26 • There was a clinically important benefit of ticagrelor compared to clopidogrel for all-cause  
27 mortality at 30 days (6218 participants in 1 study, low quality evidence) and in all-cause  
28 mortality at 1 year (5648 participants in 1 study, very low quality evidence) for  
29 UA/NSTEMI with revascularisation.
- 30 • There was a clinically important benefit of ticagrelor compared to clopidogrel for cardiac  
31 mortality at 30 days (6218 participants in 1 study, low quality evidence) and in cardiac  
32 mortality at 1 year (5648 participants in 1 study, very low quality evidence) for  
33 UA/NSTEMI with revascularisation.
- 34 • There was no clinically important difference between ticagrelor and clopidogrel for re-  
35 infarction at 30 days (5934 participants in 1 study, very low quality evidence) and re-  
36 infarction at 1 year (5438 participants in 1 study, very low quality evidence) for  
37 UA/NSTEMI with revascularisation.
- 38 • There was no clinically important difference between ticagrelor and clopidogrel for major  
39 bleeding at 30 days (4958 participants in 1 study, very low quality evidence) and major  
40 bleeding at 1 year (4983 participants in 1 study, very low quality evidence) for  
41 UA/NSTEMI with revascularisation.
- 42 • There was a clinically important increase of bleeding (type not specified) at 1 year when  
43 ticagrelor was compared to clopidogrel (244 participants in 1 study, low quality evidence)  
44 for UA/NSTEMI with revascularisation.
- 45 • There was no clinically important difference between ticagrelor and clopidogrel for stroke  
46 at 30 days (6188 participants in 1 study, very low quality evidence) and stroke at 1 year  
47 (5632 participants in 1 study, very low quality evidence) for UA/NSTEMI with  
48 revascularisation.
- 49 • There was no clinically important difference between ticagrelor and clopidogrel for stent  
50 thrombosis (type not specified) at 1 year (442 participants in 1 study, very low quality  
51 evidence) for UA/NSTEMI with revascularisation.

##### 52 *Without revascularisation*

- 1 • There was a clinically important benefit of ticagrelor compared to clopidogrel for all-cause  
2 mortality at 30 days (4514 participants in 1 study, low quality evidence) and in all-cause  
3 mortality at 1 year (5217 participants in 1 study, very low quality evidence) for  
4 UA/NSTEMI without revascularisation.
- 5 • There was a clinically important benefit of ticagrelor compared to clopidogrel for cardiac  
6 mortality at 30 days (4514 participants in 1 study, low quality evidence) and in cardiac  
7 mortality at 1 year (5217 participants in 1 study, very low quality evidence) for  
8 UA/NSTEMI without revascularisation.
- 9 • There was no clinically important difference between ticagrelor and clopidogrel for re-  
10 infarction at 30 days (4479 participants in 1 study, very low quality evidence) and re-  
11 infarction at 1 year (5201 participants in 1 study, very low quality evidence) for  
12 UA/NSTEMI without revascularisation.
- 13 • There was no clinically important difference between ticagrelor and clopidogrel for major  
14 bleeding at 30 days (3964 participants in 1 study, very low quality evidence) and major  
15 bleeding at 1 year (4931 participants in 1 study, very low quality evidence) for  
16 UA/NSTEMI without revascularisation.
- 17 • There was no clinically important difference between ticagrelor and clopidogrel for stroke  
18 at 30 days (4502 participants in 1 study, very low quality evidence) and stroke at 1 year  
19 (5209 participants in 1 study, very low quality evidence) for UA/NSTEMI without  
20 revascularisation.

21

## 22 STEMI with revascularisation

- 23 • There was a clinically important benefit of ticagrelor compared to clopidogrel for all-cause  
24 mortality at 30 days (630 participants in 3 studies, low quality evidence) and in all-cause  
25 mortality at 1 year (8242 participants in 1 study, low quality evidence) for STEMI with  
26 revascularisation.
- 27 • There was a clinically important benefit of ticagrelor compared to clopidogrel for cardiac  
28 mortality at 30 days (482 participants in 3 studies, very low quality evidence) and in  
29 cardiac mortality at 1 year (8630 participants in 4 studies, low quality evidence) for  
30 STEMI with revascularisation.
- 31 • There was a clinically important benefit of ticagrelor compared to clopidogrel for re-  
32 infarction at 30 days (736 participants in 4 studies, low quality evidence) and in re-  
33 infarction at 1 year (8928 participants in 5 studies, low quality evidence) for STEMI with  
34 revascularisation.
- 35 • There was no clinically important difference between ticagrelor and to clopidogrel for  
36 major bleeding at 30 days (750 participants in 4 studies, very low quality evidence) and  
37 major bleeding at 1 year (8135 participants in 3 studies, low quality evidence) for STEMI  
38 with revascularisation.
- 39 • There was a clinically important increase in minor bleeding at 30 days (750 participants in  
40 4 studies, low quality evidence) when ticagrelor was compared to clopidogrel. There was  
41 however no clinically important difference between ticagrelor and clopidogrel for minor  
42 bleeding at 1 year (8313 participants in 3 studies, low quality evidence) for STEMI with  
43 revascularisation.
- 44 • There was no clinically important difference between ticagrelor and clopidogrel for stroke  
45 at 30 days (318 participants in 2 studies, very low quality evidence) and stroke at 1 year  
46 (8630 participants in 4 studies, low quality evidence) for STEMI with revascularisation.
- 47 • There was no clinically important difference between ticagrelor and clopidogrel for need  
48 for revascularisation at 30 days (442 participants in 2 studies, low quality evidence).  
49 There was however a clinically important difference between ticagrelor and clopidogrel  
50 for need for revascularisation at 1 year (1140 participants in 3 studies, moderate quality  
51 evidence) for STEMI with revascularisation.
- 52 • There was a clinically important benefit of ticagrelor compared to clopidogrel for stent  
53 thrombosis (definite or probable) at 30 days (174 participants in 1 study, low quality

- 1 evidence). There was however no clinically important difference between ticagrelor and  
2 clopidogrel for stent thrombosis (type not specified) at 1 year (644 participants in 2  
3 studies, very low quality evidence) and stent thrombosis (definite and probable) at 1 year  
4 (7544 participants in 1 study, low quality evidence) for STEMI with revascularisation.
- 5 • There was a clinically important increase in breathing adverse effects at 30 days (318  
6 participants in 2 studies, low quality evidence) and at 1 year (7471 participants in 1 study,  
7 moderate quality evidence) when ticagrelor was compared to clopidogrel for STEMI with  
8 revascularisation.
  - 9 • There was a clinically important increase in bradycardiac adverse effects at 30 days (318  
10 participants in 2 studies, very low quality evidence) when ticagrelor was compared to  
11 clopidogrel. There was however no clinically important difference between ticagrelor and  
12 clopidogrel for bradycardiac adverse effects at 1 year (7715 participants in 2 studies, low  
13 quality evidence) for STEMI with revascularisation.
  - 14 • There was a clinically important increase in other adverse effects at 30 days (418  
15 participants in 3 studies, low quality evidence) when ticagrelor was compared to  
16 clopidogrel. There was however no clinically difference between ticagrelor and  
17 clopidogrel for other adverse effects at 1 year (7471 participants in 1 study, low quality  
18 evidence) for STEMI with revascularisation.
  - 19 • There was a clinically important benefit of ticagrelor compared to clopidogrel for  
20 unplanned urgent readmission at 30 days (144 participants in 1 study, very low quality  
21 evidence) for STEMI with revascularisation.

22

### 23 **Prasugrel versus clopidogrel**

#### 24 ACS with/without revascularisation

- 25 • There was a clinically important benefit of prasugrel compared to clopidogrel for all-cause  
26 mortality at 30 days (13142 participants in 4 studies, low quality evidence). There was  
27 however no clinically important difference between prasugrel and clopidogrel for all-cause  
28 mortality at 1 year (15126 participants in 3 studies, moderate quality evidence) for ACS  
29 with/without revascularisation.
- 30 • There was a clinically important benefit of prasugrel compared to clopidogrel for cardiac  
31 mortality at 30 days (13049 participants in 3 studies, low quality evidence) and at 1 year  
32 (15051 participants in 2 studies, low quality evidence) for ACS with/without  
33 revascularisation.
- 34 • There was no clinically important difference between prasugrel and clopidogrel for re-  
35 infarction at 30 days (13111 participants in 4 studies, low quality evidence). There was  
36 however a clinically important benefit of prasugrel when compared to clopidogrel for re-  
37 infarction at 1 year (15051 participants in 3 studies, low quality evidence) for ACS  
38 with/without revascularisation.
- 39 • There was no clinically important difference between prasugrel and clopidogrel for major  
40 bleeding at 30 days (12994 participants in 3 studies, very low quality evidence) and at 1  
41 year (14900 participants in 2 studies, low quality evidence) for ACS with/without  
42 revascularisation.
- 43 • There was no clinically important difference between prasugrel and clopidogrel for minor  
44 bleeding at 30 days (3754 participants in 2 studies, very low quality evidence) and at 1  
45 year (1443 participants in 1 study, low quality evidence) for ACS with/without  
46 revascularisation.
- 47 • There was no clinically important difference between prasugrel and clopidogrel for stroke  
48 at 30 days (13049 participants in 3 studies, very low quality evidence) and at 1 year  
49 (15126 participants in 3 studies, very low quality evidence) for ACS with/without  
50 revascularisation.
- 51 • There was no clinically important difference between prasugrel and clopidogrel for need  
52 for revascularisation at 30 days (3723 participants in 2 studies, low quality evidence) and

- 1 at 1 year (13683 participants in 2 studies, low quality evidence) for ACS with/without  
2 revascularisation.
- 3 • There was no clinically important difference between prasugrel and clopidogrel for stent  
4 thrombosis (type not specified) at 30 days (282 participants in 2 studies, very low quality  
5 evidence) and stent thrombosis (definite or probable) at 1 year (15051 participants in 2  
6 studies, moderate quality evidence) for ACS with/without revascularisation.
- 7 • There was no clinically important difference between prasugrel and clopidogrel for other  
8 adverse effects at 30 days (282 participants in 2 studies, very low quality evidence) and  
9 at 1 year (14900 participants in 2 studies, very low quality evidence) for ACS with/without  
10 revascularisation.
- 11 • There was no clinically important difference between prasugrel and clopidogrel for  
12 unplanned urgent readmission at 30 days (189 participants in 1 study, very low quality  
13 evidence) and at 1 year (1443 participants in 1 study, very low quality evidence) for ACS  
14 with/without revascularisation.

### 15 UA/NSTEMI with/without revascularisation

#### 16 *With revascularisation*

- 17 • There was no clinically important difference between prasugrel and clopidogrel for  
18 cardiac mortality at 1 year (10074 participants in 1 study, low quality evidence) for  
19 UA/NSTEMI with revascularisation.
- 20 • There was a clinically important benefit of prasugrel compared to clopidogrel for re-  
21 infarction at 1 year (10074 participants in 1 study, low quality evidence) for UA/NSTEMI  
22 with revascularisation.
- 23 • There was no clinically important difference between prasugrel and clopidogrel for major  
24 bleeding at 1 year (9981 participants in 1 study, low quality evidence) for UA/NSTEMI  
25 with revascularisation.
- 26 • There was no clinically important difference between prasugrel and clopidogrel for stroke  
27 at 1 year (10074 participants in 1 study, very low quality evidence) for UA/NSTEMI with  
28 revascularisation.
- 29 • There was no clinically important difference between prasugrel and clopidogrel for stroke  
30 at 1 year (9326 participants in 1 study, very low quality evidence) for UA/NSTEMI with  
31 revascularisation in people aged <75 years.

#### 32 *Without revascularisation*

- 33 • There was a clinically important benefit of prasugrel compared to clopidogrel for all-cause  
34 mortality at 30 days (9326 participants in 1 study, low quality evidence) for UA/NSTEMI  
35 without revascularisation.
- 36 • There was a clinically important benefit of prasugrel compared to clopidogrel for cardiac  
37 mortality at 30 days (9326 participants in 1 study for UA/NSTEMI without  
38 revascularisation
- 39 • There was no clinically important difference between prasugrel and clopidogrel for  
40 cardiac mortality at 1 year (9326 participants in 1 study, very low quality evidence) for  
41 UA/NSTEMI without revascularisation.
- 42 • There was no clinically important difference between prasugrel and clopidogrel for re-  
43 infarction at 30 days (9326 participants in 1 study, very low quality evidence) for  
44 UA/NSTEMI with revascularisation in people aged <75 years.
- 45 • There was no clinically important difference between prasugrel and clopidogrel for re-  
46 infarction at 1 year (9326 participants in 1 study, low quality evidence) for UA/NSTEMI  
47 without revascularisation.
- 48 • There was no clinically important difference between prasugrel and clopidogrel for major  
49 bleeding at 30 days (9240 participants in 1 study, low quality evidence) for UA/NSTEMI  
50 without revascularisation

- 1 • There was no clinically important difference between prasugrel and clopidogrel for  
2 stroke at 30 days (9326 participants in 1 study, low quality evidence) for UA/NSTEMI  
3 without revascularisation  
4 • There was no clinically important difference between prasugrel and clopidogrel for health-  
5 related quality of life (measures: EQ5D, SAQ Physical, SF-12 physical, SF-12 mental,  
6 SF-36) at 1 year (1774-5764 participants in 1 study, moderate quality evidence) for  
7 UA/NSTEMI without revascularisation.

#### 8 STEMI with revascularisation

- 9 • There was a clinically important benefit of prasugrel compared to clopidogrel for all-cause  
10 mortality at 30 days (3596 participants in 2 studies, low quality evidence) and all-cause  
11 mortality at 1 year (3534 participants in 1 study, low quality evidence) for STEMI with  
12 revascularisation.  
13 • There was a clinically important benefit of prasugrel compared to clopidogrel for cardiac  
14 mortality at 30 days (3534 participants in 1 study, low quality evidence) and cardiac  
15 mortality at 1 year (3534 participants in 1 study, low quality evidence) for STEMI with  
16 revascularisation.  
17 • There was however a clinically important benefit of prasugrel when compared to  
18 clopidogrel for re-infarction at 30 days (3596 participants in 2 studies, low quality  
19 evidence) and at 1 year (3534 participants in 1 study, low quality evidence) for STEMI  
20 with revascularisation.  
21 • There was no clinically important difference between prasugrel and clopidogrel for major  
22 bleeding (3534 participants in 1 study, very low quality evidence) and bleeding (major  
23 and minor) at 30 days (62 participants in 1 study, low quality evidence) and at 1 year  
24 (3534 participants in 1 study, very low quality evidence) for STEMI with revascularisation.  
25 • There was no clinically important difference between prasugrel and clopidogrel for minor  
26 bleeding at 30 days (3534 participants in 1 study, low quality evidence) for STEMI with  
27 revascularisation.  
28 • There was no clinically important difference between prasugrel and clopidogrel for stroke  
29 at 30 days (3534 participants in 1 study, low quality evidence) and at 1 year (3534  
30 participants in 1 study, very low quality evidence) for STEMI with revascularisation.  
31 • There was no clinically important difference between prasugrel and clopidogrel for need  
32 for revascularisation at 30 days (3534 participants in 1 study, low quality evidence) and at  
33 1 year (3534 participants in 1 study, low quality evidence) for STEMI with  
34 revascularisation.  
35 • There was no clinically important difference between prasugrel and clopidogrel for stent  
36 thrombosis (definite or probable) at 30 days (3534 participants in 1 study, low quality  
37 evidence), stent thrombosis (type not specified) and 30 days (62 participants in 1 study,  
38 very low quality evidence) for STEMI with revascularisation.  
39 • There was a clinically important benefit for prasugrel compared to clopidogrel for other  
40 adverse effects at 30 days (62 participants in 1 study, low quality evidence) for STEMI  
41 with revascularisation.

#### 42 **Ticagrelor versus prasugrel**

##### 43 ACS with/without revascularisation

- 44 • There was a clinically important harm in all-cause mortality at 30 days (1698 participants  
45 in 6 studies, low quality evidence) and at 1 year (4018 participants in 1 study, low quality  
46 evidence) when ticagrelor was compared to prasugrel for ACS with/without  
47 revascularisation.  
48 • There was a clinically important benefit of ticagrelor when compared to prasugrel for  
49 cardiac mortality at 30 days (1543 participants in 3 studies, low quality evidence). There  
50 was however a clinically important harm in cardiac mortality at 1 year (4018 participants  
51 in 1 study, very low quality evidence) when ticagrelor was compared to prasugrel for ACS  
52 with/without revascularisation.

- 1 • There was no clinically important difference between ticagrelor and prasugrel for re-  
2 infarction at 30 days (1430 participants in 4 studies, very low quality evidence). There  
3 was however a clinically important harm in re-infarction at 1 year (4018 participants in 1  
4 study, low quality evidence) when ticagrelor was compared with prasugrel for ACS  
5 with/without revascularisation.
- 6 • There was no clinically important difference between ticagrelor and prasugrel for major  
7 bleeding at 30 days (1698 participants in 6 studies, very low quality evidence) and at 1  
8 year (3762 participants in 1 study, very low quality evidence) for ACS with/without  
9 revascularisation.
- 10 • There was no clinically important difference between ticagrelor and prasugrel for stroke at  
11 30 days (1593 participants in 4 studies, very low quality evidence) and at 1 year (4018  
12 participants in 1 study, very low quality evidence) for ACS with/without revascularisation.

### 13 UA/NSTEMI with revascularisation

- 14 • There was a clinically important benefit of ticagrelor compared to prasugrel for all-cause  
15 mortality at 30 days (313 participants in 2 studies, very low quality evidence) for  
16 UA/STEMI with revascularisation for UA/STEMI with revascularisation.
- 17 • There was a clinically important benefit of ticagrelor when compared to prasugrel for  
18 cardiac mortality at 30 days (313 participants in 2 studies, low quality evidence) for  
19 UA/STEMI with revascularisation.
- 20 • There was a clinically important benefit of ticagrelor when compared to prasugrel for re-  
21 infarction at 30 days (100 participants in 1 study, low quality evidence) for UA/STEMI with  
22 revascularisation.
- 23 • There was no clinically important difference between ticagrelor and prasugrel for major  
24 bleeding at 30 days (313 participants in 2 studies, very low quality evidence) for  
25 UA/STEMI with revascularisation.
- 26 • There was no clinically important difference between ticagrelor and prasugrel for stroke at  
27 30 days (313 participants in 2 studies, low quality evidence) for UA/STEMI with  
28 revascularisation.
- 29 • There was no clinically important difference between ticagrelor and prasugrel for stent  
30 thrombosis (definite or probable) at 1 year (4018 participants in 1 study, very low quality  
31 evidence) for UA/STEMI with revascularisation.

### 32 STEMI with revascularisation

- 33 • There was a clinically important benefit of ticagrelor compared to prasugrel for all-cause  
34 mortality at 30 days (1385 participants in 1 study, low quality evidence) for STEMI with  
35 revascularisation.
- 36 • There was a clinically important benefit of prasugrel when compared to ticagrelor for  
37 cardiac mortality at 30 days (1230 participants in 1 study, low quality evidence) for STEMI  
38 with revascularisation.
- 39 • There was no clinically important difference between ticagrelor and prasugrel for re-  
40 infarction at 30 days (1330 participants in 3 studies, very low quality evidence) for STEMI  
41 with revascularisation.
- 42 • There was no clinically important difference between ticagrelor and prasugrel for major  
43 bleeding at 30 days (1385 participants in 4 studies, very low quality evidence) for STEMI  
44 with revascularisation.
- 45 • There was no clinically important difference between ticagrelor and prasugrel for minor  
46 bleeding at 30 days (1385 participants in 4 studies, very low quality evidence) for STEMI  
47 with revascularisation.
- 48 • There was no clinically important difference between ticagrelor and prasugrel for stroke at  
49 30 days (1280 participants in 2 studies, very low quality evidence) for STEMI with  
50 revascularisation.

- 1 • There was no clinically important difference between ticagrelor and prasugrel for need for  
2 revascularisation at 30 days (1230 participants in 1 study, low quality evidence) for  
3 STEMI with revascularisation.
- 4 • There was no clinically important difference between ticagrelor and prasugrel for stent  
5 thrombosis (definite) at 30 days (1230 participants in 1 study, low quality evidence) for  
6 STEMI with revascularisation.
- 7 • There was no clinically important difference between ticagrelor and prasugrel for stent  
8 thrombosis (type not specified) at 30 days (100 participants in 2 studies, low quality  
9 evidence) for STEMI with revascularisation.
- 10 • There was no clinically important difference between ticagrelor and prasugrel for  
11 breathing adverse effects at 30 days (50 participants in 1 study, low quality evidence) for  
12 STEMI with revascularisation.
- 13 • There was no clinically important difference between ticagrelor and prasugrel for  
14 bradycardic adverse effects at 30 days (50 participants in 1 study, very low quality  
15 evidence) for STEMI with revascularisation.
- 16 • There was a clinically important harm in other adverse effects at 30 days (139  
17 participants in 3 studies, very low quality evidence) when ticagrelor was compared with  
18 prasugrel for STEMI with revascularisation.

## 19 Network meta-analyses

20

### 21 *All-cause mortality at 30 days*

- 22 • Fourteen studies were included in the network; prasugrel and ticagrelor may both be  
23 more effective than clopidogrel in reducing the risk of mortality. Prasugrel may be  
24 more effective than ticagrelor. However, there was uncertainty in the network. No  
25 inconsistency was identified.

26 •

### 27 *New MI at 30 days*

- 28 • Eleven studies were included in the network; ticagrelor is more effective than  
29 clopidogrel in reducing the risk of MI. Prasugrel may be more effective than  
30 clopidogrel. Ticagrelor may be more effective than prasugrel. However, there was  
31 uncertainty in the network. No inconsistency was identified.

32

### 33 *Stroke at 30 days*

- 34 • Eight studies were included in the network; prasugrel may be more effective than  
35 clopidogrel and ticagrelor in reducing the risk of stroke. Clopidogrel may also be more  
36 effective than ticagrelor. However, there was uncertainty in the network. No  
37 inconsistency was identified.

38 •

### 39 *Major bleeding at 30 days*

- 40 • Ten studies were included in the network; no clinical difference between the three  
41 treatments in terms of reducing the risk of major bleeding. However, there uncertainty  
42 in the network. No inconsistency was identified.

43

### 44 *Minor bleeding at 30 days*

- 45 • Ten studies were included in the network; prasugrel is more effective than clopidogrel  
46 and ticagrelor in reducing the risk of minor bleeding. Clopidogrel may also be more  
47 effective than ticagrelor. However, there was uncertainty in the network. Evidence of  
48 inconsistency was identified due to one study.

49

50

## 1.7.2 Health economic evidence statements

- 2 • One cost-utility analysis found that for:
- 3     ○ People with ACS managed medically or invasively ticagrelor was cost effective
- 4     compared to clopidogrel (ICER: £3,805 per QALY gained). This analysis was
- 5     assessed as partially applicable with potentially serious limitations.
- 6     ○ People with ACS undergoing PCI ticagrelor was cost effective compared to
- 7     prasugrel (ICER: £3,482 per QALY gained). This analysis was assessed as
- 8     partially applicable with potentially serious limitations.
- 9 • One cost-utility analysis found that ticagrelor was cost effective compared to clopidogrel
- 10 for people with ACS managed medically (ICER: £2,925 per QALY gained). This analysis
- 11 was assessed as partially applicable with potentially serious limitations.
- 12 • One cost-utility analysis found that for people with ACS undergoing PCI prasugrel was
- 13 cost effective compared to clopidogrel:
- 14     ○ for treating people with STEMI with diabetes (ICER: £1,732 per QALY gained).
- 15     ○ for treating people with STEMI and without diabetes (ICER: £7,073 per QALY
- 16     gained)
- 17     ○ for treating people with UA/NSTEMI with diabetes prasugrel was dominant (less
- 18     costly and more effective)
- 19     ○ for treating people with UA/NSTEMI without diabetes (ICER: £4,154 per QALY
- 20     gained).
- 21 This analysis was assessed as partially applicable with potentially serious limitations.
- 22 • One cost-utility analysis found that ticagrelor was cost effective compared to prasugrel
- 23 and clopidogrel for treating people with ACS undergoing PCI (ICER: £6,556 per QALY
- 24 gained compared to clopidogrel). It also found that prasugrel was extendedly dominated
- 25 by ticagrelor. This analysis was assessed as partially applicable with potentially serious
- 26 limitations.
- 27 • One cost-utility analysis found that ticagrelor was cost effective compared to prasugrel
- 28 and clopidogrel for treating people with ACS undergoing PCI (ICER: £6,210 per QALY
- 29 gained compared to prasugrel). This analysis was assessed as partially applicable with
- 30 potentially serious limitations.
- 31 • One original cost-utility analysis found that for treating people with STEMI:
- 32     ○ When 31-day to 1-year treatment effects were based on studies comparing
- 33     prasugrel to clopidogrel and ticagrelor to clopidogrel, prasugrel was cost effective
- 34     compared to ticagrelor and clopidogrel (ICERs: £3,157per QALY gained prasugrel
- 35     compared to clopidogrel; £21,822 per QALY gained ticagrelor compared to
- 36     prasugrel).
- 37     ○ When 31-day to 1-year treatment effects were based on studies comparing
- 38     prasugrel to clopidogrel and ticagrelor to prasugrel, prasugrel was cost effective
- 39     compared to clopidogrel (ICER: £3,182per QALY gained) and prasugrel was
- 40     dominant compared to ticagrelor (less costly and more effective).
- 41     ○ When 31-day to 1-year treatment effects were based on studies comparing
- 42     ticagrelor to clopidogrel and ticagrelor to prasugrel, prasugrel was cost effective,
- 43     prasugrel was cost effective compared to clopidogrel (ICER: £2,747 per QALY
- 44     gained) and prasugrel was dominant compared to ticagrelor (less costly and more
- 45     effective).
- 46 • The same original cost-utility analysis found that for treating people with UA/NSTEMI:
- 47     ○ When 31-day to 1-year treatment effects were based on studies comparing
- 48     prasugrel to clopidogrel and ticagrelor to clopidogrel, ticagrelor was cost effective
- 49     compared to prasugrel and clopidogrel (ICERs: £15,915per QALY gained
- 50     ticagrelor compared to prasugrel; £4,550 per QALY gained prasugrel compared to
- 51     clopidogrel). .
- 52     ○ When 31-day to 1-year treatment effects were based on studies comparing
- 53     prasugrel to clopidogrel and ticagrelor to prasugrel, prasugrel was cost effective
- 54     compared to clopidogrel (ICER: £4,644 per QALY gained) and prasugrel was
- 55     dominant compared to ticagrelor (less costly and more effective).



- 1           ○ When 31-day to 1-year treatment effects were based on studies comparing  
2           ticagrelor to clopidogrel and ticagrelor to prasugrel, prasugrel was cost effective  
3           compared to clopidogrel (ICER: £2,452 per QALY gained) and prasugrel was  
4           dominant compared to ticagrelor (less costly and more effective).  
5

## 1.8 The committee's discussion of the evidence

### 1.8.1 Interpreting the evidence

#### 1.8.1.1 The outcomes that matter most

9           The committee agreed that outcomes critical for decision making included: mortality up to 30  
10          days and 1 year (all-cause and cardiac); re-infarction up to 30 days and 1 year;  
11          complications related to bleeding; and health-related quality of life. While the focus of the  
12          evidence review was on initial antiplatelet therapy, the committee considered the one year  
13          time-point for these outcomes to be more critical than up to 30 days. Stroke, need for  
14          revascularisation, stent thrombosis, breathing adverse effects, bradycardia, other adverse  
15          effects and unplanned urgent readmission within 30 days for any reason were also  
16          considered important outcomes.

17          For the comparison of ticagrelor versus clopidogrel in people with ACS, evidence was  
18          reported for all critical and important outcomes (at up to 30 days and one year) except for  
19          health-related quality of life. The committee noted that not all 30-day outcomes were  
20          available from the largest study in this comparison (Wallentin, 2009; PLATO).

21          For the comparison of prasugrel versus clopidogrel in people with ACS, evidence was  
22          reported for all critical and important outcomes (at up to 30 days and up to one year) except  
23          for the adverse events of breathlessness and bradycardia, and unplanned urgent  
24          readmission within 30 days. The committee noted that not all 30-day outcomes were  
25          available from the two largest studies in this comparison (Wiviott, 2007; TRITON).

26          For the comparison of ticagrelor versus prasugrel in people with ACS, evidence was reported  
27          at up to 30 days/ 1 month for all outcomes except health-related quality of life and unplanned  
28          urgent readmission within 30 days. The committee noted that there was 1 year data available  
29          for all-cause mortality, cardiac mortality, stroke, re-infarction, major bleeding and stent  
30          thrombosis (definite and probable)

31          For the purposes of this review, bleeding scores were considered 'major' or 'minor' according  
32          to author and bleeding scale definitions. Where studies reported bleeding on multiple scales,  
33          the most relevant available scale was used in the meta-analysis based on a hierarchy as per  
34          the protocol. Stent thrombosis was included in the analyses if it was reported as 'definite  
35          and/or probable', as reported in studies. Outcome data which were not reported as definite or  
36          probable stent thrombosis were included but analysed separately.

#### 1.8.1.2 The quality of the evidence

38          The quality (certainty) of the evidence ranged from a GRADE rating of very low to moderate.  
39          The main reasons for downgrading the quality of the evidence were risk of bias, imprecision  
40          and inconsistency. The presence of selection bias in terms of lack of adequate randomisation  
41          and allocation concealment commonly resulted in a high or very high risk of bias rating but  
42          this is unlikely to have systematically favoured one intervention over the other.

#### 1.8.1.3 Benefits and harms

44          The committee considered the evidence (network meta-analyses (NMAs) and pairwise meta-  
45          analyses) for the following comparisons in people with ACS: ticagrelor versus clopidogrel;

1 prasugrel versus clopidogrel; ticagrelor versus prasugrel. The evidence included populations  
2 of overall ACS with or without revascularisation for the pairwise meta-analyses and NMAs.

3 All ACS are believed to share the same basic pathophysiology in terms of acute  
4 atherosclerotic plaque rupture leading to acute thrombus formation and compromise of  
5 coronary blood flow. For this reason, analysing the effects of anti-platelet therapy on all ACS  
6 grouped together should be a satisfactory way of evaluating differential efficacy of different  
7 therapeutic strategies. The committee also noted the many similarities in treatment of STEMI  
8 and UA/NSTEMI populations. However, STEMI is a medical emergency requiring immediate  
9 treatment, and given the well established differential onsets of action of clopidogrel,  
10 prasugrel and ticagrelor it is conceivable that this may impact their relative clinical  
11 effectiveness in STEMI patients compared to UA/NSTEMI. Moreover, whereas the majority  
12 of people with STEMI will proceed to angiography with the intention of performing PCI, a  
13 greater proportion of people with UA/NSTEMI are managed medically. Existing subgroup  
14 data in STEMI patients have also suggested that the benefits of prasugrel and ticagrelor over  
15 clopidogrel may not be as large as those seen in the overall ACS population. For these  
16 reasons, the committee wanted to examine the relative effects of clopidogrel, prasugrel and  
17 ticagrelor separately in the STEMI and UA/NSTEMI populations where trial data permitted  
18 this to be evaluated, considering substrata comparisons by condition (i.e. STEMI or  
19 UA/NSTEMI) and management approach (i.e. with or without revascularisation).

20 Additionally, the committee noted that the presence of imprecision in some of the pairwise  
21 outcome results made interpretation of the clinical benefit or harm associated with  
22 interventions challenging. However, the imprecision was predominantly in the pairwise meta-  
23 analyses for the individual subpopulations. The committee were satisfied that they could  
24 have more confidence in the results for the overall ACS population. The discussion below  
25 therefore represents the evidence from the all ACS analyses. The discussion has however  
26 been split into people that receive PCI and those who do not as prasugrel is not indicated in  
27 those that do not and so the potential treatment options vary and separate recommendations  
28 were made.

### 29 **People undergoing PCI**

30 In people undergoing PCI, dual antiplatelet therapy could be aspirin plus one of clopidogrel,  
31 prasugrel or ticagrelor. As discussed above, the committee considered the analyses using all  
32 ACS data combined to be the most informative as relative treatment effects were likely to be  
33 consistent and this will reduce imprecision. The evidence discussed below is therefore from  
34 the all ACS analyses.

### 35 ***Network meta-analyses***

36 The committee reviewed outcome data at two timepoints, 30 days and 1 year, and agreed  
37 that NMAs should be conducted if there was sufficient evidence to do so.

38 There was sufficient evidence to conduct NMAs on all ACS for five outcomes at 30 days (all-  
39 cause mortality, new myocardial infarction, stroke, major bleeding and minor bleeding). The  
40 committee agreed that these outcomes are appropriate for aiding decision-making by  
41 demonstrating the clinical effectiveness of these drugs and their safety. Following the  
42 publication of the ISAR REACT-5 trial it became technically possible to do NMAs for the 1  
43 year outcome data. However, checks prior to conducting NMAs identified inconsistencies  
44 which would have produced unreliable results and accordingly a 1 year NMA was not  
45 performed (see NMA document for more information).

46 The 30 day NMA results (relative risks, treatment ranks, probability of the outcome occurring  
47 and probability of the treatment being the best) were presented to the committee. The all-  
48 cause mortality network was the largest informed by 14 studies, the new myocardial  
49 infarction network was informed by 11 studies, the stroke network was informed by 8 studies  
50 and the bleeding networks (major and minor) were both informed by 10 studies. The NMA

1 results suggest that prasugrel and ticagrelor are more clinically effective than clopidogrel for  
2 the outcomes all-cause mortality and new myocardial infarction. The stroke data showed  
3 prasugrel to be the most beneficial agent and ticagrelor the least, but confidence intervals  
4 were wide and the committee regarded this outcome with caution. For the outcome of major  
5 bleeding there was no clear clinical difference between the three treatments. However, the  
6 NMA results indicate that prasugrel may be more clinically effective than clopidogrel and  
7 ticagrelor respectively in terms of minimising minor bleeding events. Overall the committee  
8 agreed that clopidogrel is the least clinically effective treatment option, with mixed results for  
9 prasugrel versus ticagrelor, favouring prasugrel but with sufficient uncertainty in the networks  
10 to clearly distinguish which treatment is more clinically effective (further details can be found  
11 in the NMA document).

## 12 ***Pairwise meta-analyses***

13 The committee reviewed the pairwise meta-analyses for the outcome data reported at 30  
14 days that was not included in the NMAs and pairwise meta-analysis outcome data at 1 year.

### 15 *Ticagrelor versus clopidogrel*

16 Evidence from the pairwise meta-analysis for the comparison of ticagrelor versus clopidogrel  
17 showed clinical benefit of ticagrelor for the outcome of all-cause mortality and re-infarction at  
18 1 year, and at both 30 days and 1 year when considering the need for revascularisation.  
19 Ticagrelor also reduced stent thrombosis events, but only at 1 year. For cardiac mortality, the  
20 evidence showed that clopidogrel is more effective in reducing events at 30 days only, with  
21 clinical benefit of ticagrelor at 1 year. Clopidogrel caused fewer breathing adverse events  
22 than ticagrelor at 30 days and 1 year. Breathing adverse effects, associated more often with  
23 ticagrelor, were considered by the committee to be reversible in most cases. However, the  
24 committee highlighted the difficulty in capturing evidence for those patients who discontinue  
25 drug treatment due to side effects such as breathlessness, and then subsequently  
26 experience cardiac events. There was no clinical difference between the two treatments for  
27 bleeding outcomes (major bleeding and minor bleeding) and stroke at 1 year.

### 28 *Prasugrel versus clopidogrel*

29 Evidence for the comparison of prasugrel versus clopidogrel showed clinical benefit of  
30 prasugrel for the outcomes of all-cause mortality, cardiac mortality and re-infarction at 1 year.  
31 There was no clinical difference between the two treatments for stent thrombosis (at 30 days  
32 and 1 year) and for the following outcomes at 1 year: major bleeding, minor bleeding, stroke,  
33 need for revascularisation, stent thrombosis, health-related quality of life, adverse effects and  
34 readmission.

### 35 *Ticagrelor versus prasugrel*

36 When ticagrelor was compared with prasugrel, the pairwise evidence suggested that  
37 prasugrel is more clinically effective in the long-term (up to 1 year) in terms of all-cause  
38 mortality, cardiac mortality and re-infarction. However, most of these differences were  
39 relatively small and, as already noted, the quality assessment showed uncertainty for several  
40 of the outcome measures. The committee agreed there was no clinically important difference  
41 between the two treatments for major bleeding, stroke, stent thrombosis and adverse effects  
42 (at 30 days and 1 year).

## 43 ***Discussion***

44 The committee noted and discussed additional uncertainty in the evidence due to  
45 inconsistency in the indirect and direct clinical evidence at 1 year. As described above ideally  
46 NMA would be used to bring together all the evidence at 1 year into a single set of consistent  
47 treatment effects. However, due to significant inconsistency between direct and indirect  
48 effects NMA was considered unreliable and was not undertaken. Inconsistency was identified  
49 in 3 of 4 outcomes (no data was available for ticagrelor versus prasugrel for minor bleeding)

1 between the direct and indirect estimates of relative treatment effect. For example, using the  
2 data for prasugrel and ticagrelor each compared to clopidogrel generated an odds ratio for  
3 ticagrelor versus prasugrel of 0.77 (0.61 to 0.97) which favours ticagrelor but the direct  
4 evidence from ISAR-REACT 5 gave an odds ratio of 1.24 (0.90 to 1.70) which favours  
5 prasugrel. Reinfarction was implicitly 1.08 (0.92 to 1.27) using indirect data but was 1.63  
6 (1.17 to 2.26) using the direct comparison from ISAR-REACT 5, both favouring prasugrel.  
7 Major bleeding was implicitly 0.73 (0.57 to 0.93) for the indirect comparison where the  
8 direction of effect favours ticagrelor and 1.06 (0.78 to 1.44) in the direct evidence where the  
9 direction of effect favours prasugrel. Stroke was not found to be inconsistent with 1.22 (0.80  
10 to 1.84) indirect and 1.16 (0.62 to 2.14) direct. While being aware of some differences  
11 between trials, the committee could not determine a clear explanation for the inconsistency.

12 Given the lack of an NMA to bring all data together, the committee considered whether  
13 particular evidence was more relevant to decision making than others. They noted that the  
14 data for ticagrelor and prasugrel compared with clopidogrel included some very large trials  
15 that were considered important parts of the evidence base. However, they also agreed that  
16 the 1 year evidence that directly compared these drugs from ISAR-REACT 5 was the most  
17 relevant in terms of understanding whether there were differences in clinical effects between  
18 prasugrel and ticagrelor. The committee discussed ISAR-REACT 5 in detail. Aspects of ACS  
19 management can vary between countries (such as use of radial versus femoral approach for  
20 PCI or other such specifics) and it was noted that this study was not carried out in the UK.  
21 The committee discussed if this raised any issues for interpretation in a UK context. They  
22 agreed that for STEMI the evidence was directly applicable. However the committee noted  
23 that the time to angiography for people UA/NSTEMI in the study was much shorter than is  
24 currently achieved in the UK. Given that prasugrel is only given at the time of PCI the  
25 committee agreed this made them less confident in the generalisability of the study to UK  
26 practice for UA/NSTEMI.

### 27 *Net health gains*

28 Health economic modelling undertaken for the guideline assessed overall health gain in  
29 terms of QALYs (taking into account both benefits and harms due to death, re-infarction,  
30 stroke, major bleeding and minor bleeding). The treatment option that resulted in the highest  
31 QALYs in the analysis varied between prasugrel and ticagrelor depending on which clinical  
32 data was used in the model, showing that the inconsistency identified in the evidence for  
33 individual outcomes leads to overall uncertainty in terms of health gain. When ISAR-REACT  
34 5 was incorporated prasugrel had the highest QALYs but when it was not used (and data  
35 from studies comparing ticagrelor or prasugrel to clopidogrel were used) ticagrelor had the  
36 highest QALYs. These results are discussed further in the next section about cost  
37 effectiveness.

### 38 **Conclusions**

39 Overall the committee agreed that the clinical evidence supported the use of ticagrelor and  
40 prasugrel over clopidogrel. In most cases there was not clear evidence of clinical differences  
41 between ticagrelor and prasugrel although where there was evidence it generally favoured  
42 prasugrel, exceptions being the indirect comparisons of ticagrelor and prasugrel using  
43 studies that compared each to clopidogrel that suggest benefits for ticagrelor over prasugrel  
44 in terms of mortality and major bleeding. The committee however agreed that the strongest  
45 evidence about the relative treatment effects of prasugrel versus ticagrelor came from the  
46 ISAR-REACT 5 study that compared them head to head and reported 1 year outcomes. The  
47 committee were satisfied this was applicable to the UK setting for people with STEMI. They  
48 agreed this was probably applicable for people with UA/NSTEMI undergoing PCI as well but  
49 noted that as the time to angiography (and so PCI) for people with UA/NSTEMI was much  
50 shorter than typical in the UK and prasugrel isn't given until the time of PCI and this  
51 introduced some additional uncertainty in this subpopulation.

1 **People not undergoing PCI**

2 In people not undergoing PCI, prasugrel is not an option and so the committee considered  
3 the evidence for ticagrelor versus clopidogrel. As discussed above, the committee  
4 considered the analyses using all ACS data combined to be the most informative as relative  
5 treatment effects were likely to be consistent and this will reduce imprecision. The evidence  
6 discussed below is therefore from the all ACS analyses.

7 Taking into account the evidence from the NMA and pairwise meta-analyses described  
8 above the committee concluded that there was evidence of clinical benefit with ticagrelor  
9 versus clopidogrel in terms of all-cause mortality, cardiac mortality and reinfarction. This was  
10 generally seen at 30 days and 1 year. There was some uncertainty in all-cause mortality at  
11 30 days as the confidence interval crossed 1. In addition, cardiac mortality in the overall ACS  
12 population at 30 days did not show a benefit for ticagrelor, but there was considerable  
13 imprecision around this estimate and it was inconsistent with all other mortality analyses.  
14 Evidence also showed a clinical benefit of ticagrelor at both 30 days and 1 year in the need  
15 for revascularisation, and evidence for reduced stent thrombosis events at 1 year.

16 The committee agreed that the evidence overall did not demonstrate a clinically important  
17 harm with ticagrelor over clopidogrel in terms of major bleeding, minor bleeding or stroke at  
18 30 days or 1 year. Minor bleeding was increased somewhat with ticagrelor but the committee  
19 agreed that minor bleeding would typically not lead to any long term health implications. In  
20 addition, in the NMA 30 day analysis there was uncertainty in the treatment effect as the  
21 confidence interval crossed 1. The committee noted that in the 30 day NMA and in the 1 year  
22 meta-analysis stroke was higher with ticagrelor than clopidogrel and that stroke was a  
23 significant adverse outcome with long term health consequence, but absolute differences in  
24 number of events was small and confidence intervals were wide and so the committee  
25 regarded this outcome with caution and did not consider there to be clear evidence of harm.

26 Clopidogrel caused fewer breathing adverse events than ticagrelor at 30 days and 1 year.  
27 These were considered by the committee to be reversible in most cases and so were not  
28 likely to have a substantial impact on health long term. However, the committee highlighted  
29 the difficulty in capturing evidence for those patients who discontinue drug treatment due to  
30 side effects such as breathlessness, and then subsequently experience cardiac events.

31 Cost-utility analyses found that QALYs (that took account of both benefits and harms due to  
32 death, re-infarction, stroke and bleeding) found an overall increase in QALYs with ticagrelor  
33 compared to clopidogrel. This included one analysis in people with ACS intended for non-  
34 invasive treatment.

35 Given the above, the committee concluded that the clinical evidence supported the use of  
36 ticagrelor over clopidogrel and that ticagrelor was the most clinically effective option in  
37 people not undergoing PCI where only clopidogrel and ticagrelor are the treatment options.  
38 The data is dominated by people with UA/NSTEMI because far fewer people with STEMI are  
39 managed without PCI, but the committee felt that the conclusions could be extrapolated to  
40 STEMI since the basic pathophysiology of NSTEMI and STEMI is almost identical and they  
41 considered the superiority of ticagrelor over clopidogrel in the non-PCI population as a whole  
42 to be clearcut. However, they noted that clinical studies in this area often exclude older or  
43 more high risk people and that these people may be at greater risk of bleeding. Given that  
44 some of the evidence suggested ticagrelor may increase bleeding they agreed that in people  
45 at high risk of bleeding harms might outweigh benefits and so agreed that either clopidogrel  
46 plus aspirin or aspirin alone may be more appropriate to use in this group. They agreed with  
47 the conclusion of the previous guideline committee, that those who are at higher bleeding  
48 risk are hard to define precisely but should be identified based on clinical assessment taking  
49 into account a range of factors including age and frailty.

### 1.8.2 Cost effectiveness and resource use

2 Five published economic evaluations were included for this review including the analyses  
3 that informed the most recent technology appraisal guidance for prasugrel and ticagrelor.  
4 These varied in terms of what comparators were included and what ACS population they  
5 related to.

6 Two UK analyses compared ticagrelor and clopidogrel, one that informed the ticagrelor  
7 TA236 in an ACS population (invasive and non-invasive management; analysed overall and  
8 for NSTEMI, STEMI and UA/NSTEMI separately) and the other in people with ACS intended  
9 for non-invasive therapy. In both these analyses ticagrelor was found to be cost effective  
10 compared to clopidogrel with an incremental cost effectiveness ratio around £3,000 to £5,000  
11 per QALY gained. Ticagrelor had higher costs and QALYs than clopidogrel. Both analyses  
12 were based on treatment effect data from the PLATO RCT. The committee discussed the  
13 additional studies comparing ticagrelor and clopidogrel that were identified in the review of  
14 clinical effectiveness evidence undertaken for the guideline, but it was noted that PLATO is  
15 by far the largest trial comparing ticagrelor and clopidogrel and effect sizes from the guideline  
16 meta-analysis that incorporated all available evidence were mostly similar to the PLATO  
17 study alone. The committee also discussed whether the baseline risks in the economic  
18 analysis of people intended for non-invasive therapy may be lower than in the real world as  
19 the average age in the subpopulation used in the analysis appeared lower than they would  
20 expect. However, the committee concluded that for people being medically managed, where  
21 prasugrel is not an option, the evidence supported ticagrelor being the most cost-effective  
22 option (over clopidogrel) despite being higher cost, due to the greater health benefits from  
23 use of ticagrelor.

24 For people with ACS undergoing PCI, prasugrel is also a treatment option. The UK analysis  
25 that informed the prasugrel NICE TA317 guidance found prasugrel to be cost effective  
26 compared to clopidogrel in an ACS population undergoing PCI (analysed for STEMI and  
27 NSTEMI, with and without diabetes, separately), with results varying from dominant to an  
28 incremental cost effectiveness ratio of £7,000 per QALY gained. This was based on the  
29 TRITON-TIMI 38 RCT which was included in the clinical evidence review. The committee  
30 discussed the additional studies comparing prasugrel and clopidogrel that were identified in  
31 the review of clinical effectiveness evidence undertaken for the guideline, but it was noted  
32 that TRITON-TIMI 38 is by far the largest trial comparing prasugrel and clopidogrel and effect  
33 sizes from the guideline meta analysis that incorporated all available evidence were mostly  
34 similar, although the mortality treatment effect was slightly more favourable in the TRITON-  
35 TIMI 38 trial. However, in order to determine which of the three DAPT options is most cost  
36 effective in an ACS PCI population an analysis including clopidogrel, prasugrel and ticagrelor  
37 together is required.

38 As part of the analysis that informed the ticagrelor TA236, a comparison of ticagrelor and  
39 prasugrel was also undertaken in an ACS population managed invasively. It was based on  
40 an indirect comparison of ticagrelor and prasugrel using the PLATO and TRITON-TIMI 38  
41 trials that compared each to clopidogrel. This analysis found that ticagrelor had higher costs  
42 and QALYs compared to prasugrel and was the most cost-effective option with an ICER of  
43 £3,482 per QALY gained. Although this was noted at the time of the technology appraisal,  
44 they chose not to recommend ticagrelor over prasugrel.

45 Two published economic evaluations compared ticagrelor, prasugrel and clopidogrel in an  
46 ACS population undergoing PCI. One took a Canadian cost perspective and was based on  
47 three randomised controlled trials (PLATO, TRITON-TIMI 38 and DISPERSE 2). The other  
48 used a Norwegian cost perspective and was based on two randomised controlled trials  
49 (PLATO and TRITON-TIMI 38). Both analyses found that ticagrelor had the highest costs  
50 and QALYs followed by prasugrel and then clopidogrel. However, ticagrelor was also the  
51 most cost-effective option in both analyses. The committee agreed that there were a number  
52 of limitations of these analyses, in particular that they do not take into account all the

1 currently available clinical effectiveness evidence including new head-to-head data for  
2 ticagrelor and prasugrel.

3 After reviewing the published clinical and cost effectiveness evidence, the committee  
4 considered there to be uncertainty about which intervention was the most cost-effective  
5 option for people undergoing PCI in the NHS setting and prioritised this area for new analysis  
6 as part of the development of the guideline. A decision analytic model was constructed to  
7 compare ticagrelor, prasugrel and clopidogrel in people with STEMI and UA/NSTEMI  
8 undergoing PCI from a UK NHS perspective. Relative treatment effects were based on the  
9 systematic review and meta-analyses undertaken as part of this guideline update. STEMI  
10 and UA/NSTEMI were modelled separately as baseline risks were considered likely to be  
11 different, although relative treatment effects were assumed to be the same. Relative  
12 treatment effects in the model 0 to 30 days were based on the 30 day network meta-analysis  
13 as this combines all available data into a single set of consistent treatment effects. Relative  
14 treatment effects in the model 31 days to 1 year were based on the 1 year pair-wise meta-  
15 analyses. As described above, network meta-analysis of the 1 year data was considered  
16 unreliable as there was inconsistency in the network. This means that treatment effects  
17 within the evidence network are not consistent with each other and using different data may  
18 lead to different conclusions. The model was therefore run using different combinations of  
19 the available pairwise data to explore whether this would impact conclusions – this resulted  
20 in 3 treatment effect data scenarios in the analysis.

21 In the base case analysis, the DAPT option that was most cost effective depended on the  
22 clinical data used to inform relative treatment effects between 31 days and 1 year and the  
23 ACS subpopulation. Prasugrel was the most cost effective DAPT option for both STEMI and  
24 UA/NSTEMI in scenarios 2 and 3 (where the ISAR-REACT 5 RCT comparing prasugrel and  
25 ticagrelor was used to inform the relative treatment effects between 31 days and 1 year in  
26 the model) and there was little uncertainty in this conclusion. However in scenario 1 (when  
27 meta-analysed data from studies comparing prasugrel to clopidogrel and ticagrelor to  
28 clopidogrel was used to inform the relative treatment effects between 31 days and 1 year in  
29 the model) ticagrelor was the most cost effective option for UA/NSTEMI and prasugrel was  
30 the most cost effective option for STEMI. There was some uncertainty that ticagrelor was the  
31 most cost effective option in a UA/NSTEMI population in data scenario 1 as it was only cost  
32 effective in 63% of simulations, and there was a high degree of uncertainty that prasugrel  
33 was the most cost effective option in a STEMI population as it was only cost effective in 53%  
34 of simulations and ticagrelor was cost effective in 47% of simulations. Ticagrelor had the  
35 highest costs in all scenarios and ACS subgroups but only had the highest QALYs in  
36 scenario 1. Prasugrel had higher QALYs and lower costs than ticagrelor in scenarios 2 and  
37 3, and clopidogrel had the lowest costs in all scenarios, and the lowest QALYs in scenarios 1  
38 and 3.

39 It was noted that scenario 2 (in which meta-analysed data from studies comparing prasugrel  
40 to clopidogrel and the ISAR-REACT 5 trial that compared ticagrelor to prasugrel were used  
41 to inform the relative treatment effects between 31 days and 1 year in the model) resulted in  
42 ticagrelor being ranked the 3<sup>rd</sup> most cost-effective option for both STEMI and UA/NSTEMI, as  
43 it resulted in only having slightly more QALYs than clopidogrel for STEMI and had less  
44 QALYs than clopidogrel for UA/NSTEMI. This was because using the prasugrel versus  
45 clopidogrel data combined with the prasugrel versus ticagrelor data made ticagrelor slightly  
46 worse on certain outcomes, for example, the resulting odds ratio for mortality for ticagrelor  
47 versus clopidogrel was 1.24. The committee noted that this was inconsistent with the studies  
48 that directly compared ticagrelor with clopidogrel (such as PLATO) and were concerned that  
49 excluding data from PLATO from the treatment effects was not ideal as this trial was large,  
50 closely applicable to UK practice, and recruited in the UK. Therefore despite these results  
51 they agreed that clopidogrel was the least cost effective option.

52 The committee discussed the results of the sensitivity analysis where an additional treatment  
53 effect was included in the clopidogrel group to reflect rivaroxaban use. This analysis was

1 conducted to test whether the inclusion of rivaroxaban with clopidogrel would impact  
2 conclusions as a recommendation for another antiplatelet would preclude the use of  
3 rivaroxaban which is not licensed for use with ticagrelor and prasugrel. Although  
4 incorporation of rivaroxaban increased costs and QALYs (in all scenarios, the addition of  
5 rivaroxaban resulted in the clopidogrel group having the highest lifetime costs due to the  
6 inclusion of rivaroxaban treatment costs), conclusions about which DAPT option is the most  
7 cost effective were not changed. The committee noted practice would not be greatly  
8 impacted if a recommendation for ticagrelor or prasugrel was made, as only a small  
9 proportion of people with ACS are prescribed rivaroxaban alongside clopidogrel.

## 10 **Conclusions**

### 11 People with STEMI with PCI

12 For STEMI in scenario 1, prasugrel was the most cost-effective treatment with an ICER of  
13 £3,157 per QALY gained, but it was only the most cost-effective option in 53% of simulations  
14 with ticagrelor being cost effective in 47%. In both scenario 2 and scenario 3 prasugrel was  
15 the most cost-effective, with higher QALYs, dominating ticagrelor and being the most cost-  
16 effective in 91% and 95% of simulations respectively. Scenarios 2 and 3 were largely  
17 influenced by the results from ISAR-REACT 5, and the committee agreed that this trial is  
18 reflective of how the STEMI population would be treated in the UK. Also, before the  
19 publication of ISAR-REACT 5, the committee were confident that there was evidence to  
20 show that ticagrelor and prasugrel were both more effective than clopidogrel but there was  
21 limited evidence directly comparing the effectiveness of prasugrel and ticagrelor. It was  
22 therefore agreed that the publication of ISAR-REACT 5 addressed the uncertainty around the  
23 relative effectiveness of ticagrelor and prasugrel showing that prasugrel and ticagrelor largely  
24 did not have differential benefits or harms although where there was evidence of difference it  
25 favoured prasugrel, and the cost-effectiveness analysis further supported the use of  
26 prasugrel when this study was incorporated. As a result, the committee had confidence that  
27 prasugrel should be recommended in people with STEMI undergoing PCI.

### 28 People with UA/NSTEMI with PCI

29 In UA/NSTEMI, ticagrelor was cost effective in scenario 1, with an ICER of £15,915 per  
30 QALY gained, and was the most cost effective option in 63% of simulations. Prasugrel was  
31 the most cost-effective option in scenarios 2 and 3, with it being the most cost effective  
32 option in 82% and 99% of simulations respectively. The committee agreed that although  
33 ISAR-REACT 5 demonstrated prasugrel was the most effective antiplatelet, there was some  
34 level of uncertainty regarding its applicability to UK practice, as people recruited to the trial  
35 underwent PCI within hours, whereas in the NHS time to angiography is can be up to 3 days  
36 or longer. As there was some degree of uncertainty regarding how much weight could be  
37 placed on the scenarios which utilise the ISAR-REACT 5 data, the committee agreed it was  
38 reasonable to make a recommendation to use either prasugrel or ticagrelor in this population.

### 39 People not undergoing PCI

40 One published cost effectiveness analysis looking at medically managed people showed that  
41 ticagrelor was cost effective compared to clopidogrel with an ICER of £2,925 per QALY  
42 gained. Given this and the clinical evidence the committee made a recommendation to offer  
43 ticagrelor for those who are medically managed, unless they have a high bleeding risk. As  
44 discussed in the benefit and harm section above the committee noted that clinical studies  
45 often exclude older people or people with a higher risk of bleeding and they were concerned  
46 about whether the benefit harm trade off would be the same in this population. Given this the  
47 available cost effectiveness evidence may not be generalizable to this population.



### 1.8.3 Other factors the committee took into account

2 The committee agreed that the overall body of clinical evidence suggests that prasugrel is  
3 the most clinically effective treatment option, clearly better than clopidogrel although with  
4 uncertainty regarding its superiority over ticagrelor. They acknowledged the difficulty of  
5 having to consider the cost-effectiveness data in 3 different scenarios but noted that these  
6 also showed prasugrel to be the superior treatment option in 2 of the 3 analyses. However,  
7 there was less certainty in this conclusion for UA/NSTEMI than for STEMI. For STEMI, in  
8 scenario 1 prasugrel was the most cost-effective treatment with an ICER of £3,157, but it  
9 was only most cost-effective in 53% of simulations. In both scenario 2 and scenario 3  
10 prasugrel was most cost-effective, dominating ticagrelor and being most cost-effective in  
11 91% and 95% of simulations respectively. The committee therefore had reasonable  
12 confidence that prasugrel should be the preferred option in people with STEMI. In  
13 UA/NSTEMI however, ticagrelor was preferable in scenario 1 but there was some degree of  
14 uncertainty as it was only cost effective in 63% of simulations, and prasugrel was again more  
15 cost-effective in scenarios 2 and 3, dominating ticagrelor and being the most cost-effective  
16 option in 82% and 99% of simulations respectively.

17 The committee also recognised that prasugrel is only licensed for those in whom PCI is  
18 intended, and while this is usually the case in STEMI a sizeable minority of UA/NSTEMI  
19 patients will be managed medically. Moreover, in those people who proceed to PCI, time to  
20 angiography in the UK is significantly longer in UA/NSTEMI than STEMI and the committee  
21 took this into account in formulating recommendations in two ways. Firstly, they were  
22 concerned about the practical difficulties of using prasugrel in UA/NSTEMI patients because,  
23 if there is no option other than prasugrel, in those in whom angiography cannot take place  
24 quickly there might be a wait of several days without DAPT until the coronary anatomy has  
25 been defined. Secondly, the outcome results supporting the superiority of prasugrel are  
26 significantly affected by the ISAR-REACT 5 results, and in this trial time to angiography was  
27 much shorter for the UA/NSTEMI population than is currently achieved in the UK, making the  
28 results less directly applicable to normal clinical practice in UA/NSTEMI. Taking these factors  
29 together with the clinical and cost-effectiveness data described above, the committee  
30 concluded that they needed to allow a choice of agent in UA/NSTEMI patients. In people with  
31 UA/NSTEMI for whom angiography is appropriate the choice should be between prasugrel  
32 and ticagrelor; in the minority in whom an initial decision is made to manage medically the  
33 choice should be ticagrelor which is superior to clopidogrel in clinical studies.

34 The committee therefore agreed recommendations as follows:

- 35 • For the STEMI population a recommendation was made to offer prasugrel plus  
36 aspirin
- 37 • For the UA/NSTEMI population a recommendation was made to offer either prasugrel  
38 or ticagrelor plus aspirin, thus allowing prescribers to take into account the likely time  
39 to angiography in individual circumstances
- 40 • For people in whom a clinical decision is made to manage medically, or that surgical  
41 management with CABG is appropriate, a recommendation for ticagrelor plus aspirin  
42 was made

43 The committee was aware that recommending prasugrel for people with STEMI undergoing  
44 PCI would be a significant change in practice, as the majority of people are currently given  
45 ticagrelor or clopidogrel. Audit data from the British Cardiovascular Intervention Society  
46 showed that in 2017-18 47.5% of people with STEMI that underwent PCI received ticagrelor  
47 and 7.2% were on prasugrel. It can be assumed the rest of people were taking clopidogrel.  
48 For those currently using clopidogrel there will be an increase in costs and for those currently  
49 using ticagrelor there will be a decrease. The committee agreed that as the use of ticagrelor  
50 and clopidogrel is similar, there will be some savings from people switching from ticagrelor to  
51 prasugrel, but there will be more spending for those switching from clopidogrel and  
52 prasugrel, due to the larger difference in costs between these two drugs. As a result there

1 will be a resource impact to the NHS in England overall. Audit data for UA/NSTEMI showed  
2 that 40.2% of people that underwent PCI were on ticagrelor and 1% were on prasugrel. It can  
3 be assumed the rest of people were taking clopidogrel. As a recommendation for both  
4 prasugrel and ticagrelor was made, this will lead to a substantial resource impact as both  
5 interventions cost more than clopidogrel. The number of people that are medically managed  
6 has been decreasing and audit data reported by MINAP showed that in 2017-18 84.6% of  
7 people with NSTEMI underwent an angiogram. Of these people, 82.57% underwent PCI.  
8 Audit data were not available on the use of dual-antiplatelet therapy for the UA/NSTEMI  
9 population that are medically managed, but it is likely to be similar to the PCI population as  
10 people currently tend to use the same DAPT for all ACS. As a result, the committee agreed  
11 there may be a resource impact of recommending ticagrelor in this group.

12 Whilst observational data has not been included in this review, the committee felt that it was  
13 important to note published UK registry data that aimed to assess mortality associated with  
14 ticagrelor, prasugrel and clopidogrel. The registry data showed that prasugrel is associated  
15 with fewer mortality events than ticagrelor and clopidogrel.<sup>171</sup> This is consistent with the  
16 findings from the ISAR-REACT 5 trial.

17 When reviewing the evidence for DAPT, the committee noticed that there were existing  
18 recommendations for the early administration of aspirin to people with acute UA/NSTEMI,  
19 and management advice for people with aspirin sensitivity, in CG94 which apply equally to  
20 people with STEMI. They agreed that the updated guideline should be adjusted so that the  
21 recommendations cover both STEMI and UA/NSTEMI. As part of the same discussion,  
22 committee members commented that they had seen instances of DAPT being given before  
23 confirmation that pain was due to cardiac ischaemia, for example to people with pain from  
24 peptic ulceration. This could have significant adverse consequences and a consensus  
25 recommendation was therefore agreed advising against administering two anti-platelet  
26 agents before ACS has been confirmed as the cause of symptoms.

27  
28

## References

1. Abaci A. The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses. *Turk Kardiyoloji Dernegi Arsivi*. 2015; 43(2):1-6
2. Abdel-Qadir H, Roifman I, Wijeyesundera HC. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: A decision-analytic model. *CMAJ Open*. 2015; 3(4):E438-46
3. Abergel E, Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. *Vascular Health & Risk Management*. 2010; 6:963-77
4. Agewall S, Badimon L, Drouet L, Eschenhagen T, Husted S, Simon T et al. Oral antiplatelet agents in ACS: From pharmacology to clinical differences. *Fundamental and Clinical Pharmacology*. 2011; 25(5):564-71
5. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. *Journal of the American College of Cardiology*. 2012; 60(3):193-199
6. Alexopoulos D, Kontoprias K, Gkizas V, Karanikas S, Ziakas A, Barampoutis N et al. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison. *Platelets*. 2016; 27(5):420-426
7. Alexopoulos D, Perperis A, Koniari I, Karvounis H, Patsilinakos S, Ziakas A et al. Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. *Journal of Thrombosis and Haemostasis*. 2015; 40(3):261-267
8. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. *Circulation: Cardiovascular Interventions*. 2012; 5(6):797-804
9. Alexopoulos D, Xanthopoulou I, Plakomyti TE, Theodoropoulos KC, Mavronasiou E, Damelou A et al. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. *American Heart Journal*. 2013; 165(1):73-79
10. Amico F, Amico A, Mazzoni J, Moshiyakhov M, Tamparo W. The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel. *Postgraduate Medicine*. 2016; 128(2):159-163
11. Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: An analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Journal of the American Heart Association*. 2015; 4(10):e002490
12. Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk acs undergoing ad hoc PCI. *Journal of the American College of Cardiology*. 2016; 67(6):603-613

- 1 13. Antman EM, Wiviott SD, Murphy SA, Voitek J, Hasin Y, Widimsky P et al. Early and  
2 late benefits of prasugrel in patients with acute coronary syndromes undergoing  
3 percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to Assess  
4 Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with  
5 Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *Journal of the American  
6 College of Cardiology*. 2008; 51(21):2028-2033
- 7 14. Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the  
8 newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with  
9 non-st-elevation acute coronary syndrome. *American Journal of Cardiology*. 2015;  
10 116(5):809-17
- 11 15. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH et al. Bleeding  
12 complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the  
13 PLATelet inhibition and patient Outcomes (PLATO) trial. *European Heart Journal*.  
14 2011; 32(23):2933-2944
- 15 16. Bellavia A, Wallentin L, Orsini N, James SK, Cannon CP, Himmelmann A et al. Time-  
16 based measures of treatment effect: Reassessment of ticagrelor and clopidogrel from  
17 the PLATO trial. *Open Heart*. 2017; 4(2):e000557
- 18 17. Bhatt DL. Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us? *Nature  
19 Reviews: Cardiology*. 2009; 6(12):737-738
- 20 18. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G et al.  
21 Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients  
22 with acute coronary syndromes. *International Journal of Cardiology*. 2011;  
23 150(3):325-331
- 24 19. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M et al. Prevention of  
25 stroke with ticagrelor in patients with prior myocardial infarction: Insights from  
26 PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart  
27 Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-  
28 Thrombolysis in Myocardial Infarction 54). *Circulation*. 2016; 134(12):861-871
- 29 20. Bonello L, Laine M, Cluzel M, Frere C, Mancini J, Hasan A et al. Comparison of  
30 ticagrelor versus prasugrel to prevent periprocedural myonecrosis in acute coronary  
31 syndromes. *American Journal of Cardiology*. 2015; 116(3):339-343
- 32 21. Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K et al.  
33 Outcomes in patients with ST-segment elevation acute myocardial infarction treated  
34 with clopidogrel versus prasugrel (from the INFUSE-AMI trial). *American Journal of  
35 Cardiology*. 2014; 113(9):1457-1460
- 36 22. Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D. P2Y12 receptor antagonists:  
37 Which one to choose? A systematic review and meta-analysis. *Current  
38 Pharmaceutical Design*. 2016; 22(29):4568-4576
- 39 23. Bundhun PK, Huang F. Post percutaneous coronary interventional adverse  
40 cardiovascular outcomes and bleeding events observed with prasugrel versus  
41 clopidogrel: direct comparison through a meta-analysis. *BMC Cardiovascular  
42 Disorders*. 2018; 18:78
- 43 24. Bundhun PK, Shi JX, Huang F. Head to head comparison of Prasugrel versus  
44 Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-  
45 analysis of randomized trials. *BMC Pharmacology & Toxicology*. 2017; 18:80
- 46 25. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al.  
47 Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy

- 1 for acute coronary syndromes (PLATO): A randomised double-blind study. *Lancet*.  
2 2010; 375(9711):283-293
- 3 26. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G et al.  
4 Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine  
5 diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-  
6 segment elevation acute coronary syndrome: Primary results of the DISPERSE-2  
7 trial. *Journal of the American College of Cardiology*. 2007; 50(19):1844-1851
- 8 27. Cayla G, Lapostolle F, Ecollan P, Stibbe O, Benezet JF, Henry P et al. Pre-hospital  
9 ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC  
10 population. *International Journal of Cardiology*. 2017; 244:49-53
- 11 28. Chen Y, Dong W, Wan Z, Li Z, Cong H, Hong T et al. Ticagrelor versus clopidogrel in  
12 Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.  
13 *International Journal of Cardiology*. 2015; 201:545-546
- 14 29. Chin CT, Mellstrom C, Chua TS, Matchar DB. Lifetime cost-effectiveness analysis of  
15 ticagrelor in patients with acute coronary syndromes based on the PLATO trial: A  
16 Singapore healthcare perspective *Singapore Medical Journal*. 2013; 54(3):169-175
- 17 30. Chin CT, Neely B, Magnus Ohman E, Armstrong PW, Corbalan R, White HD et al.  
18 Time-varying effects of prasugrel versus clopidogrel on the long-term risks of stroke  
19 after acute coronary syndromes: Results from the TRILOGY ACS trial. *Stroke*. 2016;  
20 47(4):1135-9
- 21 31. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H et al. Study  
22 design and rationale of a comparison of prasugrel and clopidogrel in medically  
23 managed patients with unstable angina/non-ST-segment elevation myocardial  
24 infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to  
25 medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. *American Heart  
26 Journal*. 2010; 160(1):16-22
- 27 32. Choi KN, Jin HY, Shin HC, Park YA, Seo JS, Jang JS et al. Comparison of the  
28 antiplatelet effects of once and twice daily low-dose ticagrelor and clopidogrel after  
29 percutaneous coronary intervention. *American Journal of Cardiology*. 2017;  
30 120(2):201-206
- 31 33. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P et al. Impact of  
32 clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or  
33 24-month duration of dual-antiplatelet therapy after stent implantation: A pre-specified  
34 analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading  
35 Stent-Induced Intimal Hyperplasia) trial. *European Heart Journal*. 2015; 36(20):1242-  
36 1251
- 37 34. Dalby AJ, Gottlieb S, Cyr DD, Magnus Ohman E, McGuire DK, Ruzyllo W et al. Dual  
38 antiplatelet therapy in patients with diabetes and acute coronary syndromes managed  
39 without revascularization. *American Heart Journal*. 2017; 188:156-166
- 40 35. Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S et al. A  
41 comparative evaluation of prasugrel and clopidogrel in patients with acute coronary  
42 syndrome undergoing percutaneous coronary intervention. *Journal of the Association  
43 of Physicians of India*. 2013; 61(2):114-6, 126
- 44 36. Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M. Prasugrel  
45 vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous  
46 coronary intervention: A model-based cost-effectiveness analysis for Germany,  
47 Sweden, the Netherlands, and Turkey. *Journal of Medical Economics*. 2013;  
48 16(4):510-521

- 1 37. Davies A, Sculpher M, Barrett A, Huete T, Sacristan JA, Dilla T. Prasugrel compared  
2 to clopidogrel in patients with acute coronary syndrome undergoing percutaneous  
3 coronary intervention: A Spanish model-based cost effectiveness analysis. *Farmacia*  
4 *Hospitalaria*. 2013; 37(4):307-316
- 5 38. De la Puente C, Vallejos C, Bustos L, Zaror C, Velasquez M, Lanas F. Latin  
6 American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-  
7 effective vs. clopidogrel in acute coronary syndrome in Chile. *Journal of Clinical*  
8 *Epidemiology*. 2017; 86:117-124
- 9 39. De Servi S, Cavallini C, Leonardi S, Ferlini M. Prasugrel and ticagrelor compared to  
10 clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing  
11 percutaneous coronary interventions: Certainties and uncertainties. *International*  
12 *Journal of Cardiology*. 2015; 181:443-445
- 13 40. De Servi S, Goedicke J, Ferlini M, Palmerini T, Syväne M, Montalescot G. Prasugrel  
14 versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical  
15 outcome according to culprit artery location. *International Journal of Cardiology*. 2016;  
16 223:632-638
- 17 41. De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomes for prasugrel  
18 versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial  
19 infarction: An analysis from the TRITON-TIMI 38 trial. *European Heart Journal: Acute*  
20 *Cardiovascular Care*. 2014; 3(4):363-372
- 21 42. Deharo P, Bassez C, Bonnet G, Pankert M, Quilici J, Lambert M et al. Prasugrel  
22 versus ticagrelor in acute coronary syndrome: A randomized comparison.  
23 *International Journal of Cardiology*. 2013; 170(2):e21-2
- 24 43. Dehghani P, Lavoie A, Lavi S, Crawford JJ, Harenberg S, Zimmermann RH et al.  
25 Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated  
26 STEMI patients undergoing early PCI. *American Heart Journal*. 2017; 192:105-112
- 27 44. Diodati JG, Saucedo JF, Cardillo TE, Jakubowski JA, Hennekes C, Efron MB et al.  
28 Transferring from clopidogrel loading dose to prasugrel loading dose in acute  
29 coronary syndrome patients. High on-treatment platelet reactivity analysis of the  
30 TRIPLET trial. *Thrombosis and Haemostasis*. 2014; 112(2):311-322
- 31 45. Fanari Z, Weiss S, Weintraub WS. Cost effectiveness of antiplatelet and  
32 antithrombotic therapy in the setting of acute coronary syndrome: Current perspective  
33 and literature review. *American Journal of Cardiovascular Drugs*. 2015; 15(6):415-27
- 34 46. Ferri LA, Morici N, Grosseto D, Tortorella G, Bossi I, Sganzerla P et al. A comparison  
35 of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with  
36 acute coronary syndromes undergoing early percutaneous revascularization: design  
37 and rationale of the randomized Elderly-ACS 2 study. *American Heart Journal*. 2016;  
38 181:101-106
- 39 47. Fluschnik N, Becher PM, Schnabel R, Blankenberg S, Westermann D.  
40 Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS: The  
41 end of triple therapy? *Herz*. 2018; 43(1):20-25
- 42 48. Fonarow GC. Randomization - There is no substitute. *JAMA Cardiology*. 2016;  
43 1(6):633-635
- 44 49. Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL et al. Efficacy and safety analysis  
45 of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary  
46 intervention: A meta-analysis. *Current Medical Research and Opinion*. 2015;  
47 31(12):2313-23

- 1 50. Gasche D, Ulle T, Meier B, Greiner RA. Cost-effectiveness of ticagrelor and generic  
2 clopidogrel in patients with acute coronary syndrome in Switzerland. *Swiss Medical*  
3 *Weekly*. 2013; 143:w13851
- 4 51. Ge J, Zhu J, Hong BK, Boonbaichaiyapruck S, Goh YS, Hou CJ et al. Prasugrel  
5 versus clopidogrel in Asian patients with acute coronary syndromes: Design and  
6 rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. *Current Medical*  
7 *Research and Opinion*. 2010; 26(9):2077-2085
- 8 52. Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in  
9 Japanese, Korean and Taiwanese patients with acute coronary syndrome --  
10 randomized, double-blind, phase III PHILO study. *Circulation Journal*. 2015;  
11 79(11):2452-2460
- 12 53. Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N et al. Prasugrel  
13 (Efient®) with percutaneous coronary intervention for treating acute coronary  
14 syndromes (review of TA182): Systematic review and economic analysis *Health*  
15 *Technology Assessment*. 2015; 19(29)
- 16 54. Grima DT, Brown ST, Kamboj L, Bainey KR, Goeree R, Oh P et al. Cost-  
17 effectiveness of ticagrelor versus clopidogrel in patients with acute coronary  
18 syndromes in Canada. *ClinicoEconomics and Outcomes Research*. 2014; 6:49-62
- 19 55. Han L, Zhang JJ, Jing HF, Qin L. Ticagrelor for patients with ST-segment elevation  
20 myocardial infarction after emergency percutaneous coronary intervention. *Journal of*  
21 *Biological Regulators and Homeostatic Agents*. 2019; 33(2):485-490
- 22 56. Henriksson M, Nikolic E, Ohna A, Wallentin L, Janzon M. Ticagrelor treatment in  
23 patients with acute coronary syndrome is cost-effective in Sweden and Denmark.  
24 *Scandinavian Cardiovascular Journal*. 2014; 48(3):138-147
- 25 57. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF et al. Ticagrelor  
26 versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from  
27 the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.  
28 *Circulation: Cardiovascular Quality and Outcomes*. 2012; 5(5):680-688
- 29 58. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H et al.  
30 Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with  
31 clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline  
32 characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.  
33 *American Heart Journal*. 2009; 157(4):599-605
- 34 59. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F et al. Ticagrelor vs.  
35 clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from  
36 the PLATelet inhibition and patient Outcomes (PLATO) trial. *European Heart Journal*.  
37 2010; 31(24):3006-3016
- 38 60. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH et al. Ticagrelor  
39 versus clopidogrel in acute coronary syndromes in relation to renal function: results  
40 from the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation*. 2010;  
41 122(11):1056-1067
- 42 61. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S et al. Ticagrelor  
43 versus clopidogrel in patients with acute coronary syndromes intended for non-  
44 invasive management: substudy from prospective randomised PLATelet inhibition  
45 and patient Outcomes (PLATO) trial. *BMJ*. 2011; 342:d3527

- 1 62. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW et al. Ticagrelor  
2 versus clopidogrel in patients with acute coronary syndromes and a history of stroke  
3 or transient ischemic attack. *Circulation*. 2012; 125(23):2914-2921
- 4 63. Janzon M, James S, Cannon CP, Storey RF, Mellstrom C, Nicolau JC et al. Health  
5 economic analysis of ticagrelor in patients with acute coronary syndromes intended  
6 for non-invasive therapy. *Heart*. 2015; 101(2):119-125
- 7 64. Jing R, Lin W. Comparison of ticagrelor with clopidogrel in Chinese ST-segment  
8 elevation myocardial infarction patients treated with primary percutaneous coronary  
9 intervention. *International Journal of Clinical and Experimental Medicine*. 2016;  
10 9(12):23525-23529
- 11 65. Jing Y, Ni B, Zhou D, Zhang X, Liu S. Efficacy and safety of ticagrelor in patients with  
12 acute coronary syndrome: A meta-analysis of randomized controlled trials. *Clinical  
13 and Experimental Pharmacology and Physiology*. 2018; 45(2):122-126
- 14 66. Joint Formulary Committee. British National Formulary (BNF) Online. Available from:  
15 <http://www.medicinescomplete.com> Last accessed: 08/11/2019
- 16 67. Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK et al. Ticagrelor  
17 versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective  
18 analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *American  
19 Heart Journal*. 2015; 169(6):899-905.e1
- 20 68. Kaul P, Ohman EM, Knight JD, Anstrom KJ, Roe MT, Boden WE et al. Health-related  
21 quality of life outcomes with prasugrel among medically managed non-ST-segment  
22 elevation acute coronary syndrome patients: Insights from the Targeted Platelet  
23 Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary  
24 Syndromes (TRILOGY ACS) trial. *American Heart Journal*. 2016; 178:55-64
- 25 69. Ketchum K, Peterson K, Thakurta S, Low A, McDonagh MS. Drug class review:  
26 Newer antiplatelet agents: Final update 2 report. Portland (OR). Oregon Health &  
27 Science University, 2011. Available from:  
28 <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016383/>
- 29 70. Khan N, Cox AR, Cotton JM. Pharmacokinetics and pharmacodynamics of oral  
30 P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic  
31 review. *Thrombosis Research*. 2016; 143:141-8
- 32 71. Khasa S, Khanna R, Ashfaq F, Goel PK. Pharmacodynamic evaluation of clopidogrel  
33 reloading vs. Switching to prasugrel or ticagrelor in clopidogrel resistant Indian  
34 patients. *Clinical Trials and Regulatory Science in Cardiology*. 2016; 13:14-20
- 35 72. Kim C, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG et al. Randomized comparison of  
36 strut coverage between ticagrelor and clopidogrel in acute myocardial infarction at 3-  
37 month optical coherence tomography. *Yonsei Medical Journal*. 2018; 59(5):624-632
- 38 73. Kim EK, Park TK, Yang JH, Song YB, Choi JH, Choi SH et al. Ticagrelor versus  
39 clopidogrel on myocardial infarct size in patients undergoing primary percutaneous  
40 coronary intervention. *Journal of the American College of Cardiology*. 2017; 69(16  
41 Suppl):2098-2099
- 42 74. Kimura T, Isshiki T, Ogawa H, Yokoi H, Yamaguchi T, Ikeda Y. Randomized, double-  
43 blind, dose-finding, phase II study of prasugrel in Japanese patients undergoing  
44 elective percutaneous coronary intervention. *Journal of Atherosclerosis and  
45 Thrombosis*. 2015; 22(6):557-569
- 46 75. Kitano D, Takayama T, Fukamachi D, Migita S, Morikawa T, Tamaki T et al. Impact of  
47 low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary



- 1 syndrome patients requiring primary drug-eluting stent implantation: A randomized  
2 comparative study. *Catheterization and Cardiovascular Interventions*. 2019;  
3 <https://dx.doi.org/10.1002/ccd.28277>
- 4 76. Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E et al. Discharge  
5 aspirin dose and clinical outcomes in patients with acute coronary syndromes treated  
6 with prasugrel versus clopidogrel: An analysis from the TRITON-TIMI 38 study (trial to  
7 assess improvement in therapeutic outcomes by optimizing platelet inhibition with  
8 prasugrel-thrombolysis in myocardial infarction 38). *Journal of the American College  
9 of Cardiology*. 2014; 63(3):225-232
- 10 77. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ et al. Reduction in  
11 first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in  
12 the PLATO Study. *Circulation*. 2013; 127(6):673-680
- 13 78. Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B et al. Extent of coronary  
14 artery disease and outcomes after ticagrelor administration in patients with an acute  
15 coronary syndrome: insights from the PLATelet inhibition and patient Outcomes  
16 (PLATO) trial. *American Heart Journal*. 2014; 168(1):68-75.e2
- 17 79. Kozinski M, Obonska K, Stankowska K, Navarese EP, Fabiszak T, Stolarek W et al.  
18 Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of  
19 acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.  
20 *Cardiology Journal*. 2014; 21(5):547-556
- 21 80. Kubo T, Ino Y, Matsuo Y, Shiono Y, Kameyama T, Yamano T et al. Reduction of in-  
22 stent thrombus immediately after percutaneous coronary intervention by pretreatment  
23 with prasugrel compared with clopidogrel: An optical coherence tomography study.  
24 *Journal of Cardiology*. 2017; 69(2):436-441
- 25 81. Kulik A, Chan V, Ruel M. Antiplatelet therapy and coronary artery bypass graft  
26 surgery: Perioperative safety and efficacy. *Expert Opinion on Drug Safety*. 2009;  
27 8(2):169-82
- 28 82. Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF et al. Angiographic  
29 outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). *JACC:  
30 Cardiovascular Interventions*. 2013; 6(7):671-683
- 31 83. Laine M, Frère C, Toesca R, Berbis J, Barnay P, Pansieri M et al. Ticagrelor versus  
32 prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic  
33 randomised study. *Thrombosis and Haemostasis*. 2014; 111(2):273-278
- 34 84. Laine M, Gaubert M, Frere C, Peyrol M, Thuny F, Yvorra S et al. COM parison of P  
35 latelet reactivity following pr A sugrel and ticagrelor loading dose in S T- S egment  
36 elevation myocardial infarctl on patients: The COMPASSION study. *Platelets*. 2015;  
37 26(6):570-572
- 38 85. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent  
39 P2Y<sub>12</sub> inhibitors in men versus women: A collaborative meta-analysis of randomized  
40 trials. *Journal of the American College of Cardiology*. 2017; 69(12):1549-1559
- 41 86. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH et al. Optimal duration of dual  
42 antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled  
43 trial. *Circulation*. 2014; 129(3):304-12
- 44 87. Lee DH, Kim MH, Guo LZ, Park MK, Yi SJ. Lower loading dose of prasugrel  
45 compared with conventional loading doses of clopidogrel and prasugrel in Korean  
46 patients undergoing elective coronary angiography: A randomized controlled study

- 1 evaluating pharmacodynamic efficacy. Korean Circulation Journal. 2014; 44(6):386-  
2 393
- 3 88. Lee DH, Kim MH, Park TH, Park JS, Park K, Zhang HZ et al. Comparison of  
4 prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded  
5 patients undergoing percutaneous coronary intervention (PRAISE-HPR): A study  
6 protocol for a prospective randomized controlled clinical trial. *Trials*. 2013; 14 62
- 7 89. Lee H, Koo BK, Park KW, Shin ES, Lim SW, Rha SW et al. A randomized clinical trial  
8 comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet  
9 therapy after drug-eluting coronary stent implantation: design and rationale of the  
10 Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended  
11 Antiplatelet Monotherapy (HOST-EXAM) trial. *American Heart Journal*. 2017; 185:17-  
12 25
- 13 90. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in  
14 relative and absolute effectiveness of oral P2Y<sub>12</sub> inhibition in men and women: A  
15 meta-analysis and modelling study. *Heart*. 2018; 104(8):657-664
- 16 91. Lee MS, Shlofmitz E, Haag E, Santiago L, Pollack S, Reichel N et al. Optimal same-  
17 day platelet inhibition in patients receiving drug-eluting stents with or without previous  
18 maintenance thienopyridine therapy: From the Evaluation of Platelet Inhibition in  
19 Patients Having A VerifyNow Assay (EPIPHANY) Trial. *American Journal of*  
20 *Cardiology*. 2017; 119(7):991-995
- 21 92. Lee YS, Jin CD, Kim MH, Guo LZ, Cho YR, Park K et al. Comparison of prasugrel  
22 and ticagrelor antiplatelet effects in Korean patients presenting with ST-segment  
23 elevation myocardial infarction. *Circulation Journal*. 2015; 79(6):1248-1254
- 24 93. Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity  
25 with ticagrelor versus prasugrel: A systematic review and meta-analysis. *Journal of*  
26 *Thrombosis and Haemostasis*. 2015; 13(6):931-942
- 27 94. Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW et al.  
28 Rationale and design of the Cangrelor versus standard therapy to achieve optimal  
29 Management of Platelet Inhibition PHOENIX trial. *American Heart Journal*. 2012;  
30 163(5):768-776.e2
- 31 95. Levin L, Wallentin L, Bernfort L, Andersson D, Storey RF, Bergström G et al. Health-  
32 related quality of life of ticagrelor versus clopidogrel in patients with acute coronary  
33 syndromes-results from the PLATO trial. *Value in Health*. 2013; 16(4):574-580
- 34 96. Li KB, Xu YJ, Han QL. Safety and efficacy of low-dose ticagrelor in patients with  
35 unstable angina pectoris and non-revascularization. *Chinese Journal of New Drugs*.  
36 2015; 24(21):2480-2484
- 37 97. Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J et al. Ticagrelor overcomes high platelet  
38 reactivity in patients with acute myocardial infarction or coronary artery in-stent  
39 restenosis: A randomized controlled trial. *Scientific Reports*. 2015; 5:13789
- 40 98. Li W, Guo S, Wang S, Sun X, Li Z, Sun X et al. Comparison of ticagrelor with  
41 clopidogrel in reducing interleukin-17 and myeloperoxidase expression in thrombus  
42 and improving postprocedural coronary flow in st-segment elevation myocardial  
43 infarction patients. *Journal of Pharmacy & Pharmaceutical Sciences*. 2018;  
44 21(1):207-216
- 45 99. Li XY, Su GH, Wang GX, Hu HY, Fan CJ. Switching from ticagrelor to clopidogrel in  
46 patients with ST-segment elevation myocardial infarction undergoing successful

- 1 percutaneous coronary intervention in real-world China: Occurrences, reasons, and  
2 long-term clinical outcomes. *Clinical Cardiology*. 2018; 41(11):1446-1454
- 3 100. Li Z, Li Y, Zhang T, Miao W, Su G. Comparison of the influence of ticagrelor and  
4 clopidogrel on inflammatory biomarkers and vascular endothelial function for patients  
5 with ST-segment elevation myocardial infarction receiving emergency percutaneous  
6 coronary intervention: study protocol for a randomized controlled trial. *Trials*. 2016;  
7 17:75
- 8 101. Liew D, De Abreu Lourenco R, Adena M, Chim L, Aylward P. Cost-effectiveness of  
9 12-month treatment with ticagrelor compared with clopidogrel in the management of  
10 acute coronary syndromes. *Clinical Therapeutics*. 2013; 35(8):1110-1117
- 11 102. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J et al.  
12 Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome  
13 with or without revascularization: Results from the PLATO trial. *European Heart  
14 Journal*. 2014; 35(31):2083-2093
- 15 103. Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D et al.  
16 Spontaneous MI after non-ST-segment elevation acute coronary syndrome managed  
17 without revascularization: The TRILOGY ACS Trial. *Journal of the American College  
18 of Cardiology*. 2016; 67(11):1289-1297
- 19 104. Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S et al. Ticagrelor  
20 effects on myocardial infarction and the impact of event adjudication in the PLATO  
21 (Platelet Inhibition and Patient Outcomes) trial. *Journal of the American College of  
22 Cardiology*. 2014; 63(15):1493-1499
- 23 105. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E et al. Cost-  
24 effectiveness of prasugrel versus clopidogrel in patients with acute coronary  
25 syndromes and planned percutaneous coronary intervention: results from the trial to  
26 assess improvement in therapeutic outcomes by optimizing platelet inhibition with  
27 Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. *Circulation*. 2010;  
28 121(1):71-9
- 29 106. Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus  
30 clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass  
31 surgery: Results from the CRYSSA (prevention of Coronary arteRY bypaSS  
32 occlusion After off-pump procedures) randomised study. *Heart*. 2012; 98(23):1710-  
33 1715
- 34 107. Mariani M, Mariani G, De Servi S. Efficacy and safety of prasugrel compared with  
35 clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38  
36 trials. *Expert Review of Cardiovascular Therapy*. 2009; 7(1):17-23
- 37 108. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T et al. Genetic variants in  
38 ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel  
39 and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. *Lancet*.  
40 2010; 376(9749):1312-9
- 41 109. Melloni C, Cornel JH, Hafley G, Neely ML, Clemmensen P, Zamoryakhin D et al.  
42 Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in  
43 medically managed patients with acute coronary syndromes: Insights from the  
44 TRILOGY ACS Trial. *European Heart Journal: Acute Cardiovascular Care*. 2016;  
45 5(6):443-454
- 46 110. Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in  
47 East Asian patients with acute coronary syndrome: Systematic review and meta-  
48 analysis. *Cardiovascular Revascularization Medicine*. 2018; 16(6):689-694

- 1 111. Modi NV, Anand IS. Comparative study of efficacy and safety of clopidogrel versus  
2 prasugrel in patient with acute coronary syndrome. *International Journal of*  
3 *Pharmaceutical Research*. 2012; 4(4):37-42
- 4 112. Mohammad RA, Goldberg T, Dorsch MP, Cheng JW. Antiplatelet therapy after  
5 placement of a drug-eluting stent: a review of efficacy and safety studies. *Clinical*  
6 *Therapeutics*. 2010; 32(14):2265-81
- 7 113. Mont'Alverne-Filho JR, Rodrigues-Sobrinho CR, Medeiros F, Falcão FC, Falcão JL,  
8 Silva RC et al. Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with  
9 primary angioplasty: Results of an angiographic randomized pilot study.  
10 *Catheterization and Cardiovascular Interventions*. 2016; 87(7):1187-1193
- 11 114. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O et  
12 al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The  
13 randomised, double-blind ACAPULCO study. *Thrombosis and Haemostasis*. 2010;  
14 103(1):213-223
- 15 115. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH et al.  
16 Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary  
17 intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind,  
18 randomised controlled trial. *Lancet*. 2009; 373(9665):723-731
- 19 116. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA et al. Effect  
20 of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and  
21 procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic  
22 Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial  
23 Infarction 38: an application of the classification system from the universal definition  
24 of myocardial infarction. *Circulation*. 2009; 119(21):2758-2764
- 25 117. Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I et al. 1-year  
26 outcomes of patients undergoing primary angioplasty for myocardial infarction treated  
27 with prasugrel versus ticagrelor. *Journal of the American College of Cardiology*. 2018;  
28 71(4):371-381
- 29 118. Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J et al.  
30 Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with  
31 primary percutaneous coronary intervention: Multicenter randomized PRAGUE-18  
32 Study. *Circulation*. 2016; 134(21):1603-1612
- 33 119. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K et al.  
34 Reduction in recurrent cardiovascular events with prasugrel compared with  
35 clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.  
36 *European Heart Journal*. 2008; 29(20):2473-2479
- 37 120. Musallam A, Orvin K, Perl L, Mosseri M, Arbel Y, Roguin A et al. Effect of modifying  
38 antiplatelet treatment to ticagrelor in high-risk coronary patients with low response to  
39 clopidogrel (MATTIS). *Canadian Journal of Cardiology*. 2016; 32(10):1246.e13-  
40 1246.e19
- 41 121. Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S et al. Optimal cutoff  
42 value of P2Y12 reaction units to prevent major adverse cardiovascular events in the  
43 acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS  
44 study. *International Journal of Cardiology*. 2015; 182:541-8
- 45 122. National Institute for Health and Care Excellence. Developing NICE guidelines: the  
46 manual [updated October 2018]. London. National Institute for Health and Care  
47 Excellence, 2014. Available from:  
48 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>

- 1 123. National Institute for Health and Care Excellence. Prasugrel with percutaneous  
2 coronary intervention for treating acute coronary syndromes (review of technology  
3 appraisal guidance 182). NICE technology appraisal guidance 317. London. National  
4 Institute for Health and Care Excellence, 2014. Available from:  
5 <http://guidance.nice.org.uk/TA317>
- 6 124. National Institute for Health and Clinical Excellence. Ticagrelor for the treatment of  
7 acute coronary syndromes. NICE technology appraisal guidance 236. London.  
8 National Institute for Health and Clinical Excellence, 2011. Available from:  
9 <http://guidance.nice.org.uk/TA236>
- 10 125. NCT. A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome  
11 Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are  
12 Medically Managed. 2008. Available from: <Http://clinicaltrials.gov/show/nct00699998>  
13 Last accessed: 02/01/2019
- 14 126. NCT. A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel  
15 Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo  
16 Percutaneous Coronary Intervention. 2009. Available from:  
17 <Http://clinicaltrials.gov/show/nct00830960> Last accessed: 02/01/2019
- 18 127. NCT. Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel  
19 in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary  
20 Syndromes. 2009. Available from: <Http://clinicaltrials.gov/show/nct01107899> Last  
21 accessed: 02/01/2019
- 22 128. NCT. Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity. 2011.  
23 Available from: <Https://clinicaltrials.gov/show/nct01493999> Last accessed:  
24 02/01/2019
- 25 129. NCT. Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus  
26 Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary  
27 Syndromes (ACS). 2011. Available from: <Https://clinicaltrials.gov/show/nct01294462>  
28 Last accessed: 02/01/2019
- 29 130. NCT. PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With  
30 Diabetes Mellitus. 2012. Available from: <Https://clinicaltrials.gov/show/nct01531114>  
31 Last accessed: 02/01/2019
- 32 131. NCT. Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With  
33 Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention:  
34 differences Between the Loading Dose of Prasugrel and Ticagrelor. 2013. Available  
35 from: <Https://clinicaltrials.gov/show/nct02032303> Last accessed: 02/01/2019
- 36 132. NCT. Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden  
37 During PCI: an OCT Study. 2013. Available from:  
38 <Https://clinicaltrials.gov/show/nct01826175> Last accessed: 02/01/2019
- 39 133. NCT. A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of  
40 Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS. 2013. Available  
41 from: <Https://clinicaltrials.gov/show/nct01864005> Last accessed: 02/01/2019
- 42 134. NCT. Safety Study of APD-791 With Aspirin and/or Clopidogrel. 2013. Available from:  
43 <Https://clinicaltrials.gov/show/nct02034292> Last accessed: 02/01/2019
- 44 135. NCT. Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients  
45 With Acute Coronary Syndrome. 2013. Available from:  
46 <Https://clinicaltrials.gov/show/nct01778842> Last accessed: 02/01/2019

- 1 136. NCT. Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With  
2 Ticagrelor. 2013. Available from: [Https://clinicaltrials.gov/show/nct01961856](https://clinicaltrials.gov/show/nct01961856) Last  
3 accessed: 02/01/2019
- 4 137. NCT. Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial  
5 Infarction Post Fibrinolysis. 2013. Available from:  
6 [Https://clinicaltrials.gov/show/nct01950416](https://clinicaltrials.gov/show/nct01950416) Last accessed: 02/01/2019
- 7 138. NCT. Antiplatelet Therapy After Cardiac Arrest. 2014. Available from:  
8 [Https://clinicaltrials.gov/show/nct02224274](https://clinicaltrials.gov/show/nct02224274) Last accessed: 02/01/2019
- 9 139. NCT. Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on  
10 Novel P2Y12 Inhibitors Therapy. 2014. Available from:  
11 [Https://clinicaltrials.gov/show/nct02049762](https://clinicaltrials.gov/show/nct02049762) Last accessed: 02/01/2019
- 12 140. NCT. Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis.  
13 2014. Available from: [Https://clinicaltrials.gov/show/nct02048085](https://clinicaltrials.gov/show/nct02048085) Last accessed:  
14 02/01/2019
- 15 141. NCT. Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for  
16 Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes. 2014.  
17 Available from: [Https://clinicaltrials.gov/show/nct02319941](https://clinicaltrials.gov/show/nct02319941) Last accessed:  
18 02/01/2019
- 19 142. NCT. Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTEMI-ACS Patients  
20 Undergoing Early PCI. 2014. Available from:  
21 [Https://clinicaltrials.gov/show/nct02201667](https://clinicaltrials.gov/show/nct02201667) Last accessed: 02/01/2019
- 22 143. NCT. EndoTic - Endothelium and Ticagrelor. 2014. Available from:  
23 [Https://clinicaltrials.gov/show/nct02244710](https://clinicaltrials.gov/show/nct02244710) Last accessed: 02/01/2019
- 24 144. NCT. Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD  
25 and ACS Patients. 2014. Available from: [Https://clinicaltrials.gov/show/nct02459288](https://clinicaltrials.gov/show/nct02459288)  
26 Last accessed: 02/01/2019
- 27 145. NCT. Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAN Patients  
28 With Acute Coronary Syndromes Intended for Invasive Management. 2014. Available  
29 from: [Https://clinicaltrials.gov/show/nct02094963](https://clinicaltrials.gov/show/nct02094963) Last accessed: 02/01/2019
- 30 146. NCT. Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients  
31 Submitted to Thrombolysis. 2014. Available from:  
32 [Https://clinicaltrials.gov/show/nct02215993](https://clinicaltrials.gov/show/nct02215993) Last accessed: 02/01/2019
- 33 147. NCT. Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury  
34 Post Major Non-cardiac Surgery. 2014. Available from:  
35 [Https://clinicaltrials.gov/show/nct02291419](https://clinicaltrials.gov/show/nct02291419) Last accessed: 02/01/2019
- 36 148. NCT. Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment  
37 Elevation Myocardial Infarction. 2014. Available from:  
38 [Https://clinicaltrials.gov/show/nct02224534](https://clinicaltrials.gov/show/nct02224534) Last accessed: 02/01/2019
- 39 149. NCT. Comparison of Loading Strategies With Antiplatelet Drugs in Patients  
40 Undergoing Elective Coronary Intervention. 2015. Available from:  
41 [Https://clinicaltrials.gov/show/nct02548611](https://clinicaltrials.gov/show/nct02548611) Last accessed: 02/01/2019
- 42 150. NCT. COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor  
43 Versus Clopidogrel in Patients With CKD and NSTEMI-ACS. 2015. Available from:  
44 [Https://clinicaltrials.gov/show/nct02578537](https://clinicaltrials.gov/show/nct02578537) Last accessed: 02/01/2019

- 1 151. NCT. A Multicenter Trial to Assess the Microvascular Integrity and Left Ventricular  
2 Function Recovery After Clopidogrel or Ticagrelor Administration, in Patients With  
3 STEMI Treated With Thrombolysis - The 'MIRTOS' Study. 2015. Available from:  
4 <https://clinicaltrials.gov/show/nct02429271> Last accessed: 14/08/2019
- 5 152. NCT. Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in  
6 Thrombus Aspirated From the STEMI Patients. 2015. Available from:  
7 <https://clinicaltrials.gov/show/nct02639143> Last accessed: 02/01/2019
- 8 153. NCT. Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by  
9 Ticagrelor. 2015. Available from: <https://clinicaltrials.gov/show/nct02422888> Last  
10 accessed: 02/01/2019
- 11 154. NCT. Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-  
12 ACS. 2015. Available from: <https://clinicaltrials.gov/show/nct02415803> Last  
13 accessed: 02/01/2019
- 14 155. NCT. Ticagrelor vs. Prasugrel Effects on Infarct Size. 2015. Available from:  
15 <https://clinicaltrials.gov/show/nct02507323> Last accessed: 02/01/2019
- 16 156. NCT. Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI.  
17 2016. Available from: <https://clinicaltrials.gov/show/nct02943369> Last accessed:  
18 02/01/2019
- 19 157. NCT. Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With  
20 STEMI Referred for Primary PCI. 2016. Available from:  
21 <https://clinicaltrials.gov/show/nct02978040> Last accessed: 02/01/2019
- 22 158. NCT. A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to  
23 Clopidogrel in Patients With Prior Myocardial Infarction. 2016. Available from:  
24 <https://clinicaltrials.gov/show/nct02663713> Last accessed: 02/01/2019
- 25 159. NCT. Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI. 2017. Available  
26 from: <https://clinicaltrials.gov/show/nct03182855> Last accessed: 02/01/2019
- 27 160. NCT. Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A  
28 Platelet Reactivity Study. 2017. Available from:  
29 <https://clinicaltrials.gov/show/nct03016611> Last accessed: 02/01/2019
- 30 161. NCT. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI. 2017.  
31 Available from: <https://clinicaltrials.gov/show/nct03247738> Last accessed:  
32 02/01/2019
- 33 162. NCT. TIMES: ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI  
34 Patients Treated With Primary PCI. 2017. Available from:  
35 <https://clinicaltrials.gov/show/nct03145194> Last accessed: 02/01/2019
- 36 163. NCT. Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI. 2018. Available from:  
37 <https://clinicaltrials.gov/show/nct03435133> Last accessed: 02/01/2019
- 38 164. Neumann FJ. Balancing efficacy and safety in the TRITON-TIMI 38 trial. *European*  
39 *Heart Journal*, Supplement. 2009; 11(Suppl G):G14-G17
- 40 165. Nicolau JC, Bhatt DL, Roe MT, Likhnygina Y, Neely B, Corbalán R et al.  
41 Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in  
42 patients with acute coronary syndromes treated with prasugrel versus clopidogrel and  
43 managed without revascularization: insights from the Targeted Platelet Inhibition to  
44 Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.  
45 *American Heart Journal*. 2015; 170(4):683-694.e3

- 1 166. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M. Cost-effectiveness of  
2 treating acute coronary syndrome patients with ticagrelor for 12 months: Results from  
3 the PLATO study. *European Heart Journal*. 2013; 34(3):220-228
- 4 167. Nishikawa M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Miyazaki S et al. No  
5 association between on-treatment platelet reactivity and bleeding events following  
6 percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis.  
7 *Thrombosis Research*. 2015; 136(5):947-954
- 8 168. O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW et al.  
9 Efficacy and safety of cangrelor in women versus men during percutaneous coronary  
10 intervention: Insights from the Cangrelor versus Standard Therapy to Achieve  
11 Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. *Circulation*.  
12 2016; 133(3):248-255
- 13 169. Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M et al. Effects of  
14 CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse  
15 cardiovascular events in Japanese patients with acute coronary syndrome: the  
16 PRASFIT-ACS study. *Journal of Cardiology*. 2016; 68(1):29-36
- 17 170. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER et al. Concomitant  
18 administration of clopidogrel with statins or calcium-channel blockers: Insights from  
19 the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by  
20 optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).  
21 *JACC: Cardiovascular Interventions*. 2013; 6(12):1275-1281
- 22 171. Olier I, Sirker A, Hildick-Smith DJR, Kinnaird T, Ludman P, de Belder MA et al.  
23 Association of different antiplatelet therapies with mortality after primary  
24 percutaneous coronary intervention. *Heart*. 2018; 104(20):1683-1690
- 25 172. Orban M, Limbourg T, Neumann FJ, Ferenc M, Olbrich HG, Richardt G et al. ADP  
26 receptor antagonists in patients with acute myocardial infarction complicated by  
27 cardiogenic shock: A post hoc IABP-SHOCK II trial subgroup analysis.  
28 *EuroIntervention*. 2016; 12(11):e1395-e1403
- 29 173. Organisation for Economic Co-operation and Development (OECD). Purchasing  
30 power parities (PPP). 2012. Available from: <http://www.oecd.org/sdd/prices-ppp/> Last  
31 accessed: 18/01/2019
- 32 174. Palacio S, Hart RG, Pearce LA, Benavente OR. Effect of addition of clopidogrel to  
33 aspirin on mortality: systematic review of randomized trials. *Stroke*. 2012; 43(8):2157-  
34 2162
- 35 175. Pandit A, Aryal MR, Aryal Pandit A, Jalota L, Hakim FA, Mookadam F et al. Cangrelor  
36 versus clopidogrel in percutaneous coronary intervention: A systematic review and  
37 meta-analysis. *EuroIntervention*. 2014; 9(11):1350-8
- 38 176. Paré G, Ross S, Mehta SR, Yusuf S, Anand SS, Connolly SJ et al. Effect of PON1  
39 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in  
40 the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the  
41 Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.  
42 *Circulation: Cardiovascular Genetics*. 2012; 5(2):250-256
- 43 177. Park K, Cho YR, Park JS, Park TH, Kim MH, Kim YD. Design and Rationale for  
44 comParison Between ticagrelor and clopidogrel on microcirculation in Patients with  
45 Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO)  
46 Trial. *Journal of Cardiovascular Translational Research*. 2018; 11(1):42-49



- 1 178. Park SD, Baek YS, Woo SI, Kim SH, Shin SH, Kim DH et al. Comparing the effect of  
2 clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary  
3 syndrome patients (TIME trial): study protocol for a randomized controlled trial. *Trials*.  
4 2014; 15:151
- 5 179. Park SD, Lee MJ, Baek YS, Kwon SW, Shin SH, Woo SI et al. Randomised trial to  
6 compare a protective effect of Clopidogrel Versus Ticagrelor on coronary  
7 Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).  
8 *EuroIntervention*. 2016; 12(8):e964-e971
- 9 180. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW et al. Duration of dual  
10 antiplatelet therapy after implantation of drug-eluting stents. *New England Journal of*  
11 *Medicine*. 2010; 362(15):1374-1382
- 12 181. Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW et al. Characteristics of  
13 dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.  
14 *Thrombosis and Haemostasis*. 2017; 117(6):1093-1100
- 15 182. Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N et al.  
16 Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg)  
17 prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid  
18 Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. *American Heart*  
19 *Journal*. 2014; 167(6):909-914
- 20 183. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V et al. Comparison  
21 of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial  
22 infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI  
23 study. *Journal of the American College of Cardiology*. 2013; 61(15):1601-1606
- 24 184. Patel JH, Stoner JA, Owora A, Mathew ST, Thadani U. Evidence for using clopidogrel  
25 alone or in addition to aspirin in post coronary artery bypass surgery patients.  
26 *American Journal of Cardiology*. 2009; 103(12):1687-93
- 27 185. Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J et al.  
28 Cardiovascular events in acute coronary syndrome patients with peripheral arterial  
29 disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.  
30 *European Journal of Preventive Cardiology*. 2015; 22(6):734-742
- 31 186. Patti G, Pasceri V, Mangiacapra F, Colonna G, Vizzi V, Ricottini E et al. Efficacy of  
32 clopidogrel reloading in patients with acute coronary syndrome undergoing  
33 percutaneous coronary intervention during chronic clopidogrel therapy (from the  
34 Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty trial).  
35 *American Journal of Cardiology*. 2013; 112(2):162-168
- 36 187. Paweska J, Macioch T, Perkowski P, Budaj A, Niewada M. Direct healthcare costs  
37 and cost-effectiveness of acute coronary syndromes secondary prevention with  
38 ticagrelor compared to clopidogrel: Economic evaluation from the public payer's  
39 perspective in Poland based on the PLATO trial results. *Kardiologia Polska*. 2014;  
40 72(9):823-30
- 41 188. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding  
42 and related complications in patients undergoing coronary artery bypass grafting.  
43 *Pharmacotherapy*. 2008; 28(3):376-92
- 44 189. Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST et al. Relative  
45 efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive  
46 management in non-ST-segment elevation acute coronary syndrome in the PLATO  
47 trial. *Clinical Cardiology*. 2017; 40(6):390-398

- 1 190. Pourdjabbar A, Hibbert B, Chong AY, May MR, Labinaz M, Simard T et al. A  
2 randomised study for optimising crossover from ticagrelor to clopidogrel in patients  
3 with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. *Thrombosis and*  
4 *Haemostasis*. 2017; 117(2):303-310
- 5 191. Pouwels X, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S et al.  
6 Ticagrelor for secondary prevention of atherothrombotic events after myocardial  
7 infarction: An evidence review group perspective of a NICE single technology  
8 appraisal. *Pharmacoeconomics*. 2018; 36(5):533-543
- 9 192. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM et al. Effect of  
10 prasugrel versus clopidogrel on outcomes among patients with acute coronary  
11 syndrome undergoing percutaneous coronary intervention without stent implantation:  
12 a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet  
13 inhibitionN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38  
14 substudy. *American Heart Journal*. 2009; 158(3):e21-6
- 15 193. Qaderdan K, Ishak M, Heestermans AA, Vrey E, Jukema JW, Voskuil M et al.  
16 Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary  
17 syndrome: optimization of antiplatelet treatment in patients 70 years and older--  
18 rationale and design of the POPular AGE study. *American Heart Journal*. 2015;  
19 170(5):981-985.e1
- 20 194. Rafiq S, Johansson PI, Zacho M, Stissing T, Kofoed K, Lilleor NB et al.  
21 Thrombelastographic haemostatic status and antiplatelet therapy after coronary  
22 artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic  
23 effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients:  
24 study protocol for a randomized controlled trial. *Trials*. 2012; 13:48
- 25 195. Rafique AM, Nayyar P, Wang TY, Mehran R, Baber U, Berger PB et al. Optimal  
26 P2Y12 inhibitor in patients with st-segment elevation myocardial infarction undergoing  
27 primary percutaneous coronary intervention: A network meta-analysis. *JACC:*  
28 *Cardiovascular Interventions*. 2016; 9(10):1036-46
- 29 196. Refiker M. Randomized trial of aspirin and clopidogrel versus aspirin alone for the  
30 prevention of coronary artery bypass graft occlusion: The preoperative aspirin and  
31 postoperative antiplatelets in coronary artery bypass grafting surgery. *American Heart*  
32 *Journal*. 2011; 161(5):e25
- 33 197. Ren LH, Peng JJ, Xu XL, Ye HM, Jia KY. High maintenance dose of clopidogrel  
34 improves long-term clinical outcomes in patients with elective percutaneous coronary  
35 intervention. *Chinese Medical Journal*. 2012; 92(6):408-410
- 36 198. Ren Q, Ren C, Liu X, Dong C, Zhang X. Ticagrelor vs. clopidogrel in non-ST-  
37 elevation acute coronary syndromes. *Herz*. 2016; 41(3):246-249
- 38 199. Reynard C, Body R. 15 A clinical decision tool for prescribing anti-platelet medication  
39 for patients with suspected acute coronary syndrome (PAM). *Emergency Medicine*  
40 *Journal*. 2017; 34(12):A870-A871
- 41 200. Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Did  
42 prasugrel and ticagrelor offer the same benefit in patients with acute coronary  
43 syndromes after percutaneous coronary interventions compared to clopidogrel?  
44 Insights from randomized clinical trials, registries and meta-analysis. *Current*  
45 *Pharmaceutical Design*. 2018; 24(4):465-477
- 46 201. Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG et al.  
47 Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.  
48 *New England Journal of Medicine*. 2012; 367(14):1297-1309

- 1 202. Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL et al. Ascertainment,  
2 classification, and impact of neoplasm detection during prolonged treatment with dual  
3 antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.  
4 *European Heart Journal*. 2016; 37(4):412-422
- 5 203. Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S et al.  
6 Elderly patients with acute coronary syndromes managed without revascularization:  
7 insights into the safety of long-term dual antiplatelet therapy with reduced-dose  
8 prasugrel versus standard-dose clopidogrel. *Circulation*. 2013; 128(8):823-33
- 9 204. Roffman DS. Developments in oral antiplatelet agents for the treatment of acute  
10 coronary syndromes: Clopidogrel, prasugrel, and ticagrelor. *Journal of Pharmacy  
11 Practice*. 2016; 29(3):239-49
- 12 205. Rognoni A, Cavallino C, Lupi A, Bacchini S, Rosso R, Rametta F et al. Ticagrelor:  
13 Long-term therapy in patients with coronary artery disease. *Reviews on Recent  
14 Clinical Trials*. 2016; 11(4):280-283
- 15 206. Rossington JA, Brown OI, Hoye A. Systematic review and meta-analysis of optimal  
16 P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute  
17 coronary syndrome. *Open Heart*. 2016; 3(1):e000296
- 18 207. Rudolph TK, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Hellmich M et al.  
19 Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability  
20 and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A  
21 randomized controlled trial. *International Journal of Cardiology*. 2017; 248:7-13
- 22 208. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H et al. Safety and  
23 efficacy of prasugrel compared with clopidogrel in different regions of the world.  
24 *International Journal of Cardiology*. 2012; 155(3):424-429
- 25 209. Saint Etienne C, Angoulvant D, Simeon E, Fauchier L. Antiplatelet therapy strategies  
26 after percutaneous coronary intervention in patients needing oral anticoagulation.  
27 *Future Cardiology*. 2013; 9(6):759-62
- 28 210. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S et al. Efficacy and safety of  
29 adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute  
30 coronary syndrome: the PRASFIT-ACS study. *Circulation Journal*. 2014; 78(7):1684-  
31 1692
- 32 211. Sakurai R, Burazor I, Bonneau HN, Kaneda H. Head-to-head comparison of  
33 prasugrel versus ticagrelor in patients undergoing percutaneous coronary  
34 intervention: A meta-analysis of randomized controlled trials. *Journal of Interventional  
35 Cardiology*. 2017; 30(5):457-464
- 36 212. Salisbury AC, Wang K, Cohen DJ, Li Y, Jones PG, Spertus JA. Selecting antiplatelet  
37 therapy at the time of percutaneous intervention for an acute coronary syndrome:  
38 Weighing the benefits and risks of prasugrel versus clopidogrel. *Circulation:  
39 Cardiovascular Quality and Outcomes*. 2013; 6(1):27-34
- 40 213. Sardar P, Nairooz R, Chatterjee S, Mushiyevev S, Pekler G, Visco F. Cangrelor for  
41 patients undergoing percutaneous coronary intervention: Evidence from a meta-  
42 analysis of randomized trials. *Journal of Thrombosis and Thrombolysis*. 2014;  
43 38(1):1-10
- 44 214. Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE et al.  
45 Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI  
46 patients with high on treatment platelet reactivity and genotype variation. Triplet  
47 reset trial. *International Journal of Cardiology*. 2015; 194:60-62

- 1 215. Sardella G, Mancone M, Stio RE, Cavallo E, Roma A, Colantonio R et al. Prasugrel  
2 or ticagrelor in st-segment-elevation myocardial infarction patients with diabetes  
3 mellitus. *Circulation*. 2017; 136(6):602-604
- 4 216. Sarkees ML, Bavry AA. Acute coronary syndrome (unstable angina and non-ST  
5 elevation MI). *Clinical Evidence*. 2009; 2009:209
- 6 217. Sarkees ML, Bavry AA. Non ST-elevation acute coronary syndrome. *Clinical  
7 Evidence*. 2010; 2010:209
- 8 218. Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM et al.  
9 Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from  
10 clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.  
11 *Thrombosis and Haemostasis*. 2013; 109(2):347-355
- 12 219. Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N et al. Comparison  
13 of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with  
14 acute coronary syndromes undergoing early percutaneous revascularization.  
15 *Circulation*. 2018; 137(23):2435-2445
- 16 220. Saw J, Wong GC, Mayo J, Bernstein V, Mancini GB, Ye J et al. Ticagrelor and aspirin  
17 for the prevention of cardiovascular events after coronary artery bypass graft surgery.  
18 *Heart*. 2016; 102(10):763-769
- 19 221. Sawlani NN, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW et al.  
20 Impact of cerebrovascular events older than one year on ischemic and bleeding  
21 outcomes with cangrelor in percutaneous coronary intervention. *Circulation:  
22 Cardiovascular Interventions*. 2017; 10(1):e004380
- 23 222. Schnorbus B, Daiber A, Jurk K, Warnke S, König J, Krahn U et al. Effects of  
24 clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and  
25 oxidative stress parameters and platelet function in patients undergoing coronary  
26 artery stenting for an acute coronary syndrome. A randomised, prospective,  
27 controlled study. *BMJ Open*. 2014; 4(5):e005268
- 28 223. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J et al.  
29 Ticagrelor or prasugrel in patients with acute coronary syndromes. *New England  
30 Journal of Medicine*. 2019; 381:1524-1534
- 31 224. Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ et al. Safety  
32 of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of  
33 Platelet Inhibition and Patient Outcomes) analysis. *American Heart Journal*. 2018;  
34 202:54-60
- 35 225. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S et  
36 al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients  
37 with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO  
38 (Platelet Inhibition and Patient Outcomes) trial: results of the continuous  
39 electrocardiographic assessment substudy. *Journal of the American College of  
40 Cardiology*. 2011; 57(19):1908-1916
- 41 226. Serebruany VL. Peripheral vascular outcomes in the PLATO trial: update from the  
42 FDA ticagrelor complete response review. *American Journal of Therapeutics*. 2012;  
43 19(2):160-1
- 44 227. Serebruany VL, Cherepanov V, Tomek A, Kim MH. Among antithrombotic agents,  
45 prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients  
46 with ST-elevated myocardial infarction. *International Journal of Cardiology*. 2015;  
47 195:104-10

- 1 228. Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ. Disbalance between  
2 mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The  
3 cangrelor efficacy challenge. *Thrombosis and Haemostasis*. 2013; 111(1):3-7
- 4 229. Serebruany VL, Tomek A, Pya Y, Bekbossynova M, Kim MH. Inferiority of ticagrelor  
5 in the PHILO trial: Play of chance in East Asians or nightmare confirmation of  
6 PLATO-USA? *International Journal of Cardiology*. 2016; 215:372-376
- 7 230. Shah R, Rashid A, Hwang I, Fan TM, Khouzam RN, Reed GL. Meta-analysis of the  
8 relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary  
9 syndrome. *American Journal of Cardiology*. 2017; 119(11):1723-1728
- 10 231. Shahzeb n, Ali N, Hadi A, Shah I, Gul AM, Ali J et al. Elective percutaneous coronary  
11 interventions--a comparison of efficacy of clopidogrel and prasugrel. *Journal of Ayub*  
12 *Medical College, Abbottabad*. 2015; 27(1):174-177
- 13 232. Siller-Matula JM, Huber K, Christ G, Schror K, Kubica J, Herkner H et al. Impact of  
14 clopidogrel loading dose on clinical outcome in patients undergoing percutaneous  
15 coronary intervention: A systematic review and meta-analysis *Heart*. 2011; 97(2):98-  
16 105
- 17 233. Siller-Matula JM, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M et al.  
18 Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in  
19 cardiac and non-cardiac surgery: A systematic review and meta-analysis. *European*  
20 *Heart Journal: Acute Cardiovascular Care*. 2017; 6(8):753-770
- 21 234. Singh S, Singh M, Grewal N, Khosla S. Comparative efficacy and safety of prasugrel,  
22 ticagrelor, and standard-dose and high-dose clopidogrel in patients undergoing  
23 percutaneous coronary intervention: A network meta-analysis. *American Journal of*  
24 *Therapeutics*. 2016; 23(1):e52-62
- 25 235. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ et al.  
26 Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass  
27 grafting cohort: risk-adjusted retrospective data analysis. *Journal of the American*  
28 *College of Cardiology*. 2012; 60(5):388-396
- 29 236. Solomon S, Vacek JL. Reducing cardiac ischemic events in patients with ACS:  
30 Prasugrel versus clopidogrel. *Commentary. Postgraduate Medicine*. 2010;  
31 122(1):198-200
- 32 237. Song C, Sukul D, Seth M, Dupree JM, Khandelwal A, Dixon SR et al. Ninety-day  
33 readmission and long-term mortality in medicare patients ( $\geq 65$  years) treated with  
34 ticagrelor versus prasugrel after percutaneous coronary intervention (from the Blue  
35 Cross Blue Shield of Michigan Cardiovascular Consortium). *American Journal of*  
36 *Cardiology*. 2017; 120(11):1926-1932
- 37 238. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel  
38 for cytochrome P450 2C19-genotyped subgroups: Integration of the TRITON-TIMI 38  
39 trial data. *Journal of Thrombosis and Haemostasis*. 2010; 8(8):1678-1684
- 40 239. Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Athanasiou A, Moris D et al. The  
41 role of prasugrel in the management of acute coronary syndromes: A systematic  
42 review. *European Review for Medical and Pharmacological Sciences*. 2017;  
43 21(20):4733-4743
- 44 240. Spinar J, Spinarova L, Vitovec J. PEGASUS - Ticagrelor in secondary prevention on  
45 patients after a myocardial infarction. *Vnitri Lekarstvi*. 2015; 61(6):511-515

- 1 241. Spinar J, Spinarova L, Vitovec J. Pegasus study - long-term dual antiaggregation  
2 therapy (ASA + ticagrelor) following myocardial infarction. *Kardiologicka Revue*. 2015;  
3 17(1):41-45
- 4 242. Steblovnik K, Blinc A, Mijovski MB, Fister M, Mikuz U, Noc M. Ticagrelor versus  
5 clopidogrel in comatose survivors of out-of-hospital cardiac arrest undergoing  
6 percutaneous coronary intervention and hypothermia: A randomized study.  
7 *Circulation*. 2016; 134(25):2128-2130
- 8 243. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW et al. Effect of  
9 cangrelor on periprocedural outcomes in percutaneous coronary interventions: A  
10 pooled analysis of patient-level data. *Lancet*. 2013; 382(9909):1981-92
- 11 244. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B et al.  
12 Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary  
13 syndromes: an analysis from the prospective, randomized PLATO trial. *Circulation*.  
14 2013; 128(10):1055-1065
- 15 245. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP et al.  
16 Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes  
17 intended for reperfusion with primary percutaneous coronary intervention: a Platelet  
18 Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. *Circulation*. 2010;  
19 122(21):2131-2141
- 20 246. Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel,  
21 ticagrelor, high- and standard-dose clopidogrel in patients scheduled for  
22 percutaneous coronary interventions. *Thrombosis and Haemostasis*. 2012;  
23 108(2):318-327
- 24 247. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F et al. Platelet  
25 inhibition with ticagrelor 60 mg versus 90 mg twice daily in the Pegasus-Timi 54 trial.  
26 *Journal of the American College of Cardiology*. 2016; 67(10):1145-1154
- 27 248. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S et al. Inhibitory effects  
28 of ticagrelor compared with clopidogrel on platelet function in patients with acute  
29 coronary syndromes: The PLATO (PLATElet inhibition and patient Outcomes)  
30 PLATELET substudy. *Journal of the American College of Cardiology*. 2010;  
31 56(18):1456-1462
- 32 249. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F et al.  
33 Characterization of dyspnoea in PLATO study patients treated with ticagrelor or  
34 clopidogrel and its association with clinical outcomes. *European Heart Journal*. 2011;  
35 32(23):2945-2953
- 36 250. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F et al.  
37 Pulmonary function in patients with acute coronary syndrome treated with ticagrelor  
38 or clopidogrel (from the Platelet Inhibition and Patient Outcomes pulmonary function  
39 substudy). *American Journal of Cardiology*. 2011; 108(11):1542-1546
- 40 251. Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J et al. Lower  
41 mortality following pulmonary adverse events and sepsis with ticagrelor compared to  
42 clopidogrel in the PLATO study. *Platelets*. 2014; 25(7):517-525
- 43 252. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine  
44 derivatives versus aspirin for preventing stroke and other serious vascular events in  
45 high vascular risk patients. *Cochrane Database of Systematic Reviews* 2009, Issue 4.  
46 Art. No.: CD001246. DOI: 10.1002/14651858.CD001246.pub2.

- 1 253. Sun J, Xiang Q, Li C, Wang Z, Hu K, Xie Q et al. Efficacy and safety of novel oral  
2 P2Y12 receptor inhibitors in patients with st-segment elevation myocardial infarction  
3 undergoing PCI: A systematic review and meta-analysis. *Journal of Cardiovascular*  
4 *Pharmacology*. 2017; 69(4):215-227
- 5 254. Sun JC, Teoh KH, Lamy A, Sheth T, Ellins ML, Jung H et al. Randomized trial of  
6 aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery  
7 bypass graft occlusion: The preoperative aspirin and postoperative antiplatelets in  
8 coronary artery bypass grafting study. *American Heart Journal*. 2010; 160(6):1178-  
9 1184
- 10 255. Sun JCJ. Randomized trial of aspirin and clopidogrel versus aspirin alone for the  
11 prevention of coronary artery bypass graft occlusion: The preoperative aspirin and  
12 postoperative antiplatelets in coronary artery bypass grafting study. *American Heart*  
13 *Journal*. 2011; 161(5):e27
- 14 256. Sun JCJ, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA et al. The  
15 effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and  
16 mortality in coronary artery bypass surgery: A systematic review of randomized and  
17 observational studies. *European Heart Journal*. 2008; 29(8):1057-1071
- 18 257. Sweeny JM, Angiolillo DJ, Franchi F, Rollini F, Waksman R, Raveendran G et al.  
19 Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor versus  
20 clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad hoc  
21 percutaneous coronary intervention. *Journal of the American Heart Association*.  
22 2017; 6(4):e005650
- 23 258. Tan Q, Jiang X, Huang S, Zhang T, Chen L, Xie S et al. The clinical efficacy and  
24 safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients  
25 and diabetic patients: A systematic review and meta-analysis. *PloS One*. 2017;  
26 12(5):e0177872
- 27 259. Tan XH, Liang ZH, Liu JQ, Luo YZ, Zhu KY, Li ZL. Prasugrel and ticagrelor for acute  
28 coronary syndrome: a meta-analysis. *Chinese Journal of Evidence-Based Medicine*.  
29 2014; 14(7):849-858
- 30 260. Tang W, Yeh J, Chen J, Liu M, Ke J, Tan G et al. Meta-analysis of randomized  
31 controlled trials on efficacy and safety of extended thienopyridine therapy after drug-  
32 eluting stent implantation. *Cardiovascular Diagnosis & Therapy*. 2016; 6(5):409-416
- 33 261. Tang X, Li R, Jing Q, Wang Q, Liu P, Zhang P et al. Assessment of ticagrelor versus  
34 clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing  
35 primary percutaneous coronary intervention. *Journal of Cardiovascular*  
36 *Pharmacology*. 2016; 68(2):115-120
- 37 262. Tang XF, Fan JY, Meng J, Jin C, Yuan JQ, Yang YJ. Impact of new oral or  
38 intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events  
39 in patients with coronary artery disease: a meta-analysis of randomized trials  
40 *Atherosclerosis*. 2014; 233(2):568-578
- 41 263. Tang Y, Zhang YC, Chen Y, Xiang Y. Efficacy and safety of cangrelor for patients  
42 with coronary artery disease: A meta-analysis of four randomized trials. *International*  
43 *Journal of Clinical and Experimental Medicine*. 2015; 8(1):800-808
- 44 264. Tarantini G, Ueshima D, D'Amico G, Masiero G, Musumeci G, Stone GW et al.  
45 Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus  
46 nonelderly patients with acute coronary syndrome: A systematic review and meta-  
47 analysis. *American Heart Journal*. 2018; 195:78-85

- 1 265. Theidel U, Asseburg C, Giannitsis E, Katus H. Cost-effectiveness of ticagrelor versus  
2 clopidogrel for the prevention of atherothrombotic events in adult patients with acute  
3 coronary syndrome in Germany. *Clinical Research in Cardiology*. 2013; 102(6):447-  
4 458
- 5 266. Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral  
6 arterial function in patients with a previous acute coronary syndrome. *Cardiology*.  
7 2013; 124(4):252-258
- 8 267. Udell JA, Braunwald E, Antman EM, Antman EM, Murphy SA, Montalescot G et al.  
9 Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial  
10 infarction according to timing of percutaneous coronary intervention: A TRITON-TIMI  
11 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by  
12 Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction  
13 38). *JACC: Cardiovascular Interventions*. 2014; 7(6):604-612
- 14 268. Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM et  
15 al. Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing  
16 percutaneous coronary intervention. *Journal of the American College of Cardiology*.  
17 2017; 69(2):176-185
- 18 269. Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW et al.  
19 Cangrelor versus clopidogrel on a background of unfractionated heparin (from  
20 CHAMPION PHOENIX). *American Journal of Cardiology*. 2017; 120(7):1043-1048
- 21 270. Valenti R, Marcucci R, Comito V, Marrani M, Cantini G, Migliorini A et al. Prasugrel in  
22 clopidogrel nonresponders undergoing percutaneous coronary intervention: The  
23 RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis). *JACC:*  
24 *Cardiovascular Interventions*. 2015; 8(12):1563-1570
- 25 271. Varenhorst C, Alström U, Braun O, Storey RF, Mahaffey KW, Bertilsson M et al.  
26 Causes of mortality with ticagrelor compared with clopidogrel in acute coronary  
27 syndromes. *Heart*. 2014; 100(22):1762-1769
- 28 272. Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF et al.  
29 Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in  
30 patients undergoing coronary artery bypass surgery. *Journal of the American College*  
31 *of Cardiology*. 2012; 60(17):1623-1630
- 32 273. Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A et al.  
33 Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary  
34 intervention. *Heart*. 2016; 102(8):617-625
- 35 274. Verdoia M, Barbieri L, Suryapranata H, De Luca G. Switching from clopidogrel to  
36 prasugrel in patients undergoing PCI: A meta-analytic overview. *Platelets*. 2016;  
37 27(2):93-104
- 38 275. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G et al. Benefits  
39 from new ADP-antagonists as compared to clopidogrel in patients with stable angina  
40 or acute coronary syndrome undergoing invasive management: A meta-analysis of  
41 randomized trials. *Journal of Cardiovascular Pharmacology*. 2014; 63(4):339-350
- 42 276. Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M et al. Should dual  
43 antiplatelet therapy be used in patients following coronary artery bypass surgery? A  
44 meta-analysis of randomized controlled trials. *BMC Surgery*. 2015; 15:112
- 45 277. Vito L, Versaci F, Limbruno U, Pawlowski T, Gatto L, Romagnoli E et al. Impact of  
46 oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in



- 1 patients with ST-segment elevation myocardial infarction. *Journal of Cardiovascular*  
2 *Medicine*. 2016; 17(9):701-706
- 3 278. Vlaar PJ, Svilaas T, Damman K, Smet BJ, Tijssen JG, Hillege HL et al. Impact of  
4 pretreatment with clopidogrel on initial patency and outcome in patients treated with  
5 primary percutaneous coronary intervention for ST-segment elevation myocardial  
6 infarction: a systematic review. *Circulation*. 2008; 118(18):1828-1836
- 7 279. Voeltz MD, Manoukian SV. Cangrelor in patients undergoing cardiac surgery: the  
8 BRIDGE study. *Expert Review of Cardiovascular Therapy*. 2013; 11(7):811-816
- 9 280. Vogel B, Baber U. Antiplatelet treatments: Recent evidence from randomized  
10 controlled trials. *Current Opinion in Cardiology*. 2017; 32(4):356-362
- 11 281. Waha A, Sandner S, Scheidt M, Boening A, Koch-Buettner K, Hammel D et al. A  
12 randomized, parallel group, double-blind study of ticagrelor compared with aspirin for  
13 prevention of vascular events in patients undergoing coronary artery bypass graft  
14 operation: rationale and design of the Ticagrelor in CABG (TiCAB) trial: an  
15 Investigator-Initiated trial. *American Heart Journal*. 2016; 179:69-76
- 16 282. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al.  
17 Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *New*  
18 *England Journal of Medicine*. 2009; 361(11):1045-1057
- 19 283. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J et al. Effect of  
20 CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment  
21 with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy  
22 of the PLATO trial. *Lancet*. 2010; 376(9749):1320-8
- 23 284. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP et al.  
24 Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in  
25 non-ST-elevation acute coronary syndrome patients managed with or without in-  
26 hospital revascularization: a substudy from the Prospective Randomized Platelet  
27 Inhibition and Patient Outcomes (PLATO) trial. *Circulation*. 2014; 129(3):293-303
- 28 285. Walter T, Szabo S, Kazmaier S, Swoboda S, Suselbeck T, Brueckmann M et al.  
29 Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary  
30 heart disease. *Journal of Cardiovascular Pharmacology*. 2008; 51(6):616-620
- 31 286. Wang H, Qi J, Li Y, Tang Y, Li C, Li J et al. Pharmacodynamics and  
32 pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary  
33 syndromes and chronic kidney disease. *British Journal of Clinical Pharmacology*.  
34 2018; 84(1):88-96
- 35 287. Wang H, Wang X. Efficacy and safety outcomes of ticagrelor compared with  
36 clopidogrel in elderly Chinese patients with acute coronary syndrome. *Therapeutics*  
37 *and Clinical Risk Management*. 2016; 12:1101-1105
- 38 288. Wang S, Yang X, Li Z, Zhang B, Cheng Y. Safety and efficacy of ticagrelor with  
39 emergency percutaneous coronary intervention in senile patients with ST-segment  
40 elevation myocardial infarction and dementia. *International Journal of Clinical and*  
41 *Experimental Medicine*. 2016; 9(6):11831-11837
- 42 289. Wang X, Li X, Wu H, Li R, Liu H, Wang L et al. Beneficial effect of ticagrelor on  
43 microvascular perfusion in patients with ST-segment elevation myocardial infarction  
44 undergoing a primary percutaneous coronary intervention. *Coronary Artery Disease*.  
45 2019; 30(5):317-322
- 46 290. Washam JB, Dolor RJ, Jones WS, Halim SA, Hasselblad V, Mayer SB et al. Dual  
47 antiplatelet therapy with or without oral anticoagulation in the postdischarge

- 1 management of acute coronary syndrome patients with an indication for long term  
2 anticoagulation: A systematic review *Journal of Thrombosis and Thrombolysis*. 2014;  
3 38(3):285-298
- 4 291. Watti H, Dahal K, Zabher HG, Katikaneni P, Modi K, Abdulbaki A. Comparison of  
5 prasugrel and ticagrelor in patients with acute coronary syndrome undergoing  
6 percutaneous coronary intervention: A meta-analysis of randomized and non-  
7 randomized studies. *International Journal of Cardiology*. 2017; 249:66-72
- 8 292. Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston SC et al.  
9 High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of  
10 cardiovascular events: A substudy from the CHARISMA trial. *Heart*. 2011; 97(8):626-  
11 631
- 12 293. Wein B, Coslovsky M, Jabbari R, Galatius S, Pfisterer M, Kaiser C. Prasugrel vs.  
13 clopidogrel in contemporary Western European patients with acute coronary  
14 syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis  
15 from the BASKET-PROVE cohorts. *International Journal of Cardiology*. 2017; 248:20-  
16 27
- 17 294. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J et al. A  
18 randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective  
19 and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in  
20 patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-  
21 PCI trial. *Circulation: Cardiovascular Interventions*. 2012; 5(3):336-346
- 22 295. Westman PC, Lipinski MJ, Torguson R, Waksman R. A comparison of cangrelor,  
23 prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary  
24 intervention: A network meta-analysis. *Cardiovascular Revascularization Medicine*.  
25 2017; 18(2):79-85
- 26 296. White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ et al.  
27 Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights  
28 from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel  
29 standard therapy in subjects who require percutaneous coronary intervention ).  
30 *JACC: Cardiovascular Interventions*. 2015; 8(3):424-433
- 31 297. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW et al.  
32 Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the  
33 CHAMPION trials using the universal definition of myocardial infarction. *American  
34 Heart Journal*. 2012; 163(2):182-90.e4
- 35 298. White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, Cyr DD et al. Frailty  
36 is associated with worse outcomes in non-ST-segment elevation acute coronary  
37 syndromes: insights from the TarGeted platelet Inhibition to cLarify the Optimal  
38 strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial.  
39 *European Heart Journal: Acute Cardiovascular Care*. 2016; 5(3):231-242
- 40 299. Wilcox R, Iqbal K, Costigan T, Lopez-Sendon J, Ramos Y, Widimsky P. An analysis  
41 of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the  
42 European label for prasugrel. *Current Medical Research and Opinion*. 2014;  
43 30(11):2193-2205
- 44 300. Winter JL, Lindefeld DS, Veas N, Guarda E, Valdebenito M, Méndez M et al.  
45 Angiographic and electrocardiographic parameters of myocardial reperfusion in  
46 angioplasty of patients with ST elevation acute myocardial infarction loaded with  
47 ticagrelor or clopidogrel (MICAMI-TICLO trial). *Cardiovascular Revascularization  
48 Medicine*. 2014; 15(5):284-288

- 1 301. Wisloff T, Atar D. Cost-effectiveness of antiplatelet drugs after percutaneous coronary  
2 intervention. *European Heart Journal Quality of Care & Clinical Outcomes*. 2016;  
3 2(1):52-57
- 4 302. Wisloff T, Ringerike T, Klemp M. A systematic review and economic evaluation of  
5 prasugrel compared to clopidogrel after PCI. Report nr 5-2011. Oslo. Knowledge  
6 Centre for the Health Services at The Norwegian Institute of Public Health, 2011.  
7 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK390591/>
- 8 303. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD et al.  
9 Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine  
10 P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of  
11 the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.  
12 *Circulation*. 2005; 111(25):3366-3373
- 13 304. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW et al.  
14 Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in  
15 patients with diabetes mellitus in the trial to assess improvement in therapeutic  
16 outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial  
17 Infarction 38. *Circulation*. 2008; 118(16):1626-1636
- 18 305. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP et al.  
19 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent  
20 thrombosis in patients with acute coronary syndromes treated with percutaneous  
21 coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a  
22 randomised trial. *Lancet*. 2008; 371(9621):1353-1363
- 23 306. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzylo W, Gottlieb S et al.  
24 Prasugrel versus clopidogrel in patients with acute coronary syndromes. *New*  
25 *England Journal of Medicine*. 2007; 357(20):2001-2015
- 26 307. Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM et al. Efficacy  
27 and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a  
28 core clinical cohort defined by worldwide regulatory agencies. *American Journal of*  
29 *Cardiology*. 2011; 108(7):905-911
- 30 308. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD et al.  
31 Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients  
32 with planned percutaneous coronary intervention: the Prasugrel in Comparison to  
33 Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in  
34 Myocardial Infarction 44 trial. *Circulation*. 2007; 116(25):2923-2932
- 35 309. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D et al.  
36 Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment  
37 elevation myocardial infarction with or without angiography: A secondary,  
38 prespecified analysis of the TRILOGY ACS trial. *Lancet*. 2013; 382(9892):605-13
- 39 310. Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian  
40 patients with acute coronary syndromes: A meta-analysis of randomized trials.  
41 *Journal of Comparative Effectiveness Research*. 2018; 7(3):281-291
- 42 311. Wu HB, Tian HP, Wang XC, Bai SR, Li XN, Zhang LN et al. Clinical efficacy of  
43 ticagrelor in patients undergoing emergency intervention for acute myocardial  
44 infarction and its impact on platelet aggregation rate. *American Journal of*  
45 *Translational Research*. 2018; 10(7):2175-2183
- 46 312. Wu X, Liu G, Lu J, Zheng XX, Cui JG, Zhao XY et al. Administration of ticagrelor and  
47 double-dose clopidogrel based on platelet reactivity determined by verifynow-P2Y12

- 1 for chinese subjects after elective PCI. *International Heart Journal*. 2017; 58(2):167-  
2 173
- 3 313. Xanthopoulou I, Alexopoulos D. Oral antiplatelet treatment in STEMI: Current practice  
4 and future considerations. *Current Pharmaceutical Design*. 2016; 22(29):4577-4582
- 5 314. Xia JG, Qu Y, Hu SD, Xu J, Yin CL, Xu D. Midterm follow-up outcomes of ticagrelor  
6 on acute ST segment elevation myocardial infarction undergoing emergency  
7 percutaneous coronary intervention. *Journal of Peking University Health Sciences*.  
8 2015; 47(3):494-498
- 9 315. Xiong R, Liu W, Chen L, Kang T, Ning S, Li J. A randomized controlled trial to assess  
10 the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment  
11 of acute coronary syndrome in patients with cyp2c19\*2 homozygotes. *International  
12 Journal of Clinical and Experimental Medicine*. 2015; 8(8):13310-13316
- 13 316. Yan AT, Roe MT, Neely M, Cyr DD, White H, Fox KAA et al. Early discontinuation of  
14 prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY  
15 ACS trial. *Coronary Artery Disease*. 2018; 29(6):469-476
- 16 317. Yang A, Pon Q, Lavoie A, Crawford JJ, Harenberg S, Zimmermann RH et al. Long-  
17 term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated  
18 STEMI patients undergoing early PCI. *Journal of Thrombosis and Thrombolysis*.  
19 2018; 45(2):225-233
- 20 318. Yang J, Zeng P, Cai WY. Comparison of treatment outcomes of ticagrelor and  
21 clopidogrel among patients undergoing percutaneous coronary intervention: A meta-  
22 analysis. *Journal of Huazhong University of Science and Technology Medical  
23 Sciences*. 2017; 37(5):675-680
- 24 319. Yao Z, Fu C, Li G. Analysis of antiplatelet activity and short-term prognosis of  
25 ticagrelor in AMI patients undergoing emergency PCI during perioperative period.  
26 *International Journal of Clinical and Experimental Medicine*. 2017; 10(6):9595-9600
- 27 320. Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Optimal oral antithrombotic regimes  
28 for patients with acute coronary syndrome: A network meta-analysis. *PloS One*. 2014;  
29 9(3):e90986
- 30 321. Yuan QR, Liu LJ, Zhao MZ. Observation of efficacy of ticagrelor sequential therapy  
31 on clopidogrel resistance after application of percutaneous coronary intervention to  
32 patients with acute coronary syndrome. *Journal of Shanghai Jiaotong University  
33 (Medical Science)*. 2016; 36(5):683-688
- 34 322. Yun KH, Rhee SJ, Ko JS. Comparison of the infarct size between the loading of  
35 ticagrelor and clopidogrel in patients with acute myocardial infarction undergoing  
36 primary percutaneous coronary intervention. *Korean Circulation Journal*. 2017;  
37 47(5):705-713
- 38 323. Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12  
39 inhibitors according to diabetes, age, gender, body mass index and body weight:  
40 systematic review and meta-analyses of randomized clinical trials. *Atherosclerosis*.  
41 2015; 240(2):439-45
- 42 324. Zeymer U, Hohlfeld T, Vom Dahl J, Erbel R, Münzel T, Zahn R et al. Prospective,  
43 randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg  
44 acetylsalicylic acid i.v. and 300 mg p.o. in ACS (ACUTE). *Thrombosis and  
45 Haemostasis*. 2017; 117(3):625-635
- 46 325. Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F et al. Double-blind,  
47 randomized, prospective comparison of loading doses of 600 mg clopidogrel versus

- 1           60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction  
2           scheduled for primary percutaneous intervention: The ETAMI trial (early  
3           thienopyridine treatment to improve primary PCI in patients with acute myocardial  
4           infarction). *JACC: Cardiovascular Interventions*. 2015; 8(1 Pt B):147-154
- 5    326.   Zhang L, Lu J, Dong W, Tian H, Feng W, You H et al. Meta-analysis of comparison of  
6           the newer P2Y12 inhibitors (oral preparation or intravenous) to clopidogrel in patients  
7           with acute coronary syndrome. *Journal of Cardiovascular Pharmacology*. 2017;  
8           69(3):147-155
- 9    327.   Zhang Y, Zhao Y, Pang M, Wu Y, Zhuang K, Zhang H et al. High-dose clopidogrel  
10           versus ticagrelor for treatment of acute coronary syndromes after percutaneous  
11           coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective,  
12           randomized, open-label, single-centre trial. *Acta Cardiologica*. 2016; 71(3):309-316
- 13   328.   Zhang Z, Kolm P, Mosse F, Jackson J, Zhao L, Weintraub WS. Long-term cost-  
14           effectiveness of clopidogrel in STEMI patients. *International Journal of Cardiology*.  
15           2009; 135(3):353-360
- 16   329.   Zhao Y, Shen L, Yang M, Cui J, Gao K, Sun Y et al. Feasibility of intravenous  
17           administration of aspirin in acute coronary syndrome. *Journal of Geriatric Cardiology*.  
18           2008; 5(4):212-216
- 19   330.   Zheng Z, Liu JH, Huang FJ, Yu JB. Effects of preoperative uses of aspirin and  
20           clopidogrel on patients undergoing coronary artery bypass graft surgery. *Chinese  
21           Medical Journal*. 2013; 93(38):3060-3062
- 22   331.   Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF et al. Effects of combined aspirin and  
23           clopidogrel therapy on cardiovascular outcomes: A systematic review and meta-  
24           analysis *PloS One*. 2012; 7(2):e31642
- 25   332.   Zhu K, Fu Q, Zhang N, Huang YJ, Zhang Q. Pre-PCI medication using clopidogrel  
26           and ticagrelor in the treatment of patients with acute myocardial infarction. *European  
27           Review for Medical and Pharmacological Sciences*. 2015; 19(23):4636-4641
- 28
- 29

## 1 Appendices

2 **Appendix A: Review protocols**3 **Table 21: Review protocol: Which antiplatelet is most clinically and cost effective for**  
4 **managing unstable angina or NSTEMI or for managing STEMI in adults?**

ID	Field	Content
0.	PROSPERO registration number	CRD42019147580
1.	Review title	Which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?
2.	Review question	Which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?
3.	Objective	<p>To determine the most clinically effective antiplatelet therapy in patients with UA/NSTEMI and those with STEMI</p> <p>Rationale for including this question: Current NICE technology appraisal guidance recommends prasugrel (in PCI only) and ticagrelor (in combination with aspirin) as options for people with ACS. This guidance will be incorporated unchanged to this guideline. However, there is the outstanding clinical issue about which of the available options (of clopidogrel, prasugrel and ticagrelor) should be the first choice. This review aims to provide guidance on this. Evidence is emerging on newer anti-platelets such as prasugrel.</p>
4.	Searches	<p>The following databases will be searched:</p> <ul style="list-style-type: none"> <li>• Cochrane Central Register of Controlled Trials (CENTRAL)</li> <li>• Cochrane Database of Systematic</li> </ul>

		<p>Reviews (CDSR)</p> <ul style="list-style-type: none"> <li>• Embase</li> <li>• MEDLINE</li> <li>• Cinahl</li> </ul> <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> <li>• English language</li> <li>• Human studies</li> <li>• Letters and comments are excluded.</li> </ul> <p>Other searches:</p> <ul style="list-style-type: none"> <li>• Inclusion lists of relevant systematic reviews will be checked by the reviewer.</li> </ul> <p>The searches may be re-run 6 weeks before final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p>
5.	Condition or domain being studied	Acute coronary syndrome
6.	Population	<p>Inclusion:</p> <p>People with acute coronary syndromes (UA/NSTEMI and STEMI)</p> <p>Analysed as the overall ACS population, STEMI + revascularisation, UA/NSTEMI + revascularisation and UA/NSTEMI with no revascularisation</p> <p>No stratification – population and management strategy subgroups will be investigated irrespective of heterogeneity</p> <p>Exclusion: None</p>

7.	Intervention/Exposure/Test	<p>The following drug combinations will be included:</p> <ul style="list-style-type: none"> <li>• Clopidogrel + aspirin</li> <li>• Prasugrel + aspirin</li> <li>• Ticagrelor + aspirin</li> </ul> <p>Must be initiated as part of acute management: for example peri-procedural, or during index hospitalisation.</p>
8.	Comparator/Reference standard/Confounding factors	<ul style="list-style-type: none"> <li>• Pairwise comparisons of the above dual antiplatelet therapies</li> </ul>
9.	Types of study to be included	<ul style="list-style-type: none"> <li>• Randomised Controlled Trials (RCT)</li> <li>• Systematic Reviews (SR) of RCTs</li> </ul> <p>Non-randomised studies will be excluded.</p>
10.	Other exclusion criteria	<ul style="list-style-type: none"> <li>• If management in post-acute period</li> <li>• If study population selected for high platelet reactivity (HPR)/ high on-treatment platelet reactivity (HTPR) while on clopidogrel</li> <li>• Non-English language studies</li> <li>• Abstracts will be excluded as it is expected there will be sufficient full text published studies available.</li> </ul>
11.	Context	N/A
12.	Primary outcomes (critical outcomes)	<ul style="list-style-type: none"> <li>• All-cause mortality – up to 30 days</li> <li>• All-cause mortality at 1 year</li> <li>• Cardiac mortality – up to 30 days</li> <li>• Cardiac mortality at 1 year</li> <li>• Re-infarction up to 30 days</li> <li>• Re- infarction at 1 year</li> <li>• Complications related to bleeding including haemorrhagic stroke the following hierarchy of bleeding scales will be used: <ul style="list-style-type: none"> <li>○ BARC</li> <li>○ Author's definition</li> <li>○ TIMI</li> </ul> </li> </ul>



		<ul style="list-style-type: none"> <li>○ GUSTO</li> <li>● Where possible, bleeding outcomes will be categorised into:             <ul style="list-style-type: none"> <li>○ Major bleeding (including BARC 3-5, TIMI, GUSTO and as reported by author)</li> <li>○ Minor bleeding (including BARC 1-2, TIMI, GUSTO and as reported by author)</li> </ul> </li> <li>● Health-related quality of life including EQ5D and SF-36.</li> </ul>
13.	Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> <li>● Stroke (any, type not specified)</li> <li>● Need for revascularisation</li> <li>● Early and late, probably or definite stent thrombosis</li> <li>● Breathing adverse effects</li> <li>● Bradycardic adverse effects (bradycardia, pauses and pacemaker insertion)</li> <li>● Other adverse effects of treatment</li> <li>● Unplanned urgent readmission within 30 days for any reason</li> </ul> <p>Where multiple time points are reported up to and including 30 days, only 30 day outcomes will be included.</p> <p>Where multiple time points beyond 30 days are reported and including up to 1 year, only up to 1 year outcomes will be reported.</p> <p>Where 30-day outcomes are not reported, we will include the next longest follow-up; where up to 1 year outcomes are not reported</p>
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources will be screened for inclusion.</p>

		<p>The full text of potentially eligible studies will be retrieved and will be assessed for eligibility in line with the criteria outlined above.</p> <p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>An in-house developed database; EviBase, will be used for data extraction. A standardised form is followed to extract data from studies (see <a href="#">Developing NICE guidelines: the manual</a> section 6.4) and for undertaking assessment of study quality. Summary evidence tables will be produced including information on: study setting; study population and participant demographics and baseline characteristics; details of the intervention and control interventions; study methodology' recruitment and missing data rates; outcomes and times of measurement; critical appraisal ratings.</p> <p>A second reviewer will quality assure the extracted data. Discrepancies will be identified and resolved through discussion (with a third reviewer where necessary).</p>
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p><a href="#">For Intervention reviews the following checklist will be used according to study design being assessed:</a></p> <ul style="list-style-type: none"> <li>• <a href="#">Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</a></li> <li>• <a href="#">Randomised Controlled Trial: Cochrane RoB (2.0)</a></li> </ul> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<p>Where possible, data will be meta-analysed. Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5) to combine the data given in all studies for each of the outcomes stated above. A fixed effect meta-</p>

		<p>analysis, with weighted mean differences for continuous outcomes and risk ratios for binary outcomes will be used, and 95% confidence intervals will be calculated for each outcome.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the <math>I^2</math> statistic and visually inspected. We will consider an <math>I^2</math> value greater than 50% indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random-effects.</p> <p>GRADE pro will be used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</p> <p>Publication bias is tested for when there are more than 5 studies for an outcome. Other bias will only be taken into consideration in the quality assessment if it is apparent.</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p> <p>If sufficient data is available to make a network of treatments, WinBUGS will be used for network meta-analysis.</p>
17.	Analysis of sub-groups	<ul style="list-style-type: none"> <li>• Timing of pre- and post-hospital admission administration of study drug</li> </ul>
18.	Type and method of review	<input checked="" type="checkbox"/> Intervention <input type="checkbox"/> Diagnostic <input type="checkbox"/> Prognostic <input type="checkbox"/> Qualitative <input type="checkbox"/> Epidemiologic <input type="checkbox"/> Service Delivery <input type="checkbox"/> Other (please specify)
19.	Language	English

20.	Country	England		
21.	Anticipated or actual start date	19/06/18		
22.	Anticipated completion date	14/05/20		
23.	Stage of review at time of this submission	<b>Review stage</b>	<b>Started</b>	<b>Completed</b>
		Preliminary searches	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Piloting of the study selection process	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		24.	Named contact	<p><b>5a. Named contact</b> National Guideline Centre</p> <p><b>5b Named contact e-mail</b> Acute Coronary Syndromes@nice.org.uk</p> <p><b>5e Organisational affiliation of the review</b> National Institute for Health and Care Excellence (NICE) and the National Guideline</p>

		Centre
25.	Review team members	<p>From the National Guideline Centre:</p> <ul style="list-style-type: none"> <li>• <a href="#">Dr Bernard Higgins [Guideline lead]</a></li> <li>• <a href="#">Dr Saoussen Ftouh/Ms Sedina Lewis/Ms Katherine Jones [Senior Systematic Reviewers; Systematic Reviewer]</a></li> <li>• <a href="#">Ms Annabelle Davies/Ms Kate Lovibond [Health economist; Health economists lead]</a></li> <li>• <a href="#">Ms Agnes Cuyas/Ms Jill Cobb [Information specialists]</a></li> </ul>
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <a href="#">Developing NICE guidelines: the manual</a> . Members of the guideline committee are available on the NICE website: [NICE guideline webpage].
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:

		<ul style="list-style-type: none"> <li>notifying registered stakeholders of publication</li> <li>publicising the guideline through NICE's newsletter and alerts</li> <li>issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul>
32.	Keywords	Acute coronary syndrome, anti-platelets, NSTEMI, unstable angina, STEMI
33.	Details of existing review of same topic by same authors	N/A
34.	Current review status	<input type="checkbox"/> Ongoing <input checked="" type="checkbox"/> Completed but not published <input type="checkbox"/> Completed and published <input type="checkbox"/> Completed, published and being updated <input type="checkbox"/> Discontinued
35..	Additional information	N/A
36.	Details of final publication	<a href="http://www.nice.org.uk">www.nice.org.uk</a>

1

2

3 **Table 22: Health economic review protocol**

Review question	All questions – health economic evidence
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.

<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Studies published after 2003 that were included in the previous guidelines will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>122</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.</li> </ul> <p><b>Where there is discretion</b></p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.</p> <p><i>Setting:</i></p> <ul style="list-style-type: none"> <li>• UK NHS (most applicable).</li> <li>• OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</li> <li>• OECD countries with predominantly private health insurance systems (for example, Switzerland).</li> <li>• Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.</li> </ul> <p><i>Health economic study type:</i></p> <ul style="list-style-type: none"> <li>• Cost–utility analysis (most applicable).</li> <li>• Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</li> <li>• Comparative cost analysis.</li> <li>• Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</li> </ul> <p><i>Year of analysis:</i></p> <ul style="list-style-type: none"> <li>• The more recent the study, the more applicable it will be.</li> <li>• Studies published in 2003 or later (including any such studies included in the previous guideline(s)) but that depend on unit costs and resource data entirely or</li> </ul>
------------------------	--

predominantly from before 2003 will be rated as 'Not applicable'.

- Studies published before 2003 (including any such studies included in the previous guidelines) will be excluded before being assessed for applicability and methodological limitations.

*Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.
- The following will be rated as 'Very serious limitations' and excluded: economic analyses undertaken as part of clinical studies that are excluded from the clinical review; economic models where relative treatment effects are based entirely on studies that are excluded from the clinical review.

1

2

## 3 Appendix B: Literature search strategies

4 The literature searches for this review are detailed below and complied with the methodology  
5 outlined in Developing NICE guidelines: the manual.<sup>122</sup>

6 For more information, please see the Methods report published as part of the accompanying  
7 documents for this guideline.

### B.1 Clinical search literature search strategy

9 Searches were constructed using a PICO framework where population (P) terms were  
10 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are  
11 rarely used in search strategies for interventions as these concepts may not be well  
12 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were  
13 applied to the search where appropriate.

14 **Table 23: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 16 June 2019	Exclusions Randomised controlled trials Systematic review studies
Embase (OVID)	1974 – 16 June 2019	Exclusions Randomised controlled trials
The Cochrane Library (Wiley)	Cochrane Reviews to 2019 Issue 6 of 12 CENTRAL to 2019 Issue 6 of 12	None

#### 15 Medline (Ovid) search terms

1.	Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/
2.	Heart Arrest/
3.	(acute coronary adj2 syndrome*).ti,ab.
4.	((myocardial or heart) adj infarct*).ti,ab.



Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

5.	(heart adj (attack* or event*)).ti,ab.
6.	((heart or cardiac) adj arrest*).ti,ab.
7.	(coronary adj2 thrombos*).ti,ab.
8.	(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.
9.	"non-ST-segment elevation".ti,ab.
10.	(non-STEMI or NSTEMI or nonSTEMI).ti,ab.
11.	"Q wave myocardial infarction".ti,ab.
12.	"non Q wave MI".ti,ab.
13.	NSTE-ACS.ti,ab.
14.	(subendocardial adj3 infarct*).ti,ab.
15.	((unstable or variant) adj2 angina*).ti,ab.
16.	(unstable adj2 coronary).ti,ab.
17.	or/1-16
18.	letter/
19.	editorial/
20.	news/
21.	exp historical article/
22.	Anecdotes as Topic/
23.	comment/
24.	case report/
25.	(letter or comment*).ti.
26.	or/18-25
27.	randomized controlled trial/ or random*.ti,ab.
28.	26 not 27
29.	animals/ not humans/
30.	exp Animals, Laboratory/
31.	exp Animal Experimentation/
32.	exp Models, Animal/
33.	exp Rodentia/
34.	(rat or rats or mouse or mice).ti.
35.	or/28-34
36.	17 not 35
37.	limit 36 to English language
38.	(clopidogrel or plavix or grepid).ti,ab.
39.	(ticagrelor or brilinta or brilique or possia).ti,ab.
40.	Prasugrel Hydrochloride/
41.	(prasugrel or efient or effient or prasita).ti,ab.
42.	p2y12 inhibitors.ti,ab.
43.	*Platelet Aggregation Inhibitors/
44.	(antiplatelet* adj2 (dual or therap* or treat* or combi*)).ti,ab.
45.	DAPT.ti,ab.
46.	or/38-45
47.	37 and 46
48.	randomized controlled trial.pt.
49.	controlled clinical trial.pt.

50.	randomi#ed.ti,ab.
51.	placebo.ab.
52.	randomly.ti,ab.
53.	Clinical Trials as topic.sh.
54.	trial.ti.
55.	or/48-54
56.	Meta-Analysis/
57.	exp Meta-Analysis as Topic/
58.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
59.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
60.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
61.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
62.	(search* adj4 literature).ab.
63.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
64.	cochrane.jw.
65.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
66.	or/56-65
67.	47 and (55 or 66)
68.	ASPIRIN/
69.	(aspirin or caprin or disprin or aspro or acetylsalicylic acid or 2-acetoxybenzoic acid or acetylsalicylate or solprin).ti,ab.
70.	or/68-69
71.	Factor Xa Inhibitors/
72.	(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin).ti,ab.
73.	rivaroxaban/
74.	DABIGATRAN/
75.	warfarin/
76.	or/71-75
77.	70 and 76
78.	37 and 77 and (55 or 66)
79.	67 or 78

#### 1 Embase (Ovid) search terms

1.	acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/
2.	heart arrest/
3.	(acute coronary adj2 syndrome*).ti,ab.
4.	((myocardial or heart) adj infarct*).ti,ab.
5.	(heart adj (attack* or event*)).ti,ab.
6.	((heart or cardiac) adj arrest*).ti,ab.
7.	(coronary adj2 thrombos*).ti,ab.
8.	(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.
9.	"non-ST-segment elevation".ti,ab.

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

10.	(non-STEMI or NSTEMI or nonSTEMI).ti,ab.
11.	"Q wave myocardial infarction".ti,ab.
12.	"non Q wave MI".ti,ab.
13.	NSTE-ACS.ti,ab.
14.	(subendocardial adj3 infarct*).ti,ab.
15.	((unstable or variant) adj2 angina*).ti,ab.
16.	(unstable adj2 coronary).ti,ab.
17.	or/1-16
18.	letter.pt. or letter/
19.	note.pt.
20.	editorial.pt.
21.	Case report/ or Case study/
22.	(letter or comment*).ti.
23.	or/18-22
24.	randomized controlled trial/ or random*.ti,ab.
25.	23 not 24
26.	animal/ not human/
27.	Nonhuman/
28.	exp Animal Experiment/
29.	exp Experimental animal/
30.	Animal model/
31.	exp Rodent/
32.	(rat or rats or mouse or mice).ti.
33.	or/25-32
34.	17 not 33
35.	limit 34 to English language
36.	(clopidogrel or plavix or grepid).ti,ab.
37.	clopidogrel/
38.	(ticagrelor or brilinta or briliq or possia).ti,ab.
39.	ticagrelor/
40.	(prasugrel or efient or effient or prasita).ti,ab.
41.	prasugrel/
42.	p2y12 inhibitors.ti,ab.
43.	*antithrombocytic agent/
44.	(antiplatelet* adj2 (dual or therap* or treat* or combi*)).ti,ab.
45.	DAPT.ti,ab.
46.	or/36-45
47.	35 and 46
48.	random*.ti,ab.
49.	factorial*.ti,ab.
50.	(crossover* or cross over*).ti,ab.
51.	((doubl* or singl*) adj blind*).ti,ab.
52.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
53.	crossover procedure/
54.	single blind procedure/

55.	randomized controlled trial/
56.	double blind procedure/
57.	or/48-56
58.	systematic review/
59.	meta-analysis/
60.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
61.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.
62.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
63.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
64.	(search* adj4 literature).ab.
65.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
66.	((pool* or combined) adj2 (data or trials or studies or results)).ab.
67.	cochrane.jw.
68.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
69.	or/58-67
70.	47 and (57 or 69)
71.	acetylsalicylic acid/
72.	(aspirin or caprin or disprin or aspro or acetylsalicylic acid or 2-acetoxybenzoic acid or acetylsalicylate or solprin).ti,ab.
73.	71 or 72
74.	blood clotting factor 10a inhibitor/
75.	(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin).ti,ab.
76.	apixaban/
77.	rivaroxaban/
78.	edoxaban/
79.	dabigatran/
80.	warfarin/
81.	or/74-80
82.	73 and 81
83.	35 and 82 and (57 or 69)
84.	70 or 83

## 1 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Acute Coronary Syndrome] this term only
#2.	MeSH descriptor: [Angina Pectoris] this term only
#3.	MeSH descriptor: [Angina, Unstable] this term only
#4.	MeSH descriptor: [Coronary Thrombosis] this term only
#5.	MeSH descriptor: [Myocardial Infarction] explode all trees
#6.	(or #1-#5)
#7.	MeSH descriptor: [Heart Arrest] this term only
#8.	(acute coronary near/2 syndrome*).ti,ab
#9.	((myocardial or heart) next infarct*).ti,ab
#10.	(heart next (attack* or event*)).ti,ab

#11.	((heart or cardiac) next arrest*):ti,ab
#12.	(coronary near/2 thrombos*):ti,ab
#13.	(stemi or st-segment or st segment or st-elevation or st elevation):ti,ab
#14.	non-ST-segment elevation:ti,ab
#15.	(non-STEMI or NSTEMI or nonSTEMI):ti,ab
#16.	Q wave myocardial infarction:ti,ab
#17.	non Q wave MI:ti,ab
#18.	NSTE-ACS:ti,ab
#19.	(subendocardial near/3 infarct*):ti,ab
#20.	((unstable or variant) near/2 angina*):ti,ab
#21.	(unstable near/2 coronary):ti,ab
#22.	(or #6-#21)
#23.	(clopidogrel or plavix or grepid):ti,ab
#24.	(ticagrelor or brilinta or brilique or possia):ti,ab
#25.	MeSH descriptor: [Prasugrel Hydrochloride] this term only
#26.	(prasugrel or efient or effient or prasita):ti,ab
#27.	p2y12 inhibitors:ti,ab
#28.	MeSH descriptor: [Platelet Aggregation Inhibitors] this term only
#29.	(antiplatelet* near/2 (dual or therap* or treat* or combi*)):ti,ab
#30.	DAPT:ti,ab
#31.	(or #23-#30)
#32.	#22 and #31
#33.	MeSH descriptor: [Aspirin] this term only
#34.	(aspirin or caprin or disprin or aspro or acetylsalicylic acid or 2-acetoxybenzoic acid or acetylsalicylate or solprin):ti,ab
#35.	(or #33-#34)
#36.	MeSH descriptor: [Factor Xa Inhibitors] this term only
#37.	(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin):ti,ab
#38.	MeSH descriptor: [Rivaroxaban] this term only
#39.	MeSH descriptor: [Dabigatran] this term only
#40.	MeSH descriptor: [Warfarin] this term only
#41.	(or #36-#40)
#42.	#35 and #41
#43.	#32 or #42

## B.2 Health Economics literature search strategy

2 Health economic evidence was identified by conducting a search relating to acute coronary  
3 syndromes population combined with terms for interventions in NHS Economic Evaluation  
4 Database (NHS EED – this ceased to be updated after March 2015) and the Health  
5 Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA  
6 databases are hosted by the Centre for Research and Dissemination (CRD). Additional  
7 searches were run on Medline and Embase using a filter for health economics studies.

8 **Table 24: Database date parameters and filters used**

Database	Dates searched	Search filter used
----------	----------------	--------------------

Database	Dates searched	Search filter used
Medline	01 January 2014 – 18 June 2019	Exclusions Health economics studies
Embase	01 January 2014 – 18 June 2019	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - 2003 – 31 March 2018 NHSEED - 2003 to 31 March 2015	None

## 1 Medline (Ovid) search terms

1.	Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/
2.	Heart Arrest/
3.	(acute coronary adj2 syndrome*).ti,ab.
4.	((myocardial or heart) adj infarct*).ti,ab.
5.	(heart adj (attack* or event*)).ti,ab.
6.	((heart or cardiac) adj arrest*).ti,ab.
7.	(coronary adj2 thrombos*).ti,ab.
8.	(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.
9.	"non-ST-segment elevation".ti,ab.
10.	(non-STEMI or NSTEMI or nonSTEMI).ti,ab.
11.	"Q wave myocardial infarction".ti,ab.
12.	"non Q wave MI".ti,ab.
13.	NSTE-ACS.ti,ab.
14.	(subendocardial adj3 infarct*).ti,ab.
15.	((unstable or variant) adj2 angina*).ti,ab.
16.	(unstable adj2 coronary).ti,ab.
17.	or/1-16
18.	letter/
19.	editorial/
20.	news/
21.	exp historical article/
22.	Anecdotes as Topic/
23.	comment/
24.	case report/
25.	(letter or comment*).ti.
26.	or/18-25
27.	randomized controlled trial/ or random*.ti,ab.
28.	26 not 27
29.	animals/ not humans/
30.	exp Animals, Laboratory/

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

31.	exp Animal Experimentation/
32.	exp Models, Animal/
33.	exp Rodentia/
34.	(rat or rats or mouse or mice).ti.
35.	or/28-34
36.	17 not 35
37.	limit 36 to English language
38.	Economics/
39.	Value of life/
40.	exp "Costs and Cost Analysis"/
41.	exp Economics, Hospital/
42.	exp Economics, Medical/
43.	Economics, Nursing/
44.	Economics, Pharmaceutical/
45.	exp "Fees and Charges"/
46.	exp Budgets/
47.	budget*.ti,ab.
48.	cost*.ti.
49.	(economic* or pharmaco?economic*).ti.
50.	(price* or pricing*).ti,ab.
51.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)),ab.
52.	(financ* or fee or fees).ti,ab.
53.	(value adj2 (money or monetary)).ti,ab.
54.	or/38-53
55.	37 and 54
56.	*Angiography/
57.	Angiocardiology/
58.	Coronary Angiography/
59.	Angiograph*.ti.
60.	Arteriograph*.ti.
61.	Angiocardigraph*.ti,ab.
62.	Coronary Angiograph*.ti,ab.
63.	Angiogram*.ti,ab.
64.	Cardioangiograph*.ti,ab.
65.	Angiocardigram.ti,ab.
66.	Angio Cardiograph*.ti,ab.
67.	Coronary Arteriogra*.ti,ab.
68.	Coronarograph*.ti,ab.
69.	*Myocardial Revascularization/
70.	Angioplasty, Balloon, Coronary/
71.	(Myocardial adj revasculari?ation).ti,ab.
72.	PCI.ti,ab.

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

73.	Percutaneous coronary intervention.ti,ab.
74.	Percutaneous Transluminal Coronary Angioplasty.ti,ab.
75.	PTCA.ti,ab.
76.	exp Angioplasty/
77.	Blunt microdissection.ti,ab.
78.	((laser or patch) adj angioplasty).ti,ab.
79.	Percutaneous Transluminal Angioplasty.ti,ab.
80.	Transluminal Coronary Angioplasty.ti,ab.
81.	(Balloon adj3 coronary).ti,ab.
82.	(Balloon adj3 angioplasty).ti,ab.
83.	exp STENTS/
84.	stent*.ti,ab.
85.	Or/56-84
86.	aspirin/
87.	(aspirin or acetylsalicylic acid).ti,ab.
88.	(clopidogrel or plavix).ti,ab.
89.	(ticagrelor or brilique).ti,ab.
90.	(prasugrel or efient or effient or prasita).ti,ab.
91.	Prasugrel Hydrochloride/
92.	platelet aggregation inhibitors/
93.	(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphallbbeta3 or GPIIB IIIA).ti,ab.
94.	exp Platelet Glycoprotein GPIIb-IIIa Complex/
95.	exp Receptors, Fibrinogen/
96.	(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.
97.	exp adrenergic beta-antagonists/
98.	(propranolol or angilol or inderal-la or half-inalderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.
99.	propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or celiprolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/
100.	(beta adj3 block*).ti,ab.
101.	(b adj3 block*).ti,ab.
102.	(beta adj2 antagonist*).ti,ab.
103.	Antithrombins/
104.	Antithrombin*.ti,ab.
105.	(thrombin adj3 inhibitor*).ti,ab.
106.	Hirudins/
107.	Hirudin*.ti,ab.
108.	Hirulog.ti,ab.
109.	Bivalirudin.ti,ab.
110.	Or/86-109
111.	55 and (85 or 110)



1 **Embase (Ovid) search terms**

1.	acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/
2.	heart arrest/
3.	(acute coronary adj2 syndrome*).ti,ab.
4.	((myocardial or heart) adj infarct*).ti,ab.
5.	(heart adj (attack* or event*)).ti,ab.
6.	((heart or cardiac) adj arrest*).ti,ab.
7.	(coronary adj2 thrombos*).ti,ab.
8.	(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.
9.	"non-ST-segment elevation".ti,ab.
10.	(non-STEMI or NSTEMI or nonSTEMI).ti,ab.
11.	"Q wave myocardial infarction".ti,ab.
12.	"non Q wave MI".ti,ab.
13.	NSTE-ACS.ti,ab.
14.	(subendocardial adj3 infarct*).ti,ab.
15.	((unstable or variant) adj2 angina*).ti,ab.
16.	(unstable adj2 coronary).ti,ab.
17.	or/1-16
18.	letter.pt. or letter/
19.	note.pt.
20.	editorial.pt.
21.	Case report/ or Case study/
22.	(letter or comment*).ti.
23.	or/18-22
24.	randomized controlled trial/ or random*.ti,ab.
25.	23 not 24
26.	animal/ not human/
27.	Nonhuman/
28.	exp Animal Experiment/
29.	exp Experimental animal/
30.	Animal model/
31.	exp Rodent/
32.	(rat or rats or mouse or mice).ti.
33.	or/25-32
34.	17 not 33
35.	limit 34 to English language
36.	health economics/
37.	exp economic evaluation/
38.	exp health care cost/
39.	exp fee/

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

40.	budget/
41.	funding/
42.	budget*.ti,ab.
43.	cost*.ti.
44.	(economic* or pharmaco?economic*).ti.
45.	(price* or pricing*).ti,ab.
46.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
47.	(financ* or fee or fees).ti,ab.
48.	(value adj2 (money or monetary)).ti,ab.
49.	or/36-48
50.	35 and 49
51.	angiography/
52.	angiocardiography/
53.	coronary angiography/
54.	Angiograph*.ti.
55.	Arteriograph*.ti.
56.	Angiocardiograph*.ti,ab.
57.	Coronary Angiograph*.ti,ab.
58.	Angiogram*.ti,ab.
59.	Cardioangiograph*.ti,ab.
60.	Angiocardiogram.ti,ab.
61.	Angio Cardiograph*.ti,ab.
62.	Coronary Arteriogra*.ti,ab.
63.	Coronarograph*.ti,ab.
64.	*heart muscle revascularization/
65.	transluminal coronary angioplasty/
66.	(Myocardial adj revasculari?ation).ti,ab.
67.	PCI.ti,ab.
68.	Percutaneous coronary intervention.ti,ab.
69.	Percutaneous Transluminal Coronary Angioplasty.ti,ab.
70.	PTCA.ti,ab.
71.	*angioplasty/
72.	Blunt microdissection.ti,ab.
73.	((laser or patch) adj angioplasty).ti,ab.
74.	Percutaneous Transluminal Angioplasty.ti,ab.
75.	Transluminal Coronary Angioplasty.ti,ab.
76.	(Balloon adj3 coronary).ti,ab.
77.	(Balloon adj3 angioplasty).ti,ab.
78.	exp STENTS/
79.	stent*.ti,ab.

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

80.	Or/51-79
81.	acetylsalicylic acid/
82.	(aspirin or acetylsalicylic acid).ti,ab.
83.	(clopidogrel or plavix).ti,ab.
84.	(ticagrelor or brilique).ti,ab.
85.	(prasugrel or efient or effient or prasita).ti,ab.
86.	prasugrel/
87.	antithrombocytic agent/
88.	(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIb beta3 or GPIIb IIIA).ti,ab.
89.	exp fibrinogen receptor/
90.	(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.
91.	abciximab/ or eptifibatide/ or tirofiban/
92.	exp beta adrenergic receptor blocking agent/
93.	(propranolol or angilol or inderal-la or half-inalderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevilobol or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.
94.	propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or bisoprolol fumarate/ or carvedilol/ or celiprolol/ or esmolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/ or timolol maleate/
95.	(beta adj3 block*).ti,ab.
96.	(b adj3 block*).ti,ab.
97.	(beta adj2 antagonist*).ti,ab.
98.	antithrombin/
99.	Antithrombin*.ti,ab.
100.	(thrombin adj3 inhibitor*).ti,ab.
101.	hirudin derivative/
102.	Hirudin*.ti,ab.
103.	Hirulog.ti,ab.
104.	Bivalirudin.ti,ab.
105.	Or/81-104
106.	50 and (80 or 105)

1 **NHS EED and HTA (CRD) search terms**

#1.	MeSH DESCRIPTOR Acute Coronary Syndrome
#2.	(MeSH DESCRIPTOR angina pectoris)
#3.	(MeSH DESCRIPTOR Angina, Unstable)
#4.	(MeSH DESCRIPTOR Coronary Thrombosis)
#5.	MeSH DESCRIPTOR Myocardial Infarction EXPLODE ALL TREES
#6.	#1 OR #2 OR #3 OR #4 OR #5
#7.	(MeSH DESCRIPTOR Heart Arrest)

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

#8.	((acute coronary adj2 syndrome*))
#9.	((myocardial or heart) adj infarct*))
#10.	((heart adj (attack* or event*)))
#11.	((heart or cardiac) adj arrest*))
#12.	((coronary adj2 thrombos*))
#13.	((STEMI or st-segment or st segment or st-elevation or st elevation))
#14.	("non-ST-segment elevation")
#15.	((non-STEMI or NSTEMI or nonSTEMI))
#16.	("Q wave myocardial infarction")
#17.	("non Q wave MI")
#18.	(NSTE-ACS)
#19.	(STE-ACS)
#20.	((subendocardial adj3 infarct*))
#21.	((unstable or variant) adj2 angina*))
#22.	((unstable adj2 coronary))
#23.	(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24.	(MeSH DESCRIPTOR Angiography)
#25.	(MeSH DESCRIPTOR Angiocardiography)
#26.	((MeSH DESCRIPTOR Coronary Angiography))
#27.	((Angiograph*))
#28.	((Arteriograph*))
#29.	((Angiocardiograph*))
#30.	((Coronary Angiograph*))
#31.	((Angiogram*))
#32.	((Cardioangiograph*))
#33.	((Angiocardiogram))
#34.	((Angio Cardiograph*))
#35.	((Coronary Arteriogra*))
#36.	((Coronarograph*))
#37.	(MeSH DESCRIPTOR Myocardial Revascularization)
#38.	(MeSH DESCRIPTOR Angioplasty, Balloon, Coronary)
#39.	((Myocardial adj revasculari?ation))
#40.	((PCI))
#41.	((Percutaneous coronary intervention))
#42.	((Percutaneous Transluminal Coronary Angioplasty))
#43.	((PTCA))
#44.	(MeSH DESCRIPTOR Angioplasty EXPLODE ALL TREES)
#45.	((Blunt microdissection))
#46.	((laser or patch) adj angioplasty))
#47.	((Percutaneous Transluminal Angioplasty))
#48.	((Transluminal Coronary Angioplasty))
#49.	((Balloon adj3 coronary))
#50.	((Balloon adj3 angioplasty))
#51.	(MeSH DESCRIPTOR Stents EXPLODE ALL TREES)

Acute coronary syndromes: DRAFT FOR CONSULTATION

Initial antiplatelet therapy in adults with acute coronary syndromes including unstable angina or NSTEMI and STEMI

#52.	((stent*))
#53.	(#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)
#54.	(MeSH DESCRIPTOR Aspirin)
#55.	((aspirin or acetylsalicylic acid))
#56.	((clopidogrel or plavix))
#57.	((ticagrelor or brilique))
#58.	((prasugrel or efient or effient or prasita))
#59.	MeSH DESCRIPTOR Prasugrel Hydrochloride
#60.	MeSH DESCRIPTOR Platelet Aggregation Inhibitors
#61.	((Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphallbbeta3 or GPIIB IIIA))
#62.	MeSH DESCRIPTOR Platelet Glycoprotein GPIIb-IIIa Complex EXPLODE ALL TREES
#63.	MeSH DESCRIPTOR Receptors, Fibrinogen EXPLODE ALL TREES
#64.	((Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat))
#65.	MeSH DESCRIPTOR Adrenergic beta-Antagonists EXPLODE ALL TREES
#66.	((propranolol or angilol or inderal-1a or half-inalderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or loproso or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim))
#67.	(MeSH DESCRIPTOR propranolol)
#68.	(MeSH DESCRIPTOR acebutolol)
#69.	(MeSH DESCRIPTOR atenolol)
#70.	(MeSH DESCRIPTOR bisoprolol)
#71.	(MeSH DESCRIPTOR celiprolol)
#72.	(MeSH DESCRIPTOR labetalol)
#73.	(MeSH DESCRIPTOR metoprolol)
#74.	(MeSH DESCRIPTOR nadolol)
#75.	(MeSH DESCRIPTOR nebivolol)
#76.	(MeSH DESCRIPTOR oxprenolol)
#77.	(MeSH DESCRIPTOR pindolol)
#78.	(MeSH DESCRIPTOR sotalol)
#79.	(MeSH DESCRIPTOR timolol)
#80.	((beta adj3 block*))
#81.	((b adj3 block*))
#82.	((beta adj2 antagonist*))
#83.	MeSH DESCRIPTOR Antithrombins
#84.	(Antithrombin*)
#85.	((thrombin adj3 inhibitor*))
#86.	MeSH DESCRIPTOR Hirudins
#87.	(Hirudin*)
#88.	(Hirulog)
#89.	(Bivalirudin)

#90.	#54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89
#91.	(#23 AND (#53 OR #90))

1

2

3

4


5

6

7

## Appendix C: Clinical evidence selection

**Figure 4: Flow chart of clinical study selection for the review of antiplatelet therapy**



1

2

## Appendix D: Clinical evidence tables

Study	Alexopoulos 2012 <sup>8</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=55)
Countries and setting	Conducted in Greece; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 5 days follow-up
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	STEMI: Undergoing primary percutaneous coronary intervention with stent implantation.
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients were excluded if they had a history of stroke/transient ischaemic attack, bleeding diathesis, chronic oral anticoagulation treatment, previous antiplatelet treatment, contraindications to antiplatelet therapy, PCI or coronary artery bypass grafting <3 months, haemodynamic instability, platelet count <100,000/ $\mu$ L, haematocrit <30%, creatinine clearance <30 mL/min, severe hepatic dysfunction, use of strong CYP3A inhibitors or inducers, increased risk of bradycardia, severe chronic obstructive pulmonary disease, or periprocedural IIb/IIIa inhibitors administration
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 58 (12 years); prasugrel group: 61 (13 years). Gender (M:F): 44/11. Ethnicity: Not reported
Further population details	
Extra comments	'STEMI patients undergoing primary PCI with stent implantation'. Patient's randomisation followed by immediate administration of the study drug was performed in the catheterisation laboratory, directly after angiography
Indirectness of population	No indirectness
Interventions	(n=28) Intervention 1: Antiplatelet - Ticagrelor. 180mg loading dose followed by 90mg bid maintenance dose starting 12 $\pm$ 6 hours post loading dose, until day 5. All patients received oral aspirin 325mg at first medical contact. After PCI, all patients received aspirin 100mg/d indefinitely. Duration 5 days. Concurrent medication/care: All patients received 70 U/kg of unfractionated heparin intravenously at first medical contact



Study	Alexopoulos 2012 <sup>8</sup>
	<p>and additional heparin or bivalirudin at the time of PCI per operator's discretion . Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=27) Intervention 2: Antiplatelet - Prasugrel. Prasugrel 60mg loading dose followed by 10mg daily maintenance dose starting 24 hours post loading dose, until day 5. All patients received oral aspirin 325mg at first medical contact. After PCI, all patients received aspirin 100mg/d indefinitely. Duration 5 days. Concurrent medication/care: All patients received 70 U/kg of unfractionated heparin intravenously at first medical contact and additional heparin or bivalirudin at the time of PCI per operator's discretion . Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Academic or government funding (Study supported by the Research Committee of the Patras University Medical School)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus PRASUGREL</b></p> <p>Protocol outcome 1: All-cause mortality at up to 30 days - Actual outcome for STEMI: All-cause mortality (death) at 5 days; Group 1: 1/28, Group 2: 3/27 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'There were no differences in demographic and clinical characteristics between the 2 groups'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke) at Define - Actual outcome for STEMI: Complications related to bleeding (major) at 5 days; Group 1: 0/28, Group 2: 0/27 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High; Indirectness of outcome: No indirectness ; Baseline details: 'There were no differences in demographic and clinical characteristics between the 2 groups'; Blinding details: 'single-blind study...Physicians and operators who performed platelet function testing were blind to the actual drug used, whereas an independent physician monitored bleeding and adverse event data'; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for STEMI: Complications related to bleeding (minor or minimal) at 5 days; Group 1: 3/28, Group 2: 1/27 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High; Indirectness of outcome: No indirectness ; Baseline details: 'There were no differences in demographic and clinical characteristics between the 2 groups'; Blinding details: 'single-blind study...Physicians and operators who performed platelet function testing were blind to the actual drug used, whereas an independent physician monitored bleeding and adverse event data'; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the	Quality of life; Cardiac mortality at 30 days ; Stroke; Need for revascularisation at 1 year; Early and late

<b>Study</b>	<b>Alexopoulos 2012<sup>8</sup></b>
study	stent thrombosis; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

<b>Study</b>	<b>Angiolillo 2016<sup>12</sup></b>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in USA; Setting: 15 US centres
Line of therapy	Unclear
Duration of study	Intervention + follow up: Pharmacodynamic outcomes reported at end of percutaneous coronary intervention
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnostic angiography. NSTEMI-ACS was defined as the presence of cardiac ischaemic symptoms with ischaemic changes (but not ST segment elevation) on electrocardiogram. However, normal electrocardiograms could be acceptable if the investigator considered an ACS presentation likely
Stratum	Overall: Low-risk ACS undergoing ad-hoc PCI
Subgroup analysis within study	Not applicable
Inclusion criteria	From online appendix: provision of informed consent prior to any study-specific procedures; female and/or male aged 18 years or older; patients with documented ACS who were troponin negative and undergoing ad-hoc PCI ("ad hoc PCI" is when PCI was performed immediately following diagnostic angiography); women must have been post-menopausal or surgically sterile with a negative urine pregnancy test. Women over 50 years of age were considered post-menopausal if they had been amenorrhoeic for 12 months without an alternative medical cause following cessation of all exogenous hormonal treatment; patients on aspirin as an antiplatelet medication
Exclusion criteria	From online appendix: contraindication or other reason that clopidogrel or ticagrelor should not have been administered (e.g. hypersensitivity, active bleeding, severe liver disease, history of previous intracranial bleed, gastrointestinal bleed within the past 6 months, major surgery within 30 days; use of any thienopyridine or ticagrelor within 7 days prior to randomisation; any indication for chronic oral anticoagulation (e.g. atrial fibrillation, mitral stenosis, or prosthetic heart valve); concomitant therapy with strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir), CYP3A substrates with narrow

Study	Angiolillo 2016 <sup>12</sup>
	therapeutic index (e.g. cyclosporine, quinidine), or strong CYP3A inducers (e.g. rifampin/rifampicin, phenytoin, carbamazepine); increased bleeding risk, including: recent (within 30 days) GI bleeding; any history of intracranial, intraocular, retroperitoneal, or spinal bleeding; recent (within 30 days of dosing) major trauma; sustained uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure >100mmHg; history of haemorrhagic disorders that can increase the risk of bleeding (e.g. haemophilia, von Willebrand's disease); inability to discontinue concomitant therapy with non-selective non-steroidal anti-inflammatory drug at screening; platelet count <100,000 or haemoglobin <10g/dL; known hepatic disease or any liver function test >3x upper limit of normal; any history of intolerance or allergy to ASA; patient required dialysis; participation in another investigational drug or device study within 30 days of dosing; any acute or chronic unstable condition in the past 30 days or other condition that, in the opinion of the investigator, may have either put the patient at risk or influenced the result of the study (e.g. active cancer, risk for non-compliance, risk for being lost to follow-up); patients who had been treated with glycoprotein IIb/IIIa inhibitor drugs, 14 days before randomisation for abciximab, and up to 24 hours before randomisation for eptifibatid and tirofiban, or at any time during the study; involvement in the planning and conduct of the study (applied to AstraZeneca or delegate staff, and study site staff); previous enrollment or randomisation of treatment in the present study; a suspected/manifest infection according to the World Health Organization risk categories 2, 3, and 4
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 60.1 (10.7); clopidogrel group: 63.0 (9.1). Gender (M:F): 70/30. Ethnicity: Ticagrelor group: 71.7% white, 23.9% black or African American, 4.4% other; clopidogrel group: 71.7% white; 23.9% black or African American; 4.3% other
Further population details	
Extra comments	<p>Any use of the following medication s was prohibited during the study:treatment with approved oral anticoagulants was not allowed 10 days prior to randomisation and during the study (to make sure that warfarin or other oral anticoagulants were not given in combination with ticagrelor); patients taking&gt;3 doses of NSAIDs within 10 days prior to randomisation. No NSAIDs were allowed during the study;</p> <p>After diagnostic angiography, troponin-negative ACS patients undergoing ad hoc PCI were randomly assigned (1:1) to treatment groups</p>
Indirectness of population	No indirectness
Interventions	(n=51) Intervention 1: Antiplatelet - Ticagrelor. 180mg loading dose of ticagrelor after diagnostic angiography, then 90mg maintenance dose 12±1 hour after the loading dose. Study drug loading dose was administered in the catheterisation laboratory after defining coronary anatomy and before starting PCI. Afterwards, antiplatelet treatment was left to the discretion of the treating physician. All patients received a loading dose of aspirin, as per institutional standards (160-500mg), and then 75 to 100mg daily. Duration

Study	Angiolillo 2016 <sup>12</sup>
	<p>Unclear. Concurrent medication/care: Morphine use in catheterisation laboratory. Access site, choice of anticoagulant, stent type and procedural technique were at the physicians's discretion. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=49) Intervention 2: Antiplatelet - Clopidogrel. 600mg loading dose of clopidogrel after diagnostic angiography. Study drug loading dose was administered in the catheterisation laboratory after defining coronary anatomy and before starting PCI. Afterwards, antiplatelet treatment was left to the discretion of the treating physician. All patients received a loading dose of aspirin (160-500mg), as per institutional standards, and then 75 to 100mg daily. Duration Unclear. Concurrent medication/care: Morphine use in catheterisation laboratory. Access site, choice of anticoagulant, stent type and procedural technique were at the physicians's discretion. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Study funded by industry (This study was supported by AstraZeneca)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL</b></p> <p>Protocol outcome 1: All-cause mortality at 30 days - Actual outcome for UA/NSTEMI: All-cause mortality (death) at 30 days; Group 1: 0/51, Group 2: 0/49 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar...with the exception of prior coronary artery bypass graft', which had more cases in the clopidogrel group (p=0.0168). More people in the clopidogrel group also had hypertension (p=0.0599) and prior myocardial infarction (p=0.0832); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Other adverse effects of treatment at Define  - Actual outcome for UA/NSTEMI: Other adverse effects (any adverse event) at 30 days; Group 1: 15/51, Group 2: 9/49 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar...with the exception of prior coronary artery bypass graft', which had more cases in the clopidogrel group (p=0.0168). More people in the clopidogrel group also had hypertension (p=0.0599) and prior myocardial infarction (p=0.0832); Blinding details: 'Members of the clinical staff who managed patient care were blinded to the study drug throughout the PCI procedure until final assessment of bleeding, approximately 1 hour after sheath removal. Thereafter, the study became open-label'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)</p>	

Study	Angiolillo 2016 <sup>12</sup>
	- Actual outcome for UA/NSTEMI: Complications related to bleeding (minor) at 30 days; Group 1: 2/51, Group 2: 0/49 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar...with the exception of prior coronary artery bypass graft', which had more cases in the clopidogrel group (p=0.0168). More people in the clopidogrel group also had hypertension (p=0.0599) and prior myocardial infarction (p=0.0832); Blinding details: 'Members of the clinical staff who managed patient care were blinded to the study drug throughout the PCI procedure until final assessment of bleeding, approximately 1 hour after sheath removal. Thereafter, the study became open-label'; Group 1 Number missing: ; Group 2 Number missing:
Protocol outcomes not reported by the study	Quality of life; Stroke; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Cardiac mortality at 30 days

Study	Bonello 2015 <sup>20</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=213)
Countries and setting	Conducted in France; Setting: Not reported
Line of therapy	Unclear
Duration of study	Intervention + follow up: 1-month follow up
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	UA/NSTEMI: Patients with NSTEMI-ACS and undergoing PCI
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients between 18 and 75 years old who underwent PCI for an intermediate or high-risk NSTEMI-ACS and agreeing to participate in the study were eligible
Exclusion criteria	Exclusion criteria included ST-elevation ACS, NSTEMI-ACS medically managed or intended for surgery after PCI, cardiogenic shock, cardiac arrest, contraindication to antiplatelet therapy, treatment with a P2Y12-ADP antagonist <1 month, a platelet count <100 G/L, history of bleeding diathesis, history of haemorrhagic stroke, stroke, recent surgery (<1 month), age ≥75 years old, haemodialysis, weight <60 kg, treatment with a P2Y12-ADP receptor during the previous month, oral anticoagulant therapy, and use of medication with known interference with ticagrelor or prasugrel and bradycardia
Recruitment/selection of patients	Consecutive patients with ACS

Study	Bonello 2015 <sup>20</sup>
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 61.5 (10.4 years); prasugrel group: 60 (9.6 years). Gender (M:F): 159/54. Ethnicity: Not reported
Further population details	
Extra comments	Timing of randomisation to treatment unclear
Indirectness of population	No indirectness
Interventions	<p>(n=106) Intervention 1: Antiplatelet - Ticagrelor. Patients received a 180mg loading dose of ticagrelor as soon as possible after diagnosis of NSTEMI-ACS followed by 90mg twice daily as maintenance dose. All patients received a loading dose of 150mg aspirin IV at the time of PCI. Duration 1 month post-PCI. Concurrent medication/care: All patients received their loading dose at least 4 hours before PCI (13.4 ± 8.3 hours). PCI was performed using the radial route in all cases but 2 patients in the ticagrelor group. All patients received either a bolus of heparin (100 IU/kg) during the procedure followed by ACT-adjusted additional bolus or standard bivalirudin infusion. Drug-eluting stents were used in all patients. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=107) Intervention 2: Antiplatelet - Prasugrel. Patients undergoing PCI received a 60mg loading dose of prasugrel as soon as the coronary anatomy was known and the decision to proceed to PCI taken. They received prasugrel 10mg daily as maintenance dose. All patients received a loading dose of 150mg aspirin IV at the time of PCI. Duration 1 month post-PCI. Concurrent medication/care: All patients received their loading dose at least 4 hours before PCI (13.4 ± 8.3 hours). PCI was performed using the radial route in all cases but 2 patients in the prasugrel group. All patients received either a bolus of heparin (100 IU/kg) during the procedure followed by ACT-adjusted additional bolus or standard bivalirudin infusion. Drug-eluting stents were used in all patients. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Other (The study was supported by a grant from the Assistance Publique - Hopitaux de Marseille)

#### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus PRASUGREL

Protocol outcome 1: All-cause mortality at 30 days

- Actual outcome for UA/NSTEMI: All-cause mortality (death) at 30 days; Group 1: 0/106, Group 2: 0/107

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;

Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were similar in terms of baseline characteristics'; Group 1 Number missing: ;

Group 2 Number missing:

Study	Bonello 2015 <sup>20</sup>
	<p>Protocol outcome 2: Cardiac mortality at 30 days - Actual outcome for UA/NSTEMI: Cardiac mortality (cardiovascular death) at 30 days ; Group 1: 0/106, Group 2: 0/107 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were similar in terms of baseline characteristics'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome for UA/NSTEMI: Complications related to bleeding (major, BARC &gt;2) at 30 days ; Group 1: 7/106, Group 2: 8/107 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were similar in terms of baseline characteristics'; Blinding details: open-label; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Stroke - Actual outcome for UA/NSTEMI: Stroke (any, type not specified) at 30 days ; Group 1: 0/106, Group 2: 1/107 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were similar in terms of baseline characteristics'; Blinding details: open-label; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	Dasbiswas 2013 <sup>35</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=220)
Countries and setting	Conducted in India; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 weeks treatment (median duration 14.5 weeks) with 90 days follow-up
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall: Undergoing percutaneous coronary intervention
Subgroup analysis within study	Not applicable

Study	Dasbiswas 2013 <sup>35</sup>
Inclusion criteria	Both male and female patients between 18 and 75 years of age with acute coronary syndrome undergoing PCI. The patients with unstable angina and non-ST-segment elevation MI were enrolled within 72 hours of symptom onset and with ST-segment elevation MI were enrolled either undergoing primary PCI or within 14 days after the onset of symptoms. The patients were required to weigh more than 60kg.
Exclusion criteria	Patients with cardiogenic shock, refractory ventricular arrhythmias, heart failure (NYHA class IV), active bleeding, history of bleeding diatheses, transient ischemic stroke, platelet < 100,000/mm <sup>3</sup> and haemoglobin <10 gm% were not eligible to participate in the study.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Prasugrel group, male: 54.8 (9.67); prasugrel group, female: 58.7 (8.10); clopidogrel group, male: 54.6 (9.65); clopidogrel group, female: 60.4 (10.50). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	
Extra comments	The patient should have adequate liver and kidney function. The patients received a loading dose of the study drug between randomisation and 1 hour after leaving the cardiac catheterisation laboratory
Indirectness of population	No indirectness
Interventions	<p>(n=111) Intervention 1: Antiplatelet - Prasugrel. Loading dose of 60mg prasugrel between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. Following loading dose, patients received prasugrel 10mg once daily. All patients were prescribed aspirin 325mg per day during the study. The maintenance dose was started from the next day of loading dose. Duration 12 weeks. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=109) Intervention 2: Antiplatelet - Clopidogrel. Loading dose of 300mg clopidogrel between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. Following loading dose, patients received clopidogrel 75mg once daily. All patients were prescribed aspirin 325mg per day during the study. The maintenance dose was started from the next day of loading dose. Duration 12 weeks. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Funding not stated

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL**

Protocol outcome 1: Other adverse effects of treatment at 30 days



Study	Dasbiswas 2013 <sup>35</sup>
	<p>- Actual outcome: Other adverse effects (all events) at 30 days; Group 1: 4/111, Group 2: 5/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing</p> <p>- Actual outcome: Other adverse effects (serious adverse event: tonic clonic convulsions with slurred speech and salivation) at 30 days; Group 1: 0/111, Group 2: 1/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: cardiogenic shock) at 30 days; Group 1: 0/111, Group 2: 1/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: acid peptic disease) at 30 days; Group 1: 0/111, Group 2: 1/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: non-cardiac chest pain) at 30 days; Group 1: 0/111, Group 2: 1/109 Risk of bias: All domain – Very High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: acute cerebral haemorrhage) at 30 days; Group 1: 1/111, Group 2: 0/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: right groin haematoma) at 30 days; Group 1: 1/111, Group 2: 0/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: right brachial monoparesis) at 30 days; Group 1: 1/111, Group 2: 0/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: reduction in haemoglobin %) at 30 days; Group 1: 1/111, Group 2: 0/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Other adverse effects (serious adverse event: other medically important condition - cerebral infarct) at 30 days; Group 1: 0/111, Group 2: 1/109 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Cardiac mortality at 30 days - Actual outcome: Cardiac mortality at 30 days; Group 1: 0/93, Group 2: 1/96 Risk of bias: All domain – High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: 18, Reason: At 12 weeks: suspected</p>

Study	Dasbiswas 2013 <sup>35</sup>
<p>adverse reactions (n=4); voluntary withdrawal (n=5); medically withdrawn (n=1); death (n=2); PCI not done (n=3); lost to follow-up (n=3); Group 2 Number missing: 13, Reason: At 12 weeks: suspected adverse reactions (n=3); voluntary withdrawal (n=3); death (n=1); PCI not done (n=3); lost to follow-up (n=3)</p>	
<p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome: Complications related to bleeding (major bleeding) at 30 days; Group 1: 0/111, Group 2: 0/109                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Complications related to bleeding (minor bleeding) at 30 days; Group 1: 5/111, Group 2: 1/109                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Stroke                      - Actual outcome: Stroke (any nonfatal, type not specified) at 30 days; Group 1: 1/93, Group 2: 1/96                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: 18, Reason: At 12 weeks: suspected adverse reactions (n=4); voluntary withdrawal (n=5); medically withdrawn (n=1); death (n=2); PCI not done (n=3); lost to follow-up (n=3); Group 2 Number missing: 13, Reason: At 12 weeks: suspected adverse reactions (n=3); voluntary withdrawal (n=3); death (n=1); PCI not done (n=3); lost to follow-up (n=3)</p>	
<p>Protocol outcome 5: Need for revascularisation at 30 days                      - Actual outcome: Need for revascularisation (urgent revascularisation) at 30 days; Group 1: 0/93, Group 2: 0/96                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: 18, Reason: At 12 weeks: suspected adverse reactions (n=4); voluntary withdrawal (n=5); medically withdrawn (n=1); death (n=2); PCI not done (n=3); lost to follow-up (n=3); Group 2 Number missing: 13, Reason: At 12 weeks: suspected adverse reactions (n=3); voluntary withdrawal (n=3); death (n=1); PCI not done (n=3); lost to follow-up (n=3)</p>	
<p>Protocol outcome 6: Early and late stent thrombosis                      - Actual outcome: Stent thrombosis (serious adverse event: acute stent thrombosis) at Unclear; Group 1: 0/111, Group 2: 1/109                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 7: All-cause mortality at 30 days                      - Actual outcome: All-cause mortality (death) at 30 days; Group 1: 2/111, Group 2: 1/109                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 8: Re-infarction at 30 days</p>	

Study	Dasbiswas 2013 <sup>35</sup>
	<p>- Actual outcome: Re-infarction (nonfatal myocardial infarction) at 30 days; Group 1: 0/93, Group 2: 0/96                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: 18, Reason: At 12 weeks: suspected adverse reactions (n=4); voluntary withdrawal (n=5); medically withdrawn (n=1); death (n=2); PCI not done (n=3); lost to follow-up (n=3); Group 2 Number missing: 13, Reason: At 12 weeks: suspected adverse reactions (n=3); voluntary withdrawal (n=3); death (n=1); PCI not done (n=3); lost to follow-up (n=3)</p> <p>Protocol outcome 10: Unplanned urgent readmission at within 30 days for any reason                      - Actual outcome: Unplanned urgent readmission (rehospitalisation due to cardiac event) at 30 days; Group 1: 1/93, Group 2: 1/96                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Similar age and weight; Group 1 Number missing: 18, Reason: At 12 weeks: suspected adverse reactions (n=4); voluntary withdrawal (n=5); medically withdrawn (n=1); death (n=2); PCI not done (n=3); lost to follow-up (n=3); Group 2 Number missing: 13, Reason: At 12 weeks: suspected adverse reactions (n=3); voluntary withdrawal (n=3); death (n=1); PCI not done (n=3); lost to follow-up (n=3)</p>
Protocol outcomes not reported by the study	Quality of life; Length of hospital stay

Study	Dehghani 2017 <sup>43</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=144)
Countries and setting	Conducted in Canada; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 30 days follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute STEMI on qualifying electrocardiogram (ECG) ( $\geq 1$ mV in $\geq 2$ continuous leads)
Stratum	STEMI: Fibrinolytic-treated patients undergoing early PCI
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients were eligible for enrollment if they presented within 12 hours after the onset of symptoms, had evidence of acute STEMI on qualifying electrocardiogram (ECG) ( $\geq 1$ mV in $\geq 2$ continuous leads), and, due to anticipated delay to primary PCI, received tenecteplase (TNKase; Genentech, South San Francisco, CA) as the primary mode of reperfusion. Regardless of reperfusion status or haemodynamic stability, a pharmacoinvasive strategy with an angiogram at a PCI-capable hospital within 24 hours of fibrinolysis was mandated.

Study	Dehghani 2017 <sup>43</sup>
	All patients were older than 18 years and provided written informed consent
Exclusion criteria	Major exclusion criteria were any contraindication for the use of clopidogrel or ticagrelor, a need for oral anticoagulation therapy, atrial fibrillation, an increased risk of bradycardia, PCI or coronary artery bypass surgery (CABG) during the previous 3 months, active bleeding or high risk of bleeding based on clinical assessment, known clinically important thrombocytopaenia or anaemia, concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer, and women of child-bearing age. Due to interference with the VerifyNow assay, all patients who received GPIIb/IIIa receptor antagonist before, during or after PCI were excluded from this study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 62.1 (10.2 years); clopidogrel group: 64.1 (14.0 years). Gender (M:F): 107/37. Ethnicity: Ticagrelor group: white (93.4%); clopidogrel group: white (97.1%)
Further population details	
Extra comments	Patients were randomised at the time of diagnostic angiogram and immediately went on to receive the loading dose of their assigned treatment prior to PCI. Patients had already received aspirin and clopidogrel at the time of fibrinolysis
Indirectness of population	No indirectness
Interventions	(n=76) Intervention 1: Antiplatelet - Ticagrelor. 180mg loading dose of ticagrelor followed by 90mg PO twice daily. Duration 30 days. Concurrent medication/care: All patients received 162 to 325mg of aspirin and clopidogrel adjunctive therapy at the time of fibrinolysis as per guidelines. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable 2. Use of GpIIb/IIIa : Not applicable  (n=68) Intervention 2: Antiplatelet - Clopidogrel. A loading dose of 300mg clopidogrel followed by 75mg PO daily. Duration 30 days. Concurrent medication/care: All patients received 162 to 325mg of aspirin and clopidogrel adjunctive therapy at the time of fibrinolysis as per guidelines. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable 2. Use of GpIIb/IIIa : Not applicable
Funding	Study funded by industry (This work was supported by an unrestricted investigator-initiated grant from AstraZeneca)
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL</b>	
Protocol outcome 1: All-cause mortality at 30 days - Actual outcome for STEMI: All-cause mortality at 30 days; Group 1: 1/76, Group 2: 3/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;	

Study	Dehghani 2017 <sup>43</sup>
	<p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Other adverse effects of treatment at 30 days</p> <p>- Actual outcome for STEMI: Other adverse effects (all events) at 30 days; Group 1: 13/76, Group 2: 12/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (chest pain) at 30 days; Group 1: 3/76, Group 2: 2/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (congestive heart failure) at 30 days; Group 1: 3/76, Group 2: 1/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (hypotension) at 30 days; Group 1: 3/76, Group 2: 2/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (fall) at 30 days; Group 1: 0/76, Group 2: 1/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (musculoskeletal pain) at 30 days; Group 1: 1/76, Group 2: 2/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (rash) at 30 days; Group 1: 0/76, Group 2: 2/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (tachyarrhythmia) at 30 days; Group 1: 1/76, Group 2: 1/68</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p>

Study	Dehghani 2017 <sup>43</sup>
	<p>- Actual outcome for STEMI: Other adverse effects (gingival hives) at 30 days; Group 1: 1/76, Group 2: 0/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: Other adverse effects (urinary tract infection) at 30 days; Group 1: 1/76, Group 2: 1/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Breathing adverse effects</p> <p>- Actual outcome for STEMI: Breathing adverse effects (dyspnoea) at 30 days; Group 1: 8/76, Group 2: 3/68 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing: missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Bradycardic adverse effects</p> <p>- Actual outcome for STEMI: Bradycardic adverse effects (bradycardia) at 30 days; Group 1: 1/76, Group 2: 0/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Complications related to bleeding (including haemorrhagic stroke)</p> <p>- Actual outcome for STEMI: Complications related to bleeding (major, BARC 3-5) at 30 days; Group 1: 2/76, Group 2: 1/68 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for STEMI: Complications related to bleeding (minor, BARC 1-2) at 30 days; Group 1: 9/76, Group 2: 5/68 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Stroke</p> <p>- Actual outcome for STEMI: Stroke (any, type not specified) at 30 days; Group 1: 0/76, Group 2: 0/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p>

Study	Dehghani 2017 <sup>43</sup>
	<p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: Need for revascularisation - Actual outcome for STEMI: Need for revascularisation (unplanned revascularisation) at 30 days; Group 1: 0/76, Group 2: 1/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 8: Re-infarction at 30 days - Actual outcome for STEMI: Re-infarction (myocardial infarction) at 30 days; Group 1: 0/76, Group 2: 1/68; Comments: Myocardial infarction resulted in death Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 9: Unplanned urgent readmission at 30 days for any reason - Actual outcome for STEMI: Unplanned urgent readmission (re-hospitalisation) at 30 days; Group 1: 2/76, Group 2: 4/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were similar between groups' although a higher proportion of the ticagrelor group had prior PCI (P = 0.07); Blinding details: 'Antiplatelet assignment was not blinded' ; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Early and late stent thrombosis; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Cardiac mortality at 30 days

Study	DISPERSE-2 trial: Cannon 2007 <sup>26</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=661)
Countries and setting	Conducted in Multiple countries; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 4-12 weeks follow up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients experienced ischaemic symptoms of ≥10 minutes duration at rest, with either biochemical marker evidence of myocardial infarction or electrocardiographic

<b>Study</b>	<b>DISPERSE-2 trial: Cannon 2007<sup>26</sup></b>
	evidence of ischaemia
Stratum	UA/NSTEMI: Patients with NSTEMI-ACS
Subgroup analysis within study	Not applicable
Inclusion criteria	From supplementary appendix: patients aged $\geq 18$ years and hospitalised for NSTEMI-ACS within the preceding 48 hours. Patients had to have experienced ischaemic symptoms of $\geq 10$ minutes duration at rest, with either biochemical marker evidence of myocardial infarction (defined as troponin T or I, creatine kinase [CK]-MB elevation greater than the local MI decision limit, or if these markers were not available, total CK greater than twice the local MI decision limit) or electrocardiographic evidence of ischaemia, defined as the presence of new or presumably new ST-segment depression $\geq 0.5$ mm (0.05mV), transient ST-segment elevation $\geq 1$ mm (0.1mV), or T-wave inversion $\geq 1$ mm (0.1mV) in 2 or more contiguous leads
Exclusion criteria	From supplementary appendix: persistent ST-segment elevation $\geq 20$ minutes, more than 48 hours from onset of symptoms, index event occurring as a consequence of PCI within the prior 48 hours or performance of PCI within 48 hours of randomisation (i.e. patients had to be randomised pre-PCI); angiography showing no significant coronary stenosis; and any of the following conditions associated with increased risk of bleeding: history of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intra-articular bleeding; gastrointestinal bleeding within the prior 6 months; gastric or duodenal ulcer disease verified by endoscopy or radiographic testing within the prior 6 months; persistent uncontrolled hypertension $>180/10$ mmHg; any known haemorrhagic disorder; major surgical procedure or trauma within the prior 30 days; or intracranial aneurysm or vascular malformation. Other exclusion criteria included CABG within 3 months before randomisation, non-haemorrhagic stroke within the prior 30 days, active cancer (excluding skin basal cell carcinoma), oral anticoagulation therapy within the prior 7 days or need for chronic oral anticoagulation, chronic daily dosing with nonselective nonsteroidal anti-inflammatory drugs, thrombolytic therapy within the prior 7 days, contraindications for aspirin treatment, concomitant therapy with digoxin or strong cytochrome P450 3A4 inhibitors or cytochrome P450 3A4 substrates with a narrow therapeutic index, known lactose intolerance (due to the excipient in the capsules), serum creatinine level $>3.0$ mg/dl (265 $\mu$ mol/l), known active liver disease or elevated liver function tests of alanine aminotransferase (ALT) $>2$ x the upper limit of normal or total bilirubin 1.5x the upper limit of normal at the local laboratory, haemoglobin level $<10$ g/dl (6.2mmol/l), platelet count $<100 \times 10^9$ to the power of 9/l, and participation in another investigational drug study within 1 month before randomisation
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor 90 mg group: 64 (12.1 years); ticagrelor 180mg group: 63 (11.4 years); clopidogrel group: 62 (11.0 years) based on primary safety cohort. Gender (M:F): 632/352 (based on primary safety cohort). Ethnicity: Ticagrelor group (90mg and 180mg groups combined): white 95%, non-white 5%; clopidogrel group: 94%
Further population details	



Study	DISPERSE-2 trial: Cannon 2007 <sup>26</sup>
Extra comments	Patients who had received clopidogrel before randomisation were permitted in the study, but open-label clopidogrel was discontinued after randomisation
Indirectness of population	No indirectness
Interventions	<p>(n=334) Intervention 1: Antiplatelet - Ticagrelor. Patients received 90mg of ticagrelor twice daily. Patients were subrandomised to receive or not to receive an initial loading dose of 270mg. Patients were scheduled to receive 1, 2 or 3 months of study drug, depending on when during the trial period they were enrolled. Patients received aspirin at an initial dose of up to 325mg followed by 75 to 100mg daily. For patients undergoing PCI within 48 hours post-randomisation, an additional 300mg placebo could be administered at the discretion of the treating physician. Duration 4-12 weeks. Concurrent medication/care: Patients received standard medical (anti-ischaemic and antithrombotic) and interventional treatment for ACS, including with or without a glycoprotein IIb/IIIa inhibitor, heparin, beta-blockers and statins. Patients who received clopidogrel before randomisation were permitted in the study, but open-label clopidogrel was discontinued after randomisation and replaced with study drug. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=327) Intervention 2: Antiplatelet - Clopidogrel. Patients received 300mg clopidogrel followed by 75mg once daily. Patients were scheduled to receive 1, 2 or 3 months of study drug, depending on when during the trial period they were enrolled. Patients received aspirin at an initial dose of up to 325mg followed by 75 to 100mg daily. For patients undergoing PCI within 48 hours post-randomisation, an additional 300mg clopidogrel could be administered at the discretion of the treating physician. Duration 4-12 weeks. Concurrent medication/care: Patients received standard medical (anti-ischaemic and antithrombotic) and interventional treatment for ACS, including with or without a glycoprotein IIb/IIIa inhibitor, heparin, beta-blockers and statins. Patients who received clopidogrel before randomisation were permitted in the study, but open-label clopidogrel was discontinued after randomisation and replaced with study drug. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Study funded by industry (AstraZeneca)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL**

Protocol outcome 1: All-cause mortality at 30 days

- Actual outcome for UA/NSTEMI: All-cause mortality (death) at 1 month; Group 1: 6/334, Group 2: 2/327

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;

Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;

Group 1 Number missing: ; Group 2 Number missing:

Study	DISPERSE-2 trial: Cannon 2007 <sup>26</sup>
<p>Protocol outcome 2: Cardiac mortality at 30 days                      - Actual outcome for UA/NSTEMI: Cardiac mortality (cardiovascular death) at 1 month; Group 1: 6/334, Group 2: 2/327                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;                      Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome for UA/NSTEMI: Complications related to bleeding (major) at 1 month; Group 1: 23/334, Group 2: 22/327                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;                      Group 1 Number missing: 6, Reason: Did not receive at least one dose of study drug - reason not reported; Group 2 Number missing: 0                      - Actual outcome for UA/NSTEMI: Complications related to bleeding (minor) at 1 month; Group 1: 9/334, Group 2: 4/327                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;                      Group 1 Number missing: 6, Reason: Did not receive at least one dose of study drug - reason not reported; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Stroke                      - Actual outcome for UA/NSTEMI: Stroke (any, type not specified) at 1 month; Group 1: 2/334, Group 2: 1/327                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;                      Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 5: Re-infarction at 30 days                      - Actual outcome for UA/NSTEMI: Re-infarction (myocardial infarction) at 1 month; Group 1: 7/334, Group 2: 11/327                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Including age, gender, ethnicity for primary safety cohort but not total randomised population;                      Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	ETAMI trial: Zeymer 2015 <sup>325</sup>
Study type	RCT (Patient randomised; Parallel)

Study	ETAMI trial: Zeymer 2015 <sup>325</sup>
Number of studies (number of participants)	1 (n=63)
Countries and setting	Conducted in Germany; Setting: In the ambulance or in the emergency department of a PCI hospital
Line of therapy	1st line
Duration of study	Intervention + follow up: 30-day follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute STEMI ≤ 12 h defined as angina or equivalent symptoms >30 min; or ST-segment elevation ≥ 2 electrocardiogram leads (≥ 2 mm precordial leads, ≥ 1mm limb leads, or ST depression ≥ 1 mm precordial leads in posterior myocardial infarction)
Stratum	STEMI: Intended for PPCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Age ≥ 18 years and <75 years; acute STEMI ≤ 12 h defined as angina or equivalent symptoms >30 min; or ST-segment elevation ≥ 2 electrocardiogram leads (≥ 2 mm precordial leads, ≥ 1mm limb leads, or ST depression ≥ 1 mm precordial leads in posterior myocardial infarction; planned PPCI; legal capacity (including ability to understand the nature, scope, and possible consequences of the study participation); and informed consent
Exclusion criteria	Age ≥ 75 years; body weight < 60 kg; thrombolytic therapy within 24 h before randomisation; oral anticoagulation; known haemorrhagic diathesis; history of stroke or transient ischaemic attack; cardiogenic shock; evidence of an active gastrointestinal or urogenital bleeding; major surgery within 6 weeks; contraindication to prasugrel or clopidogrel; severe renal or hepatic insufficiency; contraindication to coronary angiography; planned administration of a glycoprotein (GP) IIb/IIIa inhibitor before angiography; pregnant or nursing (lactating) women; treatment within the last 10 days with clopidogrel, prasugrel, ticlopidine or ticagrelor; uncontrollable hypertension (blood pressure ≥ 200/110 mm Hg in repeated measurements); treatment with NSAIDs; and participation in another clinical or device trial within the previous 30 days
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): prasugrel group: 59 (55-70); clopidogrel group: 64 (49-70). Gender (M:F): 45/17 (ITT population). Ethnicity: Not reported
Further population details	
Extra comments	Randomisation to treatment and administration of the drugs occurred before transfer to the catheterisation laboratory, where diagnostic coronary angiography and PPCI with stent implantation was done
Indirectness of population	No indirectness
Interventions	(n=32) Intervention 1: Antiplatelet - Prasugrel. A loading dose of 60 mg prasugrel and 8 tablets of clopidogrel placebo as early as possible. Aspirin (500 mg intravenously or 300 mg orally). Duration 30 days. Concurrent

<b>Study</b>	<b>ETAMI trial: Zeymer 2015<sup>325</sup></b>
	<p>medication/care: The administration of GP IIb/IIIa inhibitors after the diagnostic angiography and prior to or during PPCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=31) Intervention 2: Antiplatelet - Clopidogrel. A loading dose of 600 mg clopidogrel and 6 tablets of prasugrel placebo as early as possible. Aspirin (500 mg intravenously or 300 mg orally). Duration 30 days. Concurrent medication/care: The administration of GP IIb/IIIa inhibitors after the diagnostic angiography and prior to or during PPCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Other (This study was funded by Daiichi Sankyo and the Stiftung Institut für Herzinfarktforschung Ludwigshafen. Authors also received funding by industry)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL**

Protocol outcome 1: All-cause mortality at 30 days

- Actual outcome for STEMI: All-cause mortality at 30 days ; Group 1: 1/31, Group 2: 1/31

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics...did not show any significant differences'; Group 1 Number missing: 1, Reason: Although ITT was applied, for 1 patient 'the actual diagnosis turned out to be pulmonary embolism, and for this patient, study guidance decided that his data should not be included in the intention-to-treat analysis'. While this referred specially to the analysis of PRI values, the number of participants analysed for clinical events appears to exclude 1 patient; Group 2 Number missing: 0

Protocol outcome 2: Other adverse effects of treatment at 30 days

- Actual outcome for STEMI: Other adverse effects of treatment (cardiogenic shock) at 30 days ; Group 1: 1/31, Group 2: 2/31

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics...did not show any significant differences'; Group 1 Number missing: 1, Reason: Although ITT was applied, for 1 patient 'the actual diagnosis turned out to be pulmonary embolism, and for this patient, study guidance decided that his data should not be included in the intention-to-treat analysis'. While this referred specially to the analysis of PRI values, the number of participants analysed for clinical events appears to exclude 1 patient; Group 2 Number missing: 0

Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)

- Actual outcome for STEMI: Complications related to bleeding (major or minor, TIMI) at 30 days ; Group 1: 1/31, Group 2: 0/31

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics...did not show any significant differences'; Group 1 Number missing: 1, Reason: Although ITT was applied, for 1 patient 'the actual diagnosis turned out to be pulmonary embolism, and for this patient, study

Study	ETAMI trial: Zeymer 2015 <sup>325</sup>
guidance decided that his data should not be included in the intention-to-treat analysis'. While this referred specially to the analysis of PRI values, the number of participants analysed for clinical events appears to exclude 1 patient; Group 2 Number missing: 0	
<p>Protocol outcome 4: Early and late stent thrombosis</p> <p>- Actual outcome for STEMI: Stent thrombosis at 30 days ; Group 1: 0/31, Group 2: 0/31</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics...did not show any significant differences'; Group 1 Number missing: 1, Reason: Although ITT was applied, for 1 patient 'the actual diagnosis turned out to be pulmonary embolism, and for this patient, study guidance decided that his data should not be included in the intention-to-treat analysis'. While this referred specially to the analysis of PRI values, the number of participants analysed for clinical events appears to exclude 1 patient; Group 2 Number missing: 0</p>	
<p>Protocol outcome 5: Re-infarction at 30 days</p> <p>- Actual outcome for STEMI: Re-infarction at 30 days ; Group 1: 0/31, Group 2: 0/31</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics...did not show any significant differences'; Group 1 Number missing: 1, Reason: Although ITT was applied, for 1 patient 'the actual diagnosis turned out to be pulmonary embolism, and for this patient, study guidance decided that his data should not be included in the intention-to-treat analysis'. While this referred specially to the analysis of PRI values, the number of participants analysed for clinical events appears to exclude 1 patient; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life; Stroke; Need for revascularisation at 1 year; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Cardiac mortality at 30 days

Study	Han 2019 <sup>55</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=120)
Countries and setting	Conducted in China; Setting: Zhengzhou Central Hospital Affiliated to Zhengzhou University
Line of therapy	Not applicable
Duration of study	Intervention time: 12 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	STEMI
Subgroup analysis within study	Not applicable

Study	Han 2019 <sup>55</sup>
Inclusion criteria	Patients who satisfied the diagnostic criteria of STEMI released by WTO, hospitalised within 12 hours after onset, aged below 80 years, and had two or more continuous ST-segment elevation in electrocardiography (chest lead > 0.2 mV and limb lead > 0.1 mV) were included.
Exclusion criteria	Patients who had hepatic and renal insufficiency, immune disease, infectious disease, severe coagulation function, haematological system disease or malignant tumour, could not tolerate surgery, or were allergic to treatment drugs were excluded.
Recruitment/selection of patients	STEMI patients who underwent emergency PCI between January 2016 and December 2017
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 67 (8); clopidogrel group: 67 (8) years. Gender (M:F): 65/56. Ethnicity: Not reported
Further population details	
Indirectness of population	No indirectness
Interventions	<p>(n=60) Intervention 1: Antiplatelet - Ticagrelor. All the patients took 300 mg of aspirin. Patients orally took 180 mg of ticagrelor, then PCI was performed. After PCI, patients were given anti-platelet maintenance treatment, i.e. orally took 100 mg of aspirin once a day and patients were given 90 mg of ticagrelor, twice a day for at least one year. . Duration 12 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p> <p>(n=60) Intervention 2: Antiplatelet - Clopidogrel. All the patients took 300 mg of aspirin. Patients orally took 600 mg of clopidogrel, then PCI was performed. After PCI, patients were given anti-platelet maintenance treatment, i.e. orally took 100 mg of aspirin once a day and patients were given 75 mg of ticagrelor, twice a day for at least one year. . Duration 12 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p>
Funding	Funding not stated

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR + ASA versus CLOPIDOGREL + ASA**

Protocol outcome 1: Cardiac mortality at 30 days

- Actual outcome for STEMI: Cardiac mortality at 30 days; Group 1: 1/60, Group 2: 2/60

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,

<b>Study</b>	
<b>Han 2019<sup>55</sup></b>	
Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
<p>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke)</p> <p>- Actual outcome for STEMI: Major bleeding at 30 days; Group 1: 0/60, Group 2: 0/60</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome for STEMI: Minor bleeding at 30 days; Group 1: 3/60, Group 2: 4/60</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 3: Re-infarction at 30 days</p> <p>- Actual outcome for STEMI: Re-infarction at 30 days; Group 1: 2/60, Group 2: 4/60</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days ; Non-haemorrhagic stroke; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

<b>Study</b>	
<b>ISAR-REACT 5 trial: Schupke 2019<sup>223</sup></b>	
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=4018)
Countries and setting	Conducted in Germany, Italy; Setting: 23 centres: 21 centres in Germany and 2 centres in Italy
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 12 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Hospitalization for an acute coronary syndrome (unstable angina pectoris, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI)) with planned

Study	ISAR-REACT 5 trial: Schupke 2019 <sup>223</sup>
	<p>invasive strategy; age ≥18 years.                      For STEMI patients: Chest discomfort suggestive of cardiac ischemia ≥ 20 minutes at rest, within 24 h prior to randomization with 1 of the following ECG features:                      - ST-segment elevation ≥ 1 mm in ≥ 2 contiguous ECG leads or                      - new or presumably new left bundle branch block (LBBB)                      For NSTEMI or unstable angina: Chest discomfort suggestive of cardiac ischemia for ≥ 10 minutes at rest within 48 h prior to randomization + 1 of the following criteria:                      - ST-segment depression ≥ 1 mm in ≥ 1 or 2 contiguous ECG leads or                      - Troponin T or I or CK-MB greater than the upper limit of normal or                      - 2 of the following clinical criteria: Age ≥ 60 years, ≥ 3 risk factors for coronary artery disease (arterial hypertension, hypercholesterolemia, current smoker), diabetes mellitus, aspirin use in the past 7 days, severe angina (≥ 2 episodes within the last 24 hours), chronic renal dysfunction, prior MI or CABG, known CAD with ≥ 50% stenosis in ≥ 2 vessels, carotid stenosis ≥ 50% or cerebral revascularization, peripheral artery disease</p>
Exclusion criteria	<p>Examples include the following (full exclusion criteria reported in supplementary material of trial publication: (a) intolerance of or allergy to ticagrelor or prasugrel, (b) history of any stroke, transient ischemic attack or intracranial bleeding, (c) known intracranial neoplasm, intracranial arteriovenous malformation or intracranial aneurysm, (d) active bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding, (e) fibrin-specific fibrinolytic therapy less than 24 h before randomization, non-fibrin-specific fibrinolytic therapy less than 48 h before randomization, (f) known platelet count &lt; 100,000/μL at the time of screening, (g) known anemia (hemoglobin &lt; 10 g/dL) at the time of screening, (h) oral anticoagulation that cannot be safely discontinued for the duration of the study, (i) increased risk of bradycardia events, (j) index event is an acute complication (&lt; 30 days) of PCI, (k) pregnancy</p>
Recruitment/selection of patients	From September 2013 through February 2018
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 64.5 (12) years; Prasugrel group: 64.6 (12.1) years. Gender (M:F): 3062/956. Ethnicity: Not reported
Further population details	
Extra comments	Diagnosis at admission (mean %): STEMI: 41.2%; NSTEMI: 46.1%; Unstable angina: 12.7%.
Indirectness of population	No indirectness
Interventions	<p>(n=2012) Intervention 1: Antiplatelet - Ticagrelor. Therapy with ticagrelor was started at a loading dose of 180 mg and continued at a maintenance dose of 90 mg twice daily. Patients who were assigned to ticagrelor received the loading dose as soon as possible after randomization. At discharge 94.5% of patients had aspirin (100mg or less). Duration 1 year. Concurrent medication/care: n/a. Indirectness: No indirectness                      Further details: 1. Timing of administration: Administration after hospital admission (Soon as possible after</p>



<b>Study</b>	<b>ISAR-REACT 5 trial: Schupke 2019<sup>223</sup></b>
	<p>randomisation). 2. Use of GpIIb/IIIa : Not used (Glycoprotein IIb/IIIa were used in 12.3% of the patients who underwent PCI).</p> <p>(n=2006) Intervention 2: Antiplatelet - Prasugrel. Therapy with prasugrel was started at a loading dose of 60 mg and continued at a maintenance dose of 10 mg once per day. A reduced maintenance dose of 5 mg daily was recommended in patients who were 75 years of age or older and in those who had a body weight of less than 60 kg. At discharge 94.5% of patients had aspirin (100mg or less). Duration 1 year. Concurrent medication/care: In the prasugrel group, timing of the initiation of the trial drug depended on the clinical presentation. In patients with ST-segment elevation, prasugrel was to be administered as soon as possible after randomization. In patients who had acute coronary syndromes without ST-segment elevation, administration of the loading dose of prasugrel was postponed until the coronary anatomy was known (with no pretreatment before diagnostic angiography) and before proceeding to percutaneous coronary intervention (PCI) (i.e., before the guidewire crossed the lesion).. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission (As soon as possible after randomisation). 2. Use of GpIIb/IIIa : Not used (Glycoprotein IIb/IIIa inhibitors were used in 12.4% of the patients who underwent PCI).</p>
Funding	Academic or government funding (Supported by a grant from the German Center for Cardiovascular Research and Deutsches Herzzentrum Munchen. )

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR + ASA versus PRASUGREL + ASA**

Protocol outcome 1: Cardiac mortality at 1 year

- Actual outcome: Cardiac mortality at 1 year; Group 1: 63/2012, Group 2: 59/2006

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke)

- Actual outcome: Major bleeding at 1 year; Group 1: 95/1989, Group 2: 80/1773

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 23, Reason: Data on bleeding were analyzed in all patients who received at least one dose of the randomly assigned trial drug and were assessed for bleeding events up to 7 days after discontinuation of the trial drug.; Group 2 Number missing: 233, Reason: Data on bleeding were analyzed in all patients who received at least one dose of the randomly assigned trial drug and were assessed for bleeding events up to 7 days after discontinuation of the trial drug.

Study	ISAR-REACT 5 trial: Schupke 2019 <sup>223</sup>
<p>Protocol outcome 3: Stroke at 1 year                      - Actual outcome: Stroke (any) at 1 year; Group 1: 22/2012, Group 2: 19/2006                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Early and late stent thrombosis                      - Actual outcome: Definite or probable stent thrombosis at 1 year; Group 1: 26/2012, Group 2: 20/2006                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 5: All-cause mortality at 1 year                      - Actual outcome: All-cause mortality at 1 year; Group 1: 90/2012, Group 2: 73/2006                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 6: Re-infarction at 1 year                      - Actual outcome: Re-infarction at 1 year; Group 1: 96/2012, Group 2: 60/2006                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days ; Non-haemorrhagic stroke; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	Jing 2016 <sup>64</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=188)
Countries and setting	Conducted in China; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: Unclear duration of follow-up
Method of assessment of guideline	Unclear method of assessment/diagnosis

Study	Jing 2016 <sup>64</sup>
condition	
Stratum	STEMI: Treated with primary percutaneous coronary intervention
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were included if they presented with STEMI within 12 hours and planned to receive primary PCI
Exclusion criteria	Patients with the following conditions were excluded: contraindications to clopidogrel or ticagrelor; had thrombolysis within 24 hours; was on glycoprotein IIb/IIIa inhibitors prior to the PCI; was already on oral anticoagulants and needed to continue the medications after the procedure; severe bradycardia or conduction block; severe liver or kidney impairment; active bleeding or coagulation disorder; age >75 years
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Clopidogrel group: 55 (16 years); ticagrelor group: 59 (21 years). Gender (M:F): 112/76. Ethnicity: Chinese
Further population details	
Extra comments	The finally included patients were randomised to receive loading doses of the study treatments. Maintenance doses were given after the primary PCI
Indirectness of population	No indirectness
Interventions	(n=94) Intervention 1: Antiplatelet - Clopidogrel. Loading dose of 600mg clopidogrel and 300mg aspirin. After the primary PCI, a maintenance dose of 75mg clopidogrel was used daily for at least 12 months. Aspirin 100mg daily was used indefinitely. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable  (n=94) Intervention 2: Antiplatelet - Ticagrelor. Loading dose of 180mg ticagrelor and 300mg aspirin. After the primary PCI, 90mg ticagrelor was used daily for at least 12 months. Aspirin 100mg daily was used indefinitely. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Funding not stated

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CLOPIDOGREL versus TICAGRELOR**

Protocol outcome 1: All-cause mortality at 30 days

- Actual outcome for STEMI: All-cause mortality at Not reported; Group 1: 1/94, Group 2: 1/94; Comments: Deaths due to cardiac rupture

Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;

Study	Jing 2016 <sup>64</sup>
	<p>Indirectness of outcome: No indirectness ; Baseline details: 'No significant differences were noticed [in] the demographic and clinic information between the two groups'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Cardiac mortality at 30 days - Actual outcome for STEMI: Cardiac mortality at 30 days; Group 1: 1/94, Group 2: 1/94 Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'No significant differences were noticed [in] the demographic and clinic information between the two groups'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome for STEMI: Complications related to bleeding (mild) at 30 days; Group 1: 17/94, Group 2: 23/94 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High; Indirectness of outcome: No indirectness ; Baseline details: 'No significant differences were noticed [in] the demographic and clinic information between the two groups'; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for STEMI: Complications related to bleeding (life-threatening or intracranial haemorrhage (major)) at 30 days; Group 1: 0/94, Group 2: 0/94 Risk of bias: All domain – Very High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High; Indirectness of outcome: No indirectness ; Baseline details: 'No significant differences were noticed [in] the demographic and clinic information between the two groups'; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Stroke; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	Kitano 2019 <sup>75</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=78)
Countries and setting	Conducted in Japan; Setting: Nihon University Itabashi Hospital, Tokyo, Japan
Line of therapy	Not applicable
Duration of study	Intervention time: 8 months
Method of assessment of guideline	Adequate method of assessment/diagnosis: STEMI, NSTEMI and unstable angina was defined as patients

Study	Kitano 2019 <sup>75</sup>
condition	who had chest compression with ST-segment deviation or T-wave inversion in electrocardiogram, or elevated levels of cardiac biomarkers such as CKs or cardiac troponins.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients diagnosed with new-onset ACS. ACS included ST-elevation acute myocardial infarction (STEMI), non-ST elevation acute myocardial infarction, and unstable angina.
Exclusion criteria	Due to potential difficulty in acquiring the angiographic images for the entirely stented segments, subjects whose culprit lesion was left main coronary artery, ostium, or tortuous vessels were excluded. Patients with hemodialysis, severe liver dysfunction, a history of CABG or restenosis after revascularisation, more than two overlapping kinds of stents, who had recovered from cardiopulmonary arrest, or who needed oral anticoagulants were also excluded.
Recruitment/selection of patients	ACS patients admitted to the hospital between December 2014 and November 2016
Age, gender and ethnicity	Age - Mean (SD): Prasugrel group: 66 (13); clopidogrel group: 64 (11) years. Gender (M:F): 64/14. Ethnicity: Not reported
Further population details	
Extra comments	Clinical diagnosis: STEMI (prasugrel: 43.6%; clopidogrel: 53.8%), NSTEMI (prasugrel: 28.2%; clopidogrel: 28.2%), UA (prasugrel: 28.2%; clopidogrel: 17.9%)
Indirectness of population	No indirectness
Interventions	<p>(n=39) Intervention 1: Antiplatelet - Prasugrel. Patients were given 20 mg of prasugrel with a low dose of 162 mg of aspirin (loading dose). After the antiplatelet drug loading, patients underwent PCI with everolimus-eluting stent. Thereafter, the prasugrel group was given a maintenance dose of 100 mg/day of aspirin and 3.75 mg/day of prasugrel until follow-up.. Duration 8 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p> <p>(n=39) Intervention 2: Antiplatelet - Clopidogrel. Patients were given 300 mg of clopidogrel with a low dose of 162 mg of aspirin (loading dose). After the antiplatelet drug loading, patients underwent PCI with everolimus-eluting stent. Thereafter, the clopidogrel group was given a maintenance dose of 100 mg/day of aspirin and 75 mg/day of clopidogrel until follow-up.. Duration 8 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p>

Study	Kitano 2019 <sup>75</sup>
Funding	Study funded by industry (Study was financially supported by Daiichi Sankyo Co. Ltd (Tokyo, Japan) as an investigator-initiated research.)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL</b></p> <p>Protocol outcome 1: Non-haemorrhagic stroke                      - Actual outcome: Stroke (any, type not specified) at 1 year; Group 1: 1/38, Group 2: 1/37                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Withdrew consent; Group 2 Number missing: 2, Reason: Withdrew consent</p> <p>Protocol outcome 2: Need for revascularisation at 1 year                      - Actual outcome: Need for revascularisation at 1 year; Group 1: 2/38, Group 2: 2/37                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Withdrew consent; Group 2 Number missing: 2, Reason: Withdrew consent</p> <p>Protocol outcome 3: All-cause mortality at 1 year                      - Actual outcome: All-cause mortality at 1 year; Group 1: 2/38, Group 2: 1/37                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Withdrew consent; Group 2 Number missing: 2, Reason: Withdrew consent</p>	
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days ; Cardiac mortality at 30 days ; Complications related to bleeding (including haemorrhagic stroke); Early and late stent thrombosis; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	Laine 2014 <sup>83</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in France; Setting: In hospital
Line of therapy	Unclear

Study	Laine 2014 <sup>83</sup>
Duration of study	Intervention + follow up: Unclear duration of follow-up. The primary endpoint was measured at 6 and 18 hours post loading dose
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall: Diabetic patients undergoing an invasive strategy (but who did not have a cardiac arrest)
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with diabetes mellitus admitted for ACS were screened. Only those selected for an invasive strategy were eligible. In the present study only those who underwent PCI and agreed to participate in the study were included.
Exclusion criteria	Cardiac arrest, cardiogenic shock, contraindications to antiplatelet therapy, a platelet count <100 G/l, history of bleeding diathesis, bleeding, concurrent severe illness with expected survival of <1 month, surgery within one month or scheduled in the year, coumadin or other oral anticoagulant therapy, atrial fibrillation, current clopidogrel, ticagrelor or prasugrel treatment, pregnancy, liver failure, fibrinolytics, previous stroke/transient ischaemic attack, weight <60kg, age over 75 years old, platelet count <100,000/ml, haematocrit <30%, creatinin clearance <30ml/minute (min), severe hepatic dysfunction, use of strong CYP3A, inhibitors or inducers, increased risk of bradycardia or severe chronic obstructive pulmonary disease
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Ticagrelor group: 64.8 (8.9 years); prasugrel group: 62.8 (8.2 years). Gender (M:F): 76/24. Ethnicity: Not reported
Further population details	
Extra comments	Diabetes was defined as a history of diabetes mellitus under stable chronic medical therapy for at least three months. Only patients selected for an invasive strategy were eligible; they received aspirin on admission and after randomisation were assigned to treatment groups
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Antiplatelet - Ticagrelor. Patients in both groups received a 250mg intravenous loading dose of aspirin on admission followed by 75mg per os daily indefinitely. After randomisation, patients received 180mg ticagrelor as a loading dose. The maintenance dose of ticagrelor was 90mg twice daily. Duration Unclear duration of follow-up. Concurrent medication/care: Glycoprotein 2b/3a inhibitors were not used, and all patients received a 4,000 UI bolus of heparin intravenously during PCI. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable  (n=50) Intervention 2: Antiplatelet - Prasugrel. Patients in both groups received a 250mg intravenous loading

Study	Laine 2014 <sup>83</sup>
	dose of aspirin on admission followed by 75mg per os daily indefinitely. After randomisation, patients received 60mg prasugrel as a loading dose. The maintenance dose of prasugrel was 10mg daily. Duration Unclear duration of follow-up. Concurrent medication/care: Glycoprotein 2b/3a inhibitors were not used, and all patients received a 4,000 UI bolus of heparin intravenously during PCI. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Other (Supported by a grant from the Assistance-Publique Hopitaux de Marseille)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus PRASUGREL</b></p> <p><b>Protocol outcome 1: All-cause mortality at 30 days</b>                      - Actual outcome: All-cause mortality in hospital ( at 30 days); Group 1: 0/50, Group 2: 1/50; Comments: Death due to cardiogenic shock following ST elevation myocardial infarction                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'There was no difference in baseline characteristics between the two groups of patients' although a higher proportion of the ticagrelor group received aspirin, beta blockers and statins on admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p><b>Protocol outcome 2: Cardiac mortality at 30 days</b>                      - Actual outcome: Cardiac mortality in hospital ( at 30 days); Group 1: 0/50, Group 2: 1/50                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'There was no difference in baseline characteristics between the two groups of patients' although a higher proportion of the ticagrelor group received aspirin, beta blockers and statins on admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p><b>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)</b>                      - Actual outcome: Complications related to bleeding (major, BARC ≥3) in hospital ( at 30 days); Group 1: 0/50, Group 2: 0/50                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'There was no difference in baseline characteristics between the two groups of patients' although a higher proportion of the ticagrelor group received aspirin, beta blockers and statins on admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p><b>Protocol outcome 4: Stroke</b>                      - Actual outcome: Stroke (any, type not specified) in hospital ( at 30 days); Group 1: 0/50, Group 2: 0/50                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'There was no difference in baseline characteristics between the two groups of patients'</p>	



Study	Laine 2014 <sup>83</sup>
	although a higher proportion of the ticagrelor group received aspirin, beta blockers and statins on admission; Group 1 Number missing: ; Group 2 Number missing:
	Protocol outcome 5: Re-infarction at 30 days - Actual outcome: Re-infarction (myocardial infarction) in hospital ( at 30 days); Group 1: 0/50, Group 2: 1/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'There was no difference in baseline characteristics between the two groups of patients' although a higher proportion of the ticagrelor group received aspirin, beta blockers and statins on admission; Group 1 Number missing: ; Group 2 Number missing:
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	Lee 2015 <sup>92</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=39)
Countries and setting	Conducted in South Korea; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 30 days follow-up
Method of assessment of guideline condition	Method of assessment /diagnosis not stated
Stratum	STEMI: Undergoing PCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Age <20 or >80 years or body weight <50kg; previous administration of any P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor); history of stroke or transient ischaemic attack; gastrointestinal bleeding within previous 6 months, bleeding diathesis, platelet count <100,000/mm <sup>3</sup> or haemoglobin <10g/dl; known chronic renal insufficiency (serum creatine >2.5mg/dl) or hepatic dysfunction (serum liver enzyme or bilirubin >3-fold higher than the normal limit); and known severe chronic obstructive pulmonary disease or bradycardia
Recruitment/selection of patients	Not reported

Study	Lee 2015 <sup>92</sup>
Age, gender and ethnicity	Age - Mean (SD): Prasugrel group: 55 (10 years); ticagrelor group: 55 (11 years). Gender (M:F): 35/4. Ethnicity: Korean
Further population details	
Extra comments	Glycoprotein IIb/IIIa inhibitors intracoronary only were permitted for use at the discretion of the attending physician. Patients were randomised to study treatments in the emergency room prior to arrival at the cardiac catheterisation room
Indirectness of population	No indirectness
Interventions	<p>(n=19) Intervention 1: Antiplatelet - Prasugrel. A loading dose of 60mg prasugrel in combination with 300mg aspirin in the emergency room prior to arrival at the cardiac catheterisation room. Prasugrel 10mg 4 times daily was administered continuously during the follow-up as the maintenance dose. Duration 30 days. Concurrent medication/care: Glycoprotein IIb/IIIa inhibitors intracoronary only were permitted for use at the discretion of the attending physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=20) Intervention 2: Antiplatelet - Ticagrelor. A loading dose of 180mg ticagrelor in combination with 300mg aspirin in the emergency room prior to arrival at the cardiac catheterisation room. Ticagrelor 90mg twice daily was administered continuously during the follow-up as the maintenance dose. Duration 30 days. Concurrent medication/care: Glycoprotein IIb/IIIa inhibitors intracoronary only were permitted for use at the discretion of the attending physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Academic or government funding (This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Clinical Trials Global Initiative (KCGI), funded by the Ministry of Health & Welfare, funded by the Ministry of Education, Science and Technology)

#### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus TICAGRELOR

Protocol outcome 1: Other adverse effects of treatment at 30 days

- Actual outcome for STEMI: Other adverse effects (drug side effects including dyspnoea and ventricular pauses) at 30 days; Group 1: 0/19, Group 2: 0/20

Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

- Low; Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well-matched for all baseline characteristics, including age, sex, body weight, body mass index, cardiovascular risk factors, vital signs and renal function'. Baseline laboratory and procedural characteristics were also

similar between groups; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: Other adverse effects (moderate chronic kidney disease) at 30 days; Group 1: 0/19, Group 2: 1/20

Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

Study	Lee 2015 <sup>92</sup>
	- Low; Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well-matched for all baseline characteristics, including age, sex, body weight, body mass index, cardiovascular risk factors, vital signs and renal function'. Baseline laboratory and procedural characteristics were also similar between groups; Group 1 Number missing: ; Group 2 Number missing:
Protocol outcomes not reported by the study	Quality of life; Cardiac mortality at 30 days ; Complications related to bleeding (including haemorrhagic stroke); Stroke; Need for revascularisation at 1 year; Early and late stent thrombosis; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	Li 2018 <sup>99</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=653)
Countries and setting	Conducted in China; Setting: Jinan Central Hospital Affiliated Shandong University, which is a Chest Pain Centre in China.
Line of therapy	Not applicable
Duration of study	Intervention time: 12 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: STEMI was defined as ST-segment elevation in at least two contiguous leads or a new left bundle-branch block, and an increase in at least one value above the 99th percentile upper reference limit.
Stratum	STEMI
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ≥18 years of age with documented STEMI undergoing successful primary PCI.
Exclusion criteria	A history of therapy with oral anticoagulant within 12 months; platelet count < 100,000/mm <sup>3</sup> ; creatinine clearance <30 mL/min; pregnancy; bleeding diathesis; a history of malignant tumor with life expectancy <12 months; significant infection with temperature >38C.
Recruitment/selection of patients	Patients undergoing successful primary PCI were enrolled between January 2014 and March 2017.
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 60 (11); clopidogrel group: 63 (13) years. Gender (M:F): 346/96. Ethnicity: Not reported
Further population details	

Study	Li 2018 <sup>99</sup>
Indirectness of population	No indirectness
Interventions	<p>(n=329) Intervention 1: Antiplatelet - Ticagrelor. Before primary PCI, combination of a 300 mg loading dose of aspirin, a loading dose of 180 mg ticagrelor was given. The patients received ticagrelor 90 twice a day for at least 12 months, along with aspirin 100 mg daily.. Duration 12 months. Concurrent medication/care: Primary PCI with drug-eluting stents. Other drugs (i.e. beta-blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker, and proton pump inhibitors) decisions were made by the treating physicians in accordance with the practice guideline recommendations and the clinical status of patients.. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p> <p>(n=324) Intervention 2: Antiplatelet - Clopidogrel. Before primary PCI, combination of a 300 mg loading dose of aspirin, a loading dose of 600 mg clopidogrel was given. The patients received clopidogrel 75 twice a day for at least 12 months, along with aspirin 100 mg daily.. Duration 12 months. Concurrent medication/care: Primary PCI with drug-eluting stents. Other drugs (i.e. beta-blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker, and proton pump inhibitors) decisions were made by the treating physicians in accordance with the practice guideline recommendations and the clinical status of patients.. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p>
Funding	Academic or government funding (Grant from Shandong Province Science & Technology Department Plan Project grant)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR + ASA versus CLOPIDOGREL + ASA**

Protocol outcome 1: Cardiac mortality at 1 year

- Actual outcome for STEMI: Cardiac mortality at 1 year; Group 1: 3/161, Group 2: 8/281

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.

Study	Li 2018 <sup>99</sup>
	<p>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke)</p> <p>- Actual outcome for STEMI: Major bleeding at 1 year; Group 1: 2/161, Group 2: 4/281</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p> <p>- Actual outcome for STEMI: Minor bleeding at 1 year; Group 1: 28/161, Group 2: 24/281</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p>
	<p>Protocol outcome 3: Non-haemorrhagic stroke</p> <p>- Actual outcome for STEMI: Stroke (ischemic stroke) at 1 year; Group 1: 1/161, Group 2: 3/281</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p>
	<p>Protocol outcome 4: Need for revascularisation at 1 year</p> <p>- Actual outcome for STEMI: Revascularisation at 1 year; Group 1: 4/161, Group 2: 28/281</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p>

Study	Li 2018 <sup>99</sup>
	<p>Protocol outcome 5: Early and late stent thrombosis - Actual outcome for STEMI: Stent thrombosis at 1 year; Group 1: 0/161, Group 2: 4/281 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p> <p>Protocol outcome 6: Re-infarction at 1 year - Actual outcome for STEMI: Re-infarction at 1 year; Group 1: 0/161, Group 2: 6/281 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 168, Reason: 152 patients switched to clopidogrel: few switches in-hospital (most frequent cause of switching in-hospital was dyspnea), majority of switching occurred in the first month due to financial burden and local unavailability. Other reasons for missing data included death in hospital, lost to follow-up. ; Group 2 Number missing: 43, Reason: 8 patients switched to ticagrelor: 4 switches in-hospital (most frequent cause of switching in-hospital was dyspnea), 4 of the switches occurred in the first month. Reasons for switches were due to unexpected rehospitalisation for angina and stent thrombosis (n=4), physicians' suggestion (n=3), and gene detection (n=1). Other reasons for missing data included death in hospital, lost to follow-up.</p>
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days ; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	PHILO trial: Goto 2015 <sup>52</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=801)
Countries and setting	Conducted in Multiple countries; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 months follow-up

Study	PHILO trial: Goto 2015 <sup>52</sup>
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall: Planned PCI
Subgroup analysis within study	Not applicable:
Inclusion criteria	Hospitalised for ST or non-ST segment elevation with onset of symptoms during the previous 24 hours (cardiac ischaemic symptoms of ≥10 minutes duration at rest) and planned PCI
Exclusion criteria	Any contraindication against the use of clopidogrel; active bleeding or a history of bleeding; fibrinolytic therapy within 24 hours before randomisation; need for oral anticoagulation therapy; increased risk of bradycardia; and concomitant therapy with a strong CYP3A inhibitor or inducer
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 67 (12 years); clopidogrel group: 66 (11 years). Gender (M:F): Define. Ethnicity: Asian (Chinese, Japanese, Korean and unknown ethnic groups)
Further population details	
Extra comments	Patients received the study drugs directly after randomisation except treatment with clopidogrel and ticagrelor was delayed in patients undergoing CABG. The clopidogrel dosage was also adjusted for patients who had already received a loading dose or who were already taking maintenance doses of clopidogrel or ticlopidine for ≥5 days prior to randomisation
Indirectness of population	No indirectness
Interventions	<p>(n=401) Intervention 1: Antiplatelet - Ticagrelor. An initial loading dose of 180mg ticagrelor, followed by 90mg twice daily and once daily matching placebo tablets. In patients undergoing CABG, the blinded study drug (eg. active drug or placebo) was withheld for 24-72 hours in the ticagrelor group. All patients received aspirin at a dose of 75-100mg once daily (a loading dose of up to 330mg was permitted) unless aspirin was contraindicated or poorly tolerated. Duration 12 months. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=400) Intervention 2: Antiplatelet - Clopidogrel. Patients who were clopidogrel naive received an initial loading dose of 300mg clopidogrel orally or matching placebo, then 75mg once daily and placebo capsules twice daily thereafter. Patients in the clopidogrel group who had already received a loading dose or who were already taking maintenance doses of clopidogrel or ticlopidine for ≥5 days prior to randomisation were given clopidogrel 75mg once daily plus placebo capsules twice daily. All patients received aspirin at a dose of 75-100mg once daily (a loading dose of up to 330mg was permitted) unless aspirin was contraindicated or poorly tolerated. Duration 12 months. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>

<b>Study</b>	<b>PHILO trial: Goto 2015<sup>52</sup></b>
	Further details: 1. Timing of administration: Not applicable
Funding	Other author(s) funded by industry (Medical writing support was funded by AstraZeneca)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL**

**Protocol outcome 1: Other adverse effects of treatment**  
 - Actual outcome: Other adverse effects (any, excluding bleeding) at 1 year; Group 1: 327/401, Group 2: 337/400; Comments: Note that % reported appears to be different to number of events/number analysed  
 Risk of bias: All domain – Very High, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;  
 Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion ≥75 years, with a history of CABG, and with positive troponin I levels and ST depression ≥1mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:  
 - Actual outcome: Breathing adverse effects (dyspnoea) at 1 year; Group 1: 22/401, Group 2: 9/400; Comments: Note that % reported appears to be different to number of events/number analysed  
 Risk of bias: All domain – Very High, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;  
 Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion ≥75 years, with a history of CABG, and with positive troponin I levels and ST depression ≥1mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:

**Protocol outcome 2: Bradycardic adverse effects**  
 - Actual outcome: Bradycardic adverse effects (bradycardia) at 1 year; Group 1: 11/401, Group 2: 9/400; Comments: Note that % reported appears to be different to number of events/number analysed  
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;  
 Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion ≥75 years, with a history of CABG, and with positive troponin I levels and ST depression ≥1mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:  
 - Actual outcome: Bradycardic adverse effects (ventricular pauses ≥3 seconds) at 1 year; Group 1: 0/401, Group 2: 1/400; Comments: Note that % reported appears to be different to number of events/number analysed  
 Risk of bias: All domain – Very High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;



Study	PHILO trial: Goto 2015 <sup>52</sup>
	<p>Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 3: Cardiac mortality at 1 year                      - Actual outcome: Cardiac mortality at 1 year; Group 1: 9/401, Group 2: 7/400; Comments: Hazard ratio: 1.28 (95% CI 0.48-3.45)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 4: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome: Complications related to bleeding (major, PLATO-defined) at 1 year; Group 1: 40/401, Group 2: 26/400; Comments: Note that % reported appears to be different to number of events/number analysed. Hazard ratio: 1.54 (95% CI 0.94-2.53)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Complications related to bleeding (minor, PLATO-defined) at 1 year; Group 1: 59/401, Group 2: 35/400; Comments: Note that % reported appears to be different to number of events/number analysed. Hazard ratio: 1.75 (95% CI 1.15-2.67)                      Risk of bias: All domain – Very High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 5: Stroke                      - Actual outcome: Stroke (any, type not specified) at 1 year; Group 1: 9/401, Group 2: 6/400; Comments: Hazard ratio: 1.50 (0.54-4.23)                      Risk of bias: All domain – High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher</p>

Study	PHILO trial: Goto 2015 <sup>52</sup>
	<p>proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: All-cause mortality at 1 year                      - Actual outcome: All-cause mortality at 1 year; Group 1: 10/401, Group 2: 7/400; Comments: Hazard ratio: 1.42 (95% CI 0.54-3.74)                      Risk of bias: All domain – High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: Re-infarction at 1 year                      - Actual outcome: Re-infarction (myocardial infarction, excluding silent myocardial infarction) at 1 year; Group 1: 24/401, Group 2: 15/400; Comments: Hazard ratio: 1.63 (95% CI 0.85-3.11)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Ticagrelor group highlighted to have a greater prevalence of coronary risk factors, higher proportion <math>\geq 75</math> years, with a history of CABG, and with positive troponin I levels and ST depression <math>\geq 1</math>mm during the index event; clopidogrel group highlighted to have a higher proportion with a history of TIA; Blinding details: An independent, external clinical endpoint committee reviewed and adjudicated the efficacy and bleeding endpoints; an independent data and safety monitoring board monitored the trial and had access to the unblinded data; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; Early and late stent thrombosis; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study (subsidiary papers)	PLATO trial: Wallentin 2009 <sup>282</sup> (Lindholm 2014 <sup>102</sup> , Steg 2010 <sup>245</sup> )
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=18,624)
Countries and setting	Conducted in Multiple countries; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 months follow-up

Study (subsidiary papers)	PLATO trial: Wallentin 2009 <sup>282</sup> (Lindholm 2014 <sup>102</sup> , Steg 2010 <sup>245</sup> )
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute coronary syndrome with or without ST-segment elevation, with an onset of symptoms during the previous 24 hours. For patients who had an acute coronary syndrome without ST-segment elevation, at least two of the following three criteria had to be met: ST-segment changes on electrocardiography, indicating ischaemia; a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors (age ≥60 years; previous myocardial infarction or coronary artery bypass grafting (CABG); coronary artery disease with stenosis of ≥50% in at least two vessels; previous ischaemic stroke, transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of <60ml per minute per 1.73m <sup>2</sup> of body surface area). For patients who had an acute coronary syndrome with ST-segment elevation, the following two inclusion criteria had to be met: persistent ST-segment elevation of at least 0.1mV in at least two contiguous leads or a new left bundle-branch block, and the intention to perform primary PCI
Stratum	Overall: Majority underwent PCI (ticagrelor group: 64.1%; clopidogrel group: 64.6%)
Subgroup analysis within study	Not stratified but pre-specified: The consistency of effects on efficacy and safety end points was explored in 25 prespecified subgroups (including non-invasively managed patients) and 8 post hoc subgroups
Inclusion criteria	Acute coronary syndrome with or without ST-segment elevation, with an onset of symptoms during the previous 24 hours. For patients who had an acute coronary syndrome without ST-segment elevation, at least two of the following three criteria had to be met: ST-segment changes on electrocardiography, indicating ischaemia; a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors (age ≥60 years; previous myocardial infarction or coronary artery bypass grafting (CABG); coronary artery disease with stenosis of ≥50% in at least two vessels; previous ischaemic stroke, transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of <60ml per minute per 1.73m <sup>2</sup> of body surface area). For patients who had an acute coronary syndrome with ST-segment elevation, the following two inclusion criteria had to be met: persistent ST-segment elevation of at least 0.1mV in at least two contiguous leads or a new left bundle-branch block, and the intention to perform primary PCI
Exclusion criteria	Major exclusion criteria were any contraindication against the use of clopidogrel, fibrinolytic therapy within 24 hours before randomisation, a need for oral anticoagulation therapy, an increased risk of bradycardia, and concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Ticagrelor group median: 62 years (IQR or range not reported); Clopidogrel group median: 62 years (IQR or range not reported). Gender (M:F): 13336/5288. Ethnicity: Ticagrelor group: white (91.8%), black (1.2%), asian (5.8%), other (1.2%); Clopidogrel group: white (91.6%), black (1.2%), asian (6.0%), other (1.2%)
Further population details	
Extra comments	Patients underwent PCI after randomisation. Those in the clopidogrel group who had not received an open-label

<b>Study (subsidiary papers)</b>	<b>PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)</b>
	loading dose and had not been taking clopidogrel for at least 5 days before randomisation received a 300-mg loading dose followed by a dose of 75mg daily
Indirectness of population	No indirectness
Interventions	<p>(n=9333) Intervention 1: Antiplatelet - Ticagrelor. Ticagrelor was given in a loading dose of 180mg followed by a dose of 90mg twice daily. Patients undergoing PCI after randomisation received, in a blind fashion, an additional dose of ticagrelor at the time of PCI: 90mg of ticagrelor for patients who were undergoing PCI more than 24 hours after randomisation. In patients undergoing CABG, it was recommended that the study drug be withheld - in the ticagrelor group, for 24 to 72 hours. Duration 12 months. Concurrent medication/care: All patients received acetylsalicylic acid (aspirin) at a dose of 75 to 100mg daily unless they could not tolerate the drug. For those who had not been receiving aspirin, 325mg was the preferred loading dose; 325mg was also permitted as the daily dose for 6 months after stent placement. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission: Not applicable</p> <p>(n=9291) Intervention 2: Antiplatelet - Clopidogrel. Patients in the clopidogrel group who had not received an open-label loading dose and had not been taking clopidogrel for at least 5 days before randomisation received a 300-mg loading dose followed by a dose of 75mg daily. Others in the clopidogrel group continued to receive a maintenance dose of 75mg daily. Patients undergoing PCI after randomisation received, in a blind fashion, an additional dose of clopidogrel at the time of PCI: 300mg of clopidogrel, at the investigator's discretion. In patients undergoing CABG, it was recommended that the study drug be withheld - in the clopidogrel group, for 5 days. Duration 12 months. Concurrent medication/care: All patients received acetylsalicylic acid (aspirin) at a dose of 75 to 100mg daily unless they could not tolerate the drug. For those who had not been receiving aspirin, 325mg was the preferred loading dose; 325mg was also permitted as the daily dose for 6 months after stent placement. Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission: Not applicable</p>
Funding	Other (Supported by AstraZeneca)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL**

ACS (with/without revascularisation)

Protocol outcome 1: All-cause mortality at 30 days [*unpublished data*]

- Actual outcome: All-cause mortality at 30 days; Group 1: 179/9235, Group 2: 212/9186;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 -

High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 2: All-cause mortality at 1 year

- Actual outcome: All-cause mortality at 1 year; Group 1: 399/9333, Group 2: 506/9291; Comments: Hazard ratio (95% CI): 0.78 (0.69-0.89)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Cardiac mortality

- Actual outcome: Cardiac mortality (death from vascular causes) at 1 year; Group 1: 353/9333, Group 2: 442/9291; Comments: Hazard ratio for ticagrelor group: 0.79 (0.69-0.91)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Re-infarction at 30 days *[unpublished data]*

- Actual outcome: Re-infarction at 30 days; Group 1: 121/9235, Group 2: 165/9186;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 5: Re-infarction at 1 year

- Actual outcome: Re-infarction (myocardial infarction) at 1 year; Group 1: 504/9333, Group 2: 593/9291; Comments: Hazard ratio (95% CI): 0.84 (0.75 to 0.95)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 6: Complications related to bleeding at 30 days *[unpublished data]*

- Actual outcome: Complications related to bleeding (major) at 30 days; Group 1: 645/9235, Group 2: 642/9186;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 -

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 7: Complications related to bleeding at 1 year

- Actual outcome: Complications related to bleeding (major or minor) at 1 year; Group 1: 1339/9235, Group 2: 1215/9186; Comments: Hazard or odds ratio for ticagrelor group: 1.11 (1.03-1.20)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

- Actual outcome: Complications related to bleeding (major) at 1 year; Group 1: 961/9235, Group 2: 929/9186; Comments: Hazard or odds ratio for ticagrelor group: 1.04 (0.95-1.13)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

- Actual outcome: Complications related to bleeding (minor) at 1 year; Group 1: 378/9235, Group 2: 286/9186

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 8: Stroke at 30 days [*unpublished data*]

- Actual outcome: Stroke at 30 days; Group 1: 57/9235, Group 2: 43/9186;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 9: Stroke at 1 year

- Actual outcome: Stroke (ischaemic) at 1 year; Group 1: 96/9333, Group 2: 91/9291

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

- Actual outcome: Stroke (haemorrhagic) at 1 year; Group 1: 23/9333, Group 2: 13/9291

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome: Stroke (unknown) at 1 year; Group 1: 10/9333, Group 2: 2/9291

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 10: Breathing adverse effects

- Actual outcome: Breathing adverse effects (dyspnoea, any) at 1 year; Group 1: 1270/9235, Group 2: 721/9186; Comments: Hazard or odds ratio for ticagrelor group: 1.84 (1.68-2.02)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 11: Other adverse effects of treatment

- Actual outcome: Other adverse effects (heart block) at 1 year; Group 1: 67/9235, Group 2: 66/9186

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

- Actual outcome: Other adverse effects (syncope) at 1 year; Group 1: 100/9235, Group 2: 76/9186

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

Protocol outcome 12: Bradycardic adverse effects

- Actual outcome: Bradycardic adverse effects (ventricular pauses  $\geq 3$  seconds) at 30 days; Group 1: 21/985, Group 2: 17/1006

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported  
 - Actual outcome: Bradycardic adverse effects (bradycardia) at 1 year; Group 1: 409/9235, Group 2: 372/9186  
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported  
 - Actual outcome: Bradycardic adverse effects (pacemaker insertion) at 1 year; Group 1: 82/9235, Group 2: 79/9186  
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: 98, Reason: Not reported; Group 2 Number missing: 105, Reason: Not reported

**Protocol outcome 13: Early and late stent thrombosis**

- Actual outcome: Stent thrombosis (probable or definite) at 1 year; Group 1: 118/5640, Group 2: 158/5649; Comments: Hazard ratio for ticagrelor group: 0.77 (0.62-0.95)  
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'The two treatment groups were balanced with regard to all baseline characteristics and non-study medications and procedures'; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Substrata: UA/STEMI + revascularisation

**Protocol outcome 1: All-cause mortality**

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: All-cause mortality (death) at 30 days; HR; 0.64 (95%CI 0.44 to 0.92, Comments: Kaplan-Meier estimate. Total N: 6218);  
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:  
 - Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: All-cause mortality at 1 year; HR; 0.75 (95%CI 0.53 to 1.07, Comments: Kaplan-Meier estimates. Total N: 5648);  
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:



**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

Protocol outcome 2: Cardiac mortality

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Cardiac mortality (cardiovascular death including vascular and unknown deaths) at 30 days; HR; 0.67 (95%CI 0.43 to 1.02, Comments: Kaplan-Meier estimate. Total N: 6218);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Cardiac mortality (cardiovascular death, including vascular and unknown deaths) at 1 year; HR; 0.76 (95%CI 0.52 to 1.13, Comments: Kaplan-Meier estimates. Total N: 5648);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Complications related to bleeding

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Complications related to bleeding (major) at 30 days; HR; 1.14 (95%CI 0.84 to 1.56, Comments: Kaplan-Meier estimate. Total N: 4958);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Complications related to bleeding (major or minor) at 30 days; HR; 1.20 (95%CI 0.92 to 1.56, Comments: Kaplan-Meier estimate. Total N: 4797);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Complications related to bleeding (major) at 1 year; HR; 1.10 (95%CI 0.84 to 1.44, Comments: Kaplan-Meier estimates. Total N: 4983);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Complications related to bleeding (major or minor) at 1 year; HR; 1.22 (95%CI 0.97 to 1.54, Comments: Kaplan-Meier estimates. Total N: 4842);

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Stroke

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Stroke (any, type not specified) at 30 days; HR; 1.14 (95%CI 0.54 to 2.4, Comments: Kaplan-Meier estimate. Total N: 6188);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Stroke (any, type not specified) at 1 year; HR; 1.18 (95%CI 0.6 to 2.34, Comments: Kaplan-Meier estimates. Total N: 5632);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 5: Re-infarction

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Re-infarction at 30 days; HR; 0.86 (95%CI 0.63 to 1.16, Comments: Kaplan-Meier estimate. Total N: 5934);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and revascularisation subgroup: Re-infarction (myocardial infarction excluding silent) at 1 year; HR; 0.90 (95%CI 0.68 to 1.21, Comments: Kaplan-Meier estimates. Total N: 5438);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Substrata: UA/STEMI + no revascularisation

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

Protocol outcome 1: All-cause mortality

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: All-cause mortality (death) at 30 days; HR; 0.84 (95%CI 0.63 to 1.11, Comments: Kaplan-Meier estimate. Total N: 4514);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: All-cause mortality at 1 year; HR; 0.73 (95%CI 0.57 to 0.93, Comments: Kaplan-Meier estimates. Total N: 5217);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Cardiac mortality

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Cardiac mortality (cardiovascular death including vascular and unknown deaths) at 30 days; HR; 0.84 (95%CI 0.62 to 1.14, Comments: Kaplan-Meier estimate. Total N: 4514);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 5: Complications related to bleeding (including haemorrhagic stroke)

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Cardiac mortality (cardiovascular death, including vascular and unknown deaths) at 1 year; HR; 0.75 (95%CI 0.58 to 0.98, Comments: Kaplan-Meier estimates. Total N: 5217);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Complications related to bleeding

- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major or minor) at 30 days; HR; 1.16 (95%CI 0.92 to 1.46, Comments: Kaplan-Meier estimate. Total N: 3899);

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Study (subsidiary papers)	PLATO trial: Wallentin 2009 <sup>282</sup> (Lindholm 2014 <sup>102</sup> , Steg 2010 <sup>245</sup> )
<p>2 Number missing: - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major) at 30 days; HR; 1.18 (95%CI 0.91 to 1.54, Comments: Kaplan-Meier estimate. Total N: 3964); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major or minor) at 1 year; HR; 1.07 (95%CI 0.91 to 1.25, Comments: Kaplan-Meier estimates. Total N: 4847); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major) at 1 year; HR; 1.05 (95%CI 0.88 to 1.26, Comments: Kaplan-Meier estimates. Total N: 4931); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>	<p>2 Number missing: - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major) at 30 days; HR; 1.18 (95%CI 0.91 to 1.54, Comments: Kaplan-Meier estimate. Total N: 3964); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major or minor) at 1 year; HR; 1.07 (95%CI 0.91 to 1.25, Comments: Kaplan-Meier estimates. Total N: 4847); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Complications related to bleeding (major) at 1 year; HR; 1.05 (95%CI 0.88 to 1.26, Comments: Kaplan-Meier estimates. Total N: 4931); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>
<p>Protocol outcome 4: Stroke - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Stroke (any, type not specified) at 30 days; HR; 0.84 (95%CI 0.5 to 1.4, Comments: Kaplan-Meier estimate. Total N: 4503); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Stroke (any, type not specified) at 1 year; HR; 0.92 (95%CI 0.58 to 1.46, Comments: Kaplan-Meier estimates. Total N: 5209); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>	<p>Protocol outcome 4: Stroke - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Stroke (any, type not specified) at 30 days; HR; 0.84 (95%CI 0.5 to 1.4, Comments: Kaplan-Meier estimate. Total N: 4503); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Stroke (any, type not specified) at 1 year; HR; 0.92 (95%CI 0.58 to 1.46, Comments: Kaplan-Meier estimates. Total N: 5209); Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>
<p>Protocol outcome 5: Re-infarction at 30 days - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Re-infarction at 30 days; HR; 0.89 (95%CI 0.68 to 1.17, Comments: Kaplan-</p>	<p>Protocol outcome 5: Re-infarction at 30 days - Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Re-infarction at 30 days; HR; 0.89 (95%CI 0.68 to 1.17, Comments: Kaplan-</p>

Study (subsidiary papers)	PLATO trial: Wallentin 2009 <sup>282</sup> (Lindholm 2014 <sup>102</sup> , Steg 2010 <sup>245</sup> )
<p>Meier estimate. total N: 4479);</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Re-infarction at 1 year</p> <p>- Actual outcome for UA/NSTEMI: NSTEMI-ACS and no revascularisation subgroup: Re-infarction (myocardial infarction excluding silent) at 1 year; HR; 0.94 (95%CI 0.75 to 1.17, Comments: Kaplan-Meier estimates. Total N: 5201);</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures ; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p><u>Substrata: STEMI + revascularisation</u></p> <p>Protocol outcome 1: All-cause mortality</p> <p>- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: All-cause mortality at 1 year; Group 1: 175/3752, Group 2: 216/3792; Comments: HR (95% CI): 0.82 (0.67 to 1.00)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Cardiac mortality at 30 days</p> <p>- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Cardiac mortality (cardiovascular death) at 1 year; Group 1: 159/3752, Group 2: 195/3792; Comments: HR (95% CI): 0.83 (0.67 to 1.02)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Breathing adverse effects</p>	

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Breathing adverse effects (dyspnoea) at 1 year; Group 1: 468/3719, Group 2: 314/3752  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;  
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Bradycardic adverse effects

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Bradycardic adverse effects (pacemaker placement) at 1 year; Group 1: 50/3719, Group 2: 38/3752  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;  
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Bradycardic adverse effects (bradycardia) at 1 year; Group 1: 173/3719, Group 2: 179/3752  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;  
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 5: Other adverse effects of treatment

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Other adverse effects (heart block) at 1 year; Group 1: 38/3719, Group 2: 34/3752  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;  
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Other adverse effects (syncope) at 1 year; Group 1: 39/3719, Group 2: 28/3752  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;  
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 6: Complications related to bleeding

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Complications related to bleeding (major) at 1 year; Group 1: 301/3719, Group 2: 311/3752; Comments: HR (95% CI): 0.98 (0.83 to 1.14)  
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low,

**Study (subsidiary papers)**

**PLATO trial: Wallentin 2009<sup>282</sup> (Lindholm 2014<sup>102</sup>, Steg 2010<sup>245</sup>)**

Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures; Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Complications related to bleeding (major and minor) at 1 year; Group 1: 439/3719, Group 2: 421/3752; Comments: HR (95% CI): 1.05 (0.92 to 1.21)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;

Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Complications related to bleeding (minor) at 1 year; Group 1: 160/3719, Group 2: 129/3752; Comments: HR (95% CI): 1.26 (1.00 to 1.59); note that total number of events for 'major' and 'minor' bleeding is not the same as 'major and minor' total events

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;

Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

**Protocol outcome 7: Stroke**

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Stroke (any) at 1 year; Group 1: 56/3752, Group 2: 35/3792; Comments: HR (95% CI): 1.63 (1.07 to 2.48)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;

Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Stroke (non-haemorrhagic) at 1 year; Group 1: 42/3752, Group 2: 27/3792; Comments: HR (95% CI): 1.58 (0.97 to 2.56)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;

Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:

**Protocol outcome 8: Early and late stent thrombosis**

- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Stent thrombosis (definite or probable) at 1 year; Group 1: 73/3752, Group 2: 101/3792; Comments: HR (95% CI): 0.74 (0.55 to 1.00)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;

Study (subsidiary papers)	PLATO trial: Wallentin 2009 <sup>282</sup> (Lindholm 2014 <sup>102</sup> , Steg 2010 <sup>245</sup> )
Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:	
<p>Protocol outcome 9: Re-infarction at 30 days</p> <p>- Actual outcome for STEMI: STE-ACS and planned PPCI subgroup: Re-infarction (myocardial infarction excluding silent myocardial infarction) at 1 year; Group 1: 159/3752, Group 2: 201/3792; Comments: HR (95% CI): 0.80 (0.65 to 0.98)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: Similar for baseline characteristics, non-study medications and procedures;</p> <p>Blinding details: 'An independent data and safety monitoring board monitored the trial and had access to the unblinded data'; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; Need for revascularisation at 1 year

Study	PRAGUE-18 trial: Motovska 2016 <sup>118</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1230)
Countries and setting	Conducted in Czech Republic; Setting: In hospital, with telephone visit on day 30
Line of therapy	Unclear
Duration of study	Intervention + follow up: 30 days follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: A diagnosis of acute myocardial infarction from the clinical presentation and an ECG finding of ST-segment elevation on 2 related leads at a minimum by >1mm, ST-segment depression on 3 leads at a minimum by >2mm, or a new bundle branch block
Stratum	Overall: Undergoing coronary angiography with or without PCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute myocardial infarction indicated for emergent (within 120 minutes of admission to a cardiac centre) coronary angiography with or without PCI and a signed informed consent
Exclusion criteria	History of stroke, serious bleeding within the past 6 months, indication for long-term oral anticoagulation



Study	PRAGUE-18 trial: Motovska 2016 <sup>118</sup>
	therapy, administration of clopidogrel $\geq 300\text{mg}$ or any other antiplatelet medication (except aspirin and a lower dose of clopidogrel) before randomisation, aged $>75$ years with a body weight $<60\text{kg}$ (ie. the presence of both parameters was an exclusion criterion), moderate or severe hepatic function disorder, concomitant treatment with a strong CYP3A4 inhibitor, and known hypersensitivity to prasugrel or ticagrelor
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Prasugrel group: 61.8 (42.7-78.7 years); Ticagrelor group: 61.8 (44.6-79.8 years). Gender (M:F): 928/302. Ethnicity: Not reported
Further population details	
Extra comments	Haemodynamic instability was not an exclusion criterion. Patients were randomised to treatment groups after signing the informed consent, immediately on hospital arrival (which, as a rule, was directly to the catheterisation laboratory or, in exceptional cases, to the coronary care unit). Administration of the loading dose was recommended immediately after patients signed the informed consent. In individual cases, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI
Indirectness of population	No indirectness
Interventions	<p>(n=634) Intervention 1: Antiplatelet - Prasugrel. 60mg loading dose of prasugrel and 10mg once daily as a maintenance dose. In patients aged <math>&gt;75</math> years of age or in those with a weight <math>&lt;60\text{kg}</math>, the maintenance dose of prasugrel was reduced to 5mg once daily. Administration of the loading dose was recommended immediately after the patients signed the informed consent. In individual cases in which the physician could not exclude the need for urgent surgical revascularisation on the basis of previous assessments or in cases involving haemodynamic instability, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI. In cases in which primary PCI was not performed, prasugrel therapy was discontinued and replaced by clopidogrel. The decision to perform the procedure was left to the discretion of the treating physician. Patients were advised to use the study medication for 12 months. Use of aspirin was also required with a recommendation of 100mg daily. Duration 30 days. Concurrent medication/care: The decision to administer any adjunctive medication to support PCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=596) Intervention 2: Antiplatelet - Ticagrelor. 180mg loading dose of ticagrelor and 90mg twice daily as a maintenance dose. Administration of the loading dose was recommended immediately after the patients signed the informed consent. In individual cases in which the physician could not exclude the need for urgent surgical revascularisation on the basis of previous assessments or in cases involving haemodynamic instability, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI. The decision to perform the procedure was left to the discretion of the treating physician. Patients were advised to use the study medication for 12 months. Use of aspirin was also required with a</p>

<b>Study</b>	<b>PRAGUE-18 trial: Motovska 2016<sup>118</sup></b>
	recommendation of 100mg daily. Duration 30 days. Concurrent medication/care: The decision to administer any adjunctive medication to support PCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Other (Study funding not reported. Authors disclosed receiving speaking and advisory board fees and honoraria from industry)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus TICAGRELOR**

**Protocol outcome 1: All-cause mortality at 30 days**

- Actual outcome: All-cause mortality at 30 days; Group 1: 14/634, Group 2: 16/596; Comments: Odds ratio: 0.82 (0.40-1.69)

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI  $\geq 30$  kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:

**Protocol outcome 2: Cardiac mortality at 30 days**

- Actual outcome: Cardiac mortality (death resulting from cardiovascular causes) at 30 days; Group 1: 8/634, Group 2: 8/596; Comments: Odds ratio: 0.94 (0.35-2.52)

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI  $\geq 30$  kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:

**Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)**

- Actual outcome: Complications related to bleeding (BARC 3) at 30 days; Group 1: 4/634, Group 2: 2/596; Comments: Odds ratio: 1.60 (0.29-8.81)

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI  $\geq 30$  kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome: Complications related to bleeding (BARC 5) at 30 days; Group 1: 0/634, Group 2: 0/596

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI  $\geq 30$  kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome: Complications related to bleeding (BARC 1) at 30 days; Group 1: 14/634, Group 2: 12/596; Comments: Odds ratio: 0.94 (0.43-2.05)

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;  
Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the

Study	PRAGUE-18 trial: Motovska 2016 <sup>118</sup>
<p>prasugrel group had a BMI <math>\geq 30</math> kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Complications related to bleeding (BARC 2) at 30 days; Group 1: 10/634, Group 2: 10/596; Comments: Odds ratio: 0.81 (0.33-1.97)                      Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI <math>\geq 30</math> kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Stroke                      - Actual outcome: Stroke (any, type not specified) at 30 days; Group 1: 2/634, Group 2: 1/596; Comments: Odds ratio: 1.88 (0.17-20.74)                      Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI <math>\geq 30</math> kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Early and late stent thrombosis                      - Actual outcome: Stent thrombosis (definite) at 30 days; Group 1: 3/634, Group 2: 5/596; Comments: Odds ratio: 0.56 (0.13-2.35)                      Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI <math>\geq 30</math> kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Re-infarction at 30 days                      - Actual outcome: Re-infarction at 30 days; Group 1: 8/634, Group 2: 7/596; Comments: Odds ratio: 1.07 (0.39-2.97)                      Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics were balanced between the study groups' although more of the prasugrel group had a BMI <math>\geq 30</math> kg/m<sup>2</sup> (P value 0.082); Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	RAPID trial: Parodi 2013 <sup>183</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in Italy; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: In-hospital follow up

Study	RAPID trial: Parodi 2013 <sup>183</sup>
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	STEMI: Patients with STEMI undergoing PPCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of STEMI within 21 hours of symptoms onset and informed consent
Exclusion criteria	Age <18 years; active bleeding or bleeding diathesis; any previous transient ischaemic attack/stroke; administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor; known relevant haematological deviations; life expectancy <1 year; or known severe liver or renal disease
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Prasugrel group: 67 (14 years); ticagrelor group: 67 (10 years). Gender (M:F): 39/11. Ethnicity: Not reported
Further population details	
Extra comments	Patients were randomised to study treatment before PPCI
Indirectness of population	No indirectness
Interventions	<p>(n=25) Intervention 1: Antiplatelet - Prasugrel. A 60mg loading dose of prasugrel before PPCI. The loading dose was performed as soon as possible in the Emergency Room or in the Cath Lab. Dual antiplatelet therapy (100mg aspirin associated with 5 or 10mg prasugrel) was recommended for 12 months, with a loading dose of 500mg of aspirin followed by 100mg daily dose. Duration Unclear. Concurrent medication/care: Bivalirudin: bolus 0.75mg/kg followed by 1.75mg/kg/h infusion during PCI, after PPCI a bivalirudin infusion of 0.25mg/kg/h for 4 hours was allowed; unfractionated heparin use was discouraged; and glycoprotein IIb/IIIa inhibitors were not allowed. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=25) Intervention 2: Antiplatelet - Ticagrelor. A 180mg loading dose of ticagrelor before PPCI. The loading dose was performed as soon as possible in the Emergency Room or in the Cath Lab. Dual antiplatelet therapy (100mg aspirin associated with 180mg prasugrel) was recommended for 12 months, with a loading dose of 500mg of aspirin followed by 100mg daily dose. Duration Unclear. Concurrent medication/care: Bivalirudin: bolus 0.75mg/kg followed by 1.75mg/kg/h infusion during PCI, after PPCI a bivalirudin infusion of 0.25mg/kg/h for 4 hours was allowed; unfractionated heparin use was discouraged; and glycoprotein IIb/IIIa inhibitors were not allowed. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Other (This study was supported by the "A.R. CARD" Foundation)

Study	RAPID trial: Parodi 2013 <sup>183</sup>
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus TICAGRELOR	
<p>Protocol outcome 1: All-cause mortality at 30 days                      - Actual outcome for STEMI: All-cause mortality (death) in-hospital (at 30 days); Group 1: 0/25, Group 2: 2/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Other adverse effects of treatment                      - Actual outcome for STEMI: Other adverse effects (contrast-induced nephropathy) in-hospital (at 30 days); Group 1: 0/25, Group 2: 5/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Breathing adverse effects                      - Actual outcome for STEMI: Breathing adverse effects (dyspnoea) in-hospital (at 30 days); Group 1: 0/25, Group 2: 5/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome for STEMI: Complications related to bleeding (major, TIMI) in-hospital (at 30 days); Group 1: 0/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome for STEMI: Complications related to bleeding (minor, TIMI) in-hospital (at 30 days); Group 1: 0/25, Group 2: 3/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p>	

<b>Study</b>	
<b>RAPID trial: Parodi 2013<sup>183</sup></b>	
<p>Protocol outcome 5: Early and late stent thrombosis                      - Actual outcome for STEMI: Stent thrombosis in-hospital (at 30 days); Group 1: 1/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Re-infarction at 30 days                      - Actual outcome for STEMI: Re-infarction (myocardial infarction) in-hospital (at 30 days); Group 1: 1/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched' although at least twice as many of the ticagrelor group were affected by dyslipidaemia, previous MI and previous PCI compared with the prasugrel group, and twice as many of the prasugrel group had diabetes;                      Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life; Stroke; Need for revascularisation at 1 year; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Cardiac mortality at 30 days

<b>Study</b>	
<b>RAPID II trial: Parodi 2014<sup>182</sup></b>	
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in Italy; Setting: Emergency department (with prior administration of aspirin in ambulance or at patient's home)
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 hours follow-up
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	STEMI: Undergoing primary PCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of STEMI within 12 hours of symptoms onset and informed written consent
Exclusion criteria	Age <18 years; active bleeding or bleeding diathesis; any previous transient ischaemic attack/stroke; administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, or warfarin;

<b>Study</b>	<b>RAPID II trial: Parodi 2014<sup>182</sup></b>
	known relevant haematological deviations; life expectancy of <1 year, and known severe liver or renal disease
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Prasugrel group: 67 (12 years); Ticagrelor group: 63 (11 years). Gender (M:F): 32/18. Ethnicity: Not reported
Further population details	
Extra comments	Patients pretreated by intravenous aspirin were randomised to treatment groups before PPCI. The loading dose was given as soon as possible in the emergency department or in the catheterisation laboratory
Indirectness of population	No indirectness
Interventions	<p>(n=25) Intervention 1: Antiplatelet - Prasugrel. A loading dose of 500mg intravenous aspirin was administered in the ambulance or at the patient's home followed by 100mg daily dose. A 60mg loading dose of prasugrel was given before PPCI. The loading dose of prasugrel was performed as soon as possible in the emergency department or in the catheterisation laboratory. Dual antiplatelet therapy (100mg aspirin associated with 5 or 10mg prasugrel) was recommended for 12 months. Duration 12 hours. Concurrent medication/care: Bivalirudin: bolus of 0.75mg/kg followed by 1.75mg (kg h) infusion during PPCI. After PPCI, a bivalirudin infusion of 0.25mg (kg h) for 4 hours was performed in all the patients. Unfractionated heparin use was discouraged. Glycoprotein IIb/IIIa inhibitors were not allowed. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=25) Intervention 2: Antiplatelet - Ticagrelor. A loading dose of 500mg intravenous aspirin was administered in the ambulance or at the patient's home followed by 100mg daily dose. A 360mg loading dose of ticagrelor was given before PPCI. The loading dose of ticagrelor was performed as soon as possible in the emergency department or in the catheterisation laboratory. Dual antiplatelet therapy (100mg aspirin associated with 180mg ticagrelor) was recommended for 12 months. Duration 12 hours. Concurrent medication/care: Bivalirudin: bolus of 0.75mg/kg followed by 1.75mg (kg h) infusion during PPCI. After PPCI, a bivalirudin infusion of 0.25mg (kg h) for 4 hours was performed in all the patients. Unfractionated heparin use was discouraged. Glycoprotein IIb/IIIa inhibitors were not allowed. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Other (Study funding not reported. Authors disclosed receiving consulting or lecture fees and research grant funding from industry)
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus TICAGRELOR</b>	

Study	RAPID II trial: Parodi 2014 <sup>182</sup>
<p>Protocol outcome 1: All-cause mortality at 30 days                      - Actual outcome for STEMI: All-cause mortality (death) at 12 hours (at 30 days); Group 1: 1/25, Group 2: 1/25; Comments: Death due to cardiac tamponade in the prasugrel group and due to refractory heart failure in the ticagrelor group                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Bradycardic adverse effects                      - Actual outcome for STEMI: Bradycardic adverse effects (ventricular pauses &gt;3 seconds) at 12 hours (at 30 days); Group 1: 0/25, Group 2: 1/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Other adverse effects of treatment at 30 days                      - Actual outcome for STEMI: Other adverse effects (contrast-induced nephropathy) at 12 hours (at 30 days); Group 1: 4/25, Group 2: 1/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome for STEMI: Complications related to bleeding (major, TIMI) at 12 hours (at 30 days); Group 1: 2/25, Group 2: 1/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome for STEMI: Complications related to bleeding (minor, TIMI) at 12 hours (at 30 days); Group 1: 0/25, Group 2: 2/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Stroke                      - Actual outcome for STEMI: Stroke (any, type not specified) at 12 hours (at 30 days); Group 1: 0/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p>	



Study	RAPID II trial: Parodi 2014 <sup>182</sup>
<p>Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Early and late stent thrombosis                      - Actual outcome for STEMI: Stent thrombosis (acute) at 12 hours (at 30 days); Group 1: 0/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Re-infarction at 30 days                      - Actual outcome for STEMI: Re-infarction at 12 hours (at 30 days); Group 1: 0/25, Group 2: 0/25                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The 2 groups were well matched in all baseline characteristics, but there was a higher previous PCI rate in the ticagrelor group'. There was also a higher proportion of smokers in the ticagrelor group than in the prasugrel group; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; Cardiac mortality at 30 days

Study	Savonitto 2018 <sup>219</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1455)
Countries and setting	Conducted in Italy; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 months but premature discontinuation of study (3-12 months)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: ST-segment elevation or NSTEMI-ACS had to show at least 1 of the following characteristics: elevated troponin levels, diabetes mellitus, prior myocardial infarction, ≥1 new ischaemic episode while on standard treatment during the index hospitalisation, or stent thrombosis

Study	Savonitto 2018 <sup>219</sup>
Stratum	Overall: Undergoing early percutaneous revascularisation
Subgroup analysis within study	Unclear: Subgroup analyses were conducted for the composite of all-cause mortality, myocardial infarction, disabling stroke, and rehospitalisation for cardiovascular causes or bleeding within 1 year. Treatment assignment was stratified by centre and type of ACS (STE versus NSTEMI)
Inclusion criteria	Patients >74 years of age with ST-segment elevation or NSTEMI-ACS treated with PCI during the index admission. Patients with NSTEMI-ACS had to show at least 1 of the following characteristics: elevated troponin levels, diabetes mellitus, prior myocardial infarction, ≥1 new ischaemic episode while on standard treatment during the index hospitalisation, or stent thrombosis
Exclusion criteria	Patients with a history of stroke, gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks, haemoglobin level on admission <10g/dL unless this was considered to be secondary to renal dysfunction or known myelodysplasia, platelet count <90,000 cells/mL, secondary causes of ischaemia, ongoing oral anticoagulant treatment or a spontaneous international normalised ratio >1.5 at the time of screening, concomitant severe obstructive lung disease, malignancy, or neurological deficit limiting follow-up or adherence to the study protocol. Patients unable to give at least verbal informed consent to the study or already under treatment with prasugrel or ticagrelor were also excluded
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (IQR): 80 (77-84 years). Gender (M:F): 867/576. Ethnicity: Not reported
Further population details	
Extra comments	In patients with STEMI undergoing primary PCI, the drugs could be given as soon as possible after the diagnosis, yet the first administration of the study drug could also take place after angiography or soon after PCI (eg. on arrival in the coronary care unit), particularly in patients treated during PCI with glycoprotein IIb/IIIa receptor blockers. For patients treated with bivalirudin monotherapy during PCI, it was strongly recommended that the loading dose of the investigational drugs be administered before PCI. In patients with NSTEMI-ACS, randomisation was to take place after angiography, and the loading dose should be administered either immediately before PCI or on arrival in the coronary care unit
Indirectness of population	No indirectness
Interventions	(n=720) Intervention 1: Antiplatelet - Prasugrel. 60mg loading dose of prasugrel followed by 5mg once daily. In patients with STEMI undergoing primary PCI, the drugs could be given as soon as possible after the diagnosis, yet the first administration of the study drug could also take place after angiography or soon after PCI (eg. on arrival in the coronary care unit), particularly in patients treated during PCI with glycoprotein IIb/IIIa receptor blockers. For patients treated with bivalirudin monotherapy during PCI, it was strongly recommended that the loading dose of the investigational drugs be administered before PCI. In patients with NSTEMI-ACS, randomisation was to take place after angiography, and the loading dose should be administered either immediately before PCI or on arrival in the coronary care unit. Ongoing clopidogrel

Study	Savonitto 2018 <sup>219</sup>
	<p>treatment, either preexisting or started as soon as the diagnosis of NSTEMI-ACS was made (with a loading dose of 300 or 600mg left to the investigators' discretion), did not preclude enrollment. In this case, those randomised to prasugrel received a 30mg loading dose immediately after randomisation. All patients were to receive 325mg aspirin on admission and then 75 to 100mg daily throughout follow-up. Duration 12 months. Concurrent medication/care: Proton pump inhibitors were recommended in all patients throughout the study. The selection of periprocedural anticoagulants and glycoprotein IIb/IIIa receptor blockers was left to the investigators' discretion. Whereas the use of oral anticoagulants at the time of the index event was a contraindication to enrollment in the study, their subsequent use for conditions that could have developed during follow-up (eg. atrial fibrillation) was left to the discretion of the attending physician as clinically indicated. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=735) Intervention 2: Antiplatelet - Clopidogrel. 300-600mg loading dose of clopidogrel (at investigators' discretion) followed by 75mg once daily. In patients with STEMI undergoing primary PCI, the drugs could be given as soon as possible after the diagnosis, yet the first administration of the study drug could also take place after angiography or soon after PCI ((eg. on arrival in the coronary care unit), particularly in patients treated during PCI with glycoprotein IIb/IIIa receptor blockers. For patients treated with bivalirudin monotherapy during PCI, it was strongly recommended that the loading dose of the investigational drugs be administered before PCI. In patients with NSTEMI-ACS, randomisation was to take place after angiography, and the loading dose should be administered either immediately before PCI or on arrival in the coronary care unit. Ongoing clopidogrel treatment, either preexisting or started as soon as the diagnosis of NSTEMI-ACS was made (with a loading dose of 300 or 600mg left to the investigators' discretion), did not preclude enrollment. In this case, those randomised to clopidogrel were to continue clopidogrel 75mg daily without a further loading dose. All patients were to receive 325mg aspirin on admission and then 75 to 100mg daily throughout follow-up. Duration 12 months. Concurrent medication/care: Proton pump inhibitors were recommended in all patients throughout the study. The selection of periprocedural anticoagulants and glycoprotein IIb/IIIa receptor blockers was left to the investigators' discretion. Whereas the use of oral anticoagulants at the time of the index event was a contraindication to enrollment in the study, their subsequent use for conditions that could have developed during follow-up (eg. atrial fibrillation) was left to the discretion of the attending physician as clinically indicated. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Other (The study has been promoted, managed and co-ordinated by Istituto di Ricerca e Cura a Carattere Scientifico Arcispedale Santa Maria Nuova in Reggio Emilia, Italy, and cofinanced by the pharmaceutical industry (Eli Lilly and Daiichi Sankyo))

Study	Savonitto 2018 <sup>219</sup>
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL	
<p>Protocol outcome 1: Other adverse effects of treatment</p> <p>- Actual outcome: Other adverse effects (premature study discontinuation due to adverse events) at 1 year; Group 1: 77/713, Group 2: 44/730</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Cardiac mortality</p> <p>- Actual outcome: Cardiac mortality (cardiovascular death) at 1 year; Group 1: 26/713, Group 2: 31/730; Comments: Hazard ratio: 0.85 (0.51-1.4)</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)</p> <p>- Actual outcome: Complications related to bleeding (major, BARC 3) at 1 year; Group 1: 12/713, Group 2: 12/730</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Complications related to bleeding (major, BARC 5) at 1 year; Group 1: 1/713, Group 2: 0/730</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Complications related to bleeding (minor, BARC 2) at 1 year; Group 1: 16/713, Group 2: 8/730</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Complications related to bleeding (blood transfusion, 12 red blood cell units) at 1 year; Group 1: 12/713, Group 2: 9/735</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low,</p>	

Study	Savonitto 2018 <sup>219</sup>
	<p>Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 4: Stroke                      - Actual outcome: Stroke (any, type not specified) at 1 year; Group 1: 7/713, Group 2: 13/730; Comments: Hazard ratio: 0.55 (0.22-1.37)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 5: Early and late stent thrombosis                      - Actual outcome: Stent thrombosis (probable or definite, acute) at 1 year; Group 1: 1/713, Group 2: 1/730                      Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Stent thrombosis (probable or definite, subacute) at 1 year; Group 1: 4/713, Group 2: 12/730                      Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>- Actual outcome: Stent thrombosis (probable or definite, late) at 1 year; Group 1: 0/713, Group 2: 1/730                      Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 6: All-cause mortality                      - Actual outcome: All-cause mortality at 1 year; Group 1: 36/713, Group 2: 28/730                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well</p>

Study	Savonitto 2018 <sup>219</sup>
	<p>matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: Re-infarction                      - Actual outcome: Re-infarction (myocardial infarction) at 1 year; Group 1: 14/713, Group 2: 19/730                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 8: Unplanned urgent readmission                      - Actual outcome: Unplanned urgent readmission (rehospitalisation for cardiovascular causes) at 1 year; Group 1: 55/713, Group 2: 57/730                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Unplanned urgent readmission (rehospitalisation for bleeding) at 1 year; Group 1: 15/713, Group 2: 11/730                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Baseline details: 'baseline clinical and angiographic characteristics were well matched between groups, as were the coronary intervention procedures'; Blinding details: 'open-label, blinded end point trial...Study investigators and patients were not masked to treatment allocation...Study unblinding took place after the last patient had completed the 3-month follow-up'; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; Re-infarction at 30 days; Length of hospital stay; All-cause mortality at up to 30 days

Study	Tang 2016 <sup>261</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=420)
Countries and setting	Conducted in China; Setting: All patients were hospitalised in the cardiac intensive care unit. During the 6-month follow-up, the data were recorded via telephone interviews or outpatient follow-up visits
Line of therapy	Unclear

Study	Tang 2016 <sup>261</sup>
Duration of study	Intervention + follow up: 6 month follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: ST segment elevation of >1mm in 2 or more limb leads or >2mm in 2 or more contiguous precordial leads
Stratum	STEMI: Undergoing PPCI
Subgroup analysis within study	Not applicable
Inclusion criteria	>18 years old; chest discomfort for >20 minutes and no response to nitroglycerin; time from the onset of symptoms to randomisation <12 hours; eligible for PPCI; ST segment elevation of >1mm in 2 or more limb leads or >2mm in 2 or more contiguous precordial leads; Killip class of ≤3; provision of informed consent
Exclusion criteria	Cardiogenic shock, defined as systolic blood pressure of <90/60mm Hg and no response to fluids; thrombolysis within the past 24 hours; oral anticoagulation therapy or current use of P2Y12 antagonists; malignant or life-threatening diseases; contraindications to aspirin, clopidogrel, or ticagrelor; inability to provide informed consent; suspected mechanical complications of STEMI; or coronary artery bypass graft surgery (CABG) within the previous year. Following angiography, patients were excluded if their angiographic findings included any of the following: stent thrombosis; multivessel disease requiring revascularisation or CABG; or no coronary vascular lesions
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 64.36 (11.409); Clopidogrel group: 64.18 (11.088). Gender (M:F): 288/112. Ethnicity: Not reported
Further population details	
Extra comments	Patients were randomised to treatment groups and received a loading dose before PPCI. The patients underwent angiography with or without stenting in accordance with practice guidelines
Indirectness of population	No indirectness
Interventions	(n=210) Intervention 1: Antiplatelet - Ticagrelor. Patients received 300mg of aspirin and a loading dose of 180mg ticagrelor before PPCI. After PPCI, the patients were given 100mg of aspirin daily and 90mg of ticagrelor twice daily. Duration 6 months. Concurrent medication/care: All patients without any contraindication also received conventional drugs, such as β-blockers, angiotensin-converting enzymes/angiotensin receptor blockers, and statins in accordance with the 2013 ACCF/AHA guideline for the management of STEMI: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Some patients were treated with GPIIb/IIIa inhibitors [intracoronary bolus of tirofiban (10µg/kg) plus maintenance infusion (0.15µg-1.kg-1.min-1) for 24-36 hours] in accordance with the 2014 European Society of Cardiology and the European Association for Cardio-Thoracic Surgery Guidelines on myocardial revascularisation. The doctors who performed coronary angiography decided whether clopidogrel or ticagrelor treatments were supplemented with GPIIb/IIIa

Study	Tang 2016 <sup>261</sup>
	<p>inhibitors after coronary angiography, but the doctors were blinded regarding the groups to which the patients belonged. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=210) Intervention 2: Antiplatelet - Clopidogrel. Patients received 300mg of aspirin and a loading dose of 600mg of clopidogrel before PPCI. After PPCI, the patients were given 100mg of aspirin daily and 75mg of clopidogrel once daily. Duration 6 months. Concurrent medication/care: All patients without any contraindication also received conventional drugs, such as <math>\beta</math>-blockers, angiotensin-converting enzymes/angiotensin receptor blockers, and statins in accordance with the 2013 ACCF/AHA guideline for the management of STEMI: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Some patients were treated with GPIIb/IIIa inhibitors [intracoronary bolus of tirofiban (10<math>\mu</math>g/kg) plus maintenance infusion (0.15<math>\mu</math>g-1.kg-1.min-1) for 24-36 hours] in accordance with the 2014 European Society of Cardiology and the European Association for Cardio-Thoracic Surgery Guidelines on myocardial revascularisation. The doctors who performed coronary angiography decided whether clopidogrel or ticagrelor treatments were supplemented with GPIIb/IIIa inhibitors after coronary angiography, but the doctors were blinded regarding the groups to which the patients belonged. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Funding not stated
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL</b></p> <p>Protocol outcome 1: Cardiac mortality - Actual outcome for STEMI: Cardiac mortality (cardiovascular cause) at 6 months (at 1 year); Group 1: 3/200, Group 2: 5/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p> <p>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome for STEMI: Complications related to bleeding (major, TIMI criteria) at (at 1 year); Group 1: 0/200, Group 2: 2/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular</p>	



Study	Tang 2016 <sup>261</sup>
	<p>lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p> <p>- Actual outcome for STEMI: Complications related to bleeding (minor, TIMI criteria) at 6 months (at 1 year); Group 1: 10/200, Group 2: 5/200</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p>
	<p>Protocol outcome 3: Stroke at Define</p> <p>- Actual outcome for STEMI: Stroke (any, type not specified) at 6 months (at 1 year); Group 1: 1/200, Group 2: 5/200</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p>
	<p>Protocol outcome 4: Need for revascularisation at 1 year</p> <p>- Actual outcome for STEMI: Need for revascularisation (unplanned revascularisation) at 6 months (at 1 year); Group 1: 0/200, Group 2: 3/200</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p>
	<p>Protocol outcome 5: Early and late stent thrombosis</p> <p>- Actual outcome for STEMI: Stent thrombosis at 6 months (at 1 year); Group 1: 0/200, Group 2: 3/200</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p>
	<p>Protocol outcome 6: All-cause mortality at 1 year</p> <p>- Actual outcome for STEMI: All-cause mortality at 6 months (at 1 year); Group 1: 4/200, Group 2: 6/200</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1</p>

Study	Tang 2016 <sup>261</sup>
<p>Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p> <p>Protocol outcome 7: Re-infarction at 1 year - Actual outcome for STEMI: Re-infarction (non-fatal myocardial infarction) at 6 months (at 1 year); Group 1: 0/200, Group 2: 3/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Both groups were similar in terms of baseline characteristics'; Group 1 Number missing: 10, Reason: 2 patients with stent thrombosis; 5 patients with multi-vessel disease requiring CABG; 2 patients with no coronary vascular lesions; 1 patient lost to follow-up; Group 2 Number missing: 10, Reason: 2 patients with stent thrombosis; 7 patients with multi-vessel disease requiring CABG; 1 patient with no coronary vascular lesions</p>	
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at up to 30 days ; Re-infarction at 30 days; Length of hospital stay at Define; Unplanned urgent readmission at within 30 days for any reason; All-cause mortality at up to 30 days

Study (subsidiary papers)	TRILOGY trial: Roe 2012 <sup>201</sup> (Kaul 2016 <sup>68</sup> )
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=9326)
Countries and setting	Conducted in Multiple countries; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: Study treatments continued for a minimum of 6 months and a maximum of 30 months - the median duration of exposure to a study drug was 14.8 months (interquartile range, 8.2 to 23.6 months)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients with myocardial infarction without ST-segment elevation had elevated cardiac markers, whereas patients with unstable angina with negative cardiac markers had an ST-segment depression of more than 1mm in two or more electrocardiographic leads
Stratum	UA/NSTEMI: Not undergoing revascularisation
Subgroup analysis within study	Unclear: Prespecified subgroup analyses were performed for the primary efficacy endpoint, which was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients under the age of 75 years
Inclusion criteria	Patients with acute coronary syndromes were eligible if they were selected for a final treatment strategy of

Study (subsidiary papers)	TRILOGY trial: Roe 2012 <sup>201</sup> (Kaul 2016 <sup>68</sup> )
	<p>medical management without revascularisation within 10 days after the index event. Patients with myocardial infarction without ST segment elevation had elevated cardiac markers, whereas patients with unstable angina with negative cardiac markers had an ST segment depression of more than 1mm in two or more electrocardiographic leads. Patients were required to have at least one of four risk criteria: an age of at least 60 years, the presence of diabetes mellitus, previous myocardial infarction, or previous revascularisation with either PCI or coronary artery bypass grafting (CABG). Angiography was not required for enrollment, but if such a procedure was planned, it had to be performed before randomisation. Patients who underwent angiography were required to have evidence of coronary disease (native coronary stenosis of &gt;30% or previous PCI or CABG)</p>
Exclusion criteria	<p>Major exclusion criteria included a history of transient ischaemic attack or stroke, PCI or CABG within the previous 30 days, renal failure requiring dialysis, and concomitant treatment with an oral anticoagulant</p>
Recruitment/selection of patients	<p>Not reported</p>
Age, gender and ethnicity	<p>Age - Median (IQR): Prasugrel group: 66 (58-74 years); Clopidogrel group: 66 (59-73 years). Gender (M:F): Prasugrel group: 2835/1828; clopidogrel group: 2840/1823. Ethnicity: Not reported</p>
Further population details	
Extra comments	<p>Angiography was not a requirement for enrollment, but if such as procedure was planned, it had to be performed before randomisation. Patients who underwent randomisation within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of the study drug followed by a maintenance dose. Patients who did not undergo randomisation within 72 hours were required to be treated with open-label clopidogrel before randomisation and started on a maintenance dose of the study drug after randomisation</p>
Indirectness of population	<p>No indirectness</p>
Interventions	<p>(n=4663) Intervention 1: Antiplatelet - Prasugrel. Patients who underwent randomisation within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 30mg of prasugrel, which was followed by daily blinded maintenance administration of a study drug. Patients who did not undergo randomisation within 72 hours were required to be treated with open-label clopidogrel before randomisation and were started on daily maintenance administration of a study drug after randomisation. The prasugrel maintenance dose was 10mg, which was adjusted to 5mg for patients who were 75 years of age or older or who weighed less than 60kg. Concomitant treatment with aspirin was required, and a daily dose of 100mg or less was strongly recommended. Duration 30 months. Concurrent medication/care: Not reported in study methods but the majority of patients received concomitant beta-blocker, ACE inhibitor or angiotensin-receptor blocker and statin at randomisation. Angiography was performed before randomisation in 41.2% of the prasugrel group. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>

<b>Study (subsidiary papers)</b>	<b>TRILOGY trial: Roe 2012<sup>201</sup> (Kaul 2016<sup>68</sup>)</b>
	(n=4663) Intervention 2: Antiplatelet - Clopidogrel. Patients who underwent randomisation within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 300mg of clopidogrel, which was followed by daily blinded maintenance administration of a study drug. Patients who did not undergo randomisation within 72 hours were required to be treated with open-label clopidogrel before randomisation and were started on daily maintenance administration of a study drug after randomisation. The clopidogrel maintenance dose was 75mg for all patients. Concomitant treatment with aspirin was required, and a daily dose of 100mg or less was strongly recommended. Duration 30 months. Concurrent medication/care: Not reported in study methods but the majority of patients received concomitant beta-blocker, ACE inhibitor or angiotensin-receptor blocker and statin at randomisation. Angiography was performed before randomisation in 41.4% of the clopidogrel group. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Other (Sponsor - Eli Lilly and Daiichi Sankyo)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL**

Protocol outcome 1: Quality of life

- Actual outcome for UA/NSTEMI: Health-related quality of life (in patients aged <75 years, EQ-5D) at 1 year; Group 1: mean 85.6 (SD 15); n=2888, Group 2: mean 84.6 (SD 15.3); n=2876; EuroQol group 5-dimension (EQ-5D) descriptive system 'For each dimension, responders are asked to report their status on a 3-level ordinal scale: no problems (level 1), some problems (level 2), or severe problems (level 3)...The raw EQ-5D scores were multiplied by 100 to make them more easily comaprable and to add more accuracy and discrimination between close scores with a decimal place' Top=Unclear; Comments: Baseline prasugrel group: 81.3 (16.8); baseline clopidogrel group: 80.8 (17.1)

Risk of bias: All domain – Very High, Selection - Low, Blinding - High, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 1775; Group 2 Number missing: 1787

- Actual outcome for UA/NSTEMI: Health-related quality of life (in patients aged <75 years, SAQ Physical) at 1 year; Group 1: mean 78 (SD 23.4); n=891, Group 2: mean 77 (SD 23.2); n=883; Seattle Angina Questionnaire 0-100 Top=High is good outcome; Comments: Baseline prasugrel group: 71.9 (25.0); baseline clopidogrel group: 70.7 (25.6)

Risk of bias: All domain – Very High, Selection - Low, Blinding - High, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 3772; Group 2 Number missing: 3780

- Actual outcome for UA/NSTEMI: Health-related quality of life (in patients aged <75 years, SF-12 Physical) at 1 year; Group 1: mean 44 (SD 10.7); n=891, Group 2: mean 43.7 (SD 10.7); n=883; Seattle Angina Questionnaire 0-100 Top=High is good outcome; Comments: Baseline prasugrel group: 41.3 (10.8); baseline clopidogrel group: 40.9 (11.1)

Risk of bias: All domain – Very High, Selection - Low, Blinding - High, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1

Study (subsidiary papers)	TRILOGY trial: Roe 2012 <sup>201</sup> (Kaul 2016 <sup>68</sup> )
<p>Number missing: 3772; Group 2 Number missing: 3780</p> <p>- Actual outcome for UA/NSTEMI: Health-related quality of life (in patients aged &lt;75 years, SF-12 Mental) at 1 year; Group 1: mean 49.7 (SD 10.5); n=891, Group 2: mean 49.7 (SD 10.3); n=883; Seattle Angina Questionnaire 0-100 Top=High is good outcome; Comments: Baseline prasugrel group: 48.3 (10.9); baseline clopidogrel group: 48.3 (11.5)</p> <p>Risk of bias: All domain – Very High, Selection - Low, Blinding - High, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 3772; Group 2 Number missing: 3780</p> <p>- Actual outcome for UA/NSTEMI: Health-related quality of life (in patients aged &lt;75 years, SF-36 Mental) at 1 year; Group 1: mean 48.2 (SD 11.3); n=891, Group 2: mean 47.8 (SD 11); n=883; Seattle Angina Questionnaire 0-100 Top=High is good outcome; Comments: Baseline prasugrel group: 45.9 (11.8); baseline clopidogrel group: 45.9 (12.1)</p> <p>Risk of bias: All domain – Very High, Selection - Low, Blinding - High, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 3772; Group 2 Number missing: 3780</p>	<p>Protocol outcome 2: All-cause mortality at 30 days</p> <p>- Actual outcome: All-cause mortality at 30 days; Group 1: 39/4663, Group 2: 44/4663</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Cardiac mortality at 30 days</p> <p>- Actual outcome for UA/NSTEMI: Cardiac mortality (death from cardiovascular causes) (in people aged &lt;75 years) at 1 year; HR; 1.00 (95%CI 0.78 to 1.28);</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome: Cardiac mortality (death from cardiovascular causes) at 30 days; Group 1: 35/4663, Group 2: 38/4663</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Complications related to bleeding (including haemorrhagic stroke) at Define</p> <p>- Actual outcome: Major bleeding (TIMI Criteria) at 30 days; Group 1: 7/4663, Group 2: 6/4663</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>

Study (subsidiary papers)	TRILOGY trial: Roe 2012 <sup>201</sup> (Kaul 2016 <sup>68</sup> )
Protocol outcome 5: Non-haemorrhagic stroke - Actual outcome for UA/NSTEMI: Stroke (any, type not specified) at 1 year; HR; 0.86 (95%CI 0.5 to 1.47); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Stroke at 30 days; Group 1: 12/4663, Group 2: 11/4663 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcome 6: Re-infarction at 30 days - Actual outcome: Re-infarction at 30 days; Group 1: 74/4663, Group 2: 78/4663 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcome 7: Re-infarction at 1 year - Actual outcome for UA/NSTEMI: Re-infarction (all myocardial infarctions) at 1 year; HR; 0.97 (95%CI 0.78 to 1.19); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were generally well balanced in the two study groups' ; Group 1 Number missing: ; Group 2 Number missing:	
Protocol outcomes not reported by the study	Need for revascularisation at 1 year; Early and late stent thrombosis; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study (subsidiary papers)	TRITON-TIMI 38 trial: Wiviott 2007 <sup>306</sup> (Montalescot 2009 <sup>115</sup> , Servi 2014 <sup>41, 235</sup> )
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=13,608)
Countries and setting	Conducted in Multiple countries; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 6 to 15 months follow up
Method of assessment of guideline condition	Partially adequate method of assessment/diagnosis: The inclusion criteria for patients with unstable angina or non-ST-elevation myocardial infarction were ischaemic symptoms lasting 10 minutes or more and

<b>Study (subsidiary papers)</b>	<b>TRITON-TIMI 38 trial: Wiviott 2007<sup>306</sup> (Montalescot 2009<sup>115</sup>, Servi 2014<sup>41, 235</sup>)</b>
	occurring within 72 hours before randomisation, a TIMI risk score of 3 or more, and either ST-segment deviation of 1mm or more or elevated levels of a cardiac biomarker of necrosis
Stratum	Overall: ACS undergoing PCI
Subgroup analysis within study	Not stratified but pre-specified: For composite outcome measures: UA/NSTEMI and STEMI; gender; age; diabetes; stent type; use of glycoprotein IIb/IIIa receptor-antagonist; creatinine clearance. Post-hoc subgroup analyses also included history or no history of stroke or TIA; age ≥75 years, body weight <60kg, or history of stroke or TIA, and age <75 years, body weight ≥60kg, and no history of stroke or TIA
Inclusion criteria	The inclusion criteria for patients with unstable angina or non-ST-elevation myocardial infarction were ischaemic symptoms lasting 10 minutes or more and occurring within 72 hours before randomisation, a TIMI risk score of 3 or more, and either ST-segment deviation of 1mm or more or elevated levels of a cardiac biomarker of necrosis. Patients with ST-elevation myocardial infarction could be enrolled within 12 hours after the onset of symptoms if primary PCI was planned or within 14 days after receiving medical treatment for ST-elevation myocardial infarction
Exclusion criteria	Key exclusion criteria included an increased risk of bleeding, anaemia, thrombocytopenia, a history of pathologic intracranial findings, or the use of any thienopyridine within 5 days before enrollment
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Prasugrel group median (25th percentile, 75th percentile): 61 (53-69 years); clopidogrel group median (25th percentile, 75th percentile): 61 (53-70 years). Gender (M:F): Prasugrel group: 5110/1703; clopidogrel group: 4960/1835. Ethnicity: Prasugrel group: white 92%, non-white 8%; clopidogrel group: white 93%, non-white 7 %
Further population details	
Extra comments	Randomisation was to occur before PCI was performed, and the study drug was to be administered as soon as possible after randomisation
Indirectness of population	No indirectness
Interventions	(n=6813) Intervention 1: Antiplatelet - Prasugrel. A loading dose of 60mg prasugrel was administered anytime between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. After PCI, patients received a maintenance dose of 10mg prasugrel daily. Use of aspirin was required, and a daily dose of 75 to 162mg was recommended. Duration 15 months. Concurrent medication/care: The choice of vessels treated, devices used, and adjunctive medication administered to support PCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable (n=6795) Intervention 2: Antiplatelet - Clopidogrel. A loading dose of 300mg clopidogrel was administered

<b>Study (subsidiary papers)</b>	<b>TRITON-TIMI 38 trial: Wiviott 2007<sup>306</sup> (Montalescot 2009<sup>115</sup>, Servi 2014<sup>41, 235</sup>)</b>
	anytime between randomisation and 1 hour after leaving the cardiac catheterisation laboratory. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. After PCI, patients received a maintenance dose of 75mg clopidogrel daily. Use of aspirin was required, and a daily dose of 75 to 162mg was recommended. Duration 15 months. Concurrent medication/care: The choice of vessels treated, devices used, and adjunctive medication administered to support PCI was left to the discretion of the treating physician. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Study funded by industry (Supported by research grants from Daiichi Sankyo and Eli Lilly)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRASUGREL versus CLOPIDOGREL	
<u>ACS (with/without revascularisation)</u>	
Protocol outcome 1: All-cause mortality at 1 year - Actual outcome: All-cause mortality (death from any cause) at 15 months; Group 1: 188/6813, Group 2: 197/6795; Comments: Hazard ratio for prasugrel (95% CI): 0.95 (0.78 to 1.16) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Group 1 Number missing: ; Group 2 Number missing:	
Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome: Complications related to bleeding (non-CABG-related major, TIMI) at 15 months; Group 1: 146/6741, Group 2: 111/6716; Comments: Hazard ratio for prasugrel (95% CI): 1.32 (1.03 to 1.68) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Complications related to bleeding (CABG-related major, TIMI) at 15 months; Group 1: 24/6741, Group 2: 6/6716; Comments: Hazard ratio for prasugrel (95% CI): 4.73 (1.90 to 11.82) Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Complications related to bleeding (major or minor, TIMI) at 15 months; Group 1: 303/6741, Group 2: 231/6716; Comments: Hazard ratio	



Study (subsidiary papers)	TRITON-TIMI 38 trial: Wiviott 2007 <sup>306</sup> (Montalescot 2009 <sup>115</sup> , Servi 2014 <sup>41, 235</sup> )
<p>for prasugrel (95% CI): 1.31 (1.11 to 1.56)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Other adverse effects of treatment                      - Actual outcome: Other adverse effects (severe thrombocytopenia) at 15 months; Group 1: 17/6741, Group 2: 18/6716                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Other adverse effects (neutropenia) at 15 months; Group 1: 2/6741, Group 2: 10/6716                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Cardiac mortality                      - Actual outcome: Cardiac mortality (death from cardiovascular causes) at 15 months; Group 1: 133/6813, Group 2: 150/6795; Comments: Hazard ratio for prasugrel (95% CI): 0.89 (0.70 to 1.12)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 5: Stroke                      - Actual outcome: Stroke (any non-fatal, type not specified) at 15 months; Group 1: 61/6813, Group 2: 60/6795; Comments: Hazard ratio for prasugrel (95% CI): 1.02 (0.71 to 1.45)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 6: Need for revascularisation at 1 year                      - Actual outcome: Need for revascularisation (urgent target vessel revascularisation) at 15 months; Group 1: 156/6813, Group 2: 233/6795; Comments:</p>	

Study (subsidiary papers)	TRITON-TIMI 38 trial: Wiviott 2007 <sup>306</sup> (Montalescot 2009 <sup>115</sup> , Servi 2014 <sup>41, 235</sup> )
<p>Hazard ratio for prasugrel (95% CI): 0.66 (0.56 to 0.81)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: Early and late stent thrombosis                      - Actual outcome: Stent thrombosis (definite or probable) at 15 months; Group 1: 68/6813, Group 2: 142/6795; Comments: Hazard ratio for prasugrel (95% CI): 0.48 (0.36 to 0.64)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The baseline characteristics were...well matched between groups' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p><u>STEMI + revascularisation</u></p> <p>Protocol outcome 1: All-cause mortality at 30 days                      - Actual outcome for STEMI: STEMI subgroup: all-cause mortality (death) at 30 days; Group 1: 28/1769, Group 2: 45/1765; Comments: Hazard ratio (95% CI): 0.62 (0.39-0.99)                      Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Need for revascularisation                      - Actual outcome for STEMI: STEMI subgroup: Need for revascularisation (urgent target revascularisation) at 15 months; Group 1: 38/1769, Group 2: 54/1765; Comments: Hazard ratio (95% CI): 0.70 (0.46-1.06)                      Risk of bias: All domain - Very High, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke)                      - Actual outcome for STEMI: STEMI subgroup: complications related to bleeding (major, TIMI) at 30 days; Group 1: 17/1769, Group 2: 23/1765;                      Comments: Number analysed using available case analysis. Hazard ratio (95% CI): 0.74 (0.39-1.38)                      Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p>	

Study (subsidiary papers)	TRITON-TIMI 38 trial: Wiviott 2007 <sup>306</sup> (Montalescot 2009 <sup>115</sup> , Servi 2014 <sup>41, 235</sup> )
	<p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Complications related to bleeding (including haemorrhagic stroke)</p> <p>- Actual outcome for STEMI: STEMI subgroup: complications related to bleeding (non-CABG related major, TIMI) at 15 months; Group 1: 38/1769, Group 2: 34/1765; Comments: Number analysed using available case analysis. Hazard ratio (95% CI): 1.11 (0.70-1.77)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: STEMI subgroup: complications related to bleeding (minor, TIMI) at 30 days; Group 1: 35/1769, Group 2: 57/1765;</p> <p>Comments: Number analysed using available case analysis. Hazard ratio (95% CI): 0.91 (0.62-1.32)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 4: Cardiac mortality</p> <p>- Actual outcome for STEMI: STEMI subgroup: cardiac mortality (cardiovascular death) at 30 days; Group 1: 25/1769, Group 2: 41/1765; Comments: Hazard ratio (95% CI): 0.61 (0.37-1.00)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: STEMI subgroup: cardiac mortality (cardiovascular death) at 15 months (1 year); Group 1: 43/1769, Group 2: 58/1765;</p> <p>Comments: Hazard ratio (95% CI): 0.74 (0.50-1.09)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 5: Need for revascularisation</p> <p>- Actual outcome for STEMI: STEMI subgroup: need for revascularisation (urgent target vessel revascularisation) at 30 days; Group 1: 22/1769, Group 2: 33/1765; Comments: Hazard ratio (95% CI): 0.66 (0.39-1.14)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;</p> <p>Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Early and late stent thrombosis</p>

Study (subsidiary papers)	TRITON-TIMI 38 trial: Wiviott 2007 <sup>306</sup> (Montalescot 2009 <sup>115</sup> , Servi 2014 <sup>41, 235</sup> )
<p>Protocol outcome 7: All-cause mortality at 1 year</p>	<p>- Actual outcome for STEMI: STEMI subgroup: stent thrombosis at 30 days; Group 1: 19/1769, Group 2: 39/1765; Comments: Hazard ratio (95% CI): 0.49 (0.28-0.84) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: STEMI subgroup: all-cause mortality (death) at 15 months; Group 1: 58/1769, Group 2: 76/1765; Comments: Hazard ratio (95% CI): 0.76 (0.54-1.07) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>
<p>Protocol outcome 8: Re-infarction</p>	<p>- Actual outcome for STEMI: STEMI subgroup: re-infarction (myocardial infarction) at 30 days; Group 1: 87/1769, Group 2: 123/1765; Comments: Hazard ratio (95% CI): 0.70 (0.53-0.92) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: STEMI subgroup: re-infarction (myocardial infarction) at 15 months; Group 1: 119/1769, Group 2: 157/1765; Comments: Hazard ratio (95% CI): 0.75 (0.59-0.95) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>
<p>Protocol outcome 9: Stroke</p>	<p>- Actual outcome for STEMI: STEMI subgroup: stroke (any, type not specified) at 30 days; Group 1: 7/1769, Group 2: 16/1765; Comments: Hazard ratio (95% CI): 0.43 (0.18-1.06) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p> <p>- Actual outcome for STEMI: STEMI subgroup: stroke (any, type not specified) at 15 months; Group 1: 26/1769, Group 2: 25/1765; Comments: Hazard ratio (95% CI): 1.03 (0.60-1.79) Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'Baseline characteristics were well matched'; Group 1 Number missing: ; Group 2 Number missing:</p>

**Study (subsidiary papers)**

**TRITON-TIMI 38 trial: Wiviott 2007<sup>306</sup> (Montalescot 2009<sup>115</sup>, Servi 2014<sup>41, 235</sup>)**

UA/STEMI + revascularisation

Protocol outcome 1: Stroke

- Actual outcome for UA/NSTEMI: NSTEMI-ACS subgroup: stroke (any, type not specified) at 15 months (1 year); Group 1: 49/5044, Group 2: 46/5030;

Comments: Hazard ratio (95% CI): 1.07 (0.71-1.60)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Post-hoc analysis baseline details reported for subpopulation with NSTEMI-ACS: 'Overall, baseline characteristics were well matched' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Re-infarction

- Actual outcome for UA/NSTEMI: NSTEMI-ACS subgroup: re-infarction (all myocardial infarctions) at 15 months (1 year); Group 1: 366/5044, Group 2: 476/5030; Comments: Hazard ratio (95% CI): 0.76 (0.66-0.87)

Risk of bias: All domain - All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Post-hoc analysis baseline details reported for subpopulation with NSTEMI-ACS: 'Overall, baseline characteristics were well matched' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Cardiac mortality

- Actual outcome for UA/NSTEMI: NSTEMI-ACS subgroup: cardiac mortality (cardiovascular deaths) at 15 months (1 year); Group 1: 90/5044, Group 2: 92/5030; Comments: Hazard ratio (95% CI): 0.98 (0.73-1.31)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Post-hoc analysis baseline details reported for subpopulation with NSTEMI-ACS: 'Overall, baseline characteristics were well matched' ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Complications relating to bleeding

- Actual outcome for UA/NSTEMI: NSTEMI-ACS subgroup: complications related to bleeding (non-CABG related major, TIMI) at 15 months (1 year); Group 1: 108/5001, Group 2: 77/4980; Comments: Hazard ratio (95% CI): 1.40 (1.05-1.88)

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Post-hoc analysis baseline details reported for subpopulation with NSTEMI-ACS: 'Overall, baseline characteristics were well matched' ; Blinding details: 'All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments'; Group 1 Number missing: ; Group 2 Number missing:

<b>Study (subsidiary papers)</b>	<b>TRITON-TIMI 38 trial: Wiviott 2007<sup>306</sup> (Montalescot 2009<sup>115</sup>, Servi 2014<sup>41, 235</sup>)</b>
Protocol outcomes not reported by the study	Quality of life; Length of hospital stay

<b>Study</b>	<b>Wang 2016a<sup>287</sup></b>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=200)
Countries and setting	Conducted in China; Setting: Not reported
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 months follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis of ACS made according to the European Society of Cardiology guideline
Stratum	Overall: The majority of the population underwent an invasive strategy during the study (PCI during study: 73%)
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of ACS made according to the European Society of Cardiology guideline
Exclusion criteria	Any contraindication against the use of P2Y12 inhibitors; under DAPT, anticoagulation, and fibrinolytic therapy; active bleeding or increased bleeding risk such as malignancy, surgery, trauma, fracture, or organ biopsy; clinically significant out-of-range values for platelet count or haemoglobin; had renal function failure requiring dialysis; hypertension with systolic blood pressure >180mmHg or diastolic blood pressure >110mmHg, or cardiogenic shock with systolic blood pressure <80mmHg lasting for >30 minutes
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): 79 (65-93 years). Gender (M:F): Clopidogrel group: 66/33; Ticagrelor group: 69/31. Ethnicity: Chinese
Further population details	
Extra comments	Patients older than 65 years were recruited. The initial loading dose of study drugs was administered as soon as possible after randomisation
Indirectness of population	No indirectness
Interventions	(n=100) Intervention 1: Antiplatelet - Clopidogrel. Clopidogrel was administered at a 300mg loading dose with a maintenance dose of 75mg once daily. The initial loading dose was administered as soon as possible

<b>Study</b>	<b>Wang 2016a<sup>287</sup></b>
	<p>after randomisation with the first maintenance dose administered at the usual time. All patients took aspirin at a loading dose of 300mg followed by a maintenance dose of 100mg once daily, unless aspirin was intolerant. Duration 12 months. Concurrent medication/care: not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=100) Intervention 2: Antiplatelet - Ticagrelor. Ticagrelor was administered at 180mg loading dose, and then a maintenance dose of 90mg twice daily. The initial loading dose was administered as soon as possible after randomisation with the first maintenance dose administered at the usual time. All patients took aspirin at a loading dose of 300mg followed by a maintenance dose of 100mg once daily, unless aspirin was intolerant. Duration 12 months. Concurrent medication/care: not reported. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Funding not stated
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CLOPIDOGREL versus TICAGRELOR</b></p> <p>Protocol outcome 1: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome: Complications related to bleeding (major, PLATO) at 1 year; Group 1: 6/100, Group 2: 8/100; Comments: Hazard ratio: 1.250 (0.434-3.604) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Complications related to bleeding (minor, PLATO) at 1 year; Group 1: 8/100, Group 2: 13/100; Comments: Hazard ratio: 1.531 (0.634-3.694) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Stroke - Actual outcome: Stroke (any, type not specified) at 1 year; Group 1: 3/100, Group 2: 2/100; Comments: Hazard ratio: 0.623 (0.104-3.732) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing:</p>	

Study	Wang 2016a <sup>287</sup>
<p>Protocol outcome 3: All-cause mortality at 1 year                      - Actual outcome: All-cause mortality at 1 year; Group 1: 16/100, Group 2: 9/100; Comments: Hazard ratio: 0.534 (0.236-1.209)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing:                      - Actual outcome: Cardiac mortality (cardiovascular death) at 1 year; Group 1: 15/100, Group 2: 6/100; Comments: Hazard ratio: 0.381 (0.148-0.982)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Re-infarction at 1 year                      - Actual outcome: Re-infarction (myocardial infarction) at 1 year; Group 1: 15/100, Group 2: 6/100; Comments: Hazard ratio: 0.380 (0.148-0.981)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'baseline characteristics and clinical diagnosis had no significant difference between patients taking ticagrelor and clopidogrel; they were also balanced with respect to other treatments (P&gt;0.05 for all); Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days ; Cardiac mortality at 30 days ; Need for revascularisation at 1 year; Early and late stent thrombosis; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	Wang 2016b <sup>288</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=174)
Countries and setting	Conducted in China; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 30 days follow-up
Method of assessment of guideline	Adequate method of assessment/diagnosis: Acute myocardial infarction within 12 hours after onset of chest



Study	Wang 2016b <sup>288</sup>
condition	pain; and ECG indications of sustained elevation of 2 adjacent ST segments or newly emerging left bundle branch block
Stratum	STEMI: Undergoing emergency PCI
Subgroup analysis within study	Not applicable
Inclusion criteria	Age ≥60 years; dementia; acute myocardial infarction within 12 hours after onset of chest pain; and ECG indications of sustained elevation of 2 adjacent ST segments or newly emerging left bundle branch block
Exclusion criteria	Age ≥80 years; presence of chronic obstructive pulmonary disease at acute exacerbation stage, bronchial asthma, malignant tumour, or kidney failure, any contraindication of using clopidogrel, nearly onset cerebral infarction in the last year or previous history of cerebral haemorrhage; severe sinus bradycardia (heart rate <50 beats/min), cardiogenic shock, type II atrioventricular block above degree II, receiving intravenous thrombolysis within 24 hours, and currently receiving anticoagulant therapy
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Range: 60-79 years. Gender (M:F): Ticagrelor group: 48/39; Clopidogrel group: 50/37. Ethnicity: Not reported
Further population details	
Extra comments	Patients were randomised into treatment groups. They received a loading dose of aspirin if they were not already taking aspirin. Immediately after the loading dose of aspirin, patients underwent coronary arteriography and PCI
Indirectness of population	No indirectness
Interventions	<p>(n=87) Intervention 1: Antiplatelet - Ticagrelor. Loading dose of 180mg ticagrelor and then switched to an oral maintenance dose of 90mg twice daily. Duration 30 days. Concurrent medication/care: If patients were not already taking aspirin, they received aspirin at a loading dose of 300mg. After the loading dose of aspirin, patients immediately underwent coronary arteriography and PCI. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p> <p>(n=87) Intervention 2: Antiplatelet - Clopidogrel. Loading dose of 600mg clopidogrel and then switched to an oral maintenance dose of 75mg daily. Duration 30 days. Concurrent medication/care: If patients were not already taking aspirin, they received aspirin at a loading dose of 300mg. After the loading dose of aspirin, patients immediately underwent coronary arteriography and PCI. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable</p>
Funding	Funding not stated

Study	Wang 2016b <sup>288</sup>
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR versus CLOPIDOGREL	
<p>Protocol outcome 1: Other adverse effects of treatment at up to 30 days                      - Actual outcome for STEMI: Other adverse effects (upper gastrointestinal bleeding) at 30 days; Group 1: 4/87, Group 2: 2/87; Comments: Odds ratio: 2.41 (1.17-3.20)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Breathing adverse effects                      - Actual outcome for STEMI: Breathing adverse effects (difficulty breathing) at 30 days; Group 1: 12/87, Group 2: 5/87; Comments: Odds ratio: 2.04 (1.08-2.98)                      Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Bradycardic adverse effects                      - Actual outcome for STEMI: Bradycardic adverse effects (sinus bradycardia) at 30 days; Group 1: 7/87, Group 2: 4/87; Comments: Odds ratio: 1.18 (0.89-1.35)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>- Actual outcome for STEMI: Bradycardic adverse effects (required permanent pacemaker implantation) at 30 days; Group 1: 2/87, Group 2: 2/87                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Other adverse effects                      - Actual outcome for STEMI: Other adverse effects (malignant ventricular arrhythmias) at 30 days; Group 1: 5/87, Group 2: 6/87; Comments: Odds ratio: 0.98 (0.81-1.33)                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial</p>	

Study	Wang 2016b <sup>288</sup>
	<p>infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Cardiac mortality at 30 days - Actual outcome for STEMI: Cardiac mortality (vascular causes of death) at 30 days; Group 1: 2/87, Group 2: 4/87; Comments: Odds ratio: 0.63 (0.34-0.89) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High; Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Stroke - Actual outcome for STEMI: Stroke (any, type not specified) at 30 days; Group 1: 2/87, Group 2: 2/87 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: Early and late stent thrombosis - Actual outcome for STEMI: Stent thrombosis at 30 days; Group 1: 0/87, Group 2: 4/87 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 8: Re-infarction at 30 days - Actual outcome for STEMI: Re-infarction (recurrent myocardial infarction) at 30 days; Group 1: 1/87, Group 2: 5/87; Comments: Odds ratio: 0.55 (0.12-0.79) Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness ; Baseline details: Baseline characteristics similar for gender, cardiovascular risk factors, previous myocardial infarction, anterior and inferior wall infarction, troponin I-negative and I-positive, and STEMI risk factors. However, age data were not reported by intervention group ; Group 1 Number missing: ; Group 2 Number missing:</p>
Protocol outcomes not reported by the study	Quality of life; Complications related to bleeding (including haemorrhagic stroke); Need for revascularisation at 1 year; All-cause mortality at 1 year; Length of hospital stay; Re-infarction at 1 year; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days

Study	Wang 2019 <sup>289</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=298)
Countries and setting	Conducted in China; Setting:
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	STEMI
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute myocardial ischemia lasting more than 30 minutes and ST-segment elevation of at least 0.1 mV in at least two extremity leads or at least 0.2 mV in at least two precordial leads detected on a 12-lead ECG, and the presence of symptoms for less than 12 hours.
Exclusion criteria	Cardiogenic shock, thrombolysis within the last 24 hours, oral anticoagulant therapy, indication for emergency coronary artery bypass grafting, known allergy to: aspirin, clopidogrel, ticagrelor, or heparin, active severe bleeding, pregnancy, severe uncontrolled hypertension, severe renal failure, inability to provide informed consent, and presenting with left bundle branch block.
Recruitment/selection of patients	Consecutive patients with STEMI eligible for primary PCI were enrolled from June 2015 to January 2017.
Age, gender and ethnicity	Age - Mean (SD): ticagrelor group: 60 (13); clopidogrel group: 61 (12). Gender (M:F): 236/62. Ethnicity: Not reported
Further population details	
Indirectness of population	No indirectness
Interventions	(n=150) Intervention 1: Antiplatelet - Ticagrelor. Patients were administered a loading dose of ticagrelor, 180 mg followed by 90 mg twice daily.. Duration Not reported. Concurrent medication/care: Coronary angiography and PCI were performed according to standard protocols, loaded with heparin and then additional heparin was administered to maintain an activated clotting time of more than 300 seconds. Drug-eluting stents were used for all patients. . Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Routine (Administered at operator's discretion).

<b>Study</b>	<b>Wang 2019<sup>289</sup></b>
	(n=148) Intervention 2: Antiplatelet - Clopidogrel. Patients were administered clopidogrel loading dose of 600 mg, followed by 75 mg daily. . Duration Not reported. Concurrent medication/care: Coronary angiography and PCI were performed according to standard protocols, loaded with heparin and then additional heparin was administered to maintain an activated clotting time of more than 300 seconds. Drug-eluting stents were used for all patients. . Indirectness: No indirectness Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Routine (Administered at operator's discretion).
<b>Funding</b>	Funding not stated
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR + ASA versus CLOPIDOGREL + ASA</b></p> <p><b>Protocol outcome 1: All-cause mortality at 30 days</b>          - Actual outcome for STEMI: All-cause mortality at 30 days; Group 1: 3/150, Group 2: 6/148          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p><b>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke)</b>          - Actual outcome for STEMI: Major bleeding at During hospitalisation (at 30 days); Group 1: 5/150, Group 2: 4/148          Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0          - Actual outcome for STEMI: Minor bleeding at During hospitalisation (at 30 days); Group 1: 15/150, Group 2: 10/148          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p><b>Protocol outcome 3: Need for revascularisation at 1 year</b>          - Actual outcome for STEMI: Urgent TVR at up to 1 year (6 months); Group 1: 4/150, Group 2: 11/148          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0          - Actual outcome for STEMI: Urgent TVR at 30 days;          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p><b>Protocol outcome 4: All-cause mortality at 1 year</b>          - Actual outcome for STEMI: All-cause mortality at up to 1 year (6 months); Group 1: 3/150, Group 2: 7/148          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,</p>	

Study	Wang 2019 <sup>289</sup>
Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
<p>Protocol outcome 5: Re-infarction at 30 days                      - Actual outcome for STEMI: Re-infarction at 30 days; Group 1: 3/150, Group 2: 7/148                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: Re-infarction at 1 year                      - Actual outcome for STEMI: Re-infarction at up to 1 year (6 months); Group 1: 4/150, Group 2: 10/148                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life; Cardiac mortality at 30 days ; Non-haemorrhagic stroke; Early and late stent thrombosis; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; Other adverse effects of treatment (eg. breathlessness, bradycardia) at 30 days

Study	Wu 2018 <sup>311</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=257)
Countries and setting	Conducted in China; Setting: Emergency Department of Hebei General Hospital
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 1 year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	UA/NSTEMI
Subgroup analysis within study	Not applicable
Inclusion criteria	Non STEMI patients should meet at least two of the following criteria; (1) the electrocardiogram (ECG) presented with decreased ST segments in $\geq 0.1$ mv of transient elevated ST segment; (2) assay results of the myocardial injury markers (such as Mb or CK-MB, or cTnI or cTnT) were positive; (3) patients presented with at least one of following risk factors: age $\geq 60$ years olds, hyperlipidemia, hypertension, diabetes mellitus, history of myocardial infarction $\geq 50\%$ vascular stenoses in $\geq 2$ branches of the coronary artery, history of cerebral infarction, transient ischemic attack (TIA) diagnosed by the hospital, carotid canal presented with

Study	Wu 2018 <sup>311</sup>
	<p>≥50% stenosis, history of revascularisation of cerebral blood vessels, peripheral arterial disease, and chronic renal dysfunction.</p> <p>Additionally, STEMI patients should meet the following criteria: the ECG presented with elevated ST segments in ≥ 2 consecutive leads and ≥0.1 mv, or a left bundle branch block was newly detected.</p>
Exclusion criteria	Not reported - as per the inclusion criteria
Recruitment/selection of patients	Consecutive patients treated with emergency PCI
Age, gender and ethnicity	Age - Mean (SD): Ticagrelor group: 59 (10); clopidogrel group: 61 (12). Gender (M:F): 192/52. Ethnicity: Not reported
Further population details	
Extra comments	Total study population: 232/244 (95%) - STEMI patients; 12/244 (5%) - NSTEMI patients
Indirectness of population	No indirectness
Interventions	<p>(n=129) Intervention 1: Antiplatelet - Ticagrelor. Patients in orally took a loading dose of aspirin (300 mg). After diagnosis, patients in the ticagrelor group took 180 mg of ticagrelor (qd), and subsequently took 90 mg of ticagrelor (bid) for maintenance.. Duration Not reported. Concurrent medication/care: n/a. Indirectness: No indirectness</p> <p>Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p> <p>(n=128) Intervention 2: Antiplatelet - Clopidogrel. Patients in orally took a loading dose of aspirin (300 mg). After diagnosis, patients in the clopidogrel group took 300 mg of clopidogrel (qd), and subsequently took 75 mg of clopidogrel (bid) for maintenance.. Duration Not reported. Concurrent medication/care: n/a.</p> <p>Indirectness: No indirectness</p> <p>Further details: 1. Timing of administration: Administration after hospital admission 2. Use of GpIIb/IIIa : Not stated / Unclear</p>
Funding	Academic or government funding (Fund Project: The task book of Hebei Science and Technology Project)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TICAGRELOR + ASA versus CLOPIDOGREL + ASA**

Protocol outcome 1: Other adverse effects of treatment (eg. breathlessness, bradycardia)

- Actual outcome for STEMI: Bradycardia at 1 year; Group 1: 1/124, Group 2: 0/120

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up

Study	Wu 2018 <sup>311</sup>
	<p>Protocol outcome 2: Cardiac mortality - Actual outcome for STEMI: Cardiac mortality (cardiovascular death) at 1 year; Group 1: 0/124, Group 2: 2/120 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up</p> <p>Protocol outcome 3: Complications related to bleeding (including haemorrhagic stroke) - Actual outcome for STEMI: Bleeding event, type not specified (haemorrhagic event) at 1 year; Group 1: 14/124, Group 2: 4/120 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up</p> <p>Protocol outcome 4: Non-haemorrhagic stroke - Actual outcome for STEMI: Stroke at 1 year; Group 1: 1/124, Group 2: 4/120 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up</p> <p>Protocol outcome 5: Early and late stent thrombosis - Actual outcome for STEMI: Stent thrombosis at 1 year; Group 1: 0/124, Group 2: 0/120 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up</p> <p>Protocol outcome 6: Re-infarction at 1 year - Actual outcome for STEMI: Re-infarction (recurrent myocardial infarction) at 1 year; Group 1: 0/124, Group 2: 3/120 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Lost to follow-up; Group 2 Number missing: 8, Reason: Lost to follow-up</p>
Protocol outcomes not reported by the study	Quality of life; Need for revascularisation at 1 year; All-cause mortality at 1 year; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days



Study	Yao 2017 <sup>319</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=120)
Countries and setting	Conducted in China; Setting: In hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: six-month follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: 'diagnostic criteria of the guideline from American Heart Association for acute myocardial infarction published in 2000'
Stratum	Overall: Undergoing emergency PCI
Subgroup analysis within study	Not applicable:
Inclusion criteria	'diagnostic criteria of the guideline from American Heart Association for acute myocardial infarction published in 2000; patients who are younger than 75 years old; patients who had received emergency PCI and followed up according to medical order with complete clinical data; patients took neither anticoagulants like warfarin or others, nor antiplatelet medication like clopidogrel and ticagrelor within a week'
Exclusion criteria	'patients who had severe cardiogenic shock and cardiac insufficiency; patients who had [taken] anticoagulant like warfarin within a week; patients who were complicated other diseases such as severe coagulation disorders, moderate or severe anaemia, active peptic ulceration, intracerebral haemorrhage, thieroma, etc.; patients who were allergic to aspirin, clopidogrel and ticagrelor'
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: 'average age of 60.2 ± 12.3' (clopidogrel group: 59.8 ± 10.8; ticagrelor group: 60.4 ± 12.7). Gender (M:F): 74/46 (clopidogrel group: 36/24; ticagrelor group: 38/22). Ethnicity: Not reported
Further population details	
Extra comments	Timing of randomisation to treatment unclear. Loading doses of study drugs were administered before emergency PCI
Indirectness of population	No indirectness
Interventions	(n=60) Intervention 1: Antiplatelet - Clopidogrel. Before the emergency PCI surgery, a loading dose of clopidogrel (Sanofi-Aventis Co. Ltd.) 600 mg and aspirin (Bayer AG) 300 mg were administered orally. Duration 6 months. Concurrent medication/care: All patients received basic treatment for AMI, including 'atorvastatin, isosorbide mononitrate, metoprolol and so forth every day. After PCI, they were all hypodermic injected with enoxaparin sodium (brand name: clexane, brought from Sanofi-Aventis Co. Ltd., licence number: H20100484 for anticoagulation'. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable


<b>Study</b>	<b>Yao 2017<sup>319</sup></b>
	(n=60) Intervention 2: Antiplatelet - Ticagrelor. Before the emergency PCI surgery, a loading dose of ticagrelor (AstreZeneca, AB) 180 mg and aspirin (Bayer, AG) 300 mg were administered orally. Duration 6 months. Concurrent medication/care: All patients received basic treatment for AMI, including 'atorvastatin, isosorbide mononitrate, metoprolol and so forth every day. After PCI, they were all hypodermic injected with enoxaparin sodium (brand name: clexane, brought from Sanofi-Aventis Co. Ltd., licence number: H20100484 for anticoagulation'. Indirectness: No indirectness Further details: 1. Timing of administration: Not applicable
Funding	Funding not stated
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CLOPIDOGREL versus TICAGRELOR</b></p> <p>Protocol outcome 1: Other adverse effects of treatment          - Actual outcome: Other adverse effects (recurrent angina) at 6 months (at 1 year); Group 1: 8/60, Group 2: 5/60          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;          Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';          Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Complications related to bleeding (including haemorrhagic stroke)          - Actual outcome: Complications related to bleeding (major, BARC 3-5) at 6 months (at 1 year); Group 1: 1/60, Group 2: 0/60          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;          Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';          Group 1 Number missing: ; Group 2 Number missing:          - Actual outcome: Complications related to bleeding (minor, BARC 1-2) at 6 months (at 1 year); Group 1: 24/60, Group 2: 10/60          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;          Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';          Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Need for revascularisation at 1 year          - Actual outcome: Need for revascularisation (second PCI) at 6 months; Group 1: 5/60, Group 2: 3/60          Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;          Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';          Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: All-cause mortality at 1 year</p>	

Study	Yao 2017 <sup>319</sup>
<p>- Actual outcome: All-cause mortality at 6 months; Group 1: 1/60, Group 2: 0/60                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';                      Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Re-infarction at 1 year                      - Actual outcome: Re-infarction (second myocardial infarction) at 6 months; Group 1: 6/60, Group 2: 3/60                      Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low;                      Indirectness of outcome: No indirectness ; Baseline details: 'The age, sex, primary diseases and other parameters had no statistical difference (P&gt;0.05)';                      Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life; Cardiac mortality at 30 days ; Stroke; Early and late stent thrombosis; Re-infarction at 30 days; Length of hospital stay; Unplanned urgent readmission within 30 days for any reason; All-cause mortality at 30 days</p>


## Appendix E: Forest plots

### E.1 Ticagrelor + aspirin (ASA) versus clopidogrel + ASA


**Figure 5: All-cause mortality at 30 days (ACS with/without revascularisation)**



**Figure 6: All-cause mortality at 30 days (STEMI + revascularisation)**




**Figure 7: All-cause mortality at 30 days**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.64 (0.44, 0.92); UA/NSTEMI + no revascularisation – HR 0.84 (0.63, 1.11)

**Figure 8: All-cause mortality at 1 year**




**Figure 9: All-cause mortality at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.75 (0.53, 1.06); UA/NSTEMI + no revascularisation – no difference

**Figure 10: Cardiac mortality at 30 days**




**Figure 11: Cardiac mortality at 30 days**



There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.67 (0.43, 1.02); UA/NSTEMI + no revascularisation – no difference


**Figure 12: Cardiac mortality at 1 year**



Test for subgroup differences: Chi<sup>2</sup> = 0.06, df = 1 (P = 0.81), I<sup>2</sup> = 0%


Goto 1 year; Tang 6 mos; Wallentin 1 year; Wang 1 year; Zhang 6 mos; Steg 1 year

**Figure 13: Cardiac mortality at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.76 (0.52, 1.13); UA/NSTEMI + no revascularisation – HR 0.75 (0.58, 0.98)

**Figure 14: Re-infarction at 30 days**




**Figure 15: Re-infarction at 30 days**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.86 (0.63, 1.16); UA/NSTEMI + no revascularisation – HR 0.89 (0.68, 1.17)

**Figure 16: Re-infarction at 1 year**




**Figure 17: Re-infarction at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 0.90 (0.68, 1.21); UA/NSTEMI + no revascularisation – HR 0.94 (0.75, 1.17)



**Figure 18: Major bleeding at 30 days**




**Figure 19: Major bleeding at 30 days**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 1.14 (0.84, 1.56); UA/NSTEMI + no revascularisation – HR 1.18 (0.91, 1.54)

**Figure 20: Major bleeding at 1 year**




**Figure 21: Major bleeding at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – no difference – HR 1.05 (0.88, 1.26)

**Figure 22: Minor bleeding at 30 days**




Test for subgroup differences: Chi<sup>2</sup> = 0.10, df = 1 (P = 0.75), I<sup>2</sup> = 0%

**Figure 23: Minor bleeding at 1 year**




Test for subgroup differences: Chi<sup>2</sup> = 0.02, df = 1 (P = 0.87), I<sup>2</sup> = 0%


**Figure 24: Bleeding (type not specified) at 1 year**



**Figure 25: Stroke (type not specified) at 30 days**




**Figure 26: Stroke (type not specified) at 30 days**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 1.14 (0.54, 2.40); UA/NSTEMI + no revascularisation – HR 0.84 (0.50, 1.41)

**Figure 27: Stroke (type not specified) at 1 year**




**Figure 28: Stroke (type not specified) at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager. UA/NSTEMI + revascularisation – HR 1.18 (0.60, 2.34); UA/NSTEMI + no revascularisation – no difference


**Figure 29: Need for revascularisation at 30 days**




**Figure 30: Need for revascularisation at 1 year**




**Figure 31: Stent thrombosis (type not specified) at 30 days**




**Figure 32: Stent thrombosis (probable or definite) at 1 year**




**Figure 33: Stent thrombosis (type not specified) (ACS with/without revascularisation at 1 year)**




**Figure 34: Stent thrombosis (type not specified) (NSTEMI + revascularisation) at 1 year**




**Figure 35: Breathing adverse effects at 30 days**




**Figure 36: Breathing adverse effects at 1 year**




**Figure 37: Bradycardic adverse effects at 30 days**




**Figure 38: Bradycardic adverse effects at 1 year**




**Figure 39: Other adverse effects at 30 days**



**Figure 40: Other adverse effects at 1 year**




**Figure 41: Unplanned urgent readmission at 30 days**






## E.2 Prasugrel + ASA versus clopidogrel + ASA


**Figure 42: All-cause mortality at 30 days**




**Figure 43: All-cause mortality at 1 year**




**Figure 44: Cardiac mortality at 30 days**




**Figure 45: Cardiac mortality at 1 year**




**Figure 46: Cardiac mortality (people aged <75 years) at 1 year**




**Figure 47: Re-infarction at 30 days (ACS with/without revascularisation and STEMI + revascularisation)**




**Figure 48: Re-infarction at 30 days (UA/NSTEMI + no revascularisation)**



**Figure 49: Re-infarction at 1 year**




**Figure 50: Re-infarction (people aged <75 years) at 1 year**




There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager - HR 0.97 (0.78, 1.19)


**Figure 51: Major bleeding at 30 days (ACS with/without revascularisation)**




**Figure 52: Major bleeding at 30 days (STEMI + revascularisation and UA/NSTEMI+ revascularisation)**




**Figure 53: Bleeding (major and minor) at 30 days**




**Figure 54: Major bleeding at 1 year**




**Figure 55: Minor bleeding at 30 days**



**Figure 56: Minor bleeding at 1 year**




**Figure 57: Health-related quality of life (EQ5D) (people aged <75 years) at 1 year, scale range: 0-100 (higher is better)**




Note: final scores

**Figure 58: Health-related quality of life (SAQ Physical) (people aged <75 years) at 1 year, scale range: 0-100 (higher is better)**




Note: final scores

**Figure 59: Health-related quality of life (SF-12 Physical) (people aged <75 years) at 1 year, scale range: 0-100 (higher is better)**




Note: final scores

**Figure 60: Health-related quality of life (SF-12 Mental) (people aged <75 years) at 1 year, scale range: 0-100 (higher is better)**




Note: final scores

**Figure 61: Health-related quality of life (SF-36 Mental) (people aged <75 years) at 1 year, scale range: 0-100 (higher is better)**




Note: final scores


**Figure 62: Stroke (type not specified) at 30 days**



**Figure 63: Stroke (type not specified) at 1 year**




**Figure 64: Stroke (type not specified) (people aged <75 years) at 1 year**




*There is a minor difference between the hazard ratio reported within the trial publication and hazard ratio reported in this review. Upper confidence interval could not be edited in Review Manager - HR 0.86 (0.50, 1.47)*


**Figure 65: Need for revascularisation at 30 days (ACS with/without revascularisation)**



**Figure 66: Need for revascularisation at 30 days (STEMI + revascularisation)**




**Figure 67: Need for revascularisation at 1 year**







**Figure 68: Stent thrombosis (definite or probable) at 30 days**




**Figure 69: Stent thrombosis (type not specified) at 30 days**




**Figure 70: Stent thrombosis (probable or definite) at 1 year**




**Figure 71: Other adverse effects at 30 days**




**Figure 72: Other adverse effects at 1 year**



**Figure 73: Unplanned urgent readmission at 30 days**




**Figure 74: Unplanned urgent readmission at 1 year**




## E.3 Ticagrelor + ASA versus prasugrel + ASA


**Figure 75: All-cause mortality at 30 days (ACS with/without revascularisation and UA/NSTEMI + revascularisation)**




**Figure 76: All-cause mortality at 30 days (STEMI + revascularisation)**




**Figure 77: All-cause mortality at 1 year**




**Figure 78: Cardiac mortality at 30 days (ACS with/without revascularisation and UA/NSTEMI + revascularisation)**




**Figure 79: Cardiac mortality at 30 days (STEMI + revascularisation)**




**Figure 80: Cardiac mortality at 1 year**




**Figure 81: Re-infarction at 30 days (ACS with/without revascularisation and STEMI + revascularisation)**




**Figure 82: Re-infarction at 30 days (UA/NSTEMI + revascularisation)**




**Figure 83: Re-infarction at 1 year**




**Figure 84: Major bleeding at 30 days**




**Figure 85: Major bleeding at 1 year**




**Figure 86: Minor bleeding at 30 days**




**Figure 87: Stroke (type not specified) at 30 days**




**Figure 88: Stroke (any type) at 1 year**




**Figure 89: Need for revascularisation at 30 days**




**Figure 90: Stent thrombosis (definite) at 30 days**




**Figure 91: Stent thrombosis (type not specified) at 30 days**




**Figure 92: Stent thrombosis (definite or probable) at 1 year**




**Figure 93: Breathing adverse effects at 30 days**



**Figure 94: Bradycardic adverse effects at 30 days**



**Figure 95: Other adverse effects at 30 days**





### E.3.1 Minimal important differences for continuous outcomes

The MID values reported in Table 25, were used to assess imprecision for the various continuous outcomes included in this evidence review. Continuous outcomes were only reported for the comparison: prasugrel versus clopidogrel.

**Table 25: Minimal important difference: Prasugrel + aspirin versus clopidogrel + aspirin**

Outcomes	Minimal important difference (MID)
Health-related quality of life (EQ5D) (people aged <75 years) at 1 year Scale: 0-100 (higher is better)	7.7
Health-related quality of life (SAQ Physical) (people aged <75 years) at 1 year Scale: 0-100 (higher is better)	11.6
Health-related quality of life (SF-12 Physical) (people aged <75 years) at 1 year Scale: 0-100 (higher is better)	5.4
Health-related quality of life (SF-12 Mental) (people aged <75 years) at 1 year Scale: 0-100 (higher is better)	5.2
Health-related quality of life (SF-36 Mental) (people aged <75 years) at 1 year Scale: 0-100 (higher is better)	5.5

## Appendix F: GRADE tables

**Table 26: Clinical evidence profile: ticagrelor + ASA versus clopidogrel + ASA**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	ticagrelor + ASA	clopidogrel + ASA	Relative (95% CI)	Absolute		
<b>All-cause mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
5	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>5</sup>	none	190/9940 (1.9 %)	224/9872 (2.3 %)	see comment <sup>6</sup>	4 fewer per 1000 (from 7 fewer to 0 more)	⊕○○○ VERY LOW	CRITICAL
<b>All-cause mortality - STEMI + revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	5/320 (1.6%)	10/310 (3.2%)	RR 0.48 (0.17 to 1.39)	17 fewer per 1000 (from 27 fewer to 13 more)	⊕○○○ VERY LOW	CRITICAL
<b>(HR) All-cause mortality - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.64 (0.44 to 0.93)	- <sup>3</sup>	⊕⊕○○ LOW	CRITICAL
<b>(HR) All-cause mortality - UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.84 (0.63 to 1.12)	- <sup>3</sup>	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality - ACS with/without revascularisation (follow-up 1 year)</b>												
6	randomised	serious <sup>1</sup>	no serious	no serious	serious <sup>2</sup>	none	425/10244	543/10199	RR 0.78 (0.69	12 fewer per 1000 (from 6 fewer to 17	⊕⊕○○	CRITICAL

	trials		inconsistency	indirectness			(4.1%)	(5.3%)	to 0.88)	fewer)	LOW	
<b>All-cause mortality - STEMI + revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	182/4102 (4.4%)	229/4140 (5.5%)	RR 0.8 (0.66 to 0.97)	11 fewer per 1000 (from 2 fewer to 19 fewer)	⊕⊕⊕ LOW	CRITICAL
<b>(HR) All-cause mortality - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.75 (0.53 to 1.06)	<sup>-3</sup>	⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) All-cause mortality - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.73 (0.57 to 0.93)	<sup>-3</sup>	⊕⊕⊕ VERY LOW	CRITICAL
<b>Cardiac mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	10/575 (1.7%)	9/568 (1.6%)	RR 1.1 (0.45 to 2.69)	2 more per 1000 (from 9 fewer to 27 more)	⊕⊕⊕ VERY LOW	CRITICAL
<b>Cardiac mortality - STEMI + revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	4/241 (1.7%)	7/241 (2.9%)	RR 0.57 (0.17 to 1.92)	12 fewer per 1000 (from 24 fewer to 27 more)	⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) Cardiac mortality - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.67 (0.43 to 1.04)	<sup>-3</sup>	⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) Cardiac mortality - UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.84 (0.62 to 1.12)	<sup>-3</sup>	⊕⊕⊕ VERY LOW	CRITICAL

	trials	serious <sup>1</sup>	inconsistency	indirectness					to 1.14)		VERY LOW	
<b>Cardiac mortality - ACS with/without revascularisation (follow-up 1 year)</b>												
6	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	374/10319 (3.6%)	479/10392 (4.6%)	RR 0.78 (0.69 to 0.89)	10 fewer per 1000 (from 5 fewer to 14 fewer)	⊕⊕⊕ LOW	CRITICAL
<b>Cardiac mortality - STEMI + revascularisation (follow-up 1 year)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	165/4237 (3.9%)	210/4393 (4.8%)	RR 0.81 (0.66 to 0.98)	9 fewer per 1000 (from 1 fewer to 16 fewer)	⊕⊕⊕ LOW	CRITICAL
<b>(HR) Cardiac mortality - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.76 (0.52 to 1.11)	- <sup>3</sup>	⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) Cardiac mortality - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.75 (0.58 to 0.97)	- <sup>3</sup>	⊕⊕⊕ VERY LOW	CRITICAL
<b>Re-infarction - ACS with/without revascularisation (follow-up 30 days)</b>												
6	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	134/9942 (1.3%)	193/9876 (2%)	RR 0.69 (0.56 to 0.86)	6 fewer per 1000 (from 3 fewer to 9 fewer)	⊕⊕⊕ LOW	CRITICAL
<b>Re-infarction - STEMI + revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	6/373 (1.6%)	17/363 (4.7%)	RR 0.37 (0.15 to 0.89)	30 fewer per 1000 (from 5 fewer to 40 fewer)	⊕⊕⊕ LOW	CRITICAL
<b>(HR) Re-infarction - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												

1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.86 (0.63 to 1.17)	- <sup>3</sup>	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) Re-infarction - UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.89 (0.68 to 1.16)	- <sup>3</sup>	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>Re-infarction - ACS with/without revascularisation (follow-up 1 year)</b>												
8	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	541/10529 (5.1%)	651/10600 (6.1%)	RR 0.83 (0.74 to 0.93)	10 fewer per 1000 (from 4 fewer to 16 fewer)	⊕⊕⊕⊕ LOW	CRITICAL
<b>Re-infarction - STEMI + revascularisation (follow-up 1 year)</b>												
5	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	163/4387 (3.7%)	223/4541 (4.9%)	RR 0.75 (0.61 to 0.91)	12 fewer per 1000 (from 4 fewer to 19 fewer)	⊕⊕⊕⊕ LOW	CRITICAL
<b>(HR) Re-infarction - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.90 (0.68 to 1.19)	- <sup>3</sup>	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>(HR) Re-infarction - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 0.94 (0.75 to 1.18)	- <sup>3</sup>	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>Major bleeding - ACS with/without revascularisation (follow-up 30 days)</b>												
6	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	675/9949 (6.8%)	669/9883 (6.8%)	see comment <sup>6</sup>	0 fewer per 1000 (from 7 fewer to 7 more)	⊕⊕⊕⊕ MODERATE	CRITICAL
<b>Major bleeding - STEMI + revascularisation (follow-up 30 days)</b>												

4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>5</sup>	none	7/380 (1.8%)	5/370 (1.4%)	see comment <sup>6</sup>	5 more per 1000 (from 8 fewer to 43 more)	⊕○○○ VERY LOW	CRITICAL
<b>(HR) Major bleeding - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 1.14 (0.84 to 1.56)	- <sup>3</sup>	⊕○○○ VERY LOW	CRITICAL
<b>(HR) Major bleeding - UA/NSTEMI + no revascularisation</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 1.18 (0.91 to 1.53)	- <sup>3</sup>	⊕○○○ VERY LOW	CRITICAL
<b>Major bleeding - ACS with/without revascularisation (follow-up 1 year)</b>												
6	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	1011/10157 (10%)	968/10049 (9.6%)	RR 1.04 (0.96 to 1.13)	4 more per 1000 (from 4 fewer to 13 more)	⊕⊕⊕○ MODERATE	CRITICAL
<b>Major bleeding - STEMI + revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>1</sup>	serious <sup>4</sup>	no serious indirectness	no serious imprecision	none	308/4230 (7.3%)	321/4203 (7.6%)	RR 0.96 (0.83 to 1.12)	2 fewer per 1000 (from 13 fewer to 9 more)	⊕⊕○○ LOW	CRITICAL
<b>(HR) Major bleeding - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 1.10 (0.84 to 1.44)	- <sup>3</sup>	⊕○○○ VERY LOW	CRITICAL
<b>(HR) Major bleeding - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	-	-	HR 1.05 (0.88 to 1.25)	- <sup>3</sup>	⊕○○○ VERY LOW	CRITICAL
<b>Minor bleeding - ACS with/without revascularisation (follow-up 30 days)</b>												

6	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	61/765 (8%)	40/746 (5.4%)	RR 1.49 (1.02 to 2.16)	26 more per 1000 (from 1 more to 62 more)	⊕⊕○○ LOW	CRITICAL
<b>Minor bleeding - STEMI + revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	50/380 (13.2%)	36/370 (9.7%)	RR 1.36 (0.91 to 2.02)	35 more per 1000 (from 9 fewer to 99 more)	⊕⊕○○ LOW	CRITICAL
<b>Minor bleeding - ACS with/without revascularisation (follow-up 1 year)</b>												
6	randomised trials	serious <sup>1</sup>	serious <sup>4</sup>	no serious indirectness	serious <sup>2</sup>	none	498/10157 (4.9%)	382/10227 (3.7%)	RR 1.34 (1.18 to 1.53)	13 more per 1000 (from 7 more to 20 more)	⊕○○○ VERY LOW	CRITICAL
<b>Minor bleeding - STEMI + revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	198/4080 (4.9%)	158/4233 (3.7%)	RR 1.37 (1.12 to 1.68)	14 more per 1000 (from 4 more to 25 more)	⊕⊕○○ LOW	CRITICAL
<b>Bleeding (type not specified) – UA/NSTEMI with revascularisation at 1 year (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	14/124 (11.3%)	4/120 (3.3%)	RR 3.39 (1.15 to 10)	80 more per 1000 (from 5 more to 300 more)	⊕⊕○○ LOW	CRITICAL
<b>Stroke (type not specified) - ACS with/without revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>5</sup>	none	61/9732 (0.63%)	46/9668 (0.48%)	see comment <sup>6</sup>	2 more per 1000 (from 0 fewer to 4 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Stroke (type not specified) - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>5</sup>	none	2/163 (1.2%)	2/155 (1.3%)	see comment <sup>6</sup>	0 fewer per 1000 (from 11 fewer to 77 more)	⊕○○○ VERY LOW	IMPORTANT

<b>(HR) Stroke (type not specified) - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	-	-	HR 1.14 (0.54 to 2.41)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
<b>(HR) Stroke (type not specified) - UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	-	-	HR 0.84 (0.50 to 1.41)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
<b>Stroke (type not specified) - ACS with/without revascularisation (follow-up 1 year)</b>												
6	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	143/10319 (1.4%)	127/10392 (1.2%)	RR 1.13 (0.89 to 1.43)	2 more per 1000 (from 1 fewer to 5 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Stroke (type not specified) - STEMI + revascularisation (follow-up 1 year)</b>												
4	randomised trials	serious <sup>1</sup>	serious <sup>4</sup>	no serious indirectness	no serious imprecision	none	59/4237 (1.4%)	47/4393 (1.1%)	RR 1.29 (0.88 to 1.9)	3 more per 1000 (from 1 fewer to 10 more)	⊕⊕○○ LOW	IMPORTANT
<b>(HR) Stroke (type not specified) - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	-	-	HR 1.18 (0.60 to 2.32)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
<b>(HR) Stroke (type not specified) - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	-	-	HR 0.92 (0.58 to 1.46)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
<b>Need for revascularisation - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	2/226 (0.88%)	8/216 (3.7%)	Peto OR 0.29 (0.08 to 1)	26 fewer per 1000 (from 34 fewer to 0 more)	⊕⊕○○ LOW	IMPORTANT



<b>Need for revascularisation - ACS with/without revascularisation (follow-up 1 year)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	11/571 (1.9%)	47/689 (6.8%)	RR 0.31 (0.16 to 0.6)	47 fewer per 1000 (from 27 fewer to 57 fewer)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Need for revascularisation - STEMI + revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	8/511 (1.6%)	42/629 (6.7%)	RR 0.27 (0.13 to 0.57)	49 fewer per 1000 (from 29 fewer to 58 fewer)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Stent thrombosis (type not specified) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	0/87 (0%)	4/87 (4.6%)	Peto OR 0.13 (0.02 to 0.94)	40 fewer per 1000 (from 3 fewer to 45 fewer)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (probable or definite) - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	118/5640 (2.1%)	158/5649 (2.8%)	RR 0.75 (0.59 to 0.95)	7 fewer per 1000 (from 1 fewer to 11 fewer)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (probable or definite) - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	73/3752 (1.9%)	101/3792 (2.7%)	RR 0.73 (0.54 to 0.98)	7 fewer per 1000 (from 1 fewer to 12 fewer)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (type not specified)- ACS with/without revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>5</sup>	none	0/485 (0%)	7/601 (1.2%)	see comment <sup>6</sup>	10 fewer per 1000 (from 3 fewer to 11 fewer)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (type not specified) - STEMI + revascularisation (follow-up 1 year)</b>												
2	randomised	serious <sup>1</sup>	no serious	no serious	very serious <sup>2</sup>	none	0/324	3/320	see comment <sup>6</sup>	8 fewer per 1000 (from 9 fewer to 16	⊕○○○	IMPORTANT

	trials		inconsistency	indirectness			(0%)	(0.94%)		more)	VERY LOW	
<b>Stent thrombosis (type not specified) - NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	0/161 (0%)	4/281 (1.4%)	Peto OR 0.21 (0.03 to 1.58)	11 fewer per 1000 (from 14 fewer to 8 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Breathing adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	20/163 (12.3%)	8/155 (5.2%)	RR 2.39 (1.09 to 5.27)	72 more per 1000 (from 5 more to 220 more)	⊕⊕○○ LOW	IMPORTANT
<b>Breathing adverse effects - ACS with/without revascularisation (follow-up 1 year)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	1292/9636 (13.4%)	730/9586 (7.6%)	RR 1.76 (1.62 to 1.92)	58 more per 1000 (from 47 more to 70 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Breathing adverse effects - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	468/3719 (12.6%)	314/3752 (8.4%)	RR 1.5 (1.31 to 1.72)	42 more per 1000 (from 26 more to 60 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Bradycardic adverse effects - ACS with/without revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	31/1148 (2.7%)	23/1161 (2%)	RR 1.36 (0.8 to 2.29)	7 more per 1000 (from 4 fewer to 26 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Bradycardic adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	10/163 (6.1%)	6/155 (3.9%)	RR 1.6 (0.62 to 4.1)	23 more per 1000 (from 15 fewer to 120 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Bradycardic adverse effects - ACS with/without revascularisation (follow-up 1 year)</b>												

3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	503/9760 (5.2%)	460/9706 (4.7%)	RR 1.09 (0.96 to 1.23)	4 more per 1000 (from 2 fewer to 11 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Bradycardic adverse effects - STEMI + revascularisation (follow-up 1 year)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	224/3843 (5.8%)	217/3872 (5.6%)	RR 1.04 (0.87 to 1.25)	2 more per 1000 (from 7 fewer to 14 more)	⊕⊕○○ LOW	IMPORTANT
<b>Other adverse effects - ACS with/without revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	45/214 (21%)	34/204 (16.7%)	RR 1.26 (0.85 to 1.88)	43 more per 1000 (from 25 fewer to 147 more)	⊕⊕○○ LOW	IMPORTANT
<b>Other adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	30/163 (18.4%)	25/155 (16.1%)	RR 1.14 (0.7 to 1.85)	23 more per 1000 (from 48 fewer to 137 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Other adverse effects - ACS with/without revascularisation (follow-up 1 year)</b>												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	499/9696 (5.1%)	487/9646 (5%)	RR 1.02 (0.94 to 1.11)	1 more per 1000 (from 3 fewer to 6 more)	⊕⊕⊕○ MODERATE	IMPORTANT
<b>Other adverse effects - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	77/3719 (2.1%)	62/3752 (1.7%)	RR 1.25 (0.9 to 1.75)	4 more per 1000 (from 2 fewer to 12 more)	⊕⊕○○ LOW	IMPORTANT
<b>Unplanned urgent readmission (rehospitalisation) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	2/76 (2.6%)	4/68 (5.9%)	RR 0.45 (0.08 to 2.37)	32 fewer per 1000 (from 54 fewer to 81 more)	⊕○○○ VERY LOW	IMPORTANT

- <sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs  
<sup>3</sup> Absolute effects could not be calculated as event rates were not reported  
<sup>4</sup> Downgraded by 1 because of heterogeneity, I<sup>2</sup> > 50%, p = > 0.04, unexplained by subgroup analysis  
<sup>5</sup> Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%- no imprecision  
<sup>6</sup> No relative effect due to 0 events. Risk difference calculated in Review Manager

**Table 27: Clinical evidence profile: prasugrel + ASA versus clopidogrel + ASA**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	prasugrel + ASA	clopidogrel + ASA	Relative (95% CI)	Absolute		
<b>All-cause mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	70/6574 (1.1%)	91/6568 (1.4%)	RR 0.77 (0.56 to 1.05)	3 fewer per 1000 (from 6 fewer to 1 more)	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	29/1800 (1.6%)	46/1796 (2.6%)	RR 0.63 (0.40 to 1.00)	9 fewer per 1000 (from 15 fewer to 0 more)	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality – UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	39/4663 (0.84%)	44/4663 (0.94%)	RR 0.89 (0.58 to 1.36)	1 fewer per 1000 (from 4 fewer to 3 more)	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality - ACS with/without revascularisation (follow-up 1 year)</b>												

3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	226/7564 (3%)	226/7562 (3%)	RR 1 (0.83 to 1.2)	0 fewer per 1000 (from 5 fewer to 6 more)	⊕⊕⊕○ MODERATE	CRITICAL
<b>All-cause mortality - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	58/1769 (3.3%)	76/1765 (4.3%)	RR 0.76 (0.54 to 1.06)	10 fewer per 1000 (from 20 fewer to 3 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	60/6525 (0.92%)	80/6524 (1.2%)	RR 0.75 (0.54 to 1.05)	3 fewer per 1000 (from 6 fewer to 1 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	25/1769 (1.4%)	41/1765 (2.3%)	RR 0.61 (0.37 to 1)	9 fewer per 1000 (from 15 fewer to 0 more)	⊕⊕○○ LOW	IMPORTANT
<b>Cardiac mortality – UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	35/4663 (0.75%)	38/4663 (0.81%)	RR 0.92 (0.58 to 1.46)	1 fewer per 1000 (from 3 fewer to 4 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - ACS with/without revascularisation (follow-up 1 year)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	159/7526 (2.1%)	181/7525 (2.4%)	RR 0.88 (0.71 to 1.09)	3 fewer per 1000 (from 7 fewer to 2 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	43/1769 (2.4%)	58/1765 (3.3%)	RR 0.74 (0.5 to 1.09)	9 fewer per 1000 (from 16 fewer to 3 more)	⊕⊕○○ LOW	CRITICAL

Cardiac mortality - UA/NSTEMI + revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	90/5044 (1.8%)	92/5030 (1.8%)	RR 0.98 (0.73 to 1.3)	0 fewer per 1000 (from 5 fewer to 5 more)	⊕○○○ VERY LOW	CRITICAL
(HR) Cardiac mortality - UA/NSTEMI + no revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	-	-	HR 1.00 (0.78 to 1.28)	- <sup>3</sup>	⊕○○○ VERY LOW	CRITICAL
Re-infarction - ACS with/without revascularisation (follow-up 30 days)												
4	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>7</sup>	none	161/6556 (2.5%)	201/6555 (3.1%)	see comment <sup>8</sup>	6 fewer per 1000 (from 1 fewer to 11 fewer)	⊕○○○ VERY LOW	CRITICAL
Re-infarction - STEMI + revascularisation (follow-up 30 days)												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>7</sup>	none	87/1800 (4.8%)	123/1796 (6.8%)	see comment <sup>8</sup>	20 fewer per 1000 (from 5 fewer to 32 fewer)	⊕⊕○○ LOW	CRITICAL
Re-infarction - UA/NSTEMI + no revascularisation (follow-up 30 days)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	74/4663 (1.6%)	78/4663 (1.7%)	RR 0.95 (0.69 to 1.3)	1 fewer per 1000 (from 5 fewer to 5 more)	⊕⊕○○ LOW	CRITICAL
Re-infarction - ACS with/without revascularisation (follow-up 1 year)												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	499/7526 (6.6%)	652/7525 (8.7%)	RR 0.76 (0.68 to 0.85)	21 fewer per 1000 (from 13 fewer to 28 fewer)	⊕⊕○○ LOW	CRITICAL
Re-infarction - STEMI + revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	119/1769	157/1765	RR 0.76 (0.6 to 1.0)	21 fewer per 1000 (from 4 fewer to 36 fewer)	⊕⊕○○ LOW	CRITICAL

	trials		inconsistency	indirectness			(6.7%)	(8.9%)	0.95)	fewer)	LOW	
<b>Re-infarction - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	366/5044 (7.3%)	476/5030 (9.5%)	RR 0.77 (0.67 to 0.87)	22 fewer per 1000 (from 12 fewer to 31 fewer)	⊕⊕⊕⊕ LOW	CRITICAL
<b>(HR) Re-infarction - UA/NSTEMI + no revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	-	-	HR 0.97 (0.7 to 1.21)	- <sup>3</sup>	⊕⊕⊕⊕ LOW	CRITICAL
<b>Major bleeding - ACS with/without revascularisation (follow-up 30 days)</b>												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>7</sup>	none	24/6503 (0.37%)	29/6491 (0.45%)	see comment <sup>8</sup>	1 fewer per 1000 (from 2 fewer to 2 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>Major bleeding - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	17/1769 (0.96%)	23/1765 (1.3%)	RR 0.74 (0.4 to 1.38)	3 fewer per 1000 (from 8 fewer to 5 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>Major bleeding – UA/NSTEMI + no revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	7/4623 (0.15%)	6/4617 (0.13%)	RR 1.17 (0.39 to 3.46)	0 more per 1000 (from 1 fewer to 3 more)	⊕⊕⊕⊕ LOW	CRITICAL
<b>Bleeding (major and minor) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	1/31 (3.2%)	0/31 (0%)	Peto OR 7.39 (0.15 to 372.38)	-	⊕⊕⊕⊕ LOW	CRITICAL
<b>Major bleeding - ACS with/without revascularisation (follow-up 1 year)</b>												

2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	183/7454 (2.5%)	129/7446 (1.7%)	RR 1.42 (1.13 to 1.77)	7 more per 1000 (from 2 more to 13 more)	⊕⊕○○ LOW	CRITICAL
<b>Major bleeding - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	38/1769 (2.1%)	34/1765 (1.9%)	RR 1.12 (0.71 to 1.76)	2 more per 1000 (from 6 fewer to 15 more)	⊕○○○ VERY LOW	CRITICAL
<b>Major bleeding - UA/NSTEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	108/5001 (2.2%)	77/4980 (1.5%)	RR 1.4 (1.05 to 1.87)	6 more per 1000 (from 1 more to 13 more)	⊕⊕○○ LOW	CRITICAL
<b>Minor bleeding - ACS with/without revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	serious <sup>4</sup>	no serious indirectness	serious <sup>1</sup>	none	40/1880 (2.1%)	58/1874 (3.1%)	RR 0.69 (0.46 to 1.02)	10 fewer per 1000 (from 17 fewer to 1 more)	⊕○○○ VERY LOW	CRITICAL
<b>Minor bleeding - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	35/1769 (2%)	57/1765 (3.2%)	RR 0.61 (0.4 to 0.93)	13 fewer per 1000 (from 2 fewer to 19 fewer)	⊕⊕○○ LOW	CRITICAL
<b>Minor bleeding - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	16/713 (2.2%)	8/730 (1.1%)	RR 2.05 (0.88 to 4.75)	12 more per 1000 (from 1 fewer to 41 more)	⊕⊕○○ LOW	CRITICAL
<b>Health-related quality of life - UA/NSTEMI + no revascularisation (follow-up 1 year; measured with: EQ5D; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	2888	2876	-	MD 1 higher (0.22 to 1.78 higher)	⊕⊕⊕○ MODERATE	CRITICAL



Health-related quality of life - UA/NSTEMI + no revascularisation (follow-up 1 year; measured with: SAQ Physical; range of scores: 0-100; Better indicated by lower values)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	891	883	-	MD 1 higher (1.17 lower to 3.17 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Health-related quality of life - UA/NSTEMI + no revascularisation (follow-up 1 year; measured with: SF-12 Physical; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	891	883	-	MD 0.3 higher (0.7 lower to 1.3 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Health-related quality of life - UA/NSTEMI + no revascularisation (follow-up 1 year; measured with: SF-12 Mental; range of scores: 0-100; Better indicated by lower values)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	891	883	-	MD 0 higher (0.97 lower to 0.97 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Health-related quality of life - UA/NSTEMI + no revascularisation (follow-up 1 year; measured with: SF-36; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	891	883	-	MD 0.4 higher (0.64 lower to 1.44 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Stroke (type not specified) - ACS with/without revascularisation (follow-up 30 days)												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	20/6525 (0.31%)	28/6524 (0.43%)	RR 0.71 (0.4 to 1.27)	1 fewer per 1000 (from 3 fewer to 1 more)	⊕○○○ VERY LOW	IMPORTANT
Stroke (type not specified) - STEMI + revascularisation (follow-up 30 days)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	7/1769 (0.4%)	16/1765 (0.91%)	RR 0.44 (0.18 to 1.06)	5 fewer per 1000 (from 7 fewer to 1 more)	⊕⊕○○ LOW	IMPORTANT
Stroke (type not specified) - UA/NSTEMI + no revascularisation (follow-up 30 days)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	12/4663 (0.26%)	11/4663 (0.24%)	RR 1.09 (0.48 to 2.47)	0 more per 1000 (from 1 fewer to 3 more)	⊕⊕○○ LOW	IMPORTANT

Stroke (type not specified) - ACS with/without revascularisation (follow-up 1 year)												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	69/7564 (0.91%)	74/7562 (0.98%)	RR 0.93 (0.67 to 1.29)	1 fewer per 1000 (from 3 fewer to 3 more)	⊕○○○ VERY LOW	IMPORTANT
Stroke (type not specified) - STEMI + revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	26/1769 (1.5%)	25/1765 (1.4%)	RR 1.04 (0.6 to 1.79)	1 more per 1000 (from 6 fewer to 11 more)	⊕○○○ VERY LOW	IMPORTANT
Stroke (type not specified) - UA/NSTEMI + revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	49/5044 (0.97%)	46/5030 (0.91%)	RR 1.06 (0.71 to 1.59)	1 more per 1000 (from 3 fewer to 5 more)	⊕○○○ VERY LOW	IMPORTANT
(HR) Stroke (type not specified) in people aged <75 years - (UA/NSTEMI + no revascularisation) (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	-	-	HR 0.86 (0.50 to 1.48)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
Need for revascularisation - ACS with/without revascularisation (follow-up 30 days)												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>7</sup>	none	22/1862 (1.2%)	33/1861 (1.8%)	see comment <sup>8</sup>	6 fewer per 1000 (from 11 fewer to 2 more)	⊕○○○ VERY LOW	IMPORTANT
Need for revascularisation - STEMI + revascularisation (follow-up 30 days)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	22/1769 (1.2%)	33/1765 (1.9%)	RR 0.67 (0.39 to 1.14)	6 fewer per 1000 (from 11 fewer to 3 more)	⊕⊕○○ LOW	IMPORTANT
Need for revascularisation - ACS with/without revascularisation (follow-up 1 year)												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	158/6851	235/6832	RR 0.67 (0.55 to 1.14)	11 fewer per 1000 (from 6 fewer to 15 more)	⊕⊕○○ LOW	IMPORTANT

	trials		inconsistency	indirectness			(2.3%)	(3.4%)	0.82)	fewer)	LOW	
<b>Need for revascularisation - STEMI + revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	38/1769 (2.1%)	54/1765 (3.1%)	RR 0.7 (0.47 to 1.06)	9 fewer per 1000 (from 16 fewer to 2 more)	⊕⊕⊕⊕ LOW	IMPORTANT
<b>Stent thrombosis (definite or probable) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	19/1769 (1.1%)	39/1765 (2.2%)	RR 0.49 (0.28 to 0.84)	11 fewer per 1000 (from 4 fewer to 16 fewer)	⊕⊕⊕⊕ LOW	IMPORTANT
<b>Stent thrombosis (type not specified) - ACS with/without revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>7</sup>	none	0/142 (0%)	1/140 (0.71%)	see comment <sup>8</sup>	5 fewer per 1000 (from 7 fewer to 50 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Stent thrombosis (type not specified) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	0/31 (0%)	0/31 (0%)	- <sup>5</sup>	- <sup>5</sup>	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Stent thrombosis (definite or probable) - ACS with/without revascularisation (follow-up 1 year)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	73/7526 (0.97%)	156/7525 (2.1%)	RR 0.47 (0.35 to 0.62)	11 fewer per 1000 (from 8 fewer to 13 fewer)	⊕⊕⊕⊕ MODERATE	IMPORTANT
<b>Other adverse effects - ACS with/without revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	5/142 (3.5%)	7/140 (5%)	RR 0.7 (0.23 to 2.17)	15 fewer per 1000 (from 38 fewer to 59 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Other adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												

1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	1/31 (3.2%)	2/31 (6.5%)	RR 0.5 (0.05 to 5.23)	32 fewer per 1000 (from 61 fewer to 273 more)	⊕⊕⊕⊕ LOW	IMPORTANT
<b>Other adverse effects - ACS with/without revascularisation (follow-up 1 year)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	96/7454 (1.3%)	72/7446 (0.97%)	RR 1.13 (0.44 to 2.94)	1 more per 1000 (from 5 fewer to 19 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Unplanned urgent readmission - ACS with/without revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	1/93 (1.1%)	1/96 (1%)	RR 1.03 (0.07 to 16.26)	0 more per 1000 (from 10 fewer to 159 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Unplanned urgent readmission - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	70/713 (9.8%)	68/730 (9.3%)	RR 1.05 (0.77 to 1.45)	5 more per 1000 (from 21 fewer to 42 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

<sup>1</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

<sup>2</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>3</sup> Absolute effects could not be calculated as event rates were not reported

<sup>4</sup> Downgraded by 1 because of heterogeneity, I<sup>2</sup> = > 50%, p = > 0.04, unexplained by subgroup analysis

<sup>5</sup> Zero events in both arms. Relative risk and absolute effects could not be calculated.

<sup>6</sup> Absolute effects could not be calculated due to zero events in one of the arms

<sup>7</sup> Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%- no imprecision

<sup>8</sup> No relative effect due to 0 events. Risk difference calculated in Review Manager

**Table 28: Clinical evidence profile: ticagrelor + ASA versus prasugrel + ASA**

Quality assessment							No of patients		Effect		Quality	Importance
No of	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	ticagrelor +	prasugrel +	Relative	Absolute		

studies						considerations	ASA	ASA	(95% CI)			
<b>All-cause mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
6	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	20/830 (2.4%)	19/868 (2.2%)	see comment <sup>5</sup>	2 more per 1000 (from 9 fewer to 22 more)	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality - STEMI + revascularisation (follow-up 30 days)</b>												
4	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	18/674 (2.7%)	20/711 (2.8%)	RR 0.94 (0.51 to 1.75)	2 fewer per 1000 (from 14 fewer to 21 more)	⊕⊕○○ LOW	CRITICAL
<b>All-cause mortality - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	0/156 (0%)	1/157 (0.64%)	see comment <sup>5</sup>	4 fewer per 1000 (from 6 fewer to 45 more)	⊕○○○ VERY LOW	CRITICAL
<b>All-cause mortality - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious	none	90/2012 (4.5%)	73/2006 (3.6%)	RR 1.23 (0.91 to 1.66)	8 more per 1000 (from 4 fewer to 24 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - ACS with/without revascularisation (follow-up 30 days)</b>												
3	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	8/752 (1.1%)	9/791 (1.1%)	see comment <sup>5</sup>	1 fewer per 1000 (from 7 fewer to 16 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	8/596 (1.3%)	8/634 (1.3%)	RR 1.06 (0.4 to 2.82)	1 more per 1000 (from 8 fewer to 23 more)	⊕⊕○○ LOW	CRITICAL
<b>Cardiac mortality - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	0/156 (0%)	1/157 (0.64%)	see comment <sup>5</sup>	4 fewer per 1000 (from 6 fewer to 45 more)	⊕⊕○○ LOW	CRITICAL

Cardiac mortality - ACS with/without revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	63/2012 (3.1%)	59/2006 (2.9%)	RR 1.06 (0.75 to 1.51)	2 more per 1000 (from 7 fewer to 15 more)	⊕○○○ VERY LOW	CRITICAL
Re-infarction - ACS with/without revascularisation (follow-up 30 days)												
4	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	7/696 (1%)	10/734 (1.4%)	see comment <sup>5</sup>	3 fewer per 1000 (from 9 fewer to 12 more)	⊕○○○ VERY LOW	CRITICAL
Re-infarction - STEMI + revascularisation (follow-up 30 days)												
3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	8/646 (1.2%)	8/684 (1.2%)	see comment <sup>5</sup>	1 more per 1000 (from 7 fewer to 20 more)	⊕○○○ VERY LOW	CRITICAL
Re-infarction - UA/NSTEMI + revascularisation (follow-up 30 days)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	0/50 (0%)	1/50 (2%)	Peto 0.14 (0.00 to 6.82)	17 fewer per 1000 (from 20 fewer to 102 more)	⊕⊕○○ LOW	CRITICAL
Re-infarction - ACS with/without revascularisation (follow-up 1 year)												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	96/2012 (4.8%)	60/2006 (3%)	RR 1.6 (1.16 to 2.19)	18 more per 1000 (from 5 more to 36 more)	⊕⊕○○ LOW	CRITICAL
Major bleeding - ACS with/without revascularisation (follow-up 30 days)												
6	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	10/830 (1.2%)	14/868 (1.6%)	see comment <sup>5</sup>	4 fewer per 1000 (from 11 fewer to 10 more)	⊕○○○ VERY LOW	CRITICAL
Major bleeding - STEMI + revascularisation (follow-up 30 days)												
4	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	3/674 (0.45%)	6/711 (0.84%)	see comment <sup>5</sup>	4 fewer per 1000 (from 7 fewer to 9 more)	⊕○○○ VERY	CRITICAL

											LOW	
<b>Major bleeding - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	7/156 (4.5%)	8/157 (5.1%)	see comment <sup>5</sup>	6 fewer per 1000 (from 34 fewer to 69 more)	⊕○○○ VERY LOW	CRITICAL
<b>Major bleeding - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	very serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	95/1989 (4.8%)	80/1773 (4.5%)	RR 1.06 (0.79 to 1.42)	3 more per 1000 (from 9 fewer to 19 more)	⊕○○○ VERY LOW	CRITICAL
<b>Minor bleeding - STEMI + revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	30/674 (4.5%)	25/711 (3.5%)	RR 1.25 (0.75 to 2.09)	9 more per 1000 (from 9 fewer to 38 more)	⊕○○○ VERY LOW	CRITICAL
<b>Stroke (type not specified) - ACS with/without revascularisation (follow-up 30 days)</b>												
4	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	1/777 (0.13%)	3/816 (0.37%)	see comment <sup>5</sup>	2 fewer per 1000 (from 3 fewer to 6 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Stroke (type not specified) - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	1/621 (0.16%)	2/659 (0.3%)	see comment <sup>5</sup>	1 fewer per 1000 (from 3 fewer to 13 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Stroke (type not specified) - UA/NSTEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>4</sup>	none	0/156 (0%)	1/157 (0.64%)	see comment <sup>5</sup>	5 fewer per 1000 (from 6 fewer to 36 more)	⊕⊕○○ LOW	IMPORTANT
<b>Stroke (any type) - ACS with/without revascularisation (follow-up 1 year)</b>												

1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	22/2012 (1.1%)	19/2006 (0.95%)	RR 1.15 (0.63 to 2.13)	2 more per 1000 (from 4 fewer to 11 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Need for revascularisation – STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	7/596 (1.2%)	9/634 (1.4%)	RR 0.83 (0.31 to 2.21)	2 fewer per 1000 (from 10 fewer to 17 more)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (definite) - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	5/596 (0.84%)	3/634 (0.47%)	RR 1.77 (0.43 to 7.39)	4 more per 1000 (from 3 fewer to 30 more)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (type not specified) - STEMI + revascularisation (follow-up 30 days)</b>												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	0/50 (0%)	1/50 (2%)	Peto OR 0.14 (0 to 6.82)	17 fewer per 1000 (from 20 fewer to 102 more)	⊕⊕○○ LOW	IMPORTANT
<b>Stent thrombosis (definite or probable) - ACS with/without revascularisation (follow-up 1 year)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	26/2012 (1.3%)	20/2006 (1%)	RR 1.30 (0.73 to 2.31)	3 more per 1000 (from 3 fewer to 13 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Breathing adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	5/25 (20%)	0/25 (0%)	Peto OR 8.83 (1.42 to 54.99)	- <sup>3</sup>	⊕⊕○○ LOW	IMPORTANT
<b>Bradycardic adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												
1	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	1/25 (4%)	0/25 (0%)	Peto OR 7.39 (0.15 to 372.38)	- <sup>3</sup>	⊕○○○ VERY LOW	IMPORTANT
<b>Other adverse effects - STEMI + revascularisation (follow-up 30 days)</b>												



3	randomised trials	serious <sup>2</sup>	no serious inconsistency	no serious indirectness	very serious <sup>1</sup>	none	7/70 (10%)	4/69 (5.8%)	RR 1.59 (0.53 to 4.74)	34 more per 1000 (from 27 fewer to 217 more)	⊕○○○ VERY LOW	IMPORTANT
---	-------------------	----------------------	--------------------------	-------------------------	---------------------------	------	------------	-------------	------------------------	--	------------------	-----------

<sup>1</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

<sup>2</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias


<sup>3</sup> Absolute effects could not be calculated due to zero events in one of the arms

<sup>4</sup> Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%- no imprecision

<sup>5</sup> No relative effect due to 0 events. Risk difference calculated in Review Manager

## Appendix G: Health economic evidence selection

Figure 96: Flow chart of health economic study selection for the guideline



\* Non-relevant population, intervention, comparison, design or setting; non-English language

Review A = dual-antiplatelet therapy; Review B = early invasive investigation for UA/NSTEMI; Review C = antithrombins in UA/NSTEMI; Review D = bivalirudin in STEMI; Review E = multi-vessel PCI; Review F = drug-eluting stents; Review G = combination of antiplatelets and anticoagulants; Review H = beta-blocker therapy.

# Appendix H: Health economic evidence tables

## H.1 Ticagrelor + aspirin versus prasugrel + aspirin versus clopidogrel + aspirin

Study	Abdel-Qadir 2015 <sup>2</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p><b>Economic analysis:</b> CUA (health outcome: QALYs)</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> Markov cohort state transition model with 1 month cycles. Health states included well post-ACS on DAPT, single antiplatelet therapy at end of 12 months, major bleed, repeat ACS, congestive heart failure and death. It was assumed everyone had a successful PCI procedure. Baseline and treatment effects obtained from data collected in 3 RCTs (DISPERSE-2, PLATO)</p>	<p><b>Population:</b> ACS (STEMI and NSTEMI) patients who have undergone a PCI.</p> <p><b>Cohort settings:</b> Start age: 62 Male: 61%</p> <p><b>Intervention 1:</b> Clopidogrel + aspirin daily for 12 months (dose not reported)</p> <p><b>Intervention 2:</b> Prasugrel + aspirin daily for 12 months (dose not reported)</p> <p><b>Intervention 3:</b> Ticagrelor + aspirin daily for 12 months (dose not reported)</p>	<p><b>Total costs (mean per patient):</b> Intervention 1: £22,325 Intervention 2: £22,787 Intervention 3: £22,915 Incremental (2-1): £462 (95% CI: NR; p=NR) Incremental (3-2): £128 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2012 Canadian dollars (presented here as 2012 UK pounds<sup>(b)</sup>)</p> <p><b>Cost components incorporated:</b> Drug costs, hospitalisation, major bleed, consultations with an emergency physician, a cardiologist and an interventional cardiologist, angiography and</p>	<p><b>QALYs (mean per patient):</b> Intervention 1: 7.41 Intervention 2: 7.43 Intervention 3: 7.50 Incremental (2-1): 0.02 (95% CI: NR; p=NR) Incremental (3-2): 0.07 (95% CI: NR; p=NR)</p>	<p><b>ICERs<sup>(c)</sup></b> Intervention 3 vs 1: £6,556 per QALY gained (pa) Intervention 2: extendedly dominated</p> <p>Probability most cost-effective option at £11,275/£16,912 threshold: Intervention 1: 17%/8% Intervention 2: 9%/8% Intervention 3: 74%/84%</p> <p><b>Analysis of uncertainty:</b> A wide range of sensitivity analyses around baseline risks, hazard ratios, costs, utilities and all other inputs were undertaken. Ticagrelor remained the most cost-effective option throughout the sensitivity analyses. However, when the hazard ratio for death was greater than 0.89 the ICER associated with ticagrelor compared to clopidogrel exceeded £28,187.</p>

<p>and TRITON-TIMI 38).  <b>Perspective:</b> Canadian health perspective (Ontario Ministry of Health)  <b>Time horizon:</b> Lifetime  <b>Treatment effect duration:</b><sup>(a)</sup> 1 year  <b>Discounting:</b> Costs: 5%; Outcomes: 5%</p>	<p>percutaneous coronary intervention, transthoracic echocardiogram and follow-up appointments.</p>		
<b>Data sources</b>			
<p><b>Health outcomes:</b> Baseline event rates were derived from the weighted mean of the event rates in the clopidogrel arm of the TRITON–TIMI 38, DISPERSE-2 and PLATO RCTs. The incidence of events among patients given prasugrel or ticagrelor was modelled by multiplying the baseline rate in the clopidogrel group with the corresponding hazard ratio for each event as determined from each agent’s RCT data. Rates of minor bleeding and other minor adverse effects, as well as rates of discontinuation, were determined directly for each agent with the use the TRITON-TIMI 38 and PLATO trial data. Survival beyond 12 months was based on age and sex specific Ontario life tables.</p> <p><b>Quality-of-life weights:</b> Utilities from published literature, tariff unclear and population collected in unclear. Quality of life was independent of intervention used but varied by event experienced. <b>Cost sources:</b> Ontario Drug Benefits Formulary, Ontario Case Costing Initiative and Ontario Schedule of Benefits for Physicians.</p>			
<b>Comments</b>			
<p><b>Source of funding:</b> NR. <b>Limitations:</b> 2012 Canadian healthcare perspective may not reflect the current UK context, the cost of clopidogrel used in the model is higher than the cost in the UK, discount rate used not in line with NICE reference case methods and unclear if methods used to derive utilities are consistent with NICE reference case methods. Health states incorporated in the model were different from other models in this area (it does not include stroke as a health state which is a limitation), baseline risks were obtained by calculating the weighted mean of the event rates in the clopidogrel arm of the 3 international trials and the average age used was lower than the UK average. It is unclear where information on resource use was obtained and the analysis does not reflect full body of available evidence for this area as identified in clinical review (based on 3 trials).</p>			
<p><b>Overall applicability:</b><sup>(d)</sup> Partially applicable      <b>Overall quality:</b><sup>(e)</sup> Potentially serious limitations</p>			

1 Abbreviations: ACS = acute coronary syndromes; 95% CI= 95% confidence interval; CUA= cost–utility analysis; DAPT = dual antiplatelet therapy; EQ-5D= Euroqol 5 dimensions  
2 (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER= incremental cost-effectiveness ratio; NR= not reported; pa= probabilistic analysis; QALYs=  
3 quality-adjusted life years; RCT = randomised controlled trial  
4 (a) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a  
5 difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.  
6 (b) Converted using 2012 purchasing power parities<sup>173</sup>  
7 (c) When comparing multiple comparators, a fully incremental approach is adopted that compares the treatments sequentially in rank order of effectiveness (or cost). Incremental  
8 cost-effectiveness ratios are estimated by dividing the incremental cost by the incremental effect for each consecutively more effective comparator.  
9 (d) Directly applicable / Partially applicable / Not applicable  
10 (e) Minor limitations / Potentially serious limitations / Very serious limitations

Study	Wisloff 2015 <sup>301</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p><b>Economic analysis:</b> CUA was conducted as part of sensitivity analysis (QALYs); primary analysis used life years</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> Markov cohort state transition model with half year cycles. Health states included PCI, revascularisation, MI, bleeding and death. Efficacy data of prasugrel and ticagrelor compared with clopidogrel was based on the PLATO and TRITON-TIMI-38 RCTs.</p> <p><b>Perspective:</b> Norwegian healthcare perspective</p> <p><b>Time horizon:</b> Lifetime</p> <p><b>Treatment effect duration:</b><sup>(a)</sup> 1 year</p> <p><b>Discounting:</b> Costs: 4%; Outcomes: 4%</p>	<p><b>Population:</b> ACS patients who have undergone a PCI.</p> <p><b>Cohort settings:</b> Start age: 60 Male: NR</p> <p><b>Intervention 1:</b> Clopidogrel 75mg + aspirin daily for 12 months (300mg clopidogrel loading dose)</p> <p><b>Intervention 2:</b> Prasugrel 10mg + aspirin daily for 12 months (60mg prasugrel loading dose)</p> <p><b>Intervention 3:</b> Ticagrelor 90mg twice daily + aspirin daily for 12 months (180mg ticagrelor loading dose)</p>	<p><b>Total costs (mean per patient):</b> Intervention 1: £12,526 Intervention 2: £14,236 Intervention 3: £16,099 Incremental (2–1): £1,710 (95% CI: NR; p=NR) Incremental (3–2): £1,863 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2014 Norwegian kroner (presented here as 2014 UK pounds<sup>(b)</sup>)</p> <p><b>Cost components incorporated:</b> Drug costs, costs of treatment (MI, revascularisation and bleeding), GP visits and laboratory test costs.</p>	<p><b>QALYs (mean per patient):</b> Intervention 1: 9.54 Intervention 2: 9.82 Intervention 3: 10.12 Incremental (2–1): 0.28 (95% CI: NR; p=NR) Incremental (3–2): 0.30 (95% CI: NR; p=NR)</p> <p><b>Life years (mean per patient):</b> Intervention 1: 11.96 Intervention 2: 12.32 Intervention 3: 12.70 Incremental (2–1): 0.36 (95% CI: NR; p=NR) Incremental (3–2): 0.38 (95% CI: NR; p=NR)</p>	<p><b>ICERs<sup>(c)</sup></b> Intervention 3 vs 2: £4,903 per life year gained (pa) 95% CI: NR Probability Intervention 3 cost effective (£31,428 threshold): 76%</p> <p>Intervention 2 vs 1: £4,750 per life year gained (pa) 95% CI: NR Probability Intervention 2 cost effective (£31,428 threshold): 27%</p> <p>Intervention 3 vs 2: £6,210 per QALY gained (da) 95% CI: NR Probability Intervention 3 cost effective: NR</p> <p>Intervention 2 vs 1: £6,107 per QALY gained (da) 95% CI: NR Probability Intervention 2 cost effective: NR</p> <p><b>Analysis of uncertainty:</b> A range of scenario analyses were conducted for the results in relation to cost per LYG and not the cost per QALY results. All analyses showed that ticagrelor remained the most cost-effective option in relation to LYG.</p>

**Data sources**

**Health outcomes:** Does not explain where the estimates of baseline outcomes were derived but it can be assumed it was from the PLATO and TRITON-TIMI 38 trials. The incidence of events among patients given prasugrel or ticagrelor was modelled by applying the HR of ticagrelor and prasugrel from the PLATO and TRITON-TIMI-38 trials to the clopidogrel arm. **Quality-of-life weights:** EQ-5D utility from published data, tariff used not stated and population collected in unclear. Quality of life was independent of intervention used but varied by event experienced. **Cost sources:** Norwegian Medicines Agency and published sources.

**Comments**

**Source of funding:** Oslo University Hospital. **Limitations:** 2014 Norwegian healthcare perspective may not reflect the current UK context, the cost of clopidogrel used in the model is higher than the cost in the UK, EQ-5D used but unclear if fully in line with NICE reference case methods as tariff not reported and population collected in not stated. Health states incorporated in the model were different from other models in this area (it does not include stroke as a health state which is a limitation), did not give details of how baseline risks were derived, average age used in the model is lower than UK average, it is unclear where resource use was obtained, only conducted sensitivity analyses on results related to life years and not QALYs. Analysis does not reflect full body of available evidence for this area as identified in clinical review (based on 2 trials).

**Overall applicability:**<sup>(d)</sup> Partially applicable      **Overall quality:**<sup>(e)</sup> Potentially serious limitations

Abbreviations: ACS = acute coronary syndromes; CEA= cost-effectiveness analysis; 95% CI= 95% confidence interval; CUA= cost-utility analysis; da= deterministic analysis; EQ-5D= Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER= incremental cost-effectiveness ratio; LYG = life years gained; MI = myocardial infarction; NR= not reported; pa= probabilistic analysis; QALYs= quality-adjusted life years; RCT = randomised controlled trial

- (a) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.
- (b) Converted using 2014 purchasing power parities<sup>173</sup>
- (c) When comparing multiple comparators, a fully incremental approach is adopted that compares the treatments sequentially in rank order of effectiveness (or cost). Incremental cost-effectiveness ratios are estimated by dividing the incremental cost by the incremental effect for each consecutively more effective comparator.
- (d) Directly applicable / Partially applicable / Not applicable
- (e) Minor limitations / Potentially serious limitations / Very serious limitations

**H.2 Ticagrelor + aspirin versus clopidogrel + aspirin**

14

Study	NICE TA236 2011 <sup>124(a)</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness

<p><b>Economic analysis:</b> CUA (health outcome: QALYs)</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> A one-year decision tree based on the data from the PLATO trial, with the following events: death from any cause, non-fatal stroke, non-fatal MI and no further event. This was followed by a Markov model for long term extrapolation, which included the following health states; no event, non-fatal MI, post MI, non-fatal stroke, post-stroke and dead. Non-fatal MI and non-fatal stroke were tunnel states to allow for worse prognosis in the first year. Bleeding was captured through decrements in utilities and additional costs applied within each health state. Treatment effects and resource use were based on data collected within PLATO RCT; adjustments were made to reflect UK practice where necessary.</p> <p><b>Perspective:</b> UK NHS</p>	<p><b>Population:</b> ACS patients (STEMI, NSTEMI and UA), including those managed medically or those with PCI or CABG</p> <p><b>Cohort settings:</b> Start age: 70 Male: 64.6%</p> <p><b>Intervention 1:</b> Clopidogrel 75mg + aspirin daily for 12 months (300-600mg clopidogrel loading dose)</p> <p><b>Intervention 2:</b> Ticagrelor 90mg twice daily + aspirin for 12 months (180mg ticagrelor loading dose)</p>	<p><b>Total costs (mean per patient):</b> <u>All ACS:</u> Intervention 1: £13,737 Intervention 2: £14,135 Incremental (2-1): £398 (95% CI: NR; p=NR)</p> <p><u>STEMI subgroup:</u> Intervention 1: £15,483 Intervention 2: £15,822 Incremental (2-1): £339 (95% CI: NR; p=NR)</p> <p><u>NSTEMI subgroup:</u> Intervention 1: £13,140 Intervention 2: £13,653 Incremental (2-1): £513 (95% CI: NR; p=NR)</p> <p><u>UA subgroup:</u> Intervention 1: £12,419 Intervention 2: £12,907 Incremental (2-1): £488 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2008/09 UK pounds</p>	<p><b>QALYs (mean per patient):</b> <u>All ACS:</u> Intervention 1: 6.275 Intervention 2: 6.382 Incremental (2-1): 0.107 (95% CI: NR; p=NR)</p> <p><u>STEMI subgroup:</u> Intervention 1: 7.567 Intervention 2: 7.687 Incremental (2-1): 0.120 (95% CI: NR; p=NR)</p> <p><u>NSTEMI subgroup:</u> Intervention 1: 5.345 Intervention 2: 5.443 Incremental (2-1): 0.098 (95% CI: NR; p=NR)</p> <p><u>UA subgroup:</u> Intervention 1: 7.079 Intervention 2: 7.170 Incremental (2-1): 0.091 (95% CI: NR; p=NR)</p>	<p><u>All ACS ICER:</u> £3,805 per QALY gained (pa) 95% CI: NR Probability Intervention 2 cost effective (£20K/£30K threshold): 99.9%/NR</p> <p><u>STEMI subgroup ICER:</u> £5,230 per QALY gained (da) 95% CI: NR Probability intervention 2 cost effective (£20K/£30K threshold): NR/NR</p> <p><u>NSTEMI subgroup ICER:</u> £2,825 per QALY gained (da) 95% CI: NR Probability intervention 2 cost effective (£20K/£30K threshold): NR/NR</p> <p><u>UA subgroup ICER:</u> £5,374 per QALY gained (da) 95% CI: NR Probability intervention 2 cost effective (£20K/£30K threshold): NR/NR</p> <p><b>Analysis of uncertainty:</b> A wide range of sensitivity analyses around event rates, hazard ratios, utilities and costs were undertaken. This showed that varying the parameters did not impact the conclusions apart from the cost of the 'no further event' health state. Setting the cost of this state in the ticagrelor + aspirin arm to its lowest resulted in ticagrelor + aspirin being dominant. When it was set to its</p>
---	---	---	---	---

<p><b>Time horizon:</b> Lifetime</p> <p><b>Treatment effect duration:</b><sup>(b)</sup> 1 year. The model assumed that the beneficial effect of ticagrelor does not continue beyond one year.</p> <p><b>Discounting:</b> Costs: 3.5%; Outcomes: 3.5%</p>	<p><b>Cost components incorporated:</b></p> <p>Drug costs (ticagrelor, clopidogrel and aspirin), hospitalisation, investigations, blood product and reoperations due to bleeding and drugs, event costs (stroke and MI).</p>	<p>lowest for the clopidogrel + aspirin arm the ICER was £21,000 per QALY gained.</p> <p>Different scenario analyses were conducted such as varying the discount rates and using published utility values rather than those derived from the PLATO trial, but they did not affect the results significantly.</p> <p><b>ICERs using alternative time horizons:</b></p> <table border="1"> <thead> <tr> <th></th> <th>20 yrs</th> <th>10 yrs</th> <th>5 yrs</th> <th>1 yr</th> </tr> </thead> <tbody> <tr> <td>All ACS</td> <td>£3,705</td> <td>£4,182</td> <td>£6,075</td> <td>£36,177</td> </tr> <tr> <td>STEMI</td> <td>£2,847</td> <td>£3,334</td> <td>£4,946</td> <td>£31,933</td> </tr> <tr> <td>NSTEMI</td> <td>£5,233</td> <td>£5,727</td> <td>£8,162</td> <td>£45,810</td> </tr> <tr> <td>UA</td> <td>£5,410</td> <td>£6,484</td> <td>£10,172</td> <td>£78,288</td> </tr> </tbody> </table>		20 yrs	10 yrs	5 yrs	1 yr	All ACS	£3,705	£4,182	£6,075	£36,177	STEMI	£2,847	£3,334	£4,946	£31,933	NSTEMI	£5,233	£5,727	£8,162	£45,810	UA	£5,410	£6,484	£10,172	£78,288
	20 yrs	10 yrs	5 yrs	1 yr																							
All ACS	£3,705	£4,182	£6,075	£36,177																							
STEMI	£2,847	£3,334	£4,946	£31,933																							
NSTEMI	£5,233	£5,727	£8,162	£45,810																							
UA	£5,410	£6,484	£10,172	£78,288																							

**Data sources**

**Health outcomes:** Baseline event rates for the clopidogrel + aspirin arm and treatment effects with ticagrelor + aspirin were derived from the PLATO RCT. For the 1-year decision tree a parametric time-to-event survival model with a Weibull distribution was used to determine the baseline risk. The HRs from the PLATO RCT were then applied to determine effectiveness of ticagrelor. In the Markov model, transition probabilities were estimated from the Myocardial Ischaemia National Audit Project and the General Practice Research database and UK standard life tables. The average age of patients in the PLATO trial was lower than the average age of patients with ACS in the UK; therefore age was adjusted to reflect the UK in the decision tree. **Quality-of-life weights:** EQ-5D was administered to participants in the PLATO health economics and quality of life sub-study, using the UK tariff, quality of life was independent of intervention used but varied by event experienced. **Cost sources:** UK National sources and published studies.

**Comments**

**Source of funding:** AstraZeneca UK Ltd. **Limitations:** International resource use from 2006-2008 and 2008/09 UK unit costs may not reflect current UK practice. UK practice is to give a clopidogrel loading dose of 600mg and the study allowed a clopidogrel loading dose of 300-600mg with only one fifth of patients received 600mg. Mean age of patients in the PLATO trial was lower than UK average and proportion of older patients different to UK setting but an age-adjusted event rate was used in the clopidogrel arm to attempt to address this. Analysis does not reflect full body of available evidence for this area as identified in clinical review; main analysis based on a single study (PLATO). Uncertainty in estimates of effectiveness due to participants being



able to leave the trial early and not followed up for 12 months - which effects the long-term patient outcomes in the Markov model. The health economic sub-study was used to derive data on resource use and utilities; however there was no information on how this sub-study was recruited for. Study funded by AstraZeneca.

**Overall applicability:**<sup>(c)</sup> Partially applicable      **Overall quality:**<sup>(d)</sup> Potentially serious limitations

Abbreviations: ACS = Acute coronary syndromes; CABG = coronary artery bypass graft; CI = confidence interval; CUA = cost-utility analysis; da = deterministic analysis; EQ-5D = Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER = incremental cost-effectiveness ratio; MI = myocardial infarction; NR = not reported; NSTEMI = non-ST-elevation myocardial infarction; pa = probabilistic analysis; PCI = percutaneous coronary intervention; QALY = quality-adjusted life years; RCT = randomised controlled trial; STEMI = ST-elevation myocardial infarction; UA = unstable angina

(a) Manufacturer submission for NICE TA236

(b) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.

(c) Directly applicable / Partially applicable / Not applicable

(d) Minor limitations / Potentially serious limitations / Very serious limitations

Study	Janzon 2011 <sup>63</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p><b>Economic analysis:</b> CUA (health outcome: QALYs)</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> A one-year decision tree based on the data from the PLATO trial, with the following events: death from any cause, non-fatal stroke, non-fatal MI and no further event. This was followed by a Markov model for long term extrapolation, which included the following health states; no event, non-fatal MI, post MI, non-</p>	<p><b>Population:</b> ACS patients intended for non-invasive therapy<sup>(b)</sup></p> <p><b>Cohort settings:</b> Start age: 62 Male: 71.6%</p> <p><b>Intervention 1:</b> Clopidogrel 75mg + aspirin daily for 12 months (300-600mg clopidogrel loading dose)</p> <p><b>Intervention 2:</b> Ticagrelor 90mg twice</p>	<p><b>Total costs (mean per patient):</b> Intervention 1: £12,972 Intervention 2: £13,440 Incremental (2-1): £468 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2010/11 UK pounds</p> <p><b>Cost components incorporated:</b> Drug costs (ticagrelor, clopidogrel and aspirin), bed days due to hospitalisation,</p>	<p><b>QALYs (mean per patient):</b> Intervention 1: 8.44 Intervention 2: 8.60 Incremental (2-1): 0.16</p>	<p>£2,925 per QALY gained (da) 95% CI: NR Probability Intervention 2 cost effective (£20K/30K threshold): 99.9%/99.9%</p> <p><b>Analysis of uncertainty:</b> Alternative scenarios were explored by altering the value of input parameters not associated with sampling uncertainty (therefore not varied in the probabilistic sensitivity analysis). These scenarios did not change conclusions about cost effectiveness.</p> <p>Using the treatment effect observed in the non-invasive patients rather than the overall treatment effect for all ACS patients did not change results and resulted in an ICER of £2,694 per QALY gained.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10

fatal stroke, post-stroke and dead. Treatment effects and resource use were based on data collected within the PLATO RCT. <b>Perspective:</b> UK NHS <b>Time horizon:</b> Lifetime <b>Treatment effect duration:</b> <sup>(a)</sup> 1 year. The model assumed that the beneficial effect of ticagrelor does not continue beyond one year. <b>Discounting:</b> Costs: 3.5%; Outcomes: 3.5%	daily + aspirin for 12 months (180mg ticagrelor loading dose)	investigations, blood product and reoperations due to bleeding and event costs (stroke and MI).	
---	---	---	--

**Data sources**

**Health outcomes:** Baseline event rates for the clopidogrel + aspirin arm and treatment effects with ticagrelor + aspirin were derived from the PLATO RCT. For the 1-year decision tree survival analysis was used to determine the baseline risk. The HRs from the PLATO RCT were then applied to determine effectiveness of ticagrelor. In the Markov model, transition probabilities were estimated by extrapolating out the observed hazard function of clopidogrel-treated patients in PLATO beyond 1 year of follow-up and using UK standard life tables. **Quality-of-life weights:** EQ-5D was administered to participants in the PLATO health economics and quality of life sub-study, using the UK tariff, quality of life was independent of intervention used but varied by event experienced. **Cost sources:** UK National sources and published studies.

**Comments**

**Source of funding:** AstraZeneca UK Ltd. **Limitations:** International resource use from 2006-2008 and 2010 UK unit costs may not reflect current UK practice. Only looks at patients intended for non-invasive management. Start age used in the cohort is younger than the average age of UK ACS patients and does not include prasugrel in the analysis. Does not state if bleeding was incorporated in the model, analysis does not reflect full body of available evidence for this area as identified in clinical review; analysis based on a single study (PLATO). Study was funded by AstraZeneca.

**Overall applicability:**<sup>(c)</sup> Partially applicable      **Overall quality:**<sup>(d)</sup> Potentially serious limitations

1 Abbreviations: ACS = Acute coronary syndromes; CI = confidence interval; CUA = cost-utility analysis; da = deterministic analysis; EQ-5D = Euroqol 5 dimensions (scale: 0.0  
 2 [death] to 1.0 [full health], negative values mean worse than death); ICER = incremental cost-effectiveness ratio; MI = myocardial infarction; NR = not reported; QALY = quality-  
 3 adjusted life years; RCT = randomised controlled trial

4 (a) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a  
 5 difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.

- 1 (b) Although patients were intended for non-invasive management approximately half of the patients had coronary angiography, a third had PCI, and one tenth had CABG  
 2 during the course of the study.  
 3 (c) Directly applicable / Partially applicable / Not applicable  
 4 (d) Minor limitations / Potentially serious limitations / Very serious limitations  
 5

## H.3 Ticagrelor + aspirin versus prasugrel + aspirin

Study	NICE TA236 2011 <sup>124(a)</sup>									
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness						
<p><b>Economic analysis:</b> CUA (health outcome: QALYs)</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> Based on the results of a published indirect comparison of the TRITON-TIMI-38 and PLATO trials<sup>18</sup>, and only analysed patients who were invasively managed. The model had the same health states as stated in the original analysis (see above).</p> <p><b>Perspective:</b> UK NHS  <b>Time horizon:</b> Lifetime  <b>Treatment effect duration:</b><sup>(b)</sup> 1 year  <b>Discounting:</b> Costs: 3.5%; Outcomes: 3.5%</p>	<p><b>Population:</b> ACS patients managed invasively (angiography followed by PCI/CABG if indicated)</p> <p><b>Cohort settings:</b> Start age: 70 Male: 64.6%</p> <p><b>Intervention 1:</b> Prasugrel 65mg + aspirin daily for 12 months (60mg prasugrel loading dose)</p> <p><b>Intervention 2:</b> Ticagrelor 90mg twice daily + aspirin for 12 months (180mg ticagrelor loading dose)</p>	<p><b>Total costs (mean per patient):</b> Intervention 1: £7,845 Intervention 2: £8,072 Incremental (2-1): £277 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2008/09 UK pounds</p> <p><b>Cost components incorporated:</b> Drug costs (ticagrelor, prasugrel and aspirin), hospitalisation, investigations, blood product and reoperations due to bleeding and drugs, event costs (stroke and MI).</p>	<p><b>QALYs (mean per patient):</b> Intervention 1: 8.045 Intervention 2: 8.110 Incremental (2-3): 0.065 (95% CI: NR; p=NR)</p>	<p><b>ICER (Intervention 2 versus Intervention 1):</b> £3,482 per QALY gained (da) 95% CI: NR Probability ticagrelor cost effective (£20K/30K threshold): 91.6%/NR</p> <p><b>Analysis of uncertainty:</b> Deterministic results using a different time horizon showed that ticagrelor remained cost-effective at 20, 10 and 5 years as demonstrated in the table below:</p> <table border="1"> <thead> <tr> <th>20 yrs</th> <th>10 yrs</th> <th>5 yrs</th> </tr> </thead> <tbody> <tr> <td>£3,598</td> <td>£4,562</td> <td>£7,047</td> </tr> </tbody> </table>	20 yrs	10 yrs	5 yrs	£3,598	£4,562	£7,047
20 yrs	10 yrs	5 yrs								
£3,598	£4,562	£7,047								

**Data sources**

**Health outcomes:** Baseline event rates were taken from the PLATO RCT. Relative risks were converted from the odds ratios for death, MI and stroke taken from the published indirect comparison and applied to the baseline event rates to give the event rate for prasugrel. **Quality-of-life weights:** Utilities from published literature; tariff unclear; collected in relevant population. Quality of life was independent of intervention used but varied by event experienced. **Cost sources:** UK National sources and published studies.

**Comments**

**Source of funding:** AstraZeneca UK Ltd. **Limitations:** International resource use from PLATO RCT which recruited 2006-2008 and 2008/09 UK unit costs may not reflect current UK practice. Does not include clopidogrel in the analysis. Baseline event rates were taken from the PLATO international trial, which may not reflect UK practice, however the analysis used an age-adjusted event rate to address this. Relative treatment effects for prasugrel compared to ticagrelor were estimated from an indirect comparison using studies that compared each drug to clopidogrel; while using an indirect comparison is not necessarily inappropriate the manufacturer highlighted issues with the indirect comparison and the technology appraisal committee did not think the analysis was appropriate due to differences in the target populations of the two trials, differences in the usage of clopidogrel (dosing and timing) and differences in the assessment of MI. Health state costs were calculated based on resource use collected in ticagrelor arm of the PLATO trial; in the absence of a head-to-trial collecting such data, it was assumed that these costs would be the same with prasugrel. Study was funded by AstraZeneca.

**Overall applicability:**<sup>(c)</sup> Partially applicable      **Overall quality:**<sup>(d)</sup> Potentially serious limitations

Abbreviations: CABG = coronary artery bypass graft; CCA= cost-consequences analysis; CEA= cost-effectiveness analysis; 95% CI= 95% confidence interval; CUA= cost-utility analysis; da= deterministic analysis; EQ-5D= Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER= incremental cost-effectiveness ratio; MI = myocardial infarction; NR= not reported; PCI = percutaneous coronary intervention; QALYs= quality-adjusted life years

(a) Manufacturer submission for NICE TA236. Note: this was not the primary analysis in the TA.

(b) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.

(c) Directly applicable / Partially applicable / Not applicable

(d) Minor limitations / Potentially serious limitations / Very serious limitations

**H4 Prasugrel + aspirin versus clopidogrel + aspirin**

11

Study	Greenhalgh 2015 <sup>53(a)</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness

1  
2  
3  
4  
5  
6  
7  
8  
9

<p><b>Economic analysis:</b> CUA (health outcome: QALYs)</p> <p><b>Study design:</b> Probabilistic decision analytic model</p> <p><b>Approach to analysis:</b> Markov model structure with two phases; the first phase models the within trial period and health states included bleeding, non-fatal stroke, non-fatal MI and cardiovascular/bleed death. Treatment effects based on the TRITON-TIMI 38 RCT for the initial 12 month analysis. For extrapolation beyond this point data from the CAPRIE trial was used and health states included non-fatal MI, non-fatal stroke, no prior events, prior stroke, prior MI and death. Adjustments were made to reflect UK practice where necessary</p> <p><b>Perspective:</b> UK NHS</p> <p><b>Time horizon:</b> lifetime</p>	<p><b>Population:</b> Patients with ACS undergoing primary or delayed PCI</p> <p><b>Cohort settings:</b> <u>STEMI patients with diabetes:</u> Start age: 58.0 (male); 60.9 (female) Male: 75.4%</p> <p><u>STEMI patients without diabetes:</u> Start age: 55.5 (male); 59.1 (female) Male: 84.0%</p> <p><u>UA/NSTEMI patients with diabetes:</u> Start age: 59.3 (male); 61.5 (female) Male: 68.7%</p> <p><u>UA/NSTEMI patients without diabetes:</u> Start age: 57.1 (male); 60.1 (female) Male: 80.3%</p> <p><b>Intervention 1:</b> Clopidogrel 75mg daily + aspirin for 12 months (300mg clopidogrel</p>	<p><b>Total costs (mean per patient):</b> <u>STEMI patients with diabetes:</u> Intervention 1: £19,904 Intervention 2: £20,351 Incremental (2–1): £447 (95% CI: NR; p=NR)</p> <p><u>STEMI patients without diabetes:</u> Intervention 1: £21,167 Intervention 2: £21,722 Incremental (2–1): £555 (95% CI: NR; p=NR)</p> <p><u>UA/NSTEMI patients with diabetes:</u> Intervention 1: £19,015 Intervention 2: £18,939 Incremental (2–1): –£77 (95% CI: NR; p=NR)</p> <p><u>UA/NSTEMI patients without diabetes:</u> Intervention 1: £20,328 Intervention 2: £20,576 Incremental (2–1): £248 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2012/13 UK pounds</p>	<p><b>QALYs (mean per patient):</b> <u>STEMI patients with diabetes:</u> Intervention 1: 10.05 Intervention 2: 10.33 Incremental (2–1): 0.28 (95% CI: NR; p=NR)</p> <p><u>STEMI patients without diabetes:</u> Intervention 1: 10.95 Intervention 2: 11.03 Incremental (2–1): 0.08 (95% CI: NR; p=NR)</p> <p><u>UA/NSTEMI patients with diabetes:</u> Intervention 1: 9.92 Intervention 2: 10.10 Incremental (2–1): 0.18 (95% CI: NR; p=NR)</p> <p><u>UA/NSTEMI patients without diabetes:</u> Intervention 1: 10.66 Intervention 2: 10.71 Incremental (2–1): 0.05 (95% CI: NR; p=NR)</p>	<p><b>ICER (Intervention 2 versus Intervention 1):</b> <u>STEMI patients with diabetes:</u> £1,732 per QALY gained (pa) 95% CI: NR Probability Intervention 2 cost effective (£20K/30K threshold): NR/NR</p> <p><u>STEMI patients without diabetes:</u> £7,073 per QALY gained (pa) 95% CI: NR Probability Intervention 2 cost effective (£20K/30K threshold): NR/NR</p> <p><u>UA/NSTEMI patients with diabetes:</u> Intervention 2 dominant 95% CI: NR Probability Intervention 2 cost effective (£20K/30K threshold): NR/NR</p> <p><u>UA/NSTEMI patients without diabetes:</u> £4,154 per QALY gained (pa) 95% CI: NR Probability Intervention 2 cost effective (£20K/30K threshold): NR/NR</p> <p><b>Analysis of uncertainty:</b> Univariate sensitivity analyses were performed on all model variables subject to uncertainty, and prasugrel remained cost-effective.</p> <p><b>ICERs using alternative time horizons:</b></p>
--	---	--	---	--

<b>Treatment effect duration:</b> <sup>(b)</sup> 1 year  <b>Discounting:</b> Costs: 3.5%; Outcomes: 3.5%	loading dose)  <b>Intervention 2:</b> Prasugrel 10mg daily + aspirin for 12 months (60mg prasugrel loading dose)	<b>Cost components incorporated:</b> Drug costs, repeat hospitalisations, health care costs associated with each health state.	<b>20 yrs</b>	<b>10 yrs</b>	<b>5 yrs</b>	<b>1 yr</b>
			STEMI with diabetes			
			£1,537	£2,139	£4,603	£31,915
			STEMI without diabetes			
			£7,670	£13,370	£29,607	£224,302
			UA/NSTEMI with diabetes			
			Domina nt	Dominant	£2,846	£76,856
			UA/NSTEMI without diabetes			
			£5,688	£14,276	£52,288	£1,101,662

### Data sources

**Health outcomes:** Based on treatment follow-up in TRITON-TIMI 38 RCT, risk equations were developed in order to estimate the risk of primary efficacy and safety events for the cohorts of patients receiving prasugrel and clopidogrel. Separate risk equations for the primary end point events were modelled for UA/NSTEMI and STEMI populations. These analyses used logistic models for events occurring within 3 days, and Weibull models over the remainder of the trial period (up to 12 months). For extrapolating long-term vascular events, data from the CAPRIE trial was used (this was used for TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events). In TA210, the MI sub-population model was based on CAPRIE data and used at an individual patient simulation approach. However, for this analysis the model used in TA210 was adapted to employ a long-term Markov model. Differences in age between the TRITON-TIMI 38 trial and UK population were accounted for by adjusting the initial health state utilities for each subgroup. **Quality-of-life weights:** EQ-5D, UK population valuation tariff, quality of life was independent of intervention used but varied by event experienced. EQ-5D data was obtained from the PLATO trial (ticagrelor vs clopidogrel) as the sub-study in the TRITON-TIMI 38 RCT did not recruit enough participants. **Cost sources:** NHS reference costs, NHS drug tariff and MIMS.

### Comments

**Source of funding:** NIHR. **Limitations:** International resource use from 2004-2007 and 2012 UK unit costs may not reflect current UK practice. The trial used a clopidogrel loading dose of 300mg instead of 600mg which does not reflect UK practice and analysis does not include ticagrelor. Mean age of patients in the TRITON-TIMI 38 trial was different to UK average but this was accounted for by adjusting the initial health state utilities of each subgroup. Did not use new cost data for the relevant year; instead unit costs from the previous TA report were inflated to 2012 prices. Analysis does not reflect full body of available evidence identified in clinical review; analysis based on a single study (TRITON-TIMI 38).

**Overall applicability:**<sup>(c)</sup> Partially applicable

**Overall quality:**<sup>(d)</sup> Potentially serious limitations

- 1 Abbreviations: ACS = Acute coronary syndromes; 95% CI = confidence interval; CUA = cost-utility analysis; EQ-5D = Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); ICER = incremental cost-effectiveness ratio; MI = myocardial infarction; NR = not reported; NSTEMI = non-ST-elevation myocardial
- 2

- 1 *infarction; pa = probabilistic analysis; PCI = percutaneous coronary intervention; QALY = quality-adjusted life years; RCT = randomised controlled trial; STEMI = ST-elevation*  
2 *myocardial infarction; UA = unstable angina*  
3 (a) *ERG analysis for NICE TA317*  
4 (b) *For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a*  
5 *difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.*  
6 (c) *Directly applicable / Partially applicable / Not applicable*  
7 (d) *Minor limitations / Potentially serious limitations / Very serious limitations*  
8  
9

10

## Appendix I: Excluded studies

### I.1 Excluded clinical studies

**Table 29: Studies excluded from the clinical review**

Study	Exclusion reason
Abaci 2015 <sup>1</sup>	Not available
Abergel 2010 <sup>3</sup>	Narrative review; references checked
Agewall 2011 <sup>4</sup>	Narrative review; references checked
Alexopoulos 2012 <sup>5</sup>	Incorrect study population (patients with ACS and high on-treatment platelet reactivity while on clopidogrel after PCI)
Alexopoulos 2013 <sup>9</sup>	Incorrect study population (people with ACS and high on-treatment platelet reactivity while on clopidogrel and undergoing PCI)
Alexopoulos 2015 <sup>7</sup>	Study population with HPR while on treatment (mostly with clopidogrel)
Alexopoulos 2016 <sup>6</sup>	Incorrect study comparison and no relevant outcomes
Amico 2016 <sup>10</sup>	Secondary evaluation of PLATO
Andell 2015 <sup>11</sup>	PLATO post-hoc subgroup analysis of patients with COPD
Antman 2008 <sup>13</sup>	TRITON analysis with no additional relevant outcomes
Bavishi 2015 <sup>14</sup>	Meta-analysis; references checked
Becker 2011 <sup>15</sup>	No additionally relevant outcomes from PLATO
Bellavia 2017 <sup>16</sup>	PLATO secondary analysis with no additional relevant outcomes
Bhatt 2009 <sup>17</sup>	Narrative review; references checked
Biondi-Zoccai 2011 <sup>18</sup>	Indirect comparison meta-analysis; references checked
Bonaca 2016 <sup>19</sup>	Incorrect study comparison
Brener 2014 <sup>21</sup>	Incorrect study comparison
Briasoulis 2016 <sup>22</sup>	Systematic review; references checked
Bundhun 2017 <sup>24</sup>	Systematic review; references checked
Bundhun 2018 <sup>23</sup>	Meta-analysis; references checked
Cannon 2010 <sup>25</sup>	PLATO ACS substudy with no additional relevant outcomes
Cayla 2017 <sup>27</sup>	Incorrect study comparison
Chen 2015 <sup>28</sup>	Letter publication only
Chin 2010 <sup>31</sup>	TRILOGY study design and rationale only
Chin 2013 <sup>29</sup>	No usable data from PLATO cost effectiveness analysis
Chin 2016 <sup>30</sup>	TRILOGY subgroup analysis of people with stroke
Choi 2017 <sup>32</sup>	Incorrect study comparison
Costa 2015 <sup>33</sup>	Incorrect study comparison
Dalby 2017 <sup>34</sup>	TRILOGY subgroup analysis in people with diabetes
Deharo 2013 <sup>42</sup>	Letter publication only
Diodati 2014 <sup>44</sup>	Incorrect study comparison
Fanari 2015 <sup>45</sup>	Narrative review; references checked
Ferri 2016 <sup>46</sup>	Study design and rationale only
Fluschnik 2018 <sup>47</sup>	Narrative review; references checked
Fonarow 2016 <sup>48</sup>	Cancelled by reviewer



Study	Exclusion reason
Gan 2015 <sup>49</sup>	Meta-analysis; references checked
Gasche 2013 <sup>50</sup>	No usable data from PLATO cost effectiveness analysis
Ge 2010 <sup>51</sup>	Study design and rationale only
Husted 2012 <sup>57</sup>	PLATO substudy in older adults
James 2009 <sup>58</sup>	Study design and rationale only
James 2010 <sup>59</sup>	PLATO substudy in patients with diabetes
James 2010 <sup>60</sup>	PLATO substudy in patients with chronic kidney disease
James 2011 <sup>61</sup>	PLATO ACS substudy with no additional relevant outcomes
James 2012 <sup>62</sup>	PLATO substudy in patients with a history of stroke or TIA
Jing 2018 <sup>65</sup>	Meta-analysis; reference checked
Kang 2015 <sup>67</sup>	PLATO subgroup analysis for Asian and non-Asian patients
Ketchum 2011 <sup>69</sup>	Systematic review; references checked
Khan 2016 <sup>70</sup>	Systematic review; references checked
Khasa 2016 <sup>71</sup>	Incorrect study population and treatment switching
Kim 2017 <sup>73</sup>	No relevant outcomes
Kim 2018 <sup>72</sup>	No relevant outcomes
Kimura 2015 <sup>74</sup>	Incorrect study population (excluded ACS)
Kohli 2013 <sup>77</sup>	PLATO analysis with no additional relevant outcomes (recurrent cardiovascular events not prespecified in review protocol)
Kohli 2014 <sup>76</sup>	TRITON analysis of discharge aspirin dose
Kotsia 2014 <sup>78</sup>	PLATO analysis by extent of coronary artery disease
Kozinski 2014 <sup>79</sup>	Incorrect study design
Kubo 2016 <sup>80</sup>	Incorrect study design
Kulik 2009 <sup>81</sup>	Systematic review; incorrect study comparison
Kunadian 2013 <sup>82</sup>	PLATO substudy of angiographic outcomes
Laine 2015 <sup>84</sup>	No relevant outcomes
Lau 2017 <sup>85</sup>	Meta-analysis; references checked
Lee 2013 <sup>88</sup>	Protocol only
Lee 2014 <sup>86</sup>	Incorrect study comparison
Lee 2014 <sup>87</sup>	Incorrect study population and comparison
Lee 2017 <sup>91</sup>	Incorrect study comparison
Lee 2017 <sup>89</sup>	Incorrect study comparison; design and rationale only
Lee 2018 <sup>90</sup>	Meta-analysis; references checked
Lemesle 2015 <sup>93</sup>	Systematic review; references checked
Leonardi 2012 <sup>94</sup>	Incorrect comparison; study design and rationale only
Levin 2013 <sup>95</sup>	PLATO substudy - no usable outcomes
Li 2015 <sup>97</sup>	No relevant outcomes before switching treatments
Li 2015 <sup>96</sup>	Not available
Li 2016 <sup>100</sup>	Incorrect study comparison; protocol only
Li 2018 <sup>98</sup>	No relevant outcomes
Lopes 2016 <sup>103</sup>	TRILOGY substudy of spontaneous myocardial infarction
Mahaffey 2014 <sup>104</sup>	No additional relevant outcomes for PLATO
Mahoney 2010 <sup>105</sup>	No useable additional relevant outcomes for TRITON. No usable additional relevant TRITON outcomes
Mannacio 2012 <sup>106</sup>	Incorrect study population and comparison
Mariani 2009 <sup>107</sup>	No additional relevant outcomes to TRITON

Study	Exclusion reason
Mega 2010 <sup>108</sup>	TRITON pharmacogenetic analysis
Melloni 2016 <sup>109</sup>	TRILOGY substudy of patients with chronic kidney disease
Misumida 2018 <sup>110</sup>	Meta-analysis; references checked
Modi 2012 <sup>111</sup>	Not available
Mohammad 2010 <sup>112</sup>	Narrative review; references checked
Montalescot 2010 <sup>114</sup>	Incorrect study comparison
Mont'alverne-Filho 2016 <sup>113</sup>	No relevant outcomes
Morrow 2009 <sup>116</sup>	TRITON analysis with no additional relevant outcomes
Motovska 2018 <sup>117</sup>	Incorrect study design related to switching treatments
Murphy 2008 <sup>119</sup>	TRITON secondary analysis of recurrent endpoints, no additional prespecified outcomes
Musallam 2016 <sup>120</sup>	Incorrect study population
Nakamura 2015 <sup>121</sup>	PRASFIT substudy with no additional relevant outcomes
NCT 2008 <sup>125</sup>	Not available
NCT 2009 <sup>127</sup>	Not available
NCT 2009 <sup>126</sup>	Not available
NCT 2011 <sup>128</sup>	Not available
NCT 2011 <sup>129</sup>	Not available
NCT 2012 <sup>130</sup>	Not available
NCT 2013 <sup>134</sup>	Not available
NCT 2013 <sup>133</sup>	Not available
NCT 2013 <sup>132</sup>	Not available
NCT 2013 <sup>136</sup>	Not available
NCT 2013 <sup>135</sup>	Not available
NCT 2013 <sup>137</sup>	Not available
NCT 2013 <sup>131</sup>	Not available
NCT 2014 <sup>144</sup>	Not available
NCT 2014 <sup>147</sup>	Not available
NCT 2014 <sup>143</sup>	Not available
NCT 2014 <sup>141</sup>	Not available
NCT 2014 <sup>145</sup>	Not available
NCT 2014 <sup>139</sup>	Not available
NCT 2014 <sup>142</sup>	Not available
NCT 2014 <sup>146</sup>	Not available
NCT 2014 <sup>148</sup>	Not available
NCT 2014 <sup>140</sup>	Not available
NCT 2014 <sup>138</sup>	Not available
NCT 2015 <sup>149</sup>	Not available
NCT 2015 <sup>152</sup>	Not available
NCT 2015 <sup>150</sup>	Not available
NCT 2015 <sup>155</sup>	Not available
NCT 2015 <sup>154</sup>	Not available
NCT 2015 <sup>151</sup>	Not available
NCT 2015 <sup>153</sup>	Not available
NCT 2016 <sup>156</sup>	Not available
NCT 2016 <sup>158</sup>	Not available

Study	Exclusion reason
NCT 2016 <sup>157</sup>	Not available
NCT 2017 <sup>160</sup>	Not available
NCT 2017 <sup>162</sup>	Not available
NCT 2017 <sup>161</sup>	Not available
NCT 2017 <sup>159</sup>	Not available
NCT 2018 <sup>163</sup>	Not available
Neumann 2009 <sup>164</sup>	Systematic review; references checked
Nicolau 2015 <sup>165</sup>	TRILOGY substudy of proton pump inhibitor use
Nikolic 2013 <sup>166</sup>	No usable data from PLATO cost effectiveness analysis
Nishikawa 2015 <sup>167</sup>	PRASFIT post-hoc analysis with no additional relevant outcomes
O'Donoghue 2016 <sup>168</sup>	Incorrect study comparison
Ogawa 2016 <sup>169</sup>	PRASFIT post-hoc analysis with no additional relevant outcomes
Ojeifo 2013 <sup>170</sup>	TRITON study of statins and calcium channel blocker use
Orban 2016 <sup>172</sup>	Incorrect study design
Palacio 2012 <sup>174</sup>	Systematic review; incorrect study comparison
Pandit 2014 <sup>175</sup>	Systematic review; incorrect study comparison
Paré 2012 <sup>176</sup>	Incorrect study comparison
Park 2010 <sup>180</sup>	Incorrect study comparison
Park 2014 <sup>178</sup>	Protocol only; no relevant outcomes prespecified
Park 2016 <sup>179</sup>	No relevant outcomes
Park 2018 <sup>177</sup>	Study design and rationale only
Parker 2017 <sup>181</sup>	Incorrect study comparison
Patel 2009 <sup>184</sup>	Systematic review; references checked
Patel 2015 <sup>185</sup>	PLATO substudy of patients with peripheral artery disease
Patti 2013 <sup>186</sup>	Incorrect study comparison
Pickard 2008 <sup>188</sup>	Narrative review; incorrect study comparison
Pollack 2017 <sup>189</sup>	PLATO subgroup analysis on time to drug administration in relation to angiography not relevant to review question
Pourdjabbar 2017 <sup>190</sup>	Incorrect study comparison
Pouwels 2018 <sup>191</sup>	Evaluation only
Pride 2009 <sup>192</sup>	TRITON substudy of patients undergoing PCI without stent implantation
Qaderdan 2015 <sup>193</sup>	Study design and rationale only
Rafiq 2012 <sup>194</sup>	Incorrect study comparison; protocol only
Rafique 2016 <sup>195</sup>	Network meta-analysis; references checked
Refiker 2011 <sup>196</sup>	Incorrect study comparison; commentary only
Ren 2012 <sup>197</sup>	Not available
Ren 2016 <sup>198</sup>	Incorrect study design
Reynard 2017 <sup>199</sup>	Abstract only for systematic review
Rodriguez 2018 <sup>200</sup>	Narrative review; references checked
Roe 2013 <sup>203</sup>	TRILOGY substudy of older adults
Roe 2016 <sup>202</sup>	TRILOGY substudy of neoplasm events
Roffman 2016 <sup>204</sup>	Narrative review; references checked
Rognoni 2016 <sup>205</sup>	Narrative review; references checked
Rossington 2016 <sup>206</sup>	Systematic review; references checked
Rudolph 2017 <sup>207</sup>	No relevant outcomes

Study	Exclusion reason
Ruff 2012 <sup>208</sup>	TRITON substudy by different world regions
Saint Etienne 2013 <sup>209</sup>	Incorrect study comparison
Saito 2014 <sup>210</sup>	Low dosage prasugrel
Sakurai 2017 <sup>211</sup>	Meta-analysis; references checked
Salisbury 2013 <sup>212</sup>	TRITON risk modelling substudy
Sardar 2014 <sup>213</sup>	Meta-analysis; references checked
Sardella 2015 <sup>214</sup>	Incorrect study population (excluded ACS)
Sardella 2017 <sup>215</sup>	No relevant outcomes
Sarkees 2009 <sup>216</sup>	Systematic review; references checked
Sarkees 2010 <sup>217</sup>	Systematic review; references checked
Saucedo 2013 <sup>218</sup>	No relevant outcomes
Saw 2016 <sup>220</sup>	Incorrect study comparison and population
Sawhani 2017 <sup>221</sup>	Incorrect study comparison and population
Schnorbus 2014 <sup>222</sup>	Protocol only; no relevant outcomes prespecified
Scirica 2011 <sup>225</sup>	PLATO ECG substudy
Scirica 2018 <sup>224</sup>	PLATO substudy of ECG abnormalities
Serebruany 2012 <sup>226</sup>	Narrative review; references checked
Serebruany 2013 <sup>228</sup>	Incorrect study comparison; secondary evaluation only
Serebruany 2015 <sup>227</sup>	Meta-analysis; references checked
Serebruany 2016 <sup>229</sup>	Narrative review; references checked
Servi 2015 <sup>39</sup>	Letter only
Servi 2016 <sup>40</sup>	TRITON substudy of culprit lesion site
Shah 2017 <sup>230</sup>	Network meta-analysis; references checked
Shahzeb 2015 <sup>231</sup>	Incorrect study population
Siller-Matula 2011 <sup>232</sup>	Systematic review; references checked
Siller-Matula 2017 <sup>233</sup>	Systematic review; references checked
Singh 2016 <sup>234</sup>	Network meta-analysis; references checked
Smith 2012 <sup>235</sup>	TRITON substudy with no additional relevant outcomes
Solomon 2010 <sup>236</sup>	Commentary only; no usable outcome data
Song 2017 <sup>237</sup>	Incorrect study design
Sorich 2010 <sup>238</sup>	TRITON substudy by genotype
Spartalis 2017 <sup>239</sup>	Systematic review; references checked
Spinar 2015 <sup>240</sup>	Not available
Spinar 2015 <sup>241</sup>	Not available
Steblovnik 2016 <sup>242</sup>	Incorrect study population
Steg 2013 <sup>244</sup>	PLATO substudy with no additional relevant outcomes
Steg 2013 <sup>243</sup>	Incorrect study comparison
Steiner 2012 <sup>246</sup>	Network meta-analysis; references checked
Storey 2010 <sup>248</sup>	PLATO substudy with no additional relevant outcomes
Storey 2011 <sup>250</sup>	PLATO substudy with no additional relevant outcomes
Storey 2011 <sup>249</sup>	PLATO substudy with no additional relevant outcomes
Storey 2014 <sup>251</sup>	PLATO substudy with no additional relevant outcomes
Storey 2016 <sup>247</sup>	Incorrect study comparison
Sudlow 2009 <sup>252</sup>	Cochrane systematic review, incorrect study comparison and population
Sun 2008 <sup>256</sup>	Systematic review; incorrect study comparison

Study	Exclusion reason
Sun 2010 <sup>254</sup>	Incorrect study comparison
Sun 2011 <sup>255</sup>	Incorrect study comparison; letter only
Sun 2017 <sup>253</sup>	Systematic review; references checked
Sweeny 2017 <sup>257</sup>	No relevant outcomes
Tan 2014 <sup>259</sup>	Not available
Tan 2017 <sup>258</sup>	Systematic review; references checked
Tang 2014 <sup>262</sup>	Meta-analysis; references checked
Tang 2015 <sup>263</sup>	Systematic review; incorrect study comparison
Tang 2016 <sup>260</sup>	Meta-analysis; references checked
Tarantini 2018 <sup>264</sup>	Systematic review; references checked
Theidel 2013 <sup>265</sup>	No usable data from PLATO cost effectiveness analysis
Torngren 2013 <sup>266</sup>	Incorrect study design
Udell 2014 <sup>267</sup>	TRITON substudy of outcomes by primary versus secondary PCI
Vaduganathan 2017 <sup>269</sup>	Incorrect study comparison
Vaduganathan 2017 <sup>268</sup>	Incorrect study comparison
Valenti 2015 <sup>270</sup>	Incorrect study design
Varenhorst 2012 <sup>272</sup>	PLATO substudy with no additional relevant outcomes
Varenhorst 2014 <sup>271</sup>	PLATO substudy with no additional relevant outcomes
Velders 2016 <sup>273</sup>	PLATO post-hoc subgroup analysis of patients with STEMI who underwent PPCI
Verdoia 2014 <sup>275</sup>	Meta-analysis; incorrect study comparison
Verdoia 2016 <sup>274</sup>	Meta-analysis; references checked
Verma 2015 <sup>276</sup>	Meta-analysis; incorrect study comparison
Vito 2016 <sup>277</sup>	Incorrect study comparison
Vlaar 2008 <sup>278</sup>	Systematic review; references checked
Voeltz 2013 <sup>279</sup>	Incorrect study comparison
Vogel 2017 <sup>280</sup>	Narrative review; incorrect study comparison
Waha 2016 <sup>281</sup>	Incorrect study comparison; study design and rationale only
Wallentin 2010 <sup>283</sup>	PLATO genetic substudy
Wallentin 2014 <sup>284</sup>	PLATO substudy with no additional relevant outcomes
Walter 2008 <sup>285</sup>	Incorrect study population and comparison, and no relevant outcomes
Wang 2018 <sup>286</sup>	No relevant outcomes
Washam 2014 <sup>290</sup>	Systematic review; incorrect study comparison
Watti 2017 <sup>291</sup>	Meta-analysis; references checked
Weber 2011 <sup>292</sup>	Incorrect study comparison
Wein 2017 <sup>293</sup>	Incorrect study comparison
Welsh 2012 <sup>294</sup>	Incorrect study comparison
Westman 2017 <sup>295</sup>	Network meta-analysis; references checked
White 2012 <sup>297</sup>	Incorrect study comparison
White 2015 <sup>296</sup>	Incorrect study comparison
White 2016 <sup>298</sup>	TRILOGY subanalysis by frailty
Wilcox 2014 <sup>299</sup>	TRITON subanalysis of 10mg indicated cohort
Winter 2014 <sup>300</sup>	No relevant outcomes
Wisloff 2011 <sup>302</sup>	Systematic review; references checked
Wiviott 2005 <sup>303</sup>	Patient population not defined for inclusion of ACS

Study	Exclusion reason
Wiviott 2007 <sup>308</sup>	Study population with angina but no breakdown of results for unstable angina
Wiviott 2008 <sup>305</sup>	TRITON subanalysis of patients with bare metal and drug eluting stents
Wiviott 2008 <sup>304</sup>	TRITON subanalysis of patients with/without diabetes
Wiviott 2011 <sup>307</sup>	TRITON survival analysis by core cohort, noncore and contraindicated
Wiviott 2013 <sup>309</sup>	PLATO subgroup analysis with/without angiography not relevant to review question
Wu 2017 <sup>312</sup>	Patients with coronary heart disease and high on-treatment platelet reactivity while on clopidogrel, following elective PCI
Wu 2018 <sup>310</sup>	Meta-analysis; references checked
Xanthopoulou 2016 <sup>313</sup>	Narrative review; references checked
Xia 2015 <sup>314</sup>	Not available
Xiong 2015 <sup>315</sup>	Incorrect intervention (very high maintenance dose of clopidogrel)
Yan 2018 <sup>316</sup>	TRILOGY post-hoc subanalysis of outcomes with early drug discontinuation
Yang 2017 <sup>318</sup>	Meta-analysis; references checked
Yang 2017 <sup>317</sup>	No relevant outcomes
Ye 2014 <sup>320</sup>	Network meta-analysis; references checked
Yuan 2016 <sup>321</sup>	Not available
Yun 2017 <sup>322</sup>	No relevant outcomes
Zaccardi 2015 <sup>323</sup>	Meta-analysis; references checked
Zeymer 2017 <sup>324</sup>	Incorrect study comparison
Zhang 2009 <sup>328</sup>	Incorrect study comparison
Zhang 2016 <sup>327</sup>	Incorrect intervention (very high maintenance dose of clopidogrel)
Zhang 2017 <sup>326</sup>	Meta-analysis; references checked
Zhao 2008 <sup>329</sup>	Incorrect study comparison
Zheng 2013 <sup>330</sup>	Not available
Zhou 2012 <sup>331</sup>	Systematic review; incorrect study comparison
Zhu 2015 <sup>332</sup>	Incorrect study comparison (post-PCI administration of clopidogrel to both groups)

## I.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

**Table 30: Studies excluded from the health economic review**

Reference	Reason for exclusion
Davies 2013(a) <sup>36</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing prasugrel with clopidogrel based on the same RCT <sup>53</sup> was available, this study was selectively excluded.
Davies 2013(b) <sup>37</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK

Reference	Reason for exclusion
	analysis comparing prasugrel with clopidogrel based on the same RCT <sup>53</sup> was available, this study was selectively excluded.
De La Puente 2017 <sup>38</sup>	Excluded as rated very serious limitations due to having a short time horizon and having unclear baseline and treatment effects. Also partially applicable, reasons include: Chilean setting may not reflect current UK NHS context.
Gasche 2013 <sup>50</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Grima 2015 <sup>54</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Henriksson 2014 <sup>56</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Liew 2013 <sup>101</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Nikolic 2013 <sup>166</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Paweska 2014 <sup>187</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Theidel 2013 <sup>265</sup>	This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing ticagrelor with clopidogrel based on the same RCT <sup>124</sup> was available, this study was selectively excluded.
Wein 2017 <sup>293</sup>	Excluded as rated very serious limitations due to having a very short time horizon and was based on data from two trials that were not designed to compare prasugrel and clopidogrel. Also partially applicable, reasons include: German, Danish and Swiss setting may not reflect current UK NHS context.

